DOI,Titulo_Tokens,Abstract_Tokens,Autores,Fecha,Seccion
10.3390/jimaging10090208,task adaptive angle selection computed tomography base defect detection,sparse angle x ray computed tomography ct play vital role industrial quality control lead inherent trade off scan time reconstruction quality adaptive angle selection strategy try to improve base idea geometry object investigation lead uneven distribution information content projection angle deep reinforcement learning drl have emerge effective approach adaptive angle selection x ray ct previous study focus optimize generic image quality measure use fix number angle work extend consider specific downstream task namely image base defect detection introduce flexibility number angle use leverage prior knowledge typical defect characteristic task adaptive angle selection method adaptable term angle count enable easy detection defect reconstructed image,"Wang, Tianyuan,Florian, Virginia,Schielein, Richard,Kretzer, Christian,Kasperl, Stefan,Lucka, Felix,van Leeuwen, Tristan",11/07/2024,Journal of imaging
10.1136/bmj.p2916,de sludging healthcare system,,"Hodson, Nathan",21/12/2023,BMJ (Clinical research ed.)
10.3390/jimaging10080192,railtrack davit vision transformer base approach automated railway track defect detection,railway track defect pose significant safety risk can lead accident economic loss loss life traditional manual inspection method be time consume costly prone human error paper propose railtrack davit novel vision transformer base approach railway track defect classification leverage dual attention vision transformer davit architecture railtrack davit effectively capture global local information enable accurate defect detection model be train evaluate multiple dataset include rail fastener fishplate multi fault thairailtrack comprehensive analysis model performance be provide include confusion matrix training visualization classification metric railtrack davit demonstrate superior performance compare state art cnn base method achieve high accuracy rail dataset fastener fishplate dataset multi faults dataset moreover railtrack davit outperform baseline thairailtrack dataset accuracy quickly adapt unseen image show well model stability fine tuning capability can significantly reduce time consumption apply model novel dataset practical application,"Phaphuangwittayakul, Aniwat,Harnpornchai, Napat,Ying, Fangli,Zhang, Jinming",22/06/2024,Journal of imaging
10.3390/jimaging10080197,multi scale target detection method use improved fast region convolutional neural network base enhanced backbone optimize mechanism,currently exist deep learning method exhibit many limitation multi target detection such low accuracy high rate false detection miss detection paper propose improved fast r cnn algorithm aim to enhance algorithm capability detect multi scale target algorithm have three improvement base fast r cnn firstly new algorithm use network feature extraction detection image achieve strong feature extraction capability secondly new algorithm integrate online hard example mining ohem soft non maximum suppression soft nms distance intersection union diou module improve positive negative sample imbalance problem small target be easily miss model training finally region proposal network rpn be simplify to achieve fast detection speed low miss rate multi scale training mst strategy be also use to train improved fast r cnn to achieve balance detection accuracy efficiency compare other detection model improve fast r cnn demonstrate significant advantage term score log average miss rate lamr model propose paper provide valuable insight inspiration many field such smart agriculture medical diagnosis face recognition,"Chen, Qianyong,Li, Mengshan,Lai, Zhenghui,Zhu, Jihong,Guan, Lixin",16/07/2024,Journal of imaging
10.3390/jimaging10090227,leverage perspective transformation enhanced pothole detection autonomous vehicle,road condition often degrade insufficient maintenance adverse weather significantly contribute accident exacerbate limited human reaction time sudden hazard pothole early detection distant pothole be crucial timely corrective action such reduce speed avoid obstacle to mitigate vehicle damage accident paper introduce novel approach utilize perspective transformation to enhance pothole detection different distance focus particularly distant pothole perspective transformation improve visibility clarity pothole virtually bring close enlarge feature be particularly beneficial give fix size input requirement object detection network typically significantly small raw image resolution capture camera method automatically identify region interest road area calculate corner point to generate perspective transformation matrix matrix be apply image correspond bounding box label enhance representation pothole dataset approach significantly boost detection performance use small achieve improvement average precision ap metric intersection union threshold single class evaluation notable improvement near medium far pothole respectively categorize base distance good knowledge work be first to employ perspective transformation specifically enhance detection distant pothole,"Abu-Raddaha, Abdalmalek,El-Shair, Zaid A,Rawashdeh, Samir",06/08/2024,Journal of imaging
10.3390/jimaging10090215,concrete crack detection segregation feature fusion crack isolation explainable ai base approach,scientific knowledge image base crack detection method be limit understand performance diverse crack size type environmental condition builder engineer often face difficulty image resolution detect fine crack differentiate structural non structural issue enhance algorithm analysis technique be need more accurate assessment hence research aim to generate intelligent scheme can recognize presence crack visualize percentage crack image explanation propose method fuse feature concrete surface image convolutional neural network cnn curvelet transform handcraft hc method optimize linear discriminant analysis lda extreme gradient boost xgb classifier then use feature to recognize crack study evaluate several cnn model include inception various hc technique such wavelet transform counterlet transform curvelet transform feature extraction principal component analysis pca lda be assess feature optimization classification xgb random forest rf adaptive boosting adaboost category boost catboost be test to isolate quantify crack region research combine image thresholding morphological operation contour detection convex hull method form novel algorithm two explainable ai xai tool local interpretable model agnostic explanation lime gradient weighted class activation grad be integrate propose method to enhance result clarity research introduce novel feature fusion approach enhance crack detection accuracy interpretability method demonstrate superior performance achieve accuracy two exist dataset outperform state art method additionally development algorithm isolate quantify crack region represent significant advancement image processing structural analysis propose approach provide robust reliable tool real time crack detection assessment concrete structure facilitate timely maintenance improve structural safety offer detailed explanation model decision research address critical need transparency ai application thus increase trust adoption engineering practice,"Swarna, Reshma Ahmed,Hossain, Muhammad Minoar,Khatun, Mst Rokeya,Rahman, Mohammad Motiur,Munir, Arslan",13/08/2024,Journal of imaging
10.1016/j.cell.2025.02.014,ligand induce ubiquitination unleash immune checkpoint function hinder membrane sequestration signal motif,lymphocyte activation gene have emerge promising cancer immunotherapy target mechanism underlie activation ligand engagement remain elusive here be find to undergo robust non link polyubiquitination ligand engagement promote inhibitory function instead cause degradation ubiquitination could be trigger engagement major histocompatibility complex class ii mhc class ii membrane bind not soluble fibrinogen like protein ubiquitination mediate redundantly ligase c cbl cbl b disrupt membrane binding juxtamembrane basic residue rich sequence thereby stabilize cytoplasmic tail membrane dissociate conformation enable signaling furthermore ubiquitination be crucial mediate suppression antitumor immunity vivo consistently therapeutic antibodie repress ubiquitination correlate checkpoint blockade effect moreover patient cohort analysis suggest cbl coexpression could serve biomarker response blockade collectively study reveal immune checkpoint trigger mechanism translational potential cancer immunotherapy,"Jiang, Yong,Dai, Anran,Huang, Yuwei,Li, Hua,Cui, Jian,Yang, Haochen,Si, Lu,Jiao, Tao,Ren, Zhengxu,Zhang, Ziwei,Mou, Si,Zhu, Hengrui,Guo, Wenhui,Huang, Qiang,Li, Yilin,Xue, Manman,Jiang, Jingwei,Wang, Fei,Li, Li,Zhong, Qinying,Wang, Kun,Liu, Baichuan,Wang, Jinjiao,Fan, Gaofeng,Guo, Jun,Chen, Liang,Workman, Creg J,Shen, Zhirong,Kong, Yan,Vignali, Dario A A,Xu, Chenqi,Wang, Haopeng",13/12/2023,Cell
10.1016/j.ccell.2025.02.024,drive cancer associate fibroblast hijack abscopal effect radioimmunotherapy,abscopal effect radioimmunotherapy tumor shrinkage occur irradiated field be therapeutically promising clinically rare mechanism underlie effect remain elusive here vivo genome wide crispr screening identifie potential stromal regulator abscopal effect exhibit cancer associate fibroblast expression radioimmunotherapy mediate upregulation unirradiated tumor conditional knockout cafs boost abscopal effect rewire vascular immune microenvironment to promote t cell recruitment unirradiated tumor vivo lineage tracing reveal elevated correlate radioimmunotherapy drive pericyte lineage commitment serum proteomic reveal irradiate tumor secrete trigger distant tumor pericyte cell fate transition cafs axis pharmacologically block enhance abscopal effect humanize patient derive xenograft model finding collectively illustrate induce cafs serve critical stromal regulator to hijack abscopal effect provide promise target enhance radioimmunotherapy effectiveness,"Zhang, Yan-Pei,Guo, Ze-Qin,Cai, Xiao-Ting,Rong, Zi-Xuan,Fang, Yuan,Chen, Jia-Qi,Zhuang, Kui-Mao,Ruan, Min-Jie,Ma, Si-Cong,Lin, Le-Yi,Han, Duan-Duan,Li, Yang-Si,Wang, Yuan-Yuan,Wang, Jian,Cao, Chuan-Hui,Tang, Xin-Ran,Xie, Qian-Kun,Chen, Yue,Lin, Yan,Tan, Jia-Le,Yu, Zi-Hang,Wu, Ze-Nan,Wei, Wei,Zheng, Da-Yong,Zeng, Yu-Jie,Ruan, Ying-Chen,Xu, Zi-Peng,Gu, Jun-Zi,Xiao, Lu-Shan,Liu, Li,Guan, Jian,Bai, Xue,Wu, De-Hua,Dong, Zhong-Yi",21/06/2024,Cancer cell
10.1016/j.cmet.2025.02.007,dietary timing enhance exercise modulate fat muscle crosstalk adipocyte signaling,feed rhythm regulate exercise performance muscle energy metabolism however mechanism regulate adipocyte function remain unclear here use multi omics analysis involve lipidomic find day restrict feeding drf regulate diurnal rhythm mitochondrial proteome neutral lipidome nutrient sense pathway mouse gonadal white adipose tissue gwat adipocyte specific knockdown gene encode impairs physical endurance defect be associate altered rhythmicity acyl coenzyme coa metabolism relate gene loss rhythmicity gwat lipidome circadian remodeling serum metabolite particular lactate succinate also find adipocyte regulate muscle clock gene drf notably oral administration ampk activator increase endurance muscle function time day manner require intact adipocyte signaling collectively work define adipocyte signal critical regulator circadian metabolic coordination fat muscle thereby enhance exercise performance,"Chen, Jianghui,Xiang, Jing,Zhou, Meiyu,Huang, Rongfeng,Zhang, Jianxin,Cui, Yuanting,Jiang, Xiaoqing,Li, Yang,Zhou, Runchao,Xin, Haoran,Li, Jie,Li, Lihua,Lam, Sin Man,Zhu, Jianfang,Chen, Yanxiu,Yang, Qingyuan,Xie, Zhifu,Shui, Guanghou,Deng, Fang,Zhang, Zhihui,Li, Min-Dian",16/07/2024,Cell metabolism
10.1136/bmjph-2024-001447,association composite dietary antioxidant index sarcopenia risk american adult cross sectional nhane study,background give absence specific pharmacological treatment sarcopenia identify effective lifestyle dietary intervention be imperative study aim to explore association composite dietary antioxidant index cdai sarcopenia offer new insight nutritional strategy sarcopenia prone population method cross sectional study analyse secondary datum national health nutrition examination survey cycle span weight multivariate logistic regression restrict cubic spline rcs analysis be employ to evaluate non linear association cdai sarcopenia to perform stratified analysis result study encompass american adult representative national population resident be diagnose sarcopenia adjust model high cdai be inversely associate risk sarcopenia ci high quartile cdai score low reveal significantly reduce odd sarcopenia ci rcs analysis demonstrate non linear relationship cdai sarcopenia additionally stratify analysis indicate inverse association cdai sarcopenia be more pronounced participant high educational level diagnose tumour conclusion be negative relationship cdai score prevalence sarcopenia suggest high cdai score may help manage prevent occurrence sarcopenia,"She, Yun,Zhu, Lingling,Guo, Xiangyun,Qin, Jinran,Zhou, Xiqiao,Yu, Jiangyi,Yan, Qianhua",10/05/2024,BMJ public health
10.1007/978-1-0716-3854-5_2,use dimensional culture to propagate genetically modify lung organoid,transform lung organoid have extensive application lung cancer modeling drug screening traditional two dimensional culture fail to propagate large subpopulation murine primary tumor vitro however three dimensional air liquid interface ali culture be employ to grow normal lung organoid can be use to efficiently culture cancerous lung tumor cell here detail procedure cultivate genetically modify lung organoid ali culture protocol contain two part first part describe to transduce lung epithelial cell be freshly sort lung actively grow murine organoid virus order to modify gene expression target lung cell be incubate virus h transduction then transduce cell be thoroughly wash mix stromal support cell matrigel be load transwell insert culture validate genetic modification downstream assay second part describe to isolate tumor cell grow orthotopically genetically engineer mouse model to produce organoid cell line can be use ex vivo drug discovery assay protocol tumor be isolate lung mouse finely chop wash then tumor chunk be mix matrigel ali culture finally organoid bud tumor chunk be trypsinize passage to establish organoid line together two protocol provide promising platform to study genesis progression treatment lung cancer,"Chen, Fan,Naughton, Kassandra J,Lee, Joo-Hyeon,Brainson, Christine F",15/07/2024,"Methods in molecular biology (Clifton, N.J.)"
10.1038/s42255-025-01235-8,safeguard primate skeletal muscle age desuccinylation,age induce skeletal muscle deterioration contribute sarcopenia frailty adversely impact quality life elderly however molecular mechanism primate skeletal muscle ageing remain largely unexplored here show expression be reduce aged primate skeletal muscle gender deficiency human myotube hasten cellular senescence intensifie inflammation mechanistically demonstrate be natural substrate desuccinylate lysine lead dephosphorylation suppression downstream inflammatory pathway use lentiviral vector skeletal muscle gene therapy male mouse enhance physical performance alleviate age relate muscle dysfunction study shed light molecular underpinning skeletal muscle ageing present pathway promising target combat age relate skeletal muscle degeneration,"Zhao, Qian,Jing, Ying,Jiang, Xiaoyu,Zhang, Xin,Liu, Feifei,Huang, Haoyan,Zhang, Zhihua,Wang, Haijun,Sun, Shuhui,Ma, Shuai,Zhang, Weiqi,Yu, Yang,Fu, Xiaobing,Zhao, Guoguang,Qu, Jing,Wang, Si,Liu, Guang-Hui",23/06/2024,Nature metabolism
10.1089/rej.2012.1389,protective effect ginger root extract alzheimer disease induce behavioral dysfunction rat,aim study be to assess ability traditional chinese medicinal ginger root extract gre to prevent behavioral dysfunction alzheimer disease ad rat model rat ad model be establish operation op rat be treat one time intra cerebroventricuiar injection amyloid β protein aβ continuous gavage aluminum chloride day week gre be administer intra gastrically rat day learning memory be assess rat brain section be process immunohistochemistry hematoxylin eosin nissl stain latency to show significant memory deficit be short group receive op high dose gre group receive op low moderate dose gre lg expression superoxide dismutase sod catalase cat group be up regulate compare group rat group have low level nuclear factor κb nf κb malondialdehyde mda expression rat group experiment demonstrate administration gre reverse behavioral dysfunction prevent ad like symptom rat model,"Zeng, Gao-Feng,Zhang, Zhi-Yong,Lu, Li,Xiao, De-Qiang,Zong, Shao-Hui,He, Jian-Ming",05/02/2013,Rejuvenation research
10.7861/clinmedicine.15-6-565a,tackle emerge infection clinical public health lesson west african ebola virus disease outbreak,,"Walker, Naomi F,Whitty, Christopher Jm",02/12/2015,"Clinical medicine (London, England)"
10.1038/s41593-025-01914-5,endothelial depletion disrupt core blood brain barrier pathway neurodegeneration,endothelial cell ecs help maintain blood brain barrier deteriorate many neurodegenerative disorder here show use specialized method to isolate ec microglial nucleus postmortem human cortex donor male female aged year intranuclear cellular indexing transcriptome epitope enable simultaneous profiling nuclear protein rna transcript single nucleus resolution identify disease associate subset capillary ec alzheimer disease amyotrophic lateral sclerosis frontotemporal degeneration capillary exhibit reduce nuclear β catenin β catenin downstream gene elevated tnf nf κb marker notably transcriptional change correlate loss nuclear rna bind protein also deplete neuronal nucleus disruption human mouse ec replicate alteration suggest deficiency ecs be important factor contribute blood brain barrier breakdown neurodegenerative disease,"Omar, Omar M F,Kimble, Amy L,Cheemala, Ashok,Tyburski, Jordan D,Pandey, Swati,Wu, Qian,Reese, Bo,Jellison, Evan R,Hao, Bing,Li, Yunfeng,Yan, Riqiang,Murphy, Patrick A",03/01/2024,Nature neuroscience
10.1038/s42255-025-01246-5,human gut microbial aromatic amino acid related metabolite prevent obesity intestinal immune control,obesity affect million people world gut microbiome influence body fat accumulation mechanism remain to be investigate here show association microbial aromatic amino acid metabolite serum body fat accumulation large chinese longitudinal cohort next identify hydroxyphenylacetic acid analogue effectively protect male mouse high fat diet induced obesity metabolite act intestinal mucosa to regulate immune response control lipid uptake protect obesity far demonstrate t cell b cell be not vital mediate obesity prevention innate lymphoid cell have antagonistic role together finding reveal specific microbial metabolite pivotal molecule to prohibit obesity immune control establish mechanism host modulation gut microbial metabolite,"Jiang, Zengliang,He, Liuqing,Li, Diyin,Zhuo, Laibao,Chen, Lingjun,Shi, Rui-Qi,Luo, Jianhua,Feng, Yuhui,Liang, Yuhui,Li, Danyang,Congmei, Xiao,Fu, Yuanqing,Chen, Yu-Ming,Zheng, Ju-Sheng,Tao, Liang",08/12/2023,Nature metabolism
10.1016/j.jbc.2025.108413,structural basis substrate selectivity acinetobactin biosynthetic adenylation domain base,siderophore be small molecule natural product be often produce enzyme call non ribosomal peptide synthetase nrpss many pathogenic bacteria produce to adapt low iron condition nrp bioengineere could lead production siderophore analogs potential to interrupt unique bacterial iron uptake system endow molecule antimicrobial property acinetobacter baumannii produce catecholate siderophore acinetobactin scavenge iron nutrient essential several metabolic process previous study have report synthetic analog acinetobactin disrupt iron acquisition baumannii result inhibition bacterial growth to foster long term goal use chemoenzymatic approach to produce additional analog have target adenylation domain base incorporation alternate substrate here report structure guide approach to investigate substrate selectivity base non native aryl substrate use targeted mutagenesis active site base generate mutant catalyze activation alternate substrate catalytic efficiency comparable wildtype enzyme natural substrate dihydroxybenzoic acid dhb far solve structure mutant bind non native substrate illustrate expand bind pocket support improved promiscuity base motivate to develop approach to produce analog acinetobactin include molecule could block iron uptake be readily conjugate antibiotic cargo work aim to develop structure guide approach use catecholate siderophore pathway to incorporate alternate substrate,"Ahmed, Syed Fardin,Gulick, Andrew M",29/01/2025,The Journal of biological chemistry
10.1001/jama.2025.3169,inhale sedation acute respiratory distress syndrome sesar randomize clinical trial,importance use inhaled intravenous sedation affect outcome differentially mechanically ventilate adult acute respiratory distress syndrome ard be unknown objective to determine efficacy safety inhale sevoflurane compare intravenous propofol sedation patient ard design setting participant phase randomize open label assessor blind clinical trial conduct may october day follow up adult early moderate to severe ard define ratio fraction inspire oxygen mm hg positive end expiratory pressure cm be enrol french intensive care unit intervention patient be randomize strategy inhaled sedation sevoflurane intervention group strategy intravenous sedation propofol control group to day main outcome measure primary end point be number ventilator free day day key secondary end point be day survival result patient enrol mean sd age year female be randomize sevoflurane to propofol median total duration sedation be day iqr to group number ventilator free day day be day iqr to sevoflurane group day iqr to propofol group median difference ci to standardize hazard ratio ci day survival rate be sevoflurane propofol group respectively hazard ratio ci to secondary outcome sevoflurane be associate high day mortality respectively relative risk ci to few intensive care unit free day day median iqr to iqr to median difference ci to compare propofol conclusion relevance patient moderate to severe ard inhale sedation sevoflurane result few ventilator free day day low day survival sedation propofol trial registration identifi,"Jabaudon, Matthieu,Quenot, Jean-Pierre,Badie, Julio,Audard, Jules,Jaber, Samir,Rieu, Benjamin,Varillon, Caroline,Monsel, Antoine,Thouy, François,Lorber, Julien,Cousson, Joël,Bulyez, Stéphanie,Bourenne, Jérémy,Sboui, Ghada,Lhommet, Claire,Lemiale, Virginie,Bouhemad, Belaïd,Brault, Clément,Lasocki, Sigismond,Legay, François,Lebouvier, Thomas,Durand, Arthur,Pottecher, Julien,Conia, Alexandre,Brégeaud, Delphine,Velly, Lionel,Thille, Arnaud W,Lambiotte, Fabien,L'Her, Erwan,Monchi, Mehran,Roquilly, Antoine,Berrouba, Aziz,Verdonk, Franck,Chabanne, Russell,Godet, Thomas,Garnier, Marc,Blondonnet, Raiko,Vernhes, Jérémy,Sapin, Vincent,Borao, Lucile,Futier, Emmanuel,Pereira, Bruno,Constantin, Jean-Michel",18/03/2025,JAMA
10.1016/j.lanepe.2024.101183,integrate genomic medicine national healthcare system france,integrate genomic medicine healthcare system be health policy challenge requires continuously transfer scientific advance clinic ensure equal access patient france be one first country to integrate genome sequencing clinical practice nationwide level ambition to provide more accurate diagnostic personalized treatment french government have invest m french genomic medicine initiative have so far focused patient rare disease rd cancer genetic predisposition cgp cancer have address numerous challenge to set operational organizational framework december result be return prescriber rd cgp patient median delivery time day diagnostic yield cancer patient median delivery time day future priority encompass ensure economic sustainability strengthen link research empower patient practitioner foster collaboration european partner funding december m have be invest french government,,09/09/2024,The Lancet regional health. Europe
10.1186/s12943-025-02285-y,nnmt promote acquire egfr tki resistance form lactate mediate double positive feedback loop non small cell lung cancer,background epidermal growth factor receptor tyrosine kinase inhibitor egfr tkis be remarkably effective treat egfr mutant non small cell lung cancer nsclc however patient inevitably develop acquire drug resistance result recurrence metastasis be important to identify novel effective therapeutic target to reverse acquire tki resistance result bioinformatics analysis reveal nicotinamide n methyltransferase nnmt be upregulate egfr tki resistant cell tissue mediate transcriptional activation high nnmt level be correlate poor prognosis egfr mutate nsclc patient could promote resistance egfr tkis vitro vivo mechanistically nnmt catalyze conversion nicotinamide methyl nicotinamide deplete s adenosyl methionine methyl group donor lead reduction trimethylation trimethylation subsequent epigenetic activation addition activation increase lactic acid level far promote nnmt expression mediate histone lactylation promoter thus nnmt mediate formation double positive feedback loop lactate nnmt nnmt lactate nnmt moreover combination small molecule inhibitor nnmt nnmti osimertinib exhibit promise potential treatment tki resistance nsclc osimertinib resistant xenograft model conclusion combine contribution two positive feedback loop promote egfr tki resistance nsclc finding provide new insight role histone methylation histone lactylation tki resistance pivotal nnmt mediate positive feedback loop may serve powerful therapeutic target overcome egfr tki resistance nsclc,"Dai, Jiali,Lu, Xiyi,Zhang, Chang,Qu, Tianyu,Li, Wei,Su, Jun,Guo, Renhua,Yin, Dandan,Wu, Pingping,Han, Liang,Zhang, Erbao",09/10/2024,Molecular cancer
,genome virulence determinant high virulence community acquire mrsa,background new type meticillin resistant staphylococcus aureus mrsa designate community acquire mrsa be become increasingly noticeable community strain cause fatal infection otherwise healthy individual contrast hospital acquire mrsa community acquire mrsa be more susceptible non b lactam antibiotic investigate high virulence potential certain strain bacterium method ascertain whole genome sequence strain community acquire mrsa shotgun cloning sequence cause fatal septicaemia septic arthritis month old girl north dakota usa genome strain be compare hospital acquire mrsa strain include finding meticillin resistance gene meca be carry novel allelic form type iva staphylococcal cassette chromosome mec sccmec contrast type ii type iva sccmec do not carry multiple antibiotic resistance gene report type ii sccmec contrast additional virulence gene be record genome two virulence gene be note four seven genomic island interpretation carry range virulence resistance gene be distinct display chromosome extant s aureus strain most gene be carry specific allelic form genomic island chromosome combination allelic form genomic island be genetic basis determine pathogenicity medically important phenotype s aureus include community acquire mrsa strain,"Baba, Tadashi,Takeuchi, Fumihiko,Kuroda, Makoto,Yuzawa, Harumi,Aoki, Ken-ichi,Oguchi, Akio,Nagai, Yoshimi,Iwama, Natsuko,Asano, Kazuyuki,Naimi, Timothy,Kuroda, Hiroko,Cui, Longzhu,Yamamoto, Kenji,Hiramatsu, Keiichi",05/06/2002,"Lancet (London, England)"
10.1126/science.adm9805,direct sensing dietary linoleic acid signal,diet influence macronutrient availability cell mechanism sense dietary glucose amino acid be well characterize less be know sense lipid define nutrient signal mechanism involve fatty acid bind protein mechanistic target rapamycin complex be activate essential polyunsaturate fatty acid pufa linoleic acid la directly bind regulatory associate protein mtor raptor to enhance formation functional substrate binding ultimately converge increase mtor signal proliferation amount protein be increase tumor serum triple negative compare receptor positive breast cancer patient highlight potential role biomarker mediate cellular response intake disease subtype,"Koundouros, Nikos,Nagiec, Michal J,Bullen, Nayah,Noch, Evan K,Burgos-Barragan, Guillermo,Li, Zhongchi,He, Long,Cho, Sungyun,Parang, Bobak,Leone, Dominique,Andreopoulou, Eleni,Blenis, John",14/03/2025,"Science (New York, N.Y.)"
10.1161/CIRCULATIONAHA.124.070286,mediate mitochondrial superoxide promote cardiomyocyte apoptosis impairs cardiac function suppress,background myocardial infarction mi elicits mitochondria reactive oxygen species ros production cardiomyocyte cm apoptosis nuclear factor erythroid relate factor have establish role regulate redox signal tissue homeostasis here aim to evaluate role mechanism injury induce pathological cardiac remodeling method global ko cm specific cm knockout mouse be subject mi ischemia reperfusion injury follow functional histopathological analysis primary neonatal mouse rat ventricular myocyte cms derive human induce pluripotent stem cell be use to evaluate impact cm apoptosis mitochondrial ro production chromatin immunoprecipitation sequence immunoprecipitation mass spectrometry analysis be use to uncover potential target mitoparaquat administration cm specific adeno associate virus vector be use to far confirm in vivo relevance identify signal pathway result be express mainly cms healthy human heart increase level be observe cms border zone infarcte human heart murine cardiac tissue mi global cm specific knockout significantly decrease injury induce mitochondrial ro production cm apoptosis pathological cardiac remodeling consequently improve cardiac function addition cardiac specific overexpression reverse ameliorative cardiac phenotype observe ko mouse functional study show promote neonatal mouse ventricular myocyte neonatal rat ventricular myocyte cms derive human induce pluripotent stem cell apoptosis increase mitochondrial ro production critically augment mitochondrial ros mitoparaquat blunt beneficial effect deletion cardiac function remodeling mechanistically redox regulator pair like homeodomain transcription factor be identify one main target gene specifically bind promoter increase dna methylation recruit heterogeneous nuclear ribonucleoprotein k dna methyltransferase complex thereby inhibit expression cm specific knockdown blunt beneficial effect deletion cardiac function remodeling cardiac specific overexpression attenuate mi induce mitochondrial ros production cm apoptosis as well preserve cardiac function mi conclusion promote injury induce cm apoptosis deteriorate cardiac function increase mitochondrial ro production suppress expression target mitochondrial ros signal axis may therefore represent novel therapeutic approach mi treatment,"Chen, Qishan,Zheng, Ancheng,Xu, Xiaolei,Shi, Zhenning,Yang, Mei,Sun, Shasha,Wang, Leyu,Wang, Yumeng,Zhao, Haige,Xiao, Qingzhong,Zhang, Li",18/03/2025,Circulation
10.1038/s41467-025-57924-1,astrocytic pleiotrophin deficiency prefrontal cortex contribute stress induce depressive like response male mouse,astrocyte be closely link depression prefrontal cortex pfc be important brain region involve major depressive disorder mdd however underlying mechanism astrocyte pfc contribute mdd remain unclear use single nucleus rna sequence analysis show significant reduction astrocyte attenuate pleiotrophin protein tyrosine phosphatase receptor type ptn signal astrocyte excitatory neuron communication pfc male mdd patient find reduce astrocyte ptn dorsomedial pfc male mouse depression induce chronic restraint social defeat stress knockdown astrocytic ptn induce depression relate response be reverse exogenous ptn supplementation overexpression astrocytic ptn antidepressant effect exert astrocytic ptn require interaction excitatory neuron ptn activate akt signal pathway to regulate depression relate response finding indicate ptn akt pathway may be potential therapeutic target mdd,"Chi, Dongmei,Zhang, Kun,Zhang, Jianxing,He, Zhaoli,Zhou, Hongxia,Huang, Wan,Liu, Yang,Huang, Jingxiu,Zeng, Weian,Bai, Xiaohui,Ou, Chaopeng,Ouyang, Handong",01/11/2024,Nature communications
10.5546/aap.2020.eng.433,scientific paper management do article get publish medical journal,life cycle manuscript write publication be not usually teach health care professional training article review process go author decision to communicate eventual publication detail practical aspect to be consider step responsibility different role involve be specify author editor reviewer international guideline support writing medical scientific paper be also describe,"Serra, María E",31/07/2020,Archivos argentinos de pediatria
10.1053/j.gastro.2025.01.252,mucosal macrophage govern intestinal regeneration response injury,background aim cancer patient treat radiotherapy abdominal pelvic cavity develop radiation induce enteritis condition impair quality life radiation injury deplete proliferative intestinal stem cell isc response epithelium activate regenerative program facilitate healing intestine however mechanism induce activation intestinal regenerative program be poorly characterize method study induce radiation induce enteritis mouse abdominal irradiation mimic clinical scenario imaging flow cytometric analysis investigate recruitment macrophage small intestine injury healing additionally develop co culture system mouse human intestinal organoid macrophage to explore crosstalk cell then combine vivo ablation macrophage fluorescent lineage tracing imaging bulk rna sequence rna seq single cell rna sequence scrna seq human intestinal organoid cell trajectory analysis study cellular molecular level macrophage induction intestinal regeneration result finding reveal macrophage be recruit intestinal stem cell compartment radiation injury promote fetal like reprogramming proliferation epithelial cell drive regeneration process contrast macrophage ablation lead compromise regeneration moreover scrna seq analysis identify key secrete molecule pivotal player regulate process additionally characterization human macrophage organoid co culture cell trajectory inference confirm conservation macrophage role trigger regenerative program primary human cell conclusion study identify macrophage essential contributor intestinal regeneration innate immune response target macrophage therapeutically may hold promise enhance regeneration improve quality life cancer survivor,"Moraitis, Ilias,Taelman, Jasin,Arozamena, Borja,Mularoni, Loris,Wienskowska, Olga,Sanjuan Garriga, Xavier,Arregui, Laura,Stefanovic, Milica,Modolell Farré, Ignasi,Guedea, Ferran,Diaz, Mònica,Guiu, Jordi",14/05/2024,Gastroenterology
,aspartate alanine aminotransferase fasciola hepatica,activity distribution aspartate aminotransferase ec alanine aminotransferase ec adult fasciola hepatica have be study fasciola hepatica be fractionate differential centrifugation nuclear mitochondrial cytosolic fraction activity got gpt be measure method reitman frankel isozyme pattern enzyme be also examine deae cellulose column chromatography result obtain be follow activity aspartate alanine aminotransferase be about unit unit g fasciola hepatica respectively activity enzyme be relatively low compare mammalian tissue distribution aspartate aminotransferase subcellular organelle show activity be cytosolic mitochondrial be nuclear fraction about total alanine aminotransferase activity be find mitochondrial fraction about percent cytosolic fraction aspartate aminotransferase cytosolic fraction be separate two type isozyme alanine aminotransferase cytosolic fraction give only one active peak deae cellulose column chromatography,"Park, Sun Hyo,Kwon, Nyon Soo,Lee, Hi Sung,Song, Chul Yong",01/06/1983,Kisaengch'unghak chapchi. The Korean journal of parasitology
10.1186/s40359-023-01477-9,development fear earthquake scale validity reliability study türkiye earthquake,background türkiye experience significant earthquake disaster profoundly impact province endure consequence earthquake daily life trigger widespread fear anxiety society lead scholarly investigation field objective primary objective study be to create evaluate psychometric property fear earthquake scale fes modify adaptation fear scale s tailor to measure earthquake relate experience türkiye method total turkish adult participant man woman mean age year complete fes brief psychological resilience scale bprs psychometric analysis include confirmatory factor analysis as well evaluation alternative factor structure internal consistency convergent validity criterion validity respect resilience result finding indicate turkish version fear earthquake scale have strong psychometric property term validity reliability assess various factor structure be observe two factor model represent emotional somatic response to fear exhibit well fit value cronbach alpha coefficient be calculate overall fes emotional subscale somatic subscale indicate high internal consistency additionally negative correlation resilience fes support criterion validity scale multi group confirmatory factor analysis prove measurement invariance hold gender experience earthquake not group furthermore result study reveal woman individual prior earthquake experience report high level fear earthquake conclusion fes emerge reliable valid tool assess earthquake relate fear turkish population,"Sarı, Tuğba,Taşdelen-Karçkay, Arzu,Tarcan, Şule",06/09/2023,BMC psychology
10.1126/science.ado4188,metabolic signal ceramide receptor inhibit adipocyte thermogenesis,ceramide play central role human health disease role systemic signal molecule remain poorly understand work identify membrane receptor specifically bind long chain ceramide brown beige adipocyte ceramide bind inhibit thermogenesis amp signal pathway effect be reverse absence present three cryo electron microscopy structure complex trimer bind to ceramide hydrophobic tail be deeply embed orthosteric ligand pocket have limited amount plasticity modification ceramide bind motif closely relate receptor such convert inactive active ceramide receptor finding provide structural basis adipocyte thermogenesis mediate,"Lin, Hui,Ma, Chuanshun,Cai, Kui,Guo, Lulu,Wang, Xuemei,Lv, Lin,Zhang, Chao,Lin, Jun,Zhang, Daolai,Ye, Chuan,Wang, Tengwei,Huang, Shenming,Han, Jifei,Zhang, Zihao,Gao, Junyan,Zhang, Mingxiang,Pu, Zhao,Li, Fengyang,Guo, Yongyuan,Zhou, Xiaojun,Qin, Chengxue,Yi, Fan,Yu, Xiao,Kong, Wei,Jiang, Changtao,Sun, Jin-Peng",14/03/2025,"Science (New York, N.Y.)"
10.1038/s41467-025-57906-3,ubiquinol mediate suppression mitochondria associate ferroptosis be targetable function lactate dehydrogenase b cancer,lactate dehydrogenase b ldhb fuel oxidative cancer cell metabolism convert lactate to pyruvate study uncover ldhb role counter mitochondria associate ferroptosis independently lactate function carbon source ldhb silence alter mitochondrial morphology cause lipid peroxidation reduce cancer cell viability be potentiate ferroptosis inducer ldha ldhb act parallel glutathione peroxidase dihydroorotate dehydrogenase dhodh to suppress mitochondria associate ferroptosis decrease ubiquinone coenzyme q coq ubiquinol ratio indeed supplementation mitochondria target analogue suppress mitochondrial lipid peroxidation cell death combine ldhb silence treatment consistent presence ldhb cell fraction contain mitochondrial inner membrane address underlie molecular mechanism in vitro nadh consumption assay purify human ldhb reveal ldhb catalyze transfer reduce equivalent nadh coq efficiency reaction increase addition lactate finally radiation therapy induce mitochondrial lipid peroxidation reduce tumor growth be far enhance combine ldhb silence thus ldhb mediate lactate oxidation drive coq dependent suppression mitochondria associate ferroptosis promising target combination therapy,"Deng, Haibin,Zhao, Liang,Ge, Huixiang,Gao, Yanyun,Fu, Yan,Lin, Yantang,Masoodi, Mojgan,Losmanova, Tereza,Medová, Michaela,Ott, Julien,Su, Min,Wang, Wenxiang,Peng, Ren-Wang,Dorn, Patrick,Marti, Thomas Michael",31/07/2024,Nature communications
10.1182/blood.2024026622,genetic epigenetic mechanism loss anti car t cell therapy multiple myeloma,g protein couple receptor class c group member d have emerge novel target chimeric antigen receptor car t cell therapy demonstrate promise efficacy multiple myeloma mm however disease relapse be still common mechanism resistance remain poorly understand study conduct whole genome sequencing wgs whole genome bisulfite sequence wgbs mm sample patient relapse car t cell therapy patient have loss present mixed expression genetic alteration be identify three case one have homozygous deletion gene have biallelic loss regulatory region third have homozygous deletion sequential anti bcma anti car t cell therapy genetic change be detect locus remain case however multiple hypermethylation site be present transcriptional regulatory element gene post treatment mm sample mm cell line expression be inversely correlate methylation level regulatory region furthermore azacitidine treatment induce mrna protein expression hypermethylate mm cell line finding highlight biallelic genetic inactivation hypermethylation drive epigenetic silencing be key mechanism contribute loss treatment resistance,"Ma, Sha,Xia, Jieyun,Zhang, Miao,Li, Wenyu,Xiao, Meng,Sha, Yuqian,Wang, Wenya,Zhou, Jianteng,Wang, Ying,Qi, Kunming,Fu, Chunling,Sun, Zengtian,Zhou, Dian,Sun, Qian,Qiu, Tingting,Yan, Zhiling,Zhu, Feng,Chen, Wei,Cheng, Hai,Sang, Wei,Cao, Jiang,Li, Depeng,Li, Zhenyu Zhen,Fulciniti, Mariateresa,Yao, Yao,Xu, Kailin,Niu, Mingshan",14/02/2025,Blood
10.1021/ja503015f,thieno pyrrole fuse diaza s indacene fullerene dyad utilization near infrared sensitizer ultrafast charge separation donor acceptor system,donor acceptor dyad feature near ir sensitizer derive thieno pyrrole fuse bodipy abbreviate sbdpir fullerene have be newly synthesize characterize occurrence ultrafast photoinduce electron transfer pet lead formation charge separate state dyad capable harvesting light energy near ir region be establish femtosecond transient absorption study,"Bandi, Venugopal,Das, Sushanta K,Awuah, Samuel G,You, Youngjae,D'Souza, Francis",14/05/2014,Journal of the American Chemical Society
10.1146/annurev-virology-092818-015907,cancer human lifelong search contribution infectious agent autobiographic note,review briefly cover period early life experience world war ii school education period medical student bonn hamburg düsseldorf mainly emphasize be scientific career finish medical internship period postdoc institute microbiology düsseldorf virus laboratory child hospital philadelphia senior research fellow institute virology würzburg germany subsequent appointment chairman newly establish institute virology university erlangen nürnberg similar position university freiburg then year scientific director deutsche krebsforschungszentrum heidelberg be discuss cover scientific development period emeritus period be particularly exciting lead discovery autonomously replicate plasmid derive specific bacteria link common human cancer colon breast prostate,"Zur Hausen, Harald",01/10/2019,Annual review of virology
10.1001/jama.2025.3046,optimal vasopressin initiation septic shock oviss reinforcement learning study,importance norepinephrine be first line vasopressor patient septic shock second agent such vasopressin should be add be unknown objective to derive validate reinforcement learning model to determine optimal initiation rule vasopressin adult critically ill patient receive norepinephrine septic shock design setting participant reinforcement learning be use to generate optimal rule vasopressin initiation to improve short term hospital outcome use electronic health record datum patient meet shock criterion california hospital rule be evaluate patient california dataset external dataset comprise patient us hospital use weighted importance sampling pool logistic regression inverse probability weighting exposure clinical laboratory treatment variable group hourly hour electronic health record main outcome measure primary outcome be hospital mortality result derivation cohort include man have median iqr age year sequential organ failure assessment sofa score shock onset range high score associate great mortality validation cohort be male median iqr age year sofa score validation datum model suggest vasopressin initiation more patient early relative to shock onset median iqr hour low norepinephrine dose median iqr kg min compare clinician action rule be associate large expect reward validation datum compare clinician action weight importance sampling difference ci adjusted odd hospital mortality be low vasopressin initiation be similar rule compare different odd ratio ci finding consistent external validation set conclusion relevance adult patient septic shock receive norepinephrine use vasopressin be variable reinforcement learning model develop validate several observational dataset recommend more frequent early use vasopressin average care pattern be associate reduced mortality,"Kalimouttou, Alexandre,Kennedy, Jason N,Feng, Jean,Singh, Harvineet,Saria, Suchi,Angus, Derek C,Seymour, Christopher W,Pirracchio, Romain",18/03/2025,JAMA
10.1091/mbc.E12-02-0159,mboc favorite ganglioside live cell membrane form cluster susceptible cholesterol depletion chilling,,"Kusumi, Akihiro",16/10/2012,Molecular biology of the cell
10.1186/s12883-025-04122-7,cognition mental health quality life patient chronic episodic migraine interictal period,introduction migraine be highly prevalent disable condition not only painful symptom also significant impact mental health cognitive functioning lead considerable deterioration quality life study aim to evaluate cognitive profile mental health quality life patient chronic episodic migraine interictal period to explore relationship sociodemographic clinical variable method observational descriptive cross sectional analytical study include patient diagnose chronic episodic migraine be enrol health program headache patient cognitive function anxiety depression symptom quality life interictal period be assess descriptive analysis be conduct association be evaluate configure primary type migraine alternative event cognitive impairment depression anxiety poor quality life result mean age participant be year sd be woman belong middle low socioeconomic strata patient be diagnose chronic migraine remain have episodic migraine use one more cognition altering medication be observe patient chronic migraine episodic migraine p anxiety be more prevalent patient episodic migraine depression be more common chronic migraine female gender middle socioeconomic status long disease duration be significantly associate chronic migraine patient complete mini mental state examination have cognitive impairment decrease long migraine duration well social interaction memory selective attention be most affected cognitive domain group significant association be find other variable adjust confounder conclusion chronic migraine significantly impact mental health cognition quality life depression cognitive impairment be prevalent social interaction long disease duration may protect cognitive decline highlight need multidisciplinary personalized intervention address neurological psychosocial challenge,"López-Medina, Diana Carolina,Arboleda-Ramírez, Alejandra,Ríos-Díaz, Sara,Zambrano-Cruz, Renato,Arboleda-Jaramillo, Andrés,Betancur-Henao, Cristian,Henao-Pérez, Marcela",21/10/2024,BMC neurology
10.1182/blood.2024025440,fc decoy secrete engineer t cell improve car t cell therapy b cell acute lymphoblastic leukemia,relapse refractory r r b cell acute lymphoblastic leukemia b remain challenging disease dismal prognosis revolutionary impact direct chimeric antigen receptor cell therapy patient relapse year leukemia cell intrinsic factor favor immune escape poor car t cell persistence contribute significantly clinical failure moreover expression immune checkpoint receptor icrs ligand complex bone marrow bm microenvironment may contribute to leukemia progression therapy resistance here comprehensively characterize expression icr ligand leukemic blast t cell mesenchymal stromal cell msc b bm sample diagnosis relapse compare age match healthy bm control finding reveal significant upregulated expression t cell ligand blast msc disease progression expression level b blast t cell negatively correlate clinical outcome furthermore demonstrate impairs t cell homeostasis cytotoxicity notably engineer fc decoy receptor deliver primary t cell co administer t cell bicistronic one fc construct improve anti leukemia efficacy persistence t cell b patient derive xenograft model mechanistically fc t cell treatment promote vivo expansion transduce bystander effector memory t cell determine spectral flow cytometry collectively potent persistent fc decoy armored t cell offer promising therapeutic strategy r r b patient,"Falgàs, Aïda,Lázaro-Gorines, Rodrigo,Zanetti, Samanta Romina,Rubio-Pérez, Laura,Martinez-Moreno, Alba,Vinyoles, Meritxell,Guerrero-Murillo, Mercedes,Fernandez-Fuentes, Narcís,Roca-Ho, Heleia,Tirado, Néstor,Panisello, Carla,Velasco-Hernandez, Talía,Mayado, Andrea,Pérez-Pons, Alba,Genesca, Eulalia,Ribera, Josep-Maria,Ribera, Jordi,Camos, Mireia,Ramírez-Orellana, Manuel,Anguita, Eduardo,Ballerini, Paola,Fuster, José Luis,Juan, Manel,González-Navarro, Europa Azucena Azucena,Locatelli, Franco,Stam, Ronald W W,Querol, Sergio,Velasco, Pablo,Ortiz-Maldonado, Valentín,Martínez-Cibrian, Nuria,Delgado, Julio,Orfao, Alberto,Alvarez-Vallina, Luis,Bueno, Clara,Menendez, Pablo",14/01/2025,Blood
10.1038/s41392-025-02170-6,enhancer transcription profiling reveal enhancer rna drive ferroptosis new therapeutic opportunity prostate cancer,enhancer rnas ernas subclass non coding rna transcribe enhancer region have emerge critical regulator gene expression however functional role prostate cancer remain largely unexplored study perform integrate chromatin accessibility transcriptomic analysis use atac seq rna seq twenty pair prostate cancer match benign tissue incorporate chromatin immunoprecipitation sequence datum identify subset differentially express erna significantly associate gene involve prostate development oncogenic signal pathway lactotransferrin erna ltfe be markedly downregulate prostate cancer tissue functional analysis reveal tumor suppressive role mechanistically ltfe promote transcription target gene lactotransferrin ltf interact heterogeneous nuclear ribonucleoprotein f hnrnpf facilitate enhancer promoter chromatin interaction furthermore demonstrate ltfe ltf axis facilitate ferroptosis modulate iron transport notably androgen receptor ar signal disrupt ltfe associate chromatin looping lead to ferroptosis resistance therapeutically administration ar inhibitor enzalutamide ferroptosis inducer significantly suppress tumor growth offer promising strategy castration resistant prostate cancer collectively study provide novel insight mechanistic role ernas prostate cancer highlight ltfe ltf axis critical epigenetic regulator potential therapeutic target improved treatment outcome,"Ma, Sheng,Wang, Zixian,Xiong, Zezhong,Ge, Yue,Xu, Meng-Yao,Zhang, Junbiao,Peng, Yuzheng,Zhang, Qin,Sun, Jiaxue,Xi, Zirui,Peng, Hao,Xu, Wenjie,Wang, Yanan,Li, Le,Zhang, Chunyu,Chao, Zheng,Wang, Baojun,Gao, Xu,Zhang, Xu,Wei, Gong-Hong,Wang, Zhihua",24/10/2024,Signal transduction and targeted therapy
10.1016/S0140-6736(25)00263-6,multifaceted intervention to improve diagnosis early management hospitalise patient suspect acute brain infection brazil india malawi international multicentre intervention study,background brain infection pose substantial challenge diagnosis management carry high mortality morbidity especially low income middle income country aim to improve diagnosis early management patient admit hospital adult age year old child age day suspect acute brain infection hospital brazil india malawi method hospital stakeholder policy maker patient public representative co design multifaceted clinical laboratory intervention inform evaluation routine practice intervention tailor setting include diagnostic management algorithm lumbar puncture pack testing panel staff training use multivariable logistic regression interrupt time series analysis to compare coprimary outcome percentage patient achieve syndromic diagnosis percentage achieve microbiological diagnosis before intervention study be register be complete finding jan nov screen patient enrol total patient hospital site connect four study centre brazil india malawi be recruit intervention be recruit intervention patient have assessment primary outcome patient recruit pre intervention recruit post intervention median age centre be year iqr be adult age year old child age day year patient be male be female datum race ethnicity be not record patient receive syndromic diagnosis intervention rise intervention adjust odd ratio aor ci microbiological diagnosis be make patient pre intervention increase patient post intervention aor ci interrupt time series analysis confirm increase exceed modest underlying trend improvement time percentage receive lumbar puncture time to appropriate therapy functional outcome also improve interpretation diagnosis management patient suspect acute brain infection improve follow introduction simple intervention package diverse range hospital three continent intervention be now be implement other setting part meningitis roadmap encephalitis control initiative funding uk national institute health care research,"Singh, Bhagteshwar,Lipunga, Gareth D,Thangavelu, Premkumar,Dhar, Shalley,Ferreira Cronemberger, Lorena,Abhilash, Kundavaram Paul Prabhakar,Abraham, Asha Mary,de Brito, Carlos Alexandre Antunes,Brito Ferreira, Maria Lúcia,Chandrashekar, Nagarathna,Duarte, Rui,Fajardo Modol, Anna,Ghale, Ben Chirag,Kang, Gagandeep,Gowda, Vykuntaraju K,Kuriakose, Kevin,Lant, Suzannah,Mallewa, Macpherson,Mbale, Emmie,Moore, Shona C,Mwangalika, Gloria,Kamath, Prasanna B T,Navvuga, Patricia,Nyondo-Mipando, Alinane Linda,Phiri, Tamara J,Pimentel Lopes de Melo, Camila,Pradeep, B S,Rawlinson, Rebecca,Sheha, Irene,Thomas, Priya Treesa,Newton, Charles R,de Sequeira, Patricia Carvalho,Sejvar, James J,Dua, Tarun,Turtle, Lance,Verghese, Valsan Philip,Arraes, Luciano Wagner de Melo Santiago,Desmond, Nicola,Easton, Ava,Jones, Jessica Anne,Lilford, Richard J,Netravathi, M,McGill, Fiona,Michael, Benedict D,Mwapasa, Victor,Griffiths, Michael J,Parry, Christopher M,Ravi, Vasanthapuram,Burnside, Girvan,Cornick, Jennifer,França, Rafael Freitas de Oliveira,Desai, Anita S,Rupali, Priscilla,Solomon, Tom",18/06/2024,"Lancet (London, England)"
,study pseudorabie infectious bulbar paralysis mad itch histology disease note symptomatology,histology pseudorabie differ materially various animal specie rabbit subcutaneous intradermal intramuscular inoculation lead local inflammation necrosis infection ascend peripheral nerve possibly interstitially axis cylinder correspond spinal ganglia segment spinal cord primary degeneration nerve glial cell take place nerve cell change be probably responsible cardinal symptom disease itching death ensue soon virus reach medulla visible change have be produce here intracerebral inoculation be follow characteristic lesion meninge subpial glial cell superficially place nerve cell morbid change lung be not necessarily relate presence virus specific lesion may be present intranuclear inclusion bear resemblance herpetic encephalitis yellow fever etc occur cell derive embryonic layer disease guinea pig resemble closely rabbit be modify only slightly great resistance animal monkey intracerebral inoculation widespread degeneration necrosis cortical nerve cell be accompany appearance specific nuclear alteration nerve glial cell not cell mesodermal origin lesion be find other viscera spontaneous disease cow lesion approximate more closely monkey rabbit pig vascular interstitial lesion predominate nerve cell degeneration be relatively slight typical inclusion be not observe difference probably explain benign course malady follow subcutaneous inoculation animal lymphatic system too participate reaction virus,"Hurst, E W",30/10/2009,The Journal of experimental medicine
10.1038/s41586-025-08873-8,structure mechanism human mitochondrial pyruvate carrier,mitochondrial pyruvate carrier mpc be mitochondrial inner membrane protein complex essential uptake pyruvate matrix primary carbon source tricarboxylic acid tca here report six cryo em structure human mpc three different state three structure obtain different condition intermembrane space state high resolution å structure pyruvate treat mpc occluded state å two structure matrix face state bind inhibitor inhibitory nanobody matrix side å å respectively mpc be assign heterodimer consisting transmembrane domain adopt pseudo symmetry approximate rigid body movement occur ims open state occluded state structural change primarily matrix side facilitate transition occluded state matrix face state reveal alternate access mechanism pyruvate transport bind structure inhibitor fit well interact extensively pocket open matrix side finding provide important insight mechanism underlie mpc mediate substrate transport recognition inhibition will facilitate future drug development target mpc,"Liang, Jiaming,Shi, Junhui,Song, Ailong,Lu, Meihua,Zhang, Kairan,Xu, Meng,Huang, Gaoxingyu,Lu, Peilong,Wu, Xudong,Ma, Dan",10/04/2024,Nature
10.1161/CIRCULATIONAHA.124.070243,novel hide protein encode inhibit vascular remodeling,background phenotypic switching vascular smooth muscle cell vsmcs lead neointimal hyperplasia be fundamental cause vascular remodeling disease such atherosclerosis hypertension novel hide protein encode circular rna play crucial role disease progression involvement vascular remodeling disease have not be comprehensively study study identify novel protein derive circular rna vsmcs demonstrate potential role regulate vascular remodeling method cell proliferation assay be perform to investigate effect vsmc proliferation technique such vector construction immunoprecipitation mass spectrometry dual luciferase reporter gene be use to confirm encode novel protein interaction hur human antigen r be validate technique such coimmunoprecipitation mass spectrometry proximity ligation assay experiment include rna sequence rna immunoprecipitation interaction hur c fos c fos proto oncogene mrna be reveal role neointimal hyperplasia be assess carotid artery ligation model male mouse result overexpression inhibit vsmc phenotypic switching novel protein encode interact hur to reduce c fos mrna stability thereby suppress vsmc proliferation ultimately inhibit neointimal hyperplasia male mouse conclusion uncover novel hide protein derive call inhibit vascular remodeling may serve potential therapeutic target vascular remodeling disease,"Wang, Si-Fan,Yang, Li-Yun,Zhao, An-Qi,Wang, Zhao-Yi,Wang, Sen,Gong, Miao,Zheng, Ming-Qi,Liu, Gang,Yang, Shu-Yan,Lin, Jia-Jie,Sun, Shao-Guang",18/03/2025,Circulation
10.1038/s43018-025-00927-0,design sensitive monospecific bispecific synthetic chimeric t cell receptor cancer therapy,adoptive transfer t cell express chimeric antigen receptor car be effective b cell malignancy however persistence cancer cell low level complete absence target antigen thereby evade detection car t cell lead relapse evasion mechanism highlight need receptor enhanced sensitivity multispecificity introduce synthetic chimeric t cell receptor chtcr confer superior antigen sensitivity compare car previous hybrid tcr design be readily adapt bispecific targeting chtcrs replicate structure natural tcrs form classical immune synapsis demonstrate tcr like signaling t cell express bispecific chtcr bi chtcrs be more effective bispecific car t cell eradicate tumor heterogeneous antigen expression vivo female mouse bi chtcr architecture be resilient can be design to target pair b cell multiple myeloma antigen finding provide widely applicable strategy to combat tumor heterogeneity prevent relapse,"Simon, Sylvain,Bugos, Grace,Prins, Rachel,Rajan, Anusha,Palani, Arulmozhi,Heyer, Kersten,Stevens, Andrew,Zeng, Longhui,Thompson, Kirsten A,Atilla, Pinar A,Price, Jason P,Kluesner, Mitchell G,Jaeger-Ruckstuhl, Carla A,Shabaneh, Tamer B,Olson, James M,Su, Xiaolei,Riddell, Stanley R",02/10/2024,Nature cancer
10.1016/j.immuni.2025.02.017,anti vascular endothelial growth factor treatment potentiate immune checkpoint blockade dependent reprogramming tme,anti vascular endothelial growth factor vegf treatment have show clinical activity together immune checkpoint blockade icb exact mechanism be not know show vegf blockade combination anti cytotoxic t lymphocyte associate protein anti programmed death ligand pd cholangiocarcinoma cca potentiate multimodal mechanism dependent b cell activate factor baff lead proinflammatory b cell response lead interleukin dependent expansion rewiring t regulatory cell treg anti tumor t fragile state translate approach clinic observe immunological change characterize treg cell expansion rewire fragile unstable state explore effect vegf receptor signal treg cell transcriptional programming establish mouse model ablate expression treg cell study reveal immunological interplay result target vegf together pd blockade,"Benmebarek, Mohamed-Reda,Oguz, Cihan,Seifert, Matthias,Ruf, Benjamin,Myojin, Yuta,Bauer, Kylynda C,Huang, Patrick,Ma, Chi,Villamor-Payà, Marina,Rodriguez-Matos, Francisco,Soliman, Marlaine,Trehan, Rajiv,Monge, Cecilia,Xie, Changqing,Kleiner, David E,Wood, Bradford J,Levy, Elliot B,Budhu, Anuradha,Kedei, Noemi,Mayer, Christian T,Wang, Xin Wei,Lack, Justin,Telford, William,Korangy, Firouzeh,Greten, Tim F",08/05/2024,Immunity
10.1002/14651858.CD016133,statin prevent preeclampsia,be protocol cochrane review intervention objective be follow to evaluate relative benefit harm statin preeclampsia prevention pregnant woman,"Paraskevas, Themistoklis,Gakis, Georgios,Papapanou, Michail,Sergentanis, Theodoros N,Sotiriadis, Alexandros,Siristatidis, Charalampos S",18/03/2025,The Cochrane database of systematic reviews
10.1186/s13024-025-00822-3,alpha synuclein co pathology be associate accelerated amyloid drive tau accumulation alzheimer disease,background aggregate alpha synuclein αsyn be hallmark pathology parkinson disease also one most common co pathology alzheimer disease ad preclinical study suggest αsyn can exacerbate tau aggregation imply αsyn co pathology may specifically contribute aβ induce aggregation tau drive neurodegeneration cognitive decline ad to investigate combine novel csf base seed amplification assay saa to determine αsyn positivity tau pet neuroimaging large cohort range cognitively normal individual dementia examine αsyn co pathology accelerate aβ drive tau accumulation cognitive decline method aβ positive aβ negative subject employ amyloid pet flortaucipir tau pet csf base αsyn seed amplification assay saa to detect vivo αsyn aggregation csf p measure be available subject to assess early tau abnormality subset aβ positive aβ negative subject undergo longitudinal tau pet approximately year use linear regression model analyze αsyn saa positivity be link to strong aβ relate increase baseline fluid pet tau biomarker fast aβ drive tau pet increase more rapid cognitive decline result αsyn saa positivity be more common aβ subject increase clinical severity p most importantly αsyn positivity be also associate great amyloid associate csf p increase p high tau pet level ad typical brain region p longitudinal analysis confirm far αsyn positivity be associate fast amyloid relate tau accumulation p accelerate amyloid relate cognitive decline potentially drive drive strong tau pathology conclusion finding suggest αsyn co pathology detectable csf base saas be more prevalent advanced ad contribute development aggregated tau pathology thereby drive fast cognitive decline highlight syn co pathology may specifically accelerate amyloid drive tau pathophysiology ad underscore need to consider αsyn ad research treatment strategy,"Franzmeier, Nicolai,Roemer-Cassiano, Sebastian Niclas,Bernhardt, Alexander Maximilian,Dehsarvi, Amir,Dewenter, Anna,Steward, Anna,Biel, Davina,Frontzkowski, Lukas,Zhu, Zeyu,Gnörich, Johannes,Pescoller, Julia,Wagner, Fabian,Hirsch, Fabian,de Bruin, Hannah,Ossenkoppele, Rik,Palleis, Carla,Strübing, Felix,Schöll, Michael,Levin, Johannes,Brendel, Matthias,Höglinger, Günter U",11/10/2024,Molecular neurodegeneration
10.1016/j.cell.2025.02.012,simultaneous crispr screening spatial transcriptomic reveal intracellular intercellular functional transcriptional circuit,pool optical screen have enable study cellular interaction morphology dynamic massive scale have not yet leverage power highly plexe single cell resolve transcriptomic readout to inform molecular pathway here present combination image spatial transcriptomic parallel optical detection situ amplify guide rnas perturb fish perturb fish recover intracellular effect be consistent single cell rna sequence base readout perturbation effect perturb seq screen lipopolysaccharide response cultured monocyte uncover intercellular density dependent regulation innate immune response similarly three dimensional xenograft model perturb fish identify tumor immune interaction alter genetic knockout pair functional readout separate screen autism spectrum disorder risk gene human induce pluripotent stem cell hipsc astrocyte perturb fish show common calcium activity phenotype associated genetic interaction dysregulate molecular pathway perturb fish be thus general method study genetic molecular association spatial functional biology single cell resolution,"Binan, Loϊc,Jiang, Aiping,Danquah, Serwah A,Valakh, Vera,Simonton, Brooke,Bezney, Jon,Manguso, Robert T,Yates, Kathleen B,Nehme, Ralda,Cleary, Brian,Farhi, Samouil L",30/11/2023,Cell
10.1016/j.neuron.2025.02.014,multi cohort cerebrospinal fluid proteomic identify robust molecular signature alzheimer disease continuum,change β amyloid aβ hyperphosphorylate tau t brain cerebrospinal fluid csf precede alzheimer disease ad symptom make csf proteome potential avenue to understand disease pathophysiology facilitate reliable diagnostic therapy use at framework three stage study design discovery replication meta analysis identify analyte unique protein dysregulate ad be previously report be novel identify protein cluster four different pseudo trajectory group span ad continuum be enrich pathway include neuronal death apoptosis tau phosphorylation early stage microglia dysregulation endolysosomal dysfunction mid stage brain plasticity longevity mid stage microglia neuron crosstalk late stage use machine learning create validate highly accurate replicable area curve auc model predict ad biomarker positivity clinical status model can also identify people will convert ad,"Ali, Muhammad,Timsina, Jigyasha,Western, Daniel,Liu, Menghan,Beric, Aleksandra,Budde, John,Do, Anh,Heo, Gyujin,Wang, Lihua,Gentsch, Jen,Schindler, Suzanne E,Morris, John C,Holtzman, David M,Ruiz, Agustin,Alvarez, Ignacio,Aguilar, Miquel,Pastor, Pau,Rutledge, Jarod,Oh, Hamilton,Wilson, Edward N,Guen, Yann Le,Khalid, Rana R,Robins, Chloe,Pulford, David J,Tarawneh, Rawan,Ibanez, Laura,Wyss-Coray, Tony,Sung, Yun Ju,Cruchaga, Carlos",10/09/2024,Neuron
10.1016/j.foodchem.2018.04.067,transglutaminase mediate microencapsulation sea buckthorn supercritical extract protein isolate valorization highly value add food product,sea buckthorn carotenoid extract use supercritical fluid method be encapsulate protein isolate transglutaminase tg mediate crosslinking reaction coacervation freeze dry encapsulation efficiency be β carotene major carotenoid present powder confocal analysis reveal tg ase mediate cross link reaction enhance complex stability manner double microencapsulation be perform powder show antioxidant activity mmol trolox g dw antifungal activity penicillium expansum miug four variant domestic ice cream be obtain total carotenoid content variation mg g sample powder mg g sample extract have satisfactory antioxidant activity storage stability test show decrease total carotenoid content antioxidant activity sample day c protective effect microencapsulation be evidence,"Mihalcea, Liliana,Turturică, Mihaela,Barbu, Vasilica,Ioniţă, Elena,Pătraşcu, Livia,Cotârleţ, Mihaela,Dumitraşcu, Loredana,Aprodu, Iuliana,Râpeanu, Gabriela,Stănciuc, Nicoleta",29/01/2018,Food chemistry
10.1016/S2352-3026(24)00377-6,talicabtagene autoleucel relapsed refractory b cell malignancy result open label multicentre phase study,background low income middle income county lmic outcome relapsed refractory b cell malignancy be poor absence effective therapy report result phase study novel humanise anti chimeric antigen receptor car t cell therapy talicabtagene autoleucel patient relapsed refractory b cell malignancy method open label multicentre phase study be do six tertiary cancer centre india phase be single centre study do tata memorial hospital india patient age year old relapsed refractory b cell lymphomas phase be single arm multicentre basket trial do five tertiary cancer centre patient age year old relapsed refractory b cell acute lymphoblastic leukaemia b cell lymphoma eligible patient have life expectancy week more ecog performance status phase phase adequate organ function patient undergo apheresis to obtain at least lymphocyte to manufacture car t cell lymphodepletion therapy be do cyclophosphamide mg fludarabine mg day bendamustine mg day patient be then infuse intravenously talicabtagene autoleucel car t cell fractionated schedule day respectively phase at least car t cell kg to car t cell day phase primary endpoint be safety phase overall response rate phase efficacy analysis be do efficacy evaluable cohort patient receive target dose day lymphodepletion therapy safety analysis be do safety population patient receive talicabtagene autoleucel trial be register clinical trial registry india enrolment be closed finding patient be enrol phase may to may be enrol phase dec aug median age overall cohort be year iqr patient be male be female phase dose limit toxicity occur dose car t cell kg dose at least car t cell kg be choose phase base complete response three seven patient dose most common grade bad toxicity be haematological event anaemia patient thrombocytopenia patient neutropenia patient febrile neutropenia patient be two treatment relate death one febrile neutropenia immune effector cell associate haemophagocytic lymphohistiocytosis septic shock second pulmonary bleed multiorgan dysfunction syndrome cytokine release syndrome efficacy evaluable patient b cell lymphoma b cell acute lymphoblastic leukaemia overall response rate be ci interpretation talicabtagene autoleucel have manageable safety profile induce durable response patient relapsed refractory b cell malignancy therapy address important unmet need patient relapsed refractory b cell malignancy india funding immunoadoptive cell therapy immunoact indian council medical research icmr,"Jain, Hasmukh,Karulkar, Atharva,Kalra, Devanshi,Ravikumar, Smrithi,Shah, Shreshtha,Firfiray, Afrin,Pendhari, Juber,Jaiswal, Ankesh Kumar,Khan, Aalia,Sundharam, Manivasagam,Vaibhaw, Anand,Saroha, Ashish,Rajyopadhye, Shreewardhan,Basu, Moumita,Asija, Sweety,Chowdhury, Ambalika,Beher, Rohit,Banik, Ankit,Dwivedi, Alka,Purwar, Shalini,Narula, Gaurav,Banavali, Shripad,Jain, Nitin,Highfill, Steven L,Stroncek, David,Fry, Terry,Melinkeri, Sameer,Wilson, Lovin,Agarwal, Narendra,Aribandi, Anil,Boyella, Pavan Kumar,Shah, Nirali N,Neelapu, Sattva S,Sengar, Manju,Purwar, Rahul",23/10/2024,The Lancet. Haematology
10.1038/s41591-025-03577-y,molecular residual disease analysis adjuvant osimertinib resect egfr mutate stage ib non small cell lung cancer,osimertinib third generation epidermal growth factor receptor tyrosine kinase inhibitor be recommend adjuvant therapy resected stage ib epidermal growth factor receptor mutate non small cell lung cancer base significant disease free survival dfs overall survival improvement show previously report phase adaura trial trend increase dfs event rate completion year adjuvant treatment adaura suggest patient may benefit long adjuvant osimertinib treatment therefore explore tumor inform circulate tumor dna base molecular residual disease mrd could predict recurrence exploratory post hoc analysis patient osimertinib placebo adaura mrd precede image dfs event study median confidence interval month dfs mrd event free rate month be patient osimertinib placebo group hazard ratio confidence interval osimertinib group dfs mrd event be detect patient most event occur follow osimertinib cessation month stop osimertinib month osimertinib dfs mrd event free rate be study mrd precede dfs event most patient arm dfs mrd event free status be maintain most patient adjuvant osimertinib treatment posttreatment follow up most mrd dfs event occur osimertinib treatment discontinuation completion mrd detection could potentially identify patient may benefit long adjuvant osimertinib require clinical confirmation identifi,"Herbst, Roy S,John, Thomas,Grohé, Christian,Goldman, Jonathan W,Kato, Terufumi,Laktionov, Konstantin,Bonanno, Laura,Tiseo, Marcello,Majem, Margarita,Dómine, Manuel,Ahn, Myung-Ju,Kowalski, Dariusz M,Pérol, Maurice,Sriuranpong, Virote,Özgüroğlu, Mustafa,Bhetariya, Preetida,Markovets, Aleksandra,Rukazenkov, Yuri,Muldoon, Caitlin,Robichaux, Jacqulyne,Hartmaier, Ryan,Tsuboi, Masahiro,Wu, Yi-Long",09/09/2024,Nature medicine
10.1038/s41467-025-57452-y,heterogeneous effect genetic variant trait associate fast insulin cardiometabolic outcome,elevated fast insulin level fi indicative altered insulin secretion sensitivity may precede type diabetes cardiovascular disease onset study group fi associate genetic variant base genetic phenotypic similarity identify seven cluster distinct mechanism contribute elevated fi level cluster fall two type non diabetogenic hyperinsulinemia cluster be not associate increase risk diabetogenic hyperinsulinemia association be drive body fat distribution liver function circulate lipid inflammation million multi ancestry individual demonstrate diabetogenic hyperinsulinemia cluster specific polygenic score exhibit vary risk cardiovascular condition include coronary artery disease myocardial infarction mi stroke notably visceral adiposity cluster show sex specific effect mi risk male study underscore process decouple elevated fi level cardiovascular risk offer new avenue investigate process specific pathway disease,"Sevilla-González, Magdalena,Smith, Kirk,Wang, Ningyuan,Jensen, Aubrey E,Litkowski, Elizabeth M,Kim, Hyunkyung,DiCorpo, Daniel A,Hsu, Sarah,Cui, Jinrui,Liu, Ching-Ti,Yu, Chenglong,McNeil, John J,Lacaze, Paul,Westerman, Kenneth E,Chang, Kyong-Mi,Tsao, Philip S,Phillips, Lawrence S,Goodarzi, Mark O,Sladek, Rob,Rotter, Jerome I,Dupuis, Josée,Florez, Jose C,Merino, Jordi,Meigs, James B,Zhou, Jin J,Raghavan, Sridharan,Udler, Miriam S,Manning, Alisa K",30/04/2024,Nature communications
10.1016/S2352-3026(24)00385-5,safety activity talquetamab patient relapsed refractory multiple myeloma multicentre open label phase study,background talquetamab be first bispecific antibody approve relapsed refractory multiple myeloma phase study initial result subcutaneous talquetamab mg kg once week mg kg week show preliminary clinical activity describe safety activity result patient treat talquetamab include patient have receive previous t cell redirection therapy tcr post hoc analysis be do more mature median follow up to evaluate duration response patient treat talquetamab mg kg week method be multicentre open label phase study talquetamab phase have previously be publish mg kg once week mg kg week recommend subcutaneous dose identify phase be evaluate phase patient be year age old have at least three previous line therapy have eastern cooperative oncology group performance status to be naive expose previous tcr primary endpoint be overall response rate assess independent review committee patient receive at least one dose talquetamab safety be assess patient receive at least one dose talquetamab study be register phase phase finding jan feb patient be screen phase cohort patient screen inclusion be treat phase cohort patient be exclude study most commonly not meet eligibility criterion not have measurable disease oct patient have receive recommend talquetamab dose three group mg kg once week group mg kg week group tcr naive patient previous tcr receive recommend dose previous tcr group patient be male be female patient be white patient be black median follow up be month iqr mg kg once week group month mg kg week group month previous tcr group overall response rate be patient ci mg kg once week group patient mg kg week group patient previous tcr group most common adverse event mg kg once week mg kg week previous tcr group be cytokine release syndrome patient patient patient taste change infection most common grade adverse event be neutropenia anaemia lymphopenia fatal adverse event occur five patient mg kg once week group seven patient mg kg week group patient previous tcr group none be relate treatment interpretation talquetamab continue to demonstrate high overall response rate heavily pretreate patient relapsed refractory multiple myeloma long follow up post hoc analysis overall response rate be promise patient previous tcr include therapy target bcma target tumour adverse event be common lead few treatment discontinuation funding janssen,"Chari, Ajai,Touzeau, Cyrille,Schinke, Carolina,Minnema, Monique C,Berdeja, Jesus G,Oriol, Albert,van de Donk, Niels W C J,Rodríguez-Otero, Paula,Morillo, Daniel,Martinez-Chamorro, Carmen,Mateos, María-Victoria,Costa, Luciano J,Caers, Jo,Rasche, Leo,Krishnan, Amrita,Ye, Jing Christine,Karlin, Lionel,Lipe, Brea,Vishwamitra, Deeksha,Skerget, Sheri,Verona, Raluca,Ma, Xuewen,Qin, Xiang,Ludlage, Hein,Campagna, Michela,Masterson, Tara,Hilder, Brandi,Tolbert, Jaszianne,Renaud, Thomas,Goldberg, Jenna D,Kane, Colleen,Heuck, Christoph,San-Miguel, Jesus,Moreau, Philippe",29/08/2024,The Lancet. Haematology
10.1186/s13045-025-01676-4,second primary malignancy follow car t cell therapy patient hematologic malignancy,chimeric antigen receptor t cell car t therapy have transform management patient relapse refractory r r hematologic malignancy include b cell lymphoma multiple myeloma mm datum pertain efficacy toxicity associate car t have be widely report be limited datum long term complication retrospectively analyze patient treat car t r r b cell lymphoma mm ohio state university minimum two year follow up median age be year median number prior treatment be four median follow up month range patient develop second primary malignancy spm non melanoma skin cancer be most common follow hematologic malignancy non skin solid tumor squamous cell carcinoma account skin cancer myelodysplastic syndrome acute myeloid leukemia be predominant hematologic malignancy solid tumor include bladder prostate breast cancer distinct pattern spm suggest potential car t relate risk warrant vigilant post treatment surveillance further study be necessary to elucidate underlying mechanism predictive factor guide long term management spm risk car t survivor,"Umyarova, Elvira,Pei, Charles,Pellegrino, William,Zhao, Qiuhong,Sharma, Nidhi,Benson, Don,Cottini, Francesca,Bezerra, Evandro,Brammer, Jonathan,Bumma, Naresh,Choe, Hannah,Denlinger, Nathan,Devarakonda, Srinivas,Khan, Abdullah,Penza, Sam,Rosko, Ashley,Vasu, Sumithira,Wall, Sarah,Alinari, Lapo,Baiocchi, Robert,Bond, David A,Christian, Beth,Hanel, Walter,Maddocks, Kami,Reneau, John,Sawalha, Yazeed,Habib, Alma,Sigmund, Audrey,Voorhees, Timothy J,de Lima, Marcos,Epperla, Narendranath",24/12/2024,Journal of hematology & oncology
10.1016/S0140-6736(24)02722-3,ivonescimab pembrolizumab pd positive non small cell lung cancer randomise double blind phase study china,background ivonescimab be bispecific antibody program cell death protein vascular endothelial growth factor yield promise clinical outcome patient advanced non small cell lung cancer early phase study compare efficacy safety ivonescimab pembrolizumab patient program cell death pd advanced non small cell lung cancer method be randomised double blind phase trial hospital china eligible patient be age year old have locally advanced metastatic pd positive non small cell lung cancer sensitise epidermal growth factor receptor mutation anaplastic lymphoma kinase translocation eastern cooperative oncology group performance status patient be randomly assign to receive mg kg ivonescimab mg pembrolizumab intravenously week randomisation be stratify histology clinical stage pd expression primary endpoint be progression free survival pfs assess mask independent radiographic review committee recist intention to treat population study be register recruitment be complete trial ongoing final analysis to be report later finding nov aug screen patient be randomly assign to receive ivonescimab pembrolizumab preplanne interim analysis median pfs be significantly long ivonescimab pembrolizumab month stratify hazard ratio hr ci one side pfs benefit ivonescimab pembrolizumab be broadly consistent prespecified subgroup include patient pd tumour proportion score tps hr ci pd tps high hr grade high treatment relate adverse event occur patient ivonescimab patient pembrolizumab immune relate adverse event grade high be observe patient ivonescimab patient pembrolizumab ivonescimab demonstrate manageable safety profile patient squamous non squamous non small cell lung cancer patient squamous cell carcinoma grade high treatment relate adverse event be comparable two group interpretation ivonescimab significantly improve pf compare pembrolizumab previously untreated patient advanced pd positive non small cell lung cancer therefore ivonescimab might represent treatment option first line setting pd positive advanced non small cell lung cancer funding akeso biopharma,"Xiong, Anwen,Wang, Lei,Chen, Jianhua,Wu, Lin,Liu, Baogang,Yao, Jun,Zhong, Hua,Li, Jie,Cheng, Ying,Sun, Yulan,Ge, Hui,Yao, Jifang,Shi, Qin,Zhou, Ming,Chen, Bolin,Han, Zhengxiang,Wang, Jinliang,Bu, Qing,Zhao, Yanqiu,Chen, Junqiang,Nie, Ligong,Li, Gaofeng,Li, Xingya,Yu, Xinmin,Ji, Yinghua,Sun, Daqiang,Ai, Xiaohong,Chu, Qian,Lin, Yu,Hao, Jiqing,Huang, Dingzhi,Zhou, Chengzhi,Shan, Jinlu,Yang, Hongzhong,Liu, Xuewen,Wang, Jing,Shang, Yanhong,Mei, Xiaodong,Yang, Jie,Lu, Dongmei,Hu, Mingxiu,Wang, Zhongmin Maxwell,Li, Baiyong,Xia, Michelle,Zhou, Caicun",14/09/2024,"Lancet (London, England)"
10.1002/advs.202413125,integration circulate tumor dna metabolic parameter fludeoxyglucose positron emission tomography outcome prediction unresectable locally advanced non small cell lung cancer,prospective study explore prognostic value circulate tumor dna ctdna positron emission tomography compute tomograpy pet ct unresectable locally advanced non small cell lung cancer la nsclc treat definitive chemoradiotherapy crt discovery set include patient baseline post crt plasma sample pet ct be perform baseline patient undergo mid treatment scan gy baseline ctdna be detect patient pre treatment ctdna concentration correlate total metabolic tumor volume tmtv p total lesion glycolysis tlg p not treatment response survival however patient undetectable ctdna low tmtv show significantly long progression free survival pfs month p post crt ctdna be detect patient ctdna concentration p variant allele frequency vaf p significantly decline undetectable post crt ctdna associate long pfs p overall survival os p high correlate improved pfs os similar finding be obtain test patient result highlight post crt ctdna robust prognostic marker potentially identify patient may forgo ici consolidation,"Wu, Leilei,Zhang, Zhenshan,Jiang, Chenxue,Li, Li,Sun, Xiaojiang,Bai, Menglin,Liu, Ming,Xiong, Kangli,Shang, Jinbiao,Yu, Jinming,Yuan, Shuanghu,Yang, Yang,Xu, Yaping",27/02/2025,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"
10.1093/bjs/znaf005,extend pharmacological thromboprophylaxis clinically relevant venous thromboembolism major abdominal pelvic surgery international prospective propensity score weight cohort study,background be low certainty evidence impact extend pharmacological prophylaxis venous thromboembolism associate morbidity mortality aim study be to determine efficacy safety extended prophylaxis major abdominopelvic surgery prevention clinically relevant venous thromboembolism hospital discharge method cardiovascular outcome major abdominal surgery cascade be prospective international cohort study consecutive adult patient undergo major abdominopelvic surgery be enrol january may extend prophylaxis be consider least day anticoagulant prescription surgery primary efficacy outcome be clinically relevant venous thromboembolism primary safety outcome be clinically relevant bleeding day surgery european medicine agency definition independent association outcome extended prophylaxis be explore use mixed effect logistic regression propensity score weighting result total patient median age year woman country be include extended prophylaxis prescription rate be patient post discharge venous thromboembolism bleeding rate be patient patient respectively weighting extend prophylaxis be not significantly associate increase bleed risk p decrease venous thromboembolism incidence overall cohort p subgroup analysis patient undergo complex major surgery active cancer p conclusion modern practice incidence postoperative venous thromboembolism be low extended prophylaxis appear safe clinical efficacy remain uncertain further work be require to define patient stand to benefit,,29/07/2024,The British journal of surgery
10.1007/s13304-025-02139-8,current state art adrenal surgery italy cancer risk surgical adrenal lesion crisal survey,adrenalectomy be grow worldwide frequent diagnosis incidentaloma use minimally invasive surgery mis factor use to identify malignant lesion well surgical technique be uncertain context definition high volume center expert surgeon be debate italian society endoscopic surgery new technology sice develop nationwide survey to investigate state art adrenal surgery italy web base survey comprise question be develop distribute italian surgeon involve adrenal surgery two hundred forty eight answer be analyze consensus be reach survey participant regard local infiltration rapid growth lesion marker malignancy nearly participant use mis case malignant adrenal lesion lateral anterior transperitoneal approach be most common italian surgeon approximately participant believe adrenalectomy year be need to define expert surgeon at least procedure year to define high volume center approximately half participant perform adrenalectomy year center median volume procedure year base participant feedback survey highlight local infiltration rapid growth most significant marker malignant adrenal lesion open adrenalectomy remain gold standard suspect malignant lesion nearly participant practice mis even case lateral anterior transperitoneal approach emerge most familiar italian surgeon substantial proportion italian patient adrenal lesion undergo surgery perform surgeon annual case volume procedure center low annual volume adrenalectomy moreover be lack standardized definition expert surgeon high volume center context,"Corallino, Diletta,Passera, Roberto,Inama, Marco",18/11/2024,Updates in surgery
10.1186/s12967-025-06368-8,genetic insight idiopathic pulmonary fibrosis multi omics approach to identify potential therapeutic target,objective to identify potential therapeutic target evaluate safety profile idiopathic pulmonary fibrosis ipf use comprehensive multi omics approach method integrate genomic transcriptomic datum to identify therapeutic target ipf first conduct transcriptome wide association study twas use omnibus transcriptome test use expression reference summary datum otter framework combine plasma expression quantitative trait loci eqtl datum ipf genome wide association study gwas summary statistic global biobank discovery finngen duplication then apply mendelian randomization mr to explore causal relationship rna seq co expression analysis bulk single cell spatial transcriptomic be use to identify critical gene follow molecular docking to evaluate druggability finally phenome wide mr phew mr use gwa datum disease uk biobank assess potential adverse effect identify gene result identify gene associate ipf discovery dataset gene duplication dataset overlap gene twas mr analysis reveal causal gene discovery dataset link increase to decrease ipf risk summary data base mr smr confirm six essential gene bulk rna seq show upregulation downregulation ipf single cell rna seq reveal gene expression change cell type molecular docking identify bind solid affinity essential gene respiratory drug phew mr highlight potential side effect conclusion identify six key gene potential drug target ipf molecular docking reveal strong drug affinity phew mr analysis highlight therapeutic potential associated risk finding offer new insight ipf treatment further investigation potential side effect,"Wen, Zhuofeng,Liang, Weixuan,Yang, Ziyang,Liu, Junjie,Yang, Jing,Xu, Runge,Lin, Keye,Pan, Jia,Chen, Zisheng",13/12/2024,Journal of translational medicine
10.1002/anie.201601989,position carbon fluorine bond π cloud aromatic ring different type arene activation,be know fluoro group have only small effect rate electrophilic aromatic substitution imagine instead carbon fluorine c f bond position tightly π cloud aryl ring orthogonal noncovalent arrangement could instead stabilize positively charge arene intermediate transition state give rise novel electrophilic aromatic substitution chemistry herein report synthesis study molecule contain rigid c interaction play prominent role reaction chemistry spectroscopy example establish c interaction can bring fold increase relative rate aromatic nitration reaction afford functionalization activate ring exclusively overall result establish fluoro through space directing activate group complement traditional role fluorine slightly deactivate aryl substituent nitration,"Holl, Maxwell Gargiulo,Struble, Mark D,Singal, Prakhar,Siegler, Maxime A,Lectka, Thomas",29/02/2016,Angewandte Chemie (International ed. in English)
10.1038/s41591-025-03600-2,target antibody drug conjugate advanced solid tumor phase trial,antibody drug conjugate adcs have emerge transformative modality treatment solid tumor novel target adc leverage tumor microenvironment activable linker payload platform couple novel topoisomerase inhibitor protease cleavable linker here report finding large scale global multicenter phase trial evaluate safety pharmacokinetic preliminary efficacy patient advanced solid tumor refractory standard therapy trial include dose escalation part phase dose expansion part phase total patient be enrol multiple tumor type include extensive stage small cell lung cancer es sclc nasopharyngeal carcinoma npc non small cell lung cancer esophageal squamous cell carcinoma other solid tumor maximum tolerate dose be determined to be mg recommend expansion dose be select mg mg week most common grade high treatment relate adverse event include neutropenia leukopenia anemia only case interstitial lung disease case infusion reaction be observe encourage anti tumor activity be observe particularly patient es sclc objective response rate orr npc orr lung adenocarcinoma orr lymphoepithelioma like carcinoma orr significant correlation membrane expression orr be find demonstrate acceptable safety profile promising efficacy heavily pretreate patient advanced solid tumor particularly es sclc npc lymphoepithelioma like carcinoma phase clinical trial patient sclc npc have already be initiate identifier,"Ma, Yuxiang,Yang, Yunpeng,Huang, Yan,Fang, Wenfeng,Xue, Jinhui,Meng, Xiangjiao,Fan, Yun,Fu, Siqing,Wu, Lin,Zheng, Yulong,Liu, Jian,Liu, Zhihua,Zhuang, Wu,Rosen, Seth,Qu, Song,Li, Bihui,Li, Mingjun,Zhao, Yanqiu,Yang, Shujun,Ji, Yinghua,Sommerhalder, David,Luo, Suxia,Yang, Kunyu,Li, Jingao,Lv, Dongqing,Zhang, Peng,Zhao, Yuanyuan,Hong, Shaodong,Zhang, Yang,Zhao, Shen,Chin, Steve,Zhang, Xian,Lian, Wei,Cai, Jiaqiang,Xue, Tongtong,Zhang, Li,Zhao, Hongyun",08/10/2024,Nature medicine
10.1126/science.adv3451,cryo em reveal mechanism natural rna multivalency,homo oligomerization biological macromolecule lead functional assembly be critical understand various cellular process however rna quaternary structure have be rarely report comparative genomics analysis have identify rna family contain hundred sequence adopt conserve secondary structure likely fold complex three dimensional structure use cryo electron microscopy cryo em to determine structure four rna family include arrpof ole forming dimer rool golld form hexameric octameric dodecameric nanostructure to å resolution homo oligomeric assembly reveal plethora structural motif contribute rna multivalency include kiss loop palindromic base pairing stacking metal ion coordination pseudoknot minor groove interaction result provide molecular basis intermolecular interaction drive rna multivalency potential functional relevance,"Wang, Liu,Xie, Jiahao,Gong, Tao,Wu, Hao,Tu, Yifan,Peng, Xin,Shang, Sitong,Jia, Xinyu,Ma, Haiyun,Zou, Jian,Xu, Sheng,Zheng, Xin,Zhang, Dong,Liu, Yang,Zhang, Chong,Luo, Yongbo,Huang, Zirui,Shao, Bin,Ying, Binwu,Cheng, Yu,Guo, Yingqiang,Lai, Ying,Huang, Dingming,Liu, Jianquan,Wei, Yuquan,Sun, Siqi,Zhou, Xuedong,Su, Zhaoming",14/03/2025,"Science (New York, N.Y.)"
10.1016/j.ccell.2025.02.009,single cell multi stage spatial evolutional map esophageal carcinogenesis,cancer development involve co evolution cancer cell surround microenvironment dynamic interaction physical architecture remains poorly understand here present spatial transcriptomic map single cell resolution encompass multi stage field view patient to chart evolutionary trajectory human esophageal squamous cell carcinoma escc analyze million cell reveal escc progression be drive proliferative epithelial cell subpopulation acquire dedifferentiate invasive characteristic late precancerous stage cell disrupt epithelial stromal interface recruit normal fibroblast signal transform cancer associate fibroblast cafs interaction lead formation caf epi caf epithelial cell niche tumor edge shield tumor immune surveillance caf epi niche formation be key indicator progression escc other squamous cell carcinoma patient outcome,"Chang, Jiang,Lu, Junting,Liu, Qingyi,Xiang, Tao,Zhang, Shaosen,Yi, Yonglin,Li, Dongxu,Liu, Tianyuan,Liu, Zeyuan,Chen, Xinjie,Dong, Zhenghao,Li, Cainan,Yi, HanZhang,Yu, Siqi,Huang, Luwei,Qu, Fangfei,Wang, Mengdi,Wang, Dehe,Dong, Hao,Cheng, Guoyu,Zhu, Liang,Li, Jiachen,Li, Chenying,Wu, Pujie,Xie, Xiaoting,Teschendorff, Andrew E,Lin, Dongxin,Wang, Xiaoqun,Wu, Chen",04/06/2024,Cancer cell
10.1002/ctm2.70270,target mediate mrna circularisation translation to enhance vulnerability ferroptosis hepatocellular carcinoma,background rna methylcytosine play important role progression hepatocellular carcinoma hcc dysregulation ferroptosis be closely associate hcc however effect epigenetic mrna modification ferroptosis hcc remain unclear method study ferroptosis be evaluate detect lipid reactive oxygen specie lipid ros ferrous ion hydroxynonenal hne xenograft mouse model diethylnitrosamine hcc model so forth regulatory mechanism mrna translation be elucidate use rna sequencing ribosome sequence rna immunoprecipitation bisulphite sequencing immunoprecipitation spectrometry assay dual luciferase reporter rip qpcr co ip rna pulldown methylate rna immunoprecipitation polymerase chain reaction qpcr assay be perform to validate mechanism regulate mrna translation modification result here find promote translation ring finger protein mrna modification thereby inhibit ferroptosis promote hcc development moreover be identify ubiquitin ligase dihydroorotate dehydrogenase dhodh promote ubiquitination inhibit autophagic degradation to counteract ferroptosis addition bind modification site region utr interact eukaryotic translation initiation factor to bridge region promote mrna circularisation translation sun rna methyltransferase be identify responsible modification mrna hcc conclusion current work reveal promote mrna translation dependent manner thereby regulate dhodh ubiquitination expression to suppress ferroptosis research shed light mechanism modify mrnas translation ferroptosis highlight promise biomarker prognosis target therapy hcc key point inhibit ferroptosis hcc regulate dhodh axis ligase mediate ubiquitination autophagic degradation dhodh bind site mrna interact to bridge promote mrna circularisation translation high expression predict poor overall survival hcc,"Li, Ouwen,An, Ke,Wang, Han,Li, Xianbin,Wang, Yueqin,Huang, Lan,Du, Yue,Qin, Nuo,Dong, Jiasheng,Wei, Jingyao,Sun, Ranran,Shi, Yong,Guo, Yanjia,Sun, Xiangyi,Yang, Ying,Yang, Yun-Gui,Kan, Quancheng,Tian, Xin",25/02/2025,Clinical and translational medicine
10.1158/0008-5472.CAN-24-1879,genomic characterization high grade serous ovarian carcinoma reveal distinct somatic feature black individual,black individual experience bad survival diagnosis high grade serous ovarian carcinoma hgsc white individual be underrepresented ovarian cancer research date understanding molecular genomic heterogeneity hgsc be base primarily evaluation tumor white individual present study perform whole exome sequence hgsc sample black patient to identify significantly mutate gene characterize mutational signature assess distribution gene expression subtype occurrence frequency somatic mutation signature self report race be compare historical datum cancer genome atla tcga technical difference formalin fix fresh frozen tissue distribution mutation variant classification major hgsc gene be nearly identical study population however de novo significantly mutate gene analysis identify gene not previously report tcga analysis include oncogene kra potential tumor suppressor obscn prevalence homologous recombination deficiency signature be high black individual immunoreactive gene expression subtype compare mesenchymal proliferative subtype finding be confirm compare datum black patient white patient identical tissue collection processing overall study suggest most feature hgsc tumor phenotype be similar black white population may be clinically relevant difference validate phenotype may be important clinical decision making would have be miss characterize tumor white individual only,"Lawson-Michod, Katherine A,Marks, Jeffrey R,Collin, Lindsay J,Nix, David A,Davidson, Natalie R,Huff, Chad D,Yu, Yao,Atkinson, Aaron,Johnson, Courtney E,Salas, Lucas A,Peres, Lauren C,Greene, Casey S,Schildkraut, Joellen M,Doherty, Jennifer A",07/02/2025,Cancer research
10.1016/j.ard.2025.02.013,obesity substantially impact rheumatic musculoskeletal disease time to act,obesity be major health problem risk factor many chronic health condition include rheumatic musculoskeletal disease rmds adult rmd live overweight obesity obesity not only increase risk develop rmds worsen disease activity pain fatigue impairs treatment response thereby reduce quality life physical function far obesity can amplify drive several comorbiditie be more prevalent rmds include hypertension cardiovascular disease type diabetes metabolic dysfunction associate steatotic liver disease moreover reciprocal risk arise rmds make hard to be physically active maintain healthy weight especially context obesogenic environment viewpoint review relevant evidence to suggest obesity confer distinctive important challenge care daily live many patient rmds advent several highly effective drug obesity also highlight research need include robust clinical trial to test efficacy effectiveness therapy part management inflammatory rmds primary agent adjuvant immune target therapeutic implement such weight management strategy should provide much need holistic approach care patient,"Sattar, Naveed,Sattar, Lindsey J,McInnes, Iain B,Siebert, Stefan,Ferguson, Lyn D",25/11/2024,Annals of the rheumatic diseases
10.1016/j.eclinm.2025.103125,deep learning base model prediction early recurrence therapy response whole slide image non muscle invasive bladder cancer retrospective multicentre study,background accurate prediction early recurrence be essential disease management patient non muscle invasive bladder cancer nmibc aim to develop validate deep learning base early recurrence predictive model erpm treatment response predictive model trpm whole slide image to assist clinical decision making method retrospective multicentre study include consecutive patient pathology confirm nmibc undergo transurethral resection bladder tumour five centre patient one hospital sun yat sen memorial hospital sun yat sen university guangzhou china be assign training internal validation cohort patient four other hospital third affiliated hospital sun yat sen university zhujiang hospital southern medical university guangzhou china fifth affiliate hospital sun yat sen university zhuhai china shenshan medical centre shanwei china be assign four independent external validation cohort base multi instance ensemble learning erpm be develop to make prediction haematoxylin eosin staining immunohistochemistry stain slide share same architecture erpm trpm be train evaluate cross validation patient receive bacillus calmette guérin bcg performance erpm be mainly evaluate compare clinical model base model integrate model area curve survival analysis be perform to assess prognostic capability erpm finding january september whole slide image patient be include to train validate model erpm be superior clinical base model predict early recurrence internal validation cohort area curve external validation cohort area curve be par integrated model also stratify recurrence free survival significantly p hazard ratio ci trpm perform well predict bcg unresponsive nmibc accuracy interpretation erpm show promising performance predict early recurrence recurrence free survival patient nmibc surgery further validation combination trpm could be use to guide management nmibc funding national natural science foundation china science technology planning project guangdong province national key research development programme china guangdong provincial clinical research centre urological disease science technology project guangzhou,"Jiang, Fan,Hong, Guibin,Zeng, Hong,Lin, Zhen,Liu, Ye,Xu, Abai,Shen, Runnan,Xie, Ye,Luo, Yun,Wang, Yun,Zhu, Mengyi,Yang, Hongkun,Wang, Haoxuan,Huang, Shuting,Chen, Rui,Lin, Tianxin,Wu, Shaoxu",03/11/2024,EClinicalMedicine
10.3389/fnut.2025.1548851,association non highdensity lipoprotein cholesterol high density lipoprotein cholesterol ratio cardiovascular kidney metabolic syndrome evidence nhanes,objective research be to analyze connection nhhr ckd occurrence use nhane will evaluate feasibility nhhr tool predict ckm syndrome offer valuable insight personalized treatment approach population method datum individual age to year be analyze having exclude be pregnant individual incomplete datum ckm syndrome be characterize simultaneous presence ckd cardiometabolic syndrome cms statistical analysis weight logistic regression model be apply account variable such age gender ethnicity educational background marital status lifestyle factor preexist health condition differently restrict cubic spline rcs be apply to investigate possible nonlinear relationship nhhr ckm study result research reveal occurrence ckm syndrome be more prevalent individual age old woman represent affect additionally nhhr level be notably elevate ckm patient compare ckm p nhhr increase prevalence ckm also rise high prevalence high nhhr quartile positive connection nhhr ckm be indicate multivariable logistic regression especially upper quartile nhhr moreover rcs analysis display noteworthy nonlinear connection nhhr ckm occurrence subgroup analysis uncover significant interaction influence bmi hypertension conclusion rise global prevalence ckm syndrome early identification high risk individual use nhhr could inform targeted prevention intervention strategy future research should focus validate nhhr diverse population explore clinical utility as well examine relationship other biomarker metabolic dysfunction to well understand ckm syndrome complex pathophysiology,"Duan, Yang,Yang, Ke,Zhang, Tianai,Guo, Xiangsheng,Yin, Qianran,Liu, He",20/12/2024,Frontiers in nutrition
10.1016/S2468-1253(24)00390-X,intestinal barrier pivotal role health inflammation cancer,intestinal barrier serve boundary mucosal immune system lamina propria external environment intestinal luman contain diverse array microorganism ingest environmental factor include pathogen food antigen toxin other foreign substance barrier have central role regulate control interaction luminal factor intestinal immune system disruption intestinal epithelial cell serve physical barrier antimicrobial peptide mucin produce act chemical barrier can lead leaky gut state intestinal wall be unable to efficiently separate intestinal flora luminal content intestinal immune system subsequent activation immune system have important role pathogenesis inflammatory bowel disease as well metabolic dysfunction associate steatohepatitis primary sclerose cholangitis colorectal cancer dysregulate intestinal barrier integrity have also be describe patient chronic inflammatory disease gastrointestinal tract include rheumatoid arthritis neurodegenerative disorder mechanistic study barrier dysfunction have reveal subsequent local activation systemic circulation activate immune cell cytokine secrete as well extracellular vesicle promote proinflammatory process gastrointestinal tract review summarise finding highlight several new therapeutic concept currently be develop attempt to control inflammatory process direct indirect modulation intestinal barrier function,"Neurath, Markus F,Artis, David,Becker, Christoph",26/09/2024,The lancet. Gastroenterology & hepatology
10.1016/j.ccell.2025.02.026,distinct t cell dynamic associate response neoadjuvant cancer immunotherapy,leverage clinical trial compare neoadjuvant anti anti anti therapy head neck squamous cell carcinoma patient combination therapy promote high pathologic response rate monotherapy major pathologic response be associate well survival to address successful immune checkpoint inhibitor ici regimen act similar distinct pathway robustly longitudinally characterize transcriptional proteomic dynamic tumor infiltrate lymphocyte til clonal manner anti reprogram type interferon response exhaustion gene program effector memory resident memory contrast anti activate expand pre existing til do not rejuvenate exhausted phenotype t effector cell anti not anti induce widespread tcr sharing different transcriptional state as well increase tcr diversity respond patient datum suggest doublet regimen specific transcriptional clonal dynamic tumor reactive t cell,"Li, Housaiyin,Zandberg, Dan P,Kulkarni, Aditi,Chiosea, Simion I,Santos, Patricia M,Isett, Brian R,Joy, Marion,Sica, Gabriel L,Contrera, Kevin J,Tatsuoka, Curtis M,Brand, Matthias,Duvvuri, Umamaheswar,Kim, Seungwon,Kubik, Mark,Sridharan, Shaum,Tu, Fei,Chen, Jie,Bruno, Tullia C,Vignali, Dario A A,Cillo, Anthony R,Bao, Riyue,Wang, Jing Hong,Vujanovic, Lazar,Ferris, Robert L",06/03/2024,Cancer cell
10.1016/j.ccell.2025.02.026,distinct t cell dynamic associate response neoadjuvant cancer immunotherapy,leverage clinical trial compare neoadjuvant anti anti anti therapy head neck squamous cell carcinoma patient combination therapy promote high pathologic response rate monotherapy major pathologic response be associate well survival to address successful immune checkpoint inhibitor ici regimen act similar distinct pathway robustly longitudinally characterize transcriptional proteomic dynamic tumor infiltrate lymphocyte til clonal manner anti reprogram type interferon response exhaustion gene program effector memory resident memory contrast anti activate expand pre existing til do not rejuvenate exhausted phenotype t effector cell anti not anti induce widespread tcr sharing different transcriptional state as well increase tcr diversity respond patient datum suggest doublet regimen specific transcriptional clonal dynamic tumor reactive t cell,"Li, Housaiyin,Zandberg, Dan P,Kulkarni, Aditi,Chiosea, Simion I,Santos, Patricia M,Isett, Brian R,Joy, Marion,Sica, Gabriel L,Contrera, Kevin J,Tatsuoka, Curtis M,Brand, Matthias,Duvvuri, Umamaheswar,Kim, Seungwon,Kubik, Mark,Sridharan, Shaum,Tu, Fei,Chen, Jie,Bruno, Tullia C,Vignali, Dario A A,Cillo, Anthony R,Bao, Riyue,Wang, Jing Hong,Vujanovic, Lazar,Ferris, Robert L",06/03/2024,Cancer cell
10.1001/jama.2025.0220,chronic myeloid leukemia review,importance chronic myeloid leukemia cml have annual incidence case people be newly diagnose approximately individual year us approximately people us million worldwide have cml observation chronic myeloid leukemia be myeloproliferative neoplasm characterize presence philadelphia chromosome be define oncogene develop fusion proto oncogene constitutively active bcr gene approximately people cml present indolent chronic phase cml define blast less blood bone marrow absence extramedullary evidence leukemia basophil less platelet count to most advanced stage be cml blastic phase cml bp characterize world health organization more blast immature cell md anderson cancer center european leukemianet more approximately to patient cml present cml bp first generation tyrosine kinase inhibitor tkis target such imatinib second generation tkis such bosutinib dasatinib nilotinib have improve cml relate mortality to year to year such patient cml have survival rate similar general age match population six tki have be approve us food drug administration include be first line treatment imatinib dasatinib bosutinib nilotinib asciminib approve treatment disease progression initial therapy dasatinib bosutinib nilotinib ponatinib asciminib effect improved survival be similar tki more patient be able to promptly achieve maintain clearance third generation tkis medication adherence be important to maintain treatment responsiveness tki be associate hematologic toxicity such myelosuppression additional agent specific adverse effect such pleural effusion dasatinib arterio occlusive event such myocardial infarction stroke peripheral artery disease nilotinib ponatinib gastrointestinal disturbance bosutinib increase amylase lipase pancreatitis ponatinib asciminib nilotinib adverse effect should be consider select tki allogeneic hematopoietic stem cell transplant be reasonably safe therapy cure rate range to base stage cml time transplant stem cell transplant be reserve patient cml do not respond second generation tkis intolerance multiple tki accelerate phase cml cml bp conclusion relevance chronic myeloid leukemia be myeloproliferative neoplasm can typically be effectively treat improve survival similar general age match population many patient require continuous tki therapy therefore tki therapy should be select consideration adverse effect patient should be help to maximize adherence tki treatment,"Jabbour, Elias,Kantarjian, Hagop",17/03/2025,JAMA
10.1038/s43018-025-00932-3,engineer bacteria near infrared light inducible expression cancer therapeutic,bacteria base therapy hold great promise cancer treatment selective tumor colonization proliferation however clinical application be hinder need safe precise control system to regulate local therapeutic payload expression release here develop near infrared nir light mediate padc base photoswitch netmap system base chimeric phytochrome activate diguanylyl cyclase padc cyclic diguanylate monophosphate dependent transcriptional activator mrkh netmap engineer bacteria exhibit antitumor performance mouse tumor model different level immunogenicity specifically immunogenic lymphoma tumor nir induce pd nanobodie enhance activation adaptive immunity low immunogenic tumor include mouse derive colon cancer model orthotopic human breast cancer cell line derive xenograft model colorectal cancer patient derive xenograft model nir induce azurin cytolysin predominantly lead tumor inhibition study identify nir light mediate therapeutic platform engineer bacteria base therapy customizable output precise dosage control,"Qiao, Longliang,Niu, Lingxue,Wang, Zhihao,Deng, Zhenqiang,Di, Dai,Ma, Xiaoding,Zhou, Yang,Kong, Deqiang,Wang, Qilin,Yin, Jianli,Jin, Lingli,Sun, Jing,Feng, Bo,Lu, Weiqiang,Cai, Fengfeng,Guan, Ningzi,Ye, Haifeng",18/12/2023,Nature cancer
10.1002/advs.202414985,mitofusin drive preimplantation development enhance chromatin incorporation histone,mitofusin play crucial role mitochondrial fusion oocyte development however function preimplantation embryonic development potential involvement epigenetic regulation remain poorly understand study be show interact key component cytoplasmic lattice oocyte early embryo deficiency mice result reduce level decrease expression translational machinery component suppress protein synthesis activity low histone abundance disruption lead failure male pronucleus formation aberrant zygotic genome activation impaired embryonic development be far demonstrate activator promote incorporation rescue early development maternally aged embryo low level additionally positive correlation protein level early human embryo be observe together finding provide new insight role regulate epigenetic reprogramme preimplantation embryo development,"Shi, Xiao-Yan,Tian, Yu,Wang, Yu-Fan,Zhang, Yi-Ran,Yin, Ying,Tian, Qing,Li, Lei,Ma, Bing-Xin,He, Ximiao,Zhou, Li-Quan",07/02/2025,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"
10.1001/jamanetworkopen.2025.0648,mizoribine cyclophosphamide lupus nephritis randomized clinical trial,importance lupus nephritis be typically treat intravenous cyclophosphamide be associate serious adverse effect oral mizoribine may be alternative induction therapy lupus nephritis however large scale long term randomize clinical study mizoribine be lack objective to assess efficacy safety oral mizoribine intravenous cyclophosphamide induction therapy chinese patient lupus nephritis design setting participant prospective multicenter parallel group open label phase randomize clinical trial recruit patient class iii iv lupus nephritis age to year center china inclusion criterion include hour urinary protein level g high systemic lupus erythematosus disease activity index high first patient be enrol november study finish march follow period be week datum be analyze september january intervention oral mizoribine mg time day cyclophosphamide intravenous dose g body surface area maximum dose g d week oral glucocorticoid main outcome measure total remission rate complete remission rate partial remission rate week prespecifie result total patient be randomize patient mean sd age year woman be treat patient mizoribine group patient cyclophosphamide group total remission rate week be patient mizoribine group patient cyclophosphamide group relative risk ratio mizoribine cyclophosphamide be ci low limit side ci be great noninferiority margin indicate mizoribine be noninferior to cyclophosphamide change other immune parameter kidney function be generally similar group incidence treatment relate treatment emergent adverse event be patient mizoribine group patient cyclophosphamide group most frequent adverse event group be upper respiratory tract infection patient patient respectively conclusion relevance randomize clinical trial show compare intravenous cyclophosphamide oral mizoribine be noninferior well tolerate use glucocorticoid induction therapy active lupus nephritis mizoribine can be use alternative intravenous cyclophosphamide induction therapy lupus nephritis trial registration identifi,"Dong, Zheyi,Luo, Ping,Sun, Shiren,Ni, Zhaohui,He, Yani,Huang, Xiangyang,Liu, Zhangsuo,Wu, Zhenbiao,Zhang, Xinzhou,Liao, Yunhua,Zhao, Jianhong,Lin, Hongli,Zhang, Xiao,Fu, Rongguo,Ding, Guohua,Xu, Yan,Wang, Lihua,Xiao, Yuefei,Shi, Shumei,Zuo, Xiaoxia,Li, Zhanguo,Qiao, Li,Wang, Rong,Li, Wenge,Wan, Jianxin,Li, Ying,Guan, Tianjun,Deng, Xiaoli,Wu, Xiaoyan,Zheng, Hongguang,Chen, Jianghua,He, Lan,Yamaguchi, Seika,Wang, Hua,Cai, Guang-Yan,Zhang, Li,Chen, Xiangmei",14/03/2025,JAMA network open
10.1038/s42255-025-01254-5,cyclic metabolic switching theory intermittent fasting,intermittent fasting ketogenic diet kds have recently attract much attention scientific literature popular culture follow long history exercise caloric restriction cr research involve cyclic metabolic switching cms ketogenic non ketogenic state kds cr may not perspective postulate beneficial effect result alternate activation adaptive cellular stress response pathway fast period follow cell growth plasticity pathway feeding period thereby establish cyclic metabolic switching cms theory health benefit may go see continuous cr kds cms owe unique interplay signal function ketone β hydroxybutyrate mitochondrial adaptation reciprocal activation autophagy mtor pathway endocrine paracrine signalling gut microbiota circadian biology cms theory may have important implication future basic research clinical trial development pharmacological intervention healthy lifestyle practice,"Mattson, Mark P",25/09/2024,Nature metabolism
10.1038/s44161-025-00622-4,maternal high fat diet exacerbate atherosclerosis development offspring epigenetic memory,maternal exposure western type diet wd increase susceptibility adult offspring to atherosclerosis partly fetal endothelial cell ecs become dysfunctional inflame due risk factor transmit maternal fetal blood exchange however underlie mechanism remain unclear here show maternal wd accelerate atherogenesis adult offspring mouse regulate chromatin dynamic activator aortic ec induce inflammatory memory chromatin level find hydroxycholesterol be involve memory establishment also act secondary stimulator amplify expression inflammatory factor enhance enrichment ecs inhibit bind chromatin reduce inflammatory response human umbilical vein ec mother hypercholesterolemia decrease atherogenesis offspring mouse expose maternal wd finding demonstrate maternal wd exacerbate ec dysfunction atherosclerosis adult offspring induce associate epigenetic memory increase chromatin accessibility inflammatory gene,"Li, Kan,Qian, Weiqi,Zhang, Fangni,Zhang, Wenhui,Lv, Huizhen,Quan, Meixi,Sun, Weiyan,Liu, Ruixin,Cao, Xinyi,Xian, Zhong,Bao, Suya,Jiang, Hongfeng,Du, Jie,Zhang, Meng,Chen, Yupeng,Zhang, Jian,Han, Cha,Ai, Ding",04/07/2024,Nature cardiovascular research
10.1053/j.gastro.2025.02.032,evolution esophageal adenocarcinoma precursor lesion stem cell,background aim metastatic cancer arise decade long succession increasingly virulent precursor lesion represent prospective target therapeutic intervention evolutionary process have be particularly vivid esophageal adenocarcinoma eac cancer associated precursor lesion include barrett esophagus be low grade dysplasia lgd high grade dysplasia hgd co exist accessible two dimensional pattern esophageal mucosa give durability precursor lesion be likely eac rely stem cell regenerative growth to assess role stem cell evolution eac apply technology selectively clone stem cell gastrointestinal tract patient match endoscopic biopsy precursor lesion implicate eac method histologically validate endoscopic biopsy series include eac hgd lgd be normal esophageal mucosa be obtain patient present eac rare cell lesion prove clonogenic be assess vitro differentiation tumorigenicity mouse molecular genetic result lesion evolution eac possess discrete set clonogenic cell mark immaturity enormous proliferative potential lesion specific differentiation fate dna sequence clone reveal intralesional heterogeneity clonal resolution mutation progression give patient be lgd hgd eac high throughput chemical screen against be stem cell reveal drug combination be similarly effective stem cell ldg hgd eac conclusion lesion evolution eac possess discrete population stem cell be potential therapeutic target,"Xian, Wa,Wang, Shan,Xie, Jingzhong,Yamamoto, Yusuke,Khorrami, Melina,Zhang, Yanting,Montes, Raul Caballero,Desales, Caycel,Khorrami, Melika,Mory, Zaal,Hoffman, Ashley,Su, Amber,Nguyen, Crystal,Davies, Peter J A,Stephan, Clifford,Pan, Shuang,Wu, Wengen,Liu, Yuxin,Siegelman, Jeremy,Waters, Rebecca E,Ross, William A,Song, Shumei,Metersky, Mark,Beer, David G,Crum, Christopher P,Stewart, Alexander J,Vincent, Matthew,Russell, Richard,Izard, Robert A,Ho, Khek Yu,Lai, Jack Hung-Sen,Bachovchin, William W,Ajani, Jaffer A,McKeon, Frank D",07/11/2024,Gastroenterology
10.1016/j.phymed.2025.156628,effective compound jinshui huanxian formula act src inhibitor to inhibit mediate lactation improve pulmonary fibrosis,background active ingredient composition jinshui huanxian formula ecc jhf consist five active ingredient icariin isoliquiritigenin nobiletin peimine paeoniflorin demonstrate notable therapeutic effect pulmonary fibrosis purpose inhibition glycolysis have be demonstrate to be effective treat experimental idiopathic pulmonary fibrosis ipf research seek to explore impact aerobic glycolysis mitigation pulmonary fibrosis ecc jhf method pulmonary fibrosis mouse model be generate administration bleomycin bleomycin degree pulmonary fibrosis be analyze hematoxylin eosin stain as well masson trichrome stain western blot wb immunofluorescence real time quantitative pcr q pcr assay fibroblast activation marker glycolysis relate gene lung tissue lactic acid la content assay kit be employ to quantify lactate concentration lung tissue fibroblast culture immunoprecipitation ip be apply to detect lactylate modify protein level mass spectrometry ms be use to analyze lactate substrate profile fibroblast wb be employ to detect lactate modification level histone target ecc jhf be analyze use network pharmacology molecular docking cellular enthusiasm transfer analysis cetsa examine binding ecc jhf src influence ecc jhf src activation be assess use wb src small interfere rna sisrc be design transfecte cell to validate function src inhibition fibroblast activation ecc jhf result blm induce pulmonary fibrosis mouse ecc jhf significantly reduce alveolar inflammation collagen deposition lung tissue fibroblast ecc jhf notably inhibit expression lactate level lactylate modifying protein ms wb analysis show ecc jhf significantly reduce level network pharmacology analysis molecular docking cetsa result indicate src serve key target ecc jhf sisrc effectively mitigate impact ecc jhf expression level activation fibroblast conclusion ecc jhf may improve pulmonary fibrosis inhibit src activation block mediate lactate production down regulate level inhibit fibroblast activation result serve significant reference advancement ecc jhf exploration ipf,"Zheng, Jiaping,Du, Yan,Shao, Wenbo,Li, Jiansheng,Zhao, Peng,Zhang, Qin",04/09/2024,Phytomedicine : international journal of phytotherapy and phytopharmacology
10.1038/s41413-025-00413-4,axis prevent osteoarthritis mitochondrial renewal metabolic switch,maintain mitochondrial homeostasis be critical preserve chondrocyte physiological condition increase resistance osteoarthritis oa however underlie mechanism govern mitochondrial self renewal energy production remain elusive study demonstrate mitochondrial damage aberrant mitophagy oa chondrocyte genetically overexpresse pten induce putative kinase protect cartilage degeneration remove defective mitochondria knockout aggravate cartilage damage impaired mitophagy directly deacetylate to promote mitophagy cartilage anabolism specifically phosphorylate site preserve active tetrameric form inhibit nuclear translocation interaction β catenin result metabolic shift increase energy production finally double knockout mouse model demonstrate role axis safeguard structural integrity articular joint improve motor function overall study provide novel insight regulation mitochondrial renewal metabolic switch oa,"Deng, Yaoge,Hou, Mingzhuang,Wu, Yubin,Liu, Yang,Xia, Xiaowei,Yu, Chenqi,Yu, Jianfeng,Yang, Huilin,Zhang, Yijian,Zhu, Xuesong",19/08/2024,Bone research
10.1210/clinem/dgaf174,role regulation intramuscular sex hormone skeletal muscle systematic review,introduction serum concentration androgen oestrogen main male female sex hormone respectively naturally fluctuate lifespan sex hormone be mainly produce gonad evidence suggest can also be locally synthesise skeletal muscle however little be know purpose intramuscular sex hormone role skeletal muscle systematic review aim to investigate intramuscular sex hormone concentration vary lifespan exercise affect intramuscular sex hormone concentration intramuscular sex hormone be associate skeletal muscle mass function method four database be search study be include contain measurement intramuscular sex hormone healthy male female free hormonal treatment rodent result thirteen study be include intramuscular testosterone be reduce old male compare young counterpart comparison intramuscular sex hormone concentration post menopausal female yield inconclusive finding chronic exercise decrease androgen oestradiol female increase androgen male acute exercise do not change intramuscular hormone concentration human increase rodent intramuscular androgen be positively associate muscle mass strength male female conflicting finding be report oestradiol androgen measure muscle mass function conclusion current evidence suggest ageing exercise differentially modulate intramuscular sex hormone concentration association muscle mass function male female model system,"Engman, Viktor,Critchlow, Annabel J,Laakkonen, Eija K,Hansen, Mette,Mason, Shaun,Lamon, Séverine",28/10/2024,The Journal of clinical endocrinology and metabolism
10.1111/ceo.13695,cardiovascular effect safety mannitol treat raise intraocular pressure,,"Atik, Alp,Chan, Elsie,Crock, Carmel,Ang, Ghee S",24/11/2019,Clinical & experimental ophthalmology
10.1016/j.ecoenv.2025.118029,network toxicology machine learn approach to investigate mechanism kidney injury melamine cyanuric acid co exposure,background past two decade high profile case melamine ma exposure have raise significant toxicological concern particularly regard food adulteration widely use fundamental organic chemical intermediate various household product ma potential unexpected toxicological synergy homolog cyanuric acid can remain concern study aim to investigate nephrotoxicity combine melamine cyanuric acid mc exposure underlie mechanism rat integrative approach combine network toxicology not bioinformatics experimental validation material method rat be expose mc dose mg kg day control mg kg day mc four week kidney pathology injury marker rna sequence rna seq datum be analyze to identify differentially express gene two group bioinformatics analysis include pathway enrichment immune microenvironment analysis be conduct to elucidate underlie mechanism mc induce kidney injury potential target protein be identify use chembl stitch genecard database hub gene be screen use three machine learning algorithm lasso regression random forest molecular complex detection molecular docking simulation be perform to assess interaction mc identify hub gene result mc exposure result severe kidney morphological histological change as well elevated level kidney injury fibrosis marker rna seq analysis reveal significant enrichment immuno inflammatory apoptosis relate pathway mc group immune microenvironment analysis confirm infiltration pro inflammatory immune cell network toxicology analysis identify potential target associate mc induce kidney injury two hub gene ren be identify key regulator renin angiotensin aldosterone system raas activation apoptosis respectively further experimental validation include western blotting immunofluorescence confirm upregulation protein molecular docking simulation demonstrate strong bind affinity mc two hub protein conclusion mc exposure induce significant kidney injury fibrosis activation raas pathway apoptosis play crucial role mc mediate nephrotoxicity however additional vivo experimental validation be lack future study should focus further exploration mechanism mc induce nephrotoxicity more rigorous experimental validation,"Wang, Zhan,Zhou, Zhaokai,Zhao, Zihao,Zhang, Junjie,Zhang, Shengli,Li, Luping,Fan, Yingzhong,Li, Qi",07/12/2024,Ecotoxicology and environmental safety
10.1038/s41588-025-02077-6,alteration pd succinylation shape anti tumor immune response melanoma,tumor undergo metabolic reprogramme to meet energetic synthetic redox demand essential malignancy often characterize increase glycolysis lactate production however role mitochondrial metabolism tumor immunity remain unclear present study integrate spatial transcriptomic bulk transcriptomic proteomic reveal strong link metabolite succinyl coa tumor immunity as well efficacy anti programmed cell death therapy patient melanoma elevated succinyl coa level α ketoglutarate succinate supplementation enhanced t cell mediate tumor elimination vitro vivo mechanistically succinylation ligand pd lysine lead degradation increase carnitine palmitoyltransferase identify succinyltransferase pd boost anti tumor activity preclinically bezafibrate hyperlipidemia drug upregulated synergize monoclonal antibody to inhibit tumor growth clinically high pd low level tumor correlate well anti therapy response suggest potential biomarker prediction treatment efficacy,"Liang, Long,Kuang, Xinwei,He, Yi,Zhu, Lin,Lau, Poyee,Li, Xin,Luo, Dingan,Gong, Lan,Zhou, Wenbin,Zhang, Fanglin,Liang, Xiaowei,Li, Zhuofeng,Hu, Bin,Liu, Dandan,Ding, Tao,Li, Hui,Zhao, Shuang,Su, Juan,Hung, Mien-Chie,Liu, Jing,Liu, Hong,Chen, Xiang",11/11/2023,Nature genetics
10.1038/s41580-025-00828-1,nuclear genome dynamic underlie dna double strand break repair,change nuclear shape spatial organization chromosome nucleus commonly occur cancer ageing other clinical context be characterize increase dna damage however relationship nuclear architecture genome organization chromosome stability health remains poorly define study explore connection positioning mobility damage dna relative various nuclear structure genomic loci have reveal nuclear cytoplasmic process affect chromosome stability review discuss dynamic mechanism regulate nuclear genome organization to promote dna double strand break dsb repair genome stability cell survival genome dynamic support dsb repair rely chromatin state repair protein condensate nuclear cytoplasmic microtubule actin filament kinesin myosin motor protein nuclear envelope various nuclear compartment chromosome topology chromatin loop extrusion diverse signal cue process be commonly alter cancer natural premature ageing indeed reshaping genome nuclear space dsb repair point new avenue therapeutic intervention may take advantage new cancer cell vulnerability aim to reverse age associate defect,"Chiolo, Irene,Altmeyer, Matthias,Legube, Gaëlle,Mekhail, Karim",21/01/2025,Nature reviews. Molecular cell biology
10.1182/blood.2024027336,safety efficacy rilzabrutinib placebo adult immune thrombocytopenia phase study,rilzabrutinib be covalent reversible btk inhibitor multiple mechanism target key immune thrombocytopenia itp disease pathophysiology phase study previously treat adult persistent chronic itp evaluate oral rilzabrutinib mg bid placebo week baseline overall median age be year range female year range median duration itp be splenectomize overall rilzabrutinib placebo patient achieve platelet response l l double baseline first week be eligible to complete double blind period primary endpoint durable platelet response platelet count l third last week rescue therapy be observe rilzabrutinib placebo patient secondary efficacy endpoint be significantly superior rilzabrutinib median time first platelet response be d rilzabrutinib responder rilzabrutinib significantly reduce rescue therapy use improve week bleeding score improve physical fatigue be sustain week treatment relate adverse event be mainly grade one rilzabrutinib patient multiple risk factor have serious treatment relate grade peripheral embolism low left leg die unrelated pneumonia itp patient fail multiple previous therapy splenectomy tpo ra rituximab fostamatinib result rapid durable platelet response reduce rescue medication use bleeding significantly improve physical fatigue show favorable safety eudract,"Kuter, David J,Ghanima, Waleed,Cooper, Nichola,Liebman, Howard Allen,Zhang, Lei,Hu, Yu,Miyakawa, Yoshitaka,Homenda, Wojciech,Morales Galindo, Luisa Elena Elena MD,Basquiera, Ana Lisa,Tan, Chuen Wen,Saydam, Guray Prof Dr,Hütter-Krönke, Marie Luise,Chai-Adisaksopha, Chatree,Gomez-Almaguer, David,Tran, Huy,Shin, Ho-Jin,Dantas da Cunha Junior, Ademar,Lazar, Zsolt,Pascual-Izquierdo, Cristina,Kirgner, Ilya,Lucchini, Elisa,Kuzmina, Ganna,Fillitz, Michael,Audia, Sylvain,Taparia, Minakshi,Cordoba, Matias,Diab, Remco,Yao, Mengjie,Gouia, Imene Dr,Lee, Michelle,Daak, Ahmed Abd Almalik",23/01/2025,Blood
10.1038/s41392-025-02190-2,target tumor intrinsic calcium bind protein augment antitumor immunity potentiate immunotherapy efficacy,immune checkpoint blockade icb have revolutionize cancer treatment therapeutic response be highly heterogeneous highlight necessity develop predictive biomarker overcome icb resistance cancer cell intrinsic feature especially can be dynamically monitor liquid biopsy represent broad scope biomarker development addition potential mode icb resistance be tumor intrinsic mechanism lead immunosuppressive tumor microenvironment tme however underlie interactive network remain elusive generalizable biomarker target strategy be still lack here uncover potential plasma calcium bind protein determine icb efficacy liquid biopsy patient lung cancer multiomic functional study have suggest tumor intrinsic expression correlate immunologically cold tme resistance icb multiple syngeneic murine tumor tissue sample patient lung cancer mechanistic investigation demonstrate interfere tumor intrinsic ubiquitin specific protease granulocyte macrophage colony stimulate factor gm csf modulatory axis could potentiate inflame tme promote like macrophage polarization t cell function gm csf priming be sufficient to enhance icb response tumor high expression preclinical model finding define potential blood base biomarker novel synergistic target cancer immunotherapy,"Guo, Yufeng,Wan, Rui,Duan, Jianchun,Yuan, Li,Wang, Zhijie,Zhong, Jia,Zhang, Xue,Ma, Zixiao,Bai, Hua,Wang, Jie",06/09/2024,Signal transduction and targeted therapy
10.1186/s13024-025-00819-y,alzheimer disease neuropathology estimation fluid imaging biomarker,alzheimer disease ad be neuropathologically characterize extracellular deposition amyloid β peptide aβ intraneuronal accumulation abnormal phosphorylate tau p τ most frequently hallmark lesion be accompany other co pathology brain may contribute cognitive impairment such vascular lesion intraneuronal accumulation phosphorylate transactive response dna bind protein α synuclein αsyn aggregate to estimate extent ad co pathology patient several biomarker have be develop specific tracer target visualize aβ plaques p τ αsyn pathology inflammation positron emission tomography addition imaging biomarker cerebrospinal fluid blood base biomarker assay reflect ad specific non specific process be already clinical use development review will introduce pathological lesion ad brain related biomarker discuss extent respective biomarker estimate pathology determine post mortem histopathological analysis become evident initial stage aβ plaque p τ pathology be not detect currently available biomarker interestingly p τ pathology precede deposition especially beginning disease biomarker be unable to detect later aβ take lead accelerate p τ pathology fit well known evolution biomarker measure time co pathology still lack clinically establish biomarker today such pathology cortical microinfarct summary specific biomarker ad relate pathology allow accurate clinical diagnosis ad base pathobiological parameter current biomarker be excellent measure respective pathology fail to detect initial stage disease post mortem analysis brain be still require accordingly neuropathological study remain essential to understand disease development especially early stage moreover be urgent need biomarker reflect co pathology such limbic predominant age relate encephalopathy relate pathology be know to modify disease interact p τ novel biomarker approach such extracellular vesicle base assay cryptic rna peptide may help to well detect co pathology future,"Thal, Dietmar Rudolf,Poesen, Koen,Vandenberghe, Rik,De Meyer, Steffi",10/07/2024,Molecular neurodegeneration
10.1186/s12872-025-04510-4,hemorrhage risk associate triple antithrombotic therapy focused real world pharmacovigilance disproportional analysis study,background triple antithrombotic therapy tat combine dual antiplatelet therapy dapt oral anticoagulant be commonly use patient require long term anticoagulation follow acute coronary syndrome percutaneous coronary intervention however tat may increase risk hemorrhage be dearth datum regard risk bleed various oral anticoagulant tat comparison dapt individual anticoagulant antiplatelet due carry present study examine real world pharmacovigilance datum method datum be extract usfda adverse event reporting system aer march june use standardized meddra query smq code haemorrhage employ case non case approach disproportionality analysis to detect safety signal hemorrhage anticoagulant antiplatelet dual antiplatelet triple antithrombotic combination report include combination dapt acetylsalicylic acid clopidogrel oral anticoagulant acenocoumarol apixaban dabigatran edoxaban rivaroxaban warfarin be analyze signal detection use frequentist report odd ratio ror proportional reporting ratio bayesian bayesian confidence propagation neural network multi item gamma poisson shrinker algorithm low limit confidence interval ror indicate high reporting risk bleed follow outcome be evaluate tat death disability hospitalization result unique report involve tat dapt individual antiplatelet most case occur elderly patient age year predominance male patient rivaroxaban combine dapt present high hemorrhage signal ror ci apixaban show low ror ci other anticoagulant be follow warfarin ror ci dabigatran ror ci acenocoumarol ror ci mortality hospitalization rate vary significantly treatment rivaroxaban link high mortality conclusion study highlight elevated hemorrhage risk associate tat particularly rivaroxaban apixaban appear safe term bleeding mortality finding underscore need cautious monitoring bleed outcome anticoagulant regimen particularly rivaroxaban combination optimize patient outcome however signal obtain study need to be validate future trial,"Sridharan, Kannan,Sivaramakrishnan, Gowri",05/12/2024,BMC cardiovascular disorders
10.1016/j.diabres.2025.112105,nonlinear association hemoglobin glycation index mortality ischemic stroke patient insight mimic iv database,aim hemoglobin glycation index hgi be closely associate adverse outcome several disease however few study have investigate correlation hgi prognosis patient critical ischemic stroke method cohort patient be establish medical information mart intensive care mimic iv database kaplan meier analysis multivariate regression model restrict cubic spline rcs be use to investigate association hgi different outcome mediation model be construct to determine mediate role white blood cell wbc count result study include participant hospital mortality differ significantly hgi group p multivariate regression analysis find low hgi be significantly associate great mortality risk nonlinear analysis reveal l shape association hgi short term mortality day hospital reverse j shaped relationship emerge long term day mortality mediation analysis reveal wbc count mediate association proportion respectively conclusion low hgi be consistently relate poor outcome patient critical ischemic stroke high could be protective factor short term might increase mortality risk long term wbc count significantly mediate association,"Huang, Xuhang,Huang, Lejun,Tao, Haoran,Ren, Meng,Yan, Li",05/02/2025,Diabetes research and clinical practice
10.1172/JCI185217,deep immunophenotyping reveal circulate activate lymphocyte individual risk rheumatoid arthritis,rheumatoid arthritis ra be systemic autoimmune disease currently universally highly effective prevention strategy identify pathogenic immune phenotype risk population prior clinical onset be crucial establish effective prevention strategy here apply multimodal single cell technology mass cytometry cite seq to characterize immunophenotype blood risk individual aris identify presence serum antibody citrullinate protein antigen acpas first degree relative fdr status compare patient establish ra people healthy control group identify significant cell expansion aris compare control include t cell t peripheral helper tph cell type t helper cell t cell also find classical monocyte be specifically expand acpa negative fdrs activate naive b cell population be expand acpa positive fdrs far uncover molecular phenotype t cell express high level relate signature transcript include integrated study provide promising approach to identify target to improve prevention strategy development ra,"Inamo, Jun,Keegan, Joshua,Griffith, Alec,Ghosh, Tusharkanti,Horisberger, Alice,Howard, Kaitlyn,Pulford, John F,Murzin, Ekaterina,Hancock, Brandon,Dominguez, Salina T,Gurra, Miranda G,Gurajala, Siddarth,Jonsson, Anna Helena,Seifert, Jennifer A,Feser, Marie L,Norris, Jill M,Cao, Ye,Apruzzese, William,Bridges, S Louis,Bykerk, Vivian P,Goodman, Susan,Donlin, Laura T,Firestein, Gary S,Bathon, Joan M,Hughes, Laura B,Filer, Andrew,Pitzalis, Costantino,Anolik, Jennifer H,Moreland, Larry,Hacohen, Nir,Guthridge, Joel M,James, Judith A,Cuda, Carla M,Perlman, Harris,Brenner, Michael B,Raychaudhuri, Soumya,Sparks, Jeffrey A,Holers, V Michael,Deane, Kevin D,Lederer, James,Rao, Deepak A,Zhang, Fan",24/07/2024,The Journal of clinical investigation
10.2337/dc24-1825,progression cerebral small vessel disease neurologically asymptomatic middle aged individual type diabetes,objective to investigate potential progression rate cerebral small vessel disease csvd brain mri neurologically asymptomatic middle aged individual type diabetes research design method total individual type diabete be re examine brain mri year initial visit baseline predictor change csvd particularly cerebral microbleed cmb white matter hyperintensitie wmhs be analyze result proportion individual type diabete csvd increase to p cmb increase to p wmhs to p follow up increase cmb be associate baseline systolic blood pressure preexist cmb increase csvd wmhs be associate only age conclusion prevalence csvd double year period middle aged individual type diabetes,"Tarkkonen, Aleksi,Kyläheiko, Iiris,Inkeri, Jussi,Eriksson, Marika I,Thorn, Lena M,Summanen, Paula A,Tatlisumak, Turgut,Groop, Per-Henrik,Putaala, Jukka,Gordin, Daniel,Martola, Juha",27/08/2024,Diabetes care
10.1182/blood.2024027270,single cell panleukemia signature hspc like blast predict drug response clinical outcome,critical role leukemic initiate cell therapy resistant population myeloid leukemia be well establish however molecular signature such cell acute lymphoblastic leukemia remain underexplored moreover role therapy response patient prognosis be yet to be systematically investigate various type acute leukemia employ single cell multiomic to analyze diagnostic specimen pediatric patient acute lymphoblastic myeloid lineage ambiguous leukemia integration single cell multiomic extensive bulk rna seq clinical dataset uncover prevalent chemotherapy resistant subpopulation resemble hematopoietic stem progenitor cell hspc like be associate poor clinical outcome subtype investigate identify core transcriptional regulatory network trn hspc like blast be combinatorically control hoxa cebpa signature can predict chemotherapy response long term clinical outcome identify share potential therapeutic target hspc like blast include pathway study provide framework link intra tumoral heterogeneity therapy response patient outcome discovery new therapeutic target pediatric acute leukemia,"Chen, Changya,Xu, Jason,Sussman, Jonathan H,Vincent, Tiffaney L,Tumulty, Joseph S,Yoshimura, Satoshi,Alikarami, Fatemeh,Yu, Wenbao,Ding, Yang-Yang,Chen, Chia-Hui,Li, Elizabeth Y,Yang, Austin,Qin, Xiaohuan,Bandyopadhyay, Shovik,Peng, Jacqueline Jiahui,Pölönen, Petri,Newman, Haley,Wood, Brent,Hu, Jianzhong,Shraim, Rawan,Hughes, Andrew D,Diorio, Caroline,Uppuluri, Lahari,Shi, Gongping,Ryan, Theresa,Fuller, Tori,Loh, Mignon L,Raetz, Elizabeth A,Hunger, Stephen P,Pounds, Stanley B,Mullighan, Charles G,Frank, David,Yang, Jun J,Bernt, Kathrin Maria,Teachey, David Trent,Tan, Kai",01/03/2025,Blood
10.1038/s41467-025-57962-9,control cardiomyocyte proliferation heart regeneration regulate expression postnatal mouse,forkhead box transcription factor be crucial control heart growth adulthood exact role cardiac repair regeneration postnatal mouse remain unclear here show deficiency promote cardiomyocyte proliferation postnatal mouse improve cardiac function homeostatic adult mouse moreover deficiency accelerate heart regeneration follow injury postnatal mouse regenerative non regenerative stage reveal directly promote expression secrete frizzle relate protein suppress activation canonical wnt β catenin signal heart regeneration increase activation β catenin deficient cardiomyocyte can be block overexpression addition overexpression suppress cardiomyocyte proliferation heart regeneration deficient mouse finding suggest negatively control cardiomyocyte proliferation heart regeneration postnatal mouse least part promote expression lead inactivation canonical wnt β catenin signaling,"Xia, Jing-Bo,Liu, Kun,Lin, Xiao-Lin,Li, Hong-Ji,Lin, Jin-Hua,Li, Li,Liang, Chi-Qian,Cao, Yan,Wen, Na,Liao, Zhao-Fu,Zhao, Hui,Park, Kyu-Sang,Song, Guo-Hua,Ye, Ze-Bing,Cai, Dong-Qing,Ju, Zhen-Yu,Qi, Xu-Feng",20/05/2024,Nature communications
10.1080/1750743X.2025.2479410,effect helicobacter pylori infection immunotherapy gastrointestinal cancer narrative review,immunotherapy gastrointestinal cancer have elicit considerable amount attention viable therapeutic option several cancer type gut microbiome whole play critical role shape immune response influence cancer progression recent evidence suggest helicobacter pylori pylori may influence immunotherapy efficacy modulate tumor microenvironment infection pylori be common affect approximately global population remain lead risk factor gastric cancer interestingly recent clinical preclinical datum have associate pylori colorectal cancer carcinogenesis gut microbiome appear to be modulator relationship immune system gastrointestinal cancer development exist therapy infection pylori may affect immunotherapy result gastroesophageal colorectal cancer favorable result be notice pylori positive patient gastric cancer colorectal cancer patient pathogen seem to impede immunotherapy action article aim to review current datum role pylori trigger gastric inflammation cancer as well potential involvement colorectal cancer development additionally seek to highlight impact pylori infection response immunotherapy gastrointestinal cancer,"Ziogou, Afroditi,Giannakodimos, Alexios,Giannakodimos, Ilias,Schizas, Dimitrios,Charalampakis, Nikolaos",15/03/2025,Immunotherapy
10.1038/s41588-025-02121-5,farm animal genotype tissue expression farmgtex project,genetic mutation drift couple natural human mediate selection migration have produce wide variety genotype phenotype farm animal here introduce farm animal genotype tissue expression farmgtex project aim to elucidate genetic determinant gene expression terrestrial aquatic domestic specie diverse biological environmental contexts specie aim to collect multiomics datum particularly genomic transcriptomic tissue healthy adult additional animal represent specific context perspective provide overview priority farmgtex advocate coordinate strategy datum analysis resource share initiative farmgtex aim to serve platform investigate context specific regulatory effect will deepen understanding molecular mechanism underlie complex phenotype knowledge insight provide farmgtex will contribute improve sustainable agriculture base food system comparative biology eventual human biomedicine,"Fang, Lingzhao,Teng, Jinyan,Lin, Qing,Bai, Zhonghao,Liu, Shuli,Guan, Dailu,Li, Bingjie,Gao, Yahui,Hou, Yali,Gong, Mian,Pan, Zhangyuan,Yu, Ying,Clark, Emily L,Smith, Jacqueline,Rawlik, Konrad,Xiang, Ruidong,Chamberlain, Amanda J,Goddard, Michael E,Littlejohn, Mathew,Larson, Greger,MacHugh, David E,O'Grady, John F,Sørensen, Peter,Sahana, Goutam,Lund, Mogens Sandø,Jiang, Zhihua,Pan, Xiangchun,Gong, Wentao,Zhang, Haihan,He, Xi,Zhang, Yuebo,Gao, Ning,He, Jun,Yi, Guoqiang,Liu, Yuwen,Tang, Zhonglin,Zhao, Pengju,Zhou, Yang,Fu, Liangliang,Wang, Xiao,Hao, Dan,Liu, Lei,Chen, Siqian,Young, Robert S,Shen, Xia,Xia, Charley,Cheng, Hao,Ma, Li,Cole, John B,Baldwin, Ransom L 6th,Li, Cong-Jun,Van Tassell, Curtis P,Rosen, Benjamin D,Bhowmik, Nayan,Lunney, Joan,Liu, Wansheng,Guan, Leluo,Zhao, Xin,Ibeagha-Awemu, Eveline M,Luo, Yonglun,Lin, Lin,Canela-Xandri, Oriol,Derks, Martijn F L,Crooijmans, Richard P M A,Gòdia, Marta,Madsen, Ole,Groenen, Martien A M,Koltes, James E,Tuggle, Christopher K,McCarthy, Fiona M,Rocha, Dominique,Giuffra, Elisabetta,Amills, Marcel,Clop, Alex,Ballester, Maria,Tosser-Klopp, Gwenola,Li, Jing,Fang, Chao,Fang, Ming,Wang, Qishan,Hou, Zhuocheng,Wang, Qin,Zhao, Fuping,Jiang, Lin,Zhao, Guiping,Zhou, Zhengkui,Zhou, Rong,Liu, Hehe,Deng, Juan,Jin, Long,Li, Mingzhou,Mo, Delin,Liu, Xiaohong,Chen, Yaosheng,Yuan, Xiaolong,Li, Jiaqi,Zhao, Shuhong,Zhang, Yi,Ding, Xiangdong,Sun, Dongxiao,Sun, Hui-Zeng,Li, Cong,Wang, Yu,Jiang, Yu,Wu, Dongdong,Wang, Wenwen,Fan, Xinzhong,Zhang, Qin,Li, Kui,Zhang, Hao,Yang, Ning,Hu, Xiaoxiang,Huang, Wen,Song, Jiuzhou,Wu, Yang,Yang, Jian,Wu, Weiwei,Kasper, Claudia,Liu, Xinfeng,Yu, Xiaofei,Cui, Leilei,Zhou, Xiang,Kim, Seyoung,Li, Wei,Im, Hae Kyung,Buckler, Edward S,Ren, Bing,Schatz, Michael C,Li, Jingyi Jessica,Palmer, Abraham A,Frantz, Laurent,Zhou, Huaijun,Zhang, Zhe,Liu, George E",21/05/2024,Nature genetics
10.1093/brain/awaf102,large scale profiling antibody reactivity glycolipid patient guillain barré syndrome,guillain barré syndrome be acute polyradiculoneuropathy precede infection often elicit production antibody target peripheral nerve antigen principally ganglioside anti ganglioside antibody be think to play key role clinical diversity disease can be helpful clinical practice extensive research clinical association individual anti ganglioside antibody specificity have be perform recent research have highlight glycolipid complex glycolipid combination may alter antibody binding target study investigate antibody reactivity pattern glycolipid glycolipid complex use combinatorial array relation clinical feature guillain barré syndrome total patient observational international guillain barré syndrome outcome study year male control healthy family infectious vaccination other neurological disease be include acute phase sera patient be screen igm igg iga reactivity glycolipid one phospholipid heteromeric complex similarly archive control sera antibody specificity reactivity pattern be analyse relation clinical feature patient be positive at least one anti glycolipid complex antibody anti anti complex antibodie well distinguish motor guillain barré syndrome miller fisher syndrome control antibody glycolipid complex outperform antibodie single glycolipid three model consist anti glycolipid complex antibodie distinguished patient guillain barré syndrome motor variant miller fisher syndrome control high sensitivity specificity perform well antibodie single glycolipid use clinical practice seven patient cluster particular antibody reactivity pattern be identify cluster be distinguish geographical region clinical variant precede campylobacter jejuni infection electrophysiological subtype medical research council sum score study entry ability to walk meter unaided week two patient cluster distinct anti complex reactivity broad restrict differ frequency axonal subtype cumulative incidence analysis anti glycolipid complex antibody be associate time require to regain ability to walk meter unaided adjustment know prognostic factor igg anti ps sulphatide remained associate fast recovery addition anti glycolipid antibody clinical prognostic model slightly improve discriminative capacity insufficiently to improve model measurement anti glycolipid antibody combinatorial array increase diagnostic yield compare assay single glycolipid identify clinically relevant antibody reactivity pattern glycolipid glycolipid complex may be useful outcome prediction guillain barré syndrome,"Thomma, Robin C M,Halstead, Susan K,de Koning, Laura C,Wiegers, Evelin E J A,Gourlay, Dawn S,Tio-Gillen, Anne P,van Rijs, Wouter,Andersen, Henning,Antonini, Giovanni,Arends, Samuel,Attarian, Shahram,Barroso, Fabio A,Bateman, Kathleen J,Benedetti, Luana,Van den Bergh, Peter,Bürmann, Jan,Busby, Mark,Casasnovas, Carlos,Dardiotis, Efthimios,Davidson, Amy,Feasby, Thomas E,Fehmi, Janev,Galassi, Giuliana,Garcia-Sobrino, Tania,Granit, Volkan,Gutiérrez-Gutiérrez, Gerardo,Hadden, Robert D M,Harbo, Thomas,Hartung, Hans-Peter,Hasan, Imran,Holt, James K L,Islam, Zhahirul,Karafiath, Summer,Katzberg, Hans D,Kolb, Noah,Kusunoki, Susumu,Kuwabara, Satoshi,Kuwahara, Motoi,Lehmann, Helmar C,Leonhard, Sonja E,Martín-Aguilar, Lorena,Monges, Soledad,Nobile-Orazio, Eduardo,Pardo, Julio,Pereon, Yann,Querol, Luis,Reisin, Ricardo C,Rinaldi, Simon,Ripellino, Paolo,Roberts, Rhys C,Scheidegger, Olivier,Shahrizaila, Nortina,Sheikh, Kazim A,Silvestri, Nicholas J,Sindrup, Soren H,Stein, Beth,Tan, Cheng Y,Tankisi, Hatice,Visser, Leo H,Waheed, Waqar,Huizinga, Ruth,Jacobs, Bart C,Willison, Hugh J",08/11/2024,Brain : a journal of neurology
10.1080/19490976.2025.2479774,human colitis associate colorectal carcinoma progression be accompany dysbiosis enriched pathobiont,dysbiosis pathobiont contribute inflammation risk colitis associate carcinoma cac animal model role human uncommon disease be unknown identify microbiome difference human cac compare longstanding inflammatory bowel disease ibd sporadic colorectal carcinoma crc twenty four cac resection be match crc ibd control method include histopathology rdna metagenomic pathobiont specific qpcr beta diversity differ diagnosis permanova p distinguish taxa include akkermansia enrich crc bacteroide spp enrich ibd non neoplastic mucosa present distinct beta diversity p cac crc tumor microbiome be similar p metastasis margin enterobacteriaceae be enrich cac bacteroidale crc pathobiont specific qpcr confirm great frequency coli enterotoxigenic bacteroide fragili cac ibd high alpha diversity be associate active inflammation advanced cancer stage short overall survival log rank p mucosal microbiome distinguish cac longstanding ibd implicate pathobiont marker disease progression integrate finding prior animal model research pathobiont promote carcinogenesis ibd patient genotoxicity host cell signal,"Masaadeh, Amr H,Eletrebi, Mohamed,Parajuli, Bishal,De Jager, Nicola,Bosch, Dustin E",17/03/2025,Gut microbes
10.1002/advs.202415756,tumor associate pancreatic stellate cell promote desmoplastic immunosuppressive niche pancreatic ductal adenocarcinoma,pancreatic stellate cell psc contribute pancreatic ductal adenocarcinoma pdac progression therapeutic resistance detailed function remain unclear study combine rna sequence assay transposase accessible chromatin use sequence atac seq sorted psc adjacent normal pdac tissue to investigate transcriptional epigenetic activation psc heterogeneity function be characterize bulk single cell spatial transcriptome as well situ sequence clinical relevance psc immunotherapy be assess use house immune checkpoint blockade icb treatment cohort finding show stress hypoxia signal activate psc pdac three common psc cpscs four tumor associate psc tpsc be identify distinct function cpsc differentiate tpsc immune enrich region tpsc stromal region tpsc exhibit cancer associate myofibroblast mycafs phenotype link poor prognosis notably tpsc locate aggressive mycafs macrophage form desmoplastic immunosuppressive niche tumor boundary promote t cell exhaustion single cell transcriptomic pdac patient treat icb reveal tpsc correlate poor immunotherapy efficacy overall study provide key insight psc pdac potential therapeutic target,"Du, Yanhua,Zhao, Yizhou,Li, Judong,Wang, Jiaxin,You, Shenglan,Zhang, Yao,Zhang, Li,Yang, Jihong,Alinejad-Rokny, Hamid,Cheng, Shujie,Shao, Chenghao,Zou, Duowu,Ye, Youqiong",27/01/2025,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"
,radiofrequency ablation pancreatic neuroendocrine tumor,background pancreatic neuroendocrine tumor pnet include broad range neoplasm span relatively benign to malignant radical resection have be advocate only curative method debulke resection can be indicate locally unresectable pnet debulke surgery improve quality life prolong overall survival disadvantage approach include bleed pancreatic fistula tumor spread alternative method would eliminate complication have be publish yet consider encouraging result study describe radiofrequency ablation rfa locally advanced pancreatic cancer question arise might be possible to use rfa resection alternative pnet case year old gentleman have be admit abdominal pain hyperglycaemic syndrome contrast enhance ct show tumor pancreatic head invade portal vein pv superior mesenteric vein vms surgery be indicate basis eus guide fnab verify pnet uncertain biological behaviour surgery confirm locally advanced tumor pancreatic head invade pv smv polymorbidity radical pancreatoduodenectomy smv resection be not indicate presence symptom rfa pnet use valleylab generator cooltip cluster electrode be perform postoperative course be uneventful final immunohistochemical examination verify well differentiate grade pnet patient be regularly monitor three year follow up quality life be evaluate use standardized eort questionnaire pain be assess ten point visual analogue scale vas ablate area be evaluate annually contrast enhance ct postoperatively abdominal pain cease pain decrease vas insulin dose be reduce international unit humulin r day ct verify tumor regression accord recist response evaluation criterion solid tumor three year follow up local progression tumor dissemination be observe conclusion present first case report patient locally advanced symptomatic pancreatic neuroendocrine tumor successfully treat intraoperative radiofrequency ablation more clinical study be need to evaluate clinical relevance cytoreductive method pnet indication,"Hlavsa, J,Procházka, V,Kala, Z,Man, M,Andrasina, T,Cíhalová, M,Válek, V,Crha, M,Svobodová, I,Urbanová, L",02/07/2011,Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
10.1038/s41586-025-08677-w,hepatic stellate cell control liver zonation size function r spondin,hepatic stellate cell hsc have central pathogenetic role development liver fibrosis however fibrosis independent homeostatic function remain poorly here demonstrate genetic depletion hsc change wnt activity zonation hepatocyte lead mark alteration liver regeneration cytochrome metabolism injury identify r spondin hsc enrich modulator wnt signal responsible hepatocyte regulatory effect hsc hsc selective deletion phenocopie effect hsc depletion hepatocyte gene expression zonation liver size regeneration cytochrome mediate detoxification exacerbate alcohol associate metabolic dysfunction associate steatotic liver disease expression decrease hsc activation be inversely associate outcome patient alcohol associate metabolic dysfunction associate steatotic liver disease protective hepatocyte regulate function hsc resemble r spondin express stromal niche other organ should be integrate current therapeutic concept,"Sugimoto, Atsushi,Saito, Yoshinobu,Wang, Guanxiong,Sun, Qiuyan,Yin, Chuan,Lee, Ki Hong,Geng, Yana,Rajbhandari, Presha,Hernandez, Celine,Steffani, Marcella,Qie, Jingran,Savage, Thomas,Goyal, Dhruv M,Ray, Kevin C,Neelakantan, Taruna V,Yin, Deqi,Melms, Johannes,Lehrich, Brandon M,Yasaka, Tyler M,Liu, Silvia,Oertel, Michael,Lan, Tian,Guillot, Adrien,Peiseler, Moritz,Filliol, Aveline,Kanzaki, Hiroaki,Fujiwara, Naoto,Ravi, Samhita,Izar, Benjamin,Brosch, Mario,Hampe, Jochen,Remotti, Helen,Argemi, Josepmaria,Sun, Zhaoli,Kendall, Timothy J,Hoshida, Yujin,Tacke, Frank,Fallowfield, Jonathan A,Blockley-Powell, Storm K,Haeusler, Rebecca A,Steinman, Jonathan B,Pajvani, Utpal B,Monga, Satdarshan P,Bataller, Ramon,Masoodi, Mojgan,Arpaia, Nicholas,Lee, Youngmin A,Stockwell, Brent R,Augustin, Hellmut G,Schwabe, Robert F",04/03/2024,Nature
10.1038/s41586-025-08858-7,author correction b cell specific checkpoint molecule regulate anti tumour immunity,,"Bod, Lloyd,Kye, Yoon-Chul,Shi, Jingwen,Torlai Triglia, Elena,Schnell, Alexandra,Fessler, Johannes,Ostrowski, Stephen M,Von-Franque, Max Y,Kuchroo, Juhi R,Barilla, Rocky M,Zaghouani, Sarah,Christian, Elena,Delorey, Toni Marie,Mohib, Kanishka,Xiao, Sheng,Slingerland, Nadine,Giuliano, Christopher J,Ashenberg, Orr,Li, Zhaorong,Rothstein, David M,Fisher, David E,Rozenblatt-Rosen, Orit,Sharpe, Arlene H,Quintana, Francisco J,Apetoh, Lionel,Regev, Aviv,Kuchroo, Vijay K",18/03/2025,Nature
10.1080/07853890.2025.2478317,explore role gut microbiota antibiotic resistance prevention,background introduction antimicrobial resistance amr evolution multiple drug resistant mdr bacteria be grave public health concern to combat pandemic amr be necessary to focus novel alternative drug development host interaction pathogen microbiome play pivotal role determine outcome pathogenesis therefore microbiome pathogen interaction be one potential target to be explore novel antimicrobial main body review focus gut microbiome have evolve significant component resistome source antibiotic resistance gene args antibiotic alter composition native microbiota host favour resistant bacteria can manifest opportunistic infection furthermore gut dysbiosis have also be link low dosage antibiotic ingestion subtherapeutic antibiotic treatment stat food environment discussion colonization mdr bacteria be potentially acquire maintain gut microbiota therefore be pivotal to understand microbial diversity role adapt pathogen amr implement several strategy to prevent treat dysbiosis be necessary include faecal microbiota transplantation probiotic prebiotic phage therapy drug delivery model antimicrobial stewardship regulation,"Dongre, Devyani S,Saha, Ujjayni B,Saroj, Sunil D",17/03/2025,Annals of medicine
10.7861/clinmedicine.15-5-457,tackle emerge infection clinical public health lesson west african ebola virus disease outbreak,magnitude west african ebola virus disease outbreak be unforeseen onset initial international response be slow high mortality panic outbreak induce have major effect health system article discuss key public health clinical lesson ebola outbreak include combine epidemiology modelling anthropology initial evidence importance fluid antibiotic management,"Walker, Naomi F,Whitty, Christopher Jm",03/10/2015,"Clinical medicine (London, England)"
10.1001/jamahealthforum.2024.5586,lifetime health effect cost effectiveness tirzepatide semaglutide adult,importance new antiobesity medication lead great weight loss low cardiometabolic risk however high cost medication have raise policy question value coverage decision objective to compare cost effectiveness antiobesity medication lifestyle modification lifestyle modification alone us design setting participant lifetime cost effectiveness analysis be conduct use validated diabetes obesity cardiovascular disease microsimulation model us adult datum be include national health nutrition examination survey individual represent million eligible us adult age to year would meet clinical trial inclusion criterion antiobesity medication individual level simulation project long term cardiometabolic outcome quality adjust life year qalys health care expenditure probabilistic sensitivity analysis subgroup analysis body mass index bmi category at least weight relate comorbidity presence comorbiditie multiple scenario analysis vary treatment discontinuation rate value base pricing benchmark be conduct future cost qaly be discount annually intervention lifestyle modification naltrexone bupropion phentermine topiramate semaglutide tirzepatide lifestyle modification alone main outcome measure obesity diabetes cardiovascular disease case avert life year qaly gain cost incur us dollar incremental cost effectiveness ratio result million eligible us adult mean age be se year be female initial mean bmi be se have at least weight relate comorbidity lifetime tirzepatide would avert obesity case uncertainty interval ui individual semaglutide would avert case ui individual tirzepatide would reduce incident case diabete ui individual semaglutide would reduce case ui individual tirzepatide would reduce cardiovascular disease case ui individual semaglutide would reduce case ui individual large incremental qaly gain tirzepatide semaglutide antiobesity medication incremental cost effectiveness ratio be qaly qaly respectively to reach qaly threshold price would require additional discount tirzepatide semaglutide current net price naltrexone bupropion be cost save low cost have probability be cost effective qaly phentermine topiramate have probability be cost effective qaly tirzepatide semaglutide have probability qaly threshold range examine qaly conclusion relevance economic evaluation find tirzepatide semaglutide offer substantial long term health benefit be not cost effective current net price effort to reduce net price new antiobesity medication be essential to ensure equitable access highly effective antiobesity medication,"Hwang, Jennifer H,Laiteerapong, Neda,Huang, Elbert S,Kim, David D",14/03/2025,JAMA health forum
10.1186/s12944-025-02508-7,association cardiometabolic index atherosclerotic cardiovascular disease acorss different glucose metabolism status insight nhane,background cardiometabolic index cmi serve significant marker diabete mellitus dm may predict potential cardiovascular disease development nevertheless correlation cmi atherosclerotic cardiovascular disease ascvd individual exhibit varying glucose metabolism status gm continue to be unclear method overall individual age above be enrol research draw national health nutrition examination survey nhane database individual study be classify three distinct category accord level fast plasma glucose glycate haemoglobin normal glucose regulation prediabete dm multivariate logistic regression model smoothed curve fit technique be apply to investigate correlation cmi ascvd risk vary gm additionally subgroup analysis stratify relevant factor be perform to identify potential effect modifier relationship result overall participant ascvd be include increase trend ascvd risk be observe successive cmi tertile adjust relate covariate significantly positive association be observe cmi ascvd p participant dm high cmi tertile have high ascvd risk compare low tertile ci smoothed curve fit consistently confirm correlation cmi ascvd diverse gms subgroup analysis interaction test highlight statistically significant difference drinking status subgroup p interaction gms subgroup p interaction conclusion research suggest positive association ascvd cmi adult united states particularly individual dm,"Wei, Qiong,Cheng, Xu,Li, Min,Wu, Keying,Chen, Meng,Zhang, Dongmei",13/10/2024,Lipids in health and disease
10.1038/s41598-025-93738-3,relationship serum uric acid level metabolism associate fatty liver disease postmenopausal woman base nhanes,study have show postmenopausal woman have more metabolic abnormality premenopausal woman consensus exist serum uric acid sua affect metabolism associate fatty liver disease mafld postmenopausal prospective observational study examine link use national health nutrition examination survey nhane datum divide woman sua level four quartile use logistic regression subgroup analysis restrict triple spline method to compare prevalence mafld postmenopausal non menopausal woman also use histogram to analyze effect bmi base index population base study involve woman include postmenopausal woman age year multivariate logistic regression show fully adjust model find participant high quartile sua have statistically significant increase risk mafld compare participant low quartile ci p subgroup analysis show significant interaction sua level specific subgroup p interaction additionally rcs threshold analysis show linear correlation p ideal inflection point p left right inflection point effect size be ci p histogram demonstrate postmenopausal bmi increase sua influence mafld high sua level bmi may enhance prevalence mafla us postmenopausal woman result study suggest monitor sua level postmenopausal period be critical determine occurrence intervention mafld,"Zhou, Xiaoding,Yue, Zongxiang,He, Shuming,Yuan, Fengjuan,He, Xingrui,Wang, Jiaqi,Wang, Rong,Luo, Ya,Yi, Qiong",05/11/2024,Scientific reports
10.1038/s42255-025-01237-6,time be now account time day effect to improve reproducibility translation metabolism research,constant expansion field metabolic research have lead more nuanced sophisticated understanding complex mechanism underlie metabolic function disease collaboration scientist various field such neuroscience immunology drug discovery have far enhance ability to probe role metabolism physiological process however many behaviour endocrine biochemical process expression gene protein metabolite have daily h biological rhythm thus peak only specific time day daily variation can lead incorrect interpretation lack reproducibility laboratory challenge translate preclinical study human review discuss biological environmental experimental factor affect circadian rhythm rodent can turn alter metabolic pathway outcome experiment recommend variable be duly consider suggest good practice designing analyse report metabolic experiment circadian context,"Deota, Shaunak,Pendergast, Julie S,Kolthur-Seetharam, Ullas,Esser, Karyn A,Gachon, Frédéric,Asher, Gad,Dibner, Charna,Benitah, Salvador Aznar,Escobar, Carolina,Muoio, Deborah M,Zhang, Eric Erquan,Hotamışlıgil, Gökhan S,Bass, Joseph,Takahashi, Joseph S,Rabinowitz, Joshua D,Lamia, Katja A,de Cabo, Rafael,Kajimura, Shingo,Longo, Valter D,Xu, Ying,Lazar, Mitchell A,Verdin, Eric,Zierath, Juleen R,Auwerx, Johan,Drucker, Daniel J,Panda, Satchidananda",21/07/2024,Nature metabolism
10.1038/s41388-025-03337-9,promote multidrug resistance suppress ferroptosis colorectal carcinoma axis,chemoresistance pose significant challenge colorectal cancer crc treatment however mechanism underlie chemoresistance remain unclear promote proliferation metastasis crc however role mechanism chemoresistance remain unknown therefore aim to investigate effect mechanism multidrug resistance crc study show high level expression be associate poor survival especially group progression follow chemotherapy overexpression increase irinotecan oxaliplatin resistance knockdown suppress multidrug resistance crc cell additionally inhibit ferroptosis associate multidrug resistance ferroptosis activator prevent overexpression mediate cell survival rna sequencing reveal signal pathway be involve process upregulated protein expression directly bind promoter to suppress transcription mediate degradation moreover glutathione peroxidase be downstream pathway crc chemoresistance inhibitor suppress expression increase ferroptosis pdx model study identify axis may be novel signal pathway mediate multidrug resistance crc study propose develop novel strategy cancer treatment to overcome drug resistance future,"Bai, Xiaoming,Duan, Tinghong,Shao, Jiaofang,Zhang, Yutong,Xing, Guangyuan,Wang, Jie,Liu, Xue,Wang, Min,He, Yuanqiao,Wang, Hai,Zhang, Zhi-Yuan,Ni, Min,Zhou, Jin-Yong,Pan, Jinshun",18/08/2024,Oncogene
10.1001/jamainternmed.2025.0115,statin use risk hepatocellular carcinoma liver fibrosis chronic liver disease,importance statin may lower risk hepatocellular carcinoma hcc mitigate liver fibrosis progression objective to evaluate association statin use risk hcc hepatic decompensation emphasis liver fibrosis progression adult patient chronic liver disease cld design setting participant cohort study use datum research patient datum registry patient year old cld baseline score high participant be group statin user nonuser datum analysis be conduct august january exposure statin use main outcome measure outcome include year cumulative incidence hcc hepatic decompensation as well transition liver fibrosis risk category base score statin use be define exposure cumulative define daily dose cddd more fibrosis progression be assess group transition low intermediate high time outcome be analyze use adjusted subhazard ratio ashr trend serial score result analysis include participant mean sd age year female male cld include statin user nonuser statin user exhibit significantly low year cumulative incidence hcc risk difference ci to hepatic decompensation risk difference ci compare nonuser ashr be ci hcc ci to hepatic decompensation exposure lipophilic statin duration statin use cddds be associate further reduction hcc hepatic decompensation risk patient serial datum patient intermediate baseline score ci statin user transition high group compare ci nonuser patient high baseline score ci statin user transition intermediate group ci transition low risk group compare ci ci nonuser respectively p conclusion relevance cohort study find statin use be associate reduce risk hcc hepatic decompensation patient cld as well improve group transition time finding provide support potential role statin prevention hcc liver disease progression,"Choi, Jonggi,Nguyen, Vy H,Przybyszewski, Eric,Song, Jiunn,Carroll, Allison,Michta, Megan,Almazan, Erik,Simon, Tracey G,Chung, Raymond T",17/03/2026,JAMA internal medicine
10.1186/s12933-025-02670-3,proteomic signature type diabete predict incidence coronary heart disease,emerge evidence reveal complex association type diabetes coronary heart disease chd share common risk factor biological pathway study aim to identify share proteomic signature chd as well share protein predict incident chd patient to develop predictive model utilize datum uk biobank participant plasma protein identify protein associate protein be also associate chd share protein determine nine protein show causal association chd include mediation analysis suggest nine protein mediate association chd integrate protein predictive model achieve desirable prediction auc future chd onset patient additionally druggability evaluation show potential therapeutic agent include establish antihypertensive nine novel compound suggest avenue dual target treatment strategy collectively finding unveil proteomic signature associate chd provide implication screen predict future chd onset patient,"Li, Yujian,Li, Dun,Lin, Jing,Zhou, Lihui,Yang, Weiling,Yin, Xin,Xu, Chenjie,Cao, Zhi,Wang, Yaogang",19/01/2025,Cardiovascular diabetology
10.1001/jamainternmed.2025.0115,statin use risk hepatocellular carcinoma liver fibrosis chronic liver disease,importance statin may lower risk hepatocellular carcinoma hcc mitigate liver fibrosis progression objective to evaluate association statin use risk hcc hepatic decompensation emphasis liver fibrosis progression adult patient chronic liver disease cld design setting participant cohort study use datum research patient datum registry patient year old cld baseline score high participant be group statin user nonuser datum analysis be conduct august january exposure statin use main outcome measure outcome include year cumulative incidence hcc hepatic decompensation as well transition liver fibrosis risk category base score statin use be define exposure cumulative define daily dose cddd more fibrosis progression be assess group transition low intermediate high time outcome be analyze use adjusted subhazard ratio ashr trend serial score result analysis include participant mean sd age year female male cld include statin user nonuser statin user exhibit significantly low year cumulative incidence hcc risk difference ci to hepatic decompensation risk difference ci compare nonuser ashr be ci hcc ci to hepatic decompensation exposure lipophilic statin duration statin use cddds be associate further reduction hcc hepatic decompensation risk patient serial datum patient intermediate baseline score ci statin user transition high group compare ci nonuser patient high baseline score ci statin user transition intermediate group ci transition low risk group compare ci ci nonuser respectively p conclusion relevance cohort study find statin use be associate reduce risk hcc hepatic decompensation patient cld as well improve group transition time finding provide support potential role statin prevention hcc liver disease progression,"Choi, Jonggi,Nguyen, Vy H,Przybyszewski, Eric,Song, Jiunn,Carroll, Allison,Michta, Megan,Almazan, Erik,Simon, Tracey G,Chung, Raymond T",17/03/2026,JAMA internal medicine
10.1126/science.adu6445,structure human mitochondrial tom vdac array,mutation ubiquitin kinase cause early onset parkinson disease be stabilize depolarized mitochondrial translocase complex have remain poorly understand determine å resolution cryo electron microscopy structure dimeric human stabilize endogenous array mitochondrial tom vdac complex symmetric arrangement two tom core complex central dimer be facilitate also bind kinase c lobe enter mitochondria proximal barrel tom core complex guide structure explain human be stabilize tom complex regulate oxidation uncover previously unknown tom vdac assembly reveal physiological substrate traverse translocation,"Callegari, Sylvie,Kirk, Nicholas S,Gan, Zhong Yan,Dite, Toby,Cobbold, Simon A,Leis, Andrew,Dagley, Laura F,Glukhova, Alisa,Komander, David",14/03/2025,"Science (New York, N.Y.)"
10.1186/s13195-025-01707-9,perivascular space white matter hyperintensitie alzheimer disease association disease progression cognitive function,background alzheimer disease ad be lead cause dementia characterize accumulation amyloid beta aβ neurofibrillary tangle recent study emphasize role vascular factor include glymphatic system ad pathogenesis particularly aβ clearance diffusion tensor image analysis perivascular space dti alps alps index have emerge novel non invasive method to evaluate glymphatic system vivo show glymphatic insufficiency ad study aim to investigate alteration function glymphatic system individual ad healthy control hc to explore association aβ cerebrovascular disease cvd white matter hyperintensitie wmh cognitive function method dti mri datum three independent study cohort actiglia ad n control delcode ad n control adni ad n control be use to evaluate perivascular space pvs integrity potential biomarker glymphatic activity dti perivascular space technique be use to measure water diffusion pvs provide index to assess efficiency glymphatic system waste clearance function wmh load be quantify flair mri use lesion segmentation tool quantify wmhs volume define region interest roi exclude participant wmhs to avoid confound alps index association cerebrospinal fluid csf ad hallmark biomarker cognitive performance mmse clinical severity cdr be assess result ad patient have significantly low alp index healthy control actiglia ad mean sd control mean sd p delcode ad mean sd control mean sd p adni ad mean sd control mean sd p alps index be associate csf aβ concentration wmh number mmse cdr wmh find rois correlate negatively alps index conclusion study highlight potential dti alps index biomarker glymphatic dysfunction ad underscore importance consider vascular factor glymphatic system pathogenesis diagnosis ad wmhs roi could cause disturbance inaccurate index,"Schirge, Philine Marie,Perneczky, Robert,Taoka, Toshiaki,Ruiz-Rizzo, Adriana L,Ersoezlue, Ersin,Forbrig, Robert,Guersel, Selim,Kurz, Carolin,Brendel, Matthias,Hellmann-Regen, Julian,Priller, Josef,Schneider, Anja,Jessen, Frank,Düzel, Emrah,Buerger, Katharina,Teipel, Stefan,Laske, Christoph,Peters, Oliver,Spruth, Eike,Fliessbach, Klaus,Rostamzadeh, Ayda,Glanz, Wenzel,Janowitz, Daniel,Kilimann, Ingo,Sodenkamp, Sebastian,Ewers, Michael,Rauchmann, Boris-Stephan",20/11/2024,Alzheimer's research & therapy
10.1371/journal.pone.0029122,pore form protein elicit pathogenicity bacillus sp caenorhabditis elegan,soil bacterium bacillus thuringiensis be pathogen insect nematode be very closely related not same specie bacillus cereus bacillus anthracis define characteristic thuringiensis set apart cereus anthracis be production crystal cry protein be pore form toxin pore form protein pfps be know pfp be important virulence factor elimination result reduce virulence many pathogenic bacteria function pfps promote virulence be incompletely understand here study effect cry protein thuringiensis pathogenesis nematode caenorhabditis elegans find thuringiensis own be not able to infect elegans addition pfp cry protein result robust lethal infection consume nematode host day lead bob bag bacteria phenotype other infection elegans characterize date infection thuringiensis show dose dependency base bacterial inoculum size base pfp concentration infection process take day pfp instigate infection process be irreversibly establish minute initial exposure remarkably treatment elegans pfp be able to instigate many other bacillus specie include anthracis even non pathogenic bacillus subtili to become lethal infectious agent elegans co culture express thuringiensis anthracis can result lethal infection elegans anthracis datum demonstrate one potential property pfps be to sensitize host bacterial infection far elegans probably other roundworm can be common host cereus group bacteria finding important ecological research implication,"Kho, Melanie F,Bellier, Audrey,Balasubramani, Venkatasamy,Hu, Yan,Hsu, Wayne,Nielsen-LeRoux, Christina,McGillivray, Shauna M,Nizet, Victor,Aroian, Raffi V",04/11/2011,PloS one
10.1038/s41598-025-89888-z,thyroid function multiple sclerosis two sample mendelian randomization study mediation analysis,multiple sclerosis ms be prevalent neurological disorder complex etiology often associate thyroid function however causal relationship two condition remains poorly understand study aim to elucidate causal relationship thyroid function ms use bidirectional mendelian randomization mr approach to investigate potential mediating role immune cell conduct two sample mr analysis use summary statistic large scale genome wide association study gwas include result sensitivity test such mr egger weight median leave one analysis to support robustness reliability finding inverse variance weight ivw method be primary approach sensitivity analysis conduct use seven additional mr method furthermore multivariable mr mediation analysis be conduct to uncover potential mediating immune cell underlie observed association mr analysis show hypothyroidism elevated thyroid stimulate hormone tsh reduce risk ms p p free thyroxine increase risk ms p mediation analysis show evidence indirect effect ms through hla dr hla dr b cell mediate proportion positive effect reverse effect total effect study provide genetic evidence may increase risk develop ms hla dr hla dr b cell mediate causal relationship thyroid function ms highlight importance far investigate role condition,"Ren, Yinghao,Wang, Xin,Wang, Weiliang,Wang, Zeyu",09/09/2024,Scientific reports
10.1016/j.jad.2025.03.037,association red blood cell distribution width albumin ratio risk depression cross sectional analysis nhane,background red blood cell distribution width albumin ratio rar serve indicator systemic inflammation nutritional status study examine relationship rar depressive disorder adult utilize datum national health nutrition examination survey nhanes method apply logistic regression to evaluate link rar depressive risk corresponding odd ratio confidence interval ci calculate restrict cubic spline rcs be adopt to assess potential linear association receiver operate characteristic roc curve be use to evaluate ability rar to predict depressive risk result present area curve auc result adjust relevant covariate positive association rar clinically relevant depression persist ci p participant high rar quartile exhibit great risk clinically relevant depression low quartile ci p linear relationship rar clinically relevant depression be identify p non linear rar show strong predictive ability depressive risk auc stratify analysis show significant interaction smoking p marital status p rar effect depression outcome conclusion elevated rar be independently link clinically relevant depression indicate potential novel biomarker mental health risk assessment further longitudinal study be necessary to establish causality evaluate clinical relevance,"Liu, Haobiao,Xiang, Rongqi,Chen, Zhuohang",12/11/2024,Journal of affective disorders
10.1126/science.add3417,tunneling nanotube like structure regulate distant cellular interaction heart formation,develop mammalian heart endocardium myocardium be separate so call cardiac jelly communication endocardium myocardium be essential cardiac morphogenesis membrane localize receptor ligand achieve interaction cardiac jelly be not understand work develop mouse cardiac morphogenesis model use variety cellular imaging genetic approach to elucidate question find myocardium endocardium interact directly microstructure term tunneling nanotube like structure tntls tntls extend cardiomyocyte cms to contact endocardial cell ecs directly tntls transport cytoplasmic protein transduce signal cms ec initiate myocardial growth heart luman to form ventricular trabeculae like structure loss tntls disturb signal interaction subsequently ventricular patterning,"Miao, Lianjie,Lu, Yangyang,Nusrat, Anika,Fan, Guizhen,Zhang, Shaohua,Zhao, Luqi,Wu, Chia-Ling,Guo, Hongyan,Huyen, Trang Le Nu,Zheng, Yi,Fan, Zhen-Chuan,Shou, Weinian,Schwartz, Robert J,Liu, Yu,Kumar, Ashok,Sui, Haixin,Serysheva, Irina I,Burns, Alan R,Wan, Leo Q,Zhou, Bin,Evans, Sylvia M,Wu, Mingfu",14/03/2025,"Science (New York, N.Y.)"
10.1186/s12885-025-13902-w,global regional national burden kidney cancer attributable risk factor adult age year old projection,background identify past future burden kidney cancer kc temporal trend old adult year global regional national level be critical effective prevention strategy method age standardize incidence prevalence mortality disability adjust life year dalys be calculate use datum global burden disease gbd study indicator be stratify sex age socio demographic index sdi correlation indicator sdi be assess temporal trend be quantify use annual average percentage change aapc future trend be predict use bayesian age period cohort bapc model result global age standardize incidence rate asir kc old adult increase people people aapc age standardize daly rate asdr remain stable significant increase be observe age standardize prevalence aapc mortality rate aapc male consistently exhibit high disease burden female additionally asir kc increase significantly age subgroup region high sdi level also show great disease burden oceania have low burden kc asir increase almost country territory czechia show high asir people asdr people smoking high body mass index bmi remain significant risk factor daly mortality old population effect be great high sdi region furthermore burden kc be expect to continue to decline conclusion global burden kc old adult increase notable regional national variation however be project to continue to decline management smoking high bmi remain major challenge people kc necessitating target clinical guideline particularly focus male old adult,"Zhou, Nan,Bai, Hongjing,Zhang, Ziyan,Yu, Baofeng,Zhao, Hong,Li, Jinbo,Zheng, Guoping",17/12/2024,BMC cancer
10.1186/s40164-025-00634-7,disparity incidence mortality disability adjust life year early onset cancer group globally systematic analysis,background global cancer burden be rise early onset cancer become more prevalent aim to investigate burden trend population disparity early onset cancer method annual incidence death disability adjust life year daly number rate early onset year cancer group be calculate global burden disease gbd dataset cover global five sdi grouping country territory estimate annual percentage change eapc incidence mortality daly rate be calculate to quantify temporal trend spearman correlation analysis be use to examine correlation rate eapc sdi result be million new early onset cancer case exclude non melanoma skin cancer nmsc result million death million daly breast tracheal bronchus lung tbl cervical colon stomach cancer be lead cause daly daly rate early onset cancer exclude nmsc change million million estimate annual percentage change eapc daly rate plateaue female decrease male ten cancer group exhibit eapc high sdi quintile have daly cause early onset cancer exclude nmsc high decline trend daly mortality rate high middle sdi quintile have high early onset mortality rate rise trend cancer incidence mortality be especially notable female middle low middle low sdi quintile conclusion global burden early onset cancer differ significantly sdi quintile gender increase burden multiple cancer group pose significant public health challenge rise burden multiple cancer type be alarming highlight need increase policy support target medical assistance to address disparity impact,"Yan, Wenxin,Liu, Min,Jing, Wenzhan,Kang, Liangyu,Zhang, Ning,Sun, Haoran,He, Jinyu,Chen, Zhongdan,Liu, Jue,Liang, Wannian,Dong, Jiahong",09/01/2025,Experimental hematology & oncology
10.1016/j.actbio.2012.11.029,sinter calcium phosphate bioceramic,calcium phosphate ceramic have become prime importance biological application field bone tissue engineering paper review sinter behaviour bioceramic conventional pressureless sintering hydroxyapatite reference compound have be extensively study physico chemistry be detail can be see competition two thermally activate phenomenon proceed solid state diffusion matter densification grain growth usually objective be to promote first prevent second literature datum be analyse sinter map grain growth densification sinter trajectory hydroxyapatite produce conventional pressureless sintering non conventional technique include two step sinter liquid phase sinter hot pressing hot isostatic press ultrahigh pressure microwave spark plasma sinter be present sinter technique may be grain growth occur mainly last step sinter relative bulk density reach maximum value often consider very advantageous most assist sinter technique do not appear very superior conventional pressureless sintering sinter tricalcium phosphate biphasic calcium phosphate be also discuss chemical composition calcium phosphate influence behaviour similarly ionic substitution hydroxyapatite tricalcium phosphate create lattice defect modify sinter rate depend nature can accelerate slow sinter rate thermal stability compound sinter temperature must also be take account control atmosphere may be require to prevent thermal decomposition flash sinter technique allow consolidation low temperature can be helpful,"Champion, E",27/07/2012,Acta biomaterialia
,to cease to proliferate new insight tctp function drosophila study,tor target rapamycin pathway underlie major signal mechanism control cell growth rheb ras homolog enrich brain be small gtpase tor similar other small gtpase rheb cycle gtp bind active state gdp bind inactive state tuberous sclerosis complex gene mutate autosomal dominant disease tuberous sclerosis be show to be rheb gap gtpase activate however guanine nucleotide exchange factor gef rheb have be miss human tctp translationally control tumor protein have be implicate cancer function vivo have not be clearly elucidate recently report molecular genetic characterization tctp function drosophila tctp dtctp display gef activity to rheb be essential rheb activation organ growth thus study provide tight linkage dtctp rheb tor pathway addendum will briefly overview finding discuss perspective future research tctp,"Choi, Kwang-Wook,Hsu, Ya-Chieh",06/03/2009,Cell adhesion & migration
10.1016/j.numecd.2025.103909,association serum uric acid high density lipoprotein cholesterol ratio cause cardiovascular disease mortality stroke cross sectional study,background aim uric acid high density lipoprotein cholesterol ratio uhr have be show to be associate multiple metabolic disease inflammation stroke be second lead cause death third lead cause disability worldwide study investigate relationship serum uhr mortality adult stroke method result study recruit participant stroke national health nutrition examination survey nhanes mortality outcome datum be determine national death index ndi multivariate hazard ratio hr confidence interval ci be assess use cox proportional risk modeling threshold effect analysis stratify analysis identify high risk mortality group participant cause mortality occur include cardiovascular disease cvd mortality multivariate adjustment uhr be significantly linearly associate cause mortality hr ci inverted u shaped relationship be observe uhr cvd mortality plateaue threshold unit increase uhr be link high risk cvd mortality hr ci however threshold unit increase uhr correspond reduction cvd mortality hr ci conclusion linear relationship uhr cause mortality as well inverted u shaped association uhr cvd mortality be observe adult stroke united states threshold cvd mortality be identify uhr,"Ding, Ling,Guo, Haipeng,Zhang, Chao,Liang, Xiaofei,Liu, YangYang",01/10/2024,"Nutrition, metabolism, and cardiovascular diseases : NMCD"
10.1016/j.nut.2025.112718,efficacy vitamin d replacement therapy case myalgic encephalomyelitis chronic fatigue syndrome vaccination,background prolong symptom have be report follow infection vaccination case lead myalgic encephalomyelitis chronic fatigue syndrome cfs patient present hospital postvaccination syndrome meet diagnostic criterion cfs conduct retrospective study patient method measure serum hydroxyvitamin d level patient develop cf vaccination august february vitamin d replacement therapy include dietary counseling sun exposure recommendation oral vitamin d supplementation evaluate change blood vitamin d level symptom improvement result initial visit patient diagnose cfs have insufficient deficient serum hydroxyvitamin d level ng ml mean sd follow vitamin d replacement therapy observe increase blood vitamin d level ng ml associate decrease cfs diagnostic symptom notably patient no long meet cfs diagnostic criterion therapy symptom sleep problem show most improvement follow autonomic symptom conclusion patient develop cf vaccination insufficient deficient vitamin d level appropriate vitamin d replacement therapy medical guidance may lead symptomatic relief be prepare randomize control trial to evaluate efficacy vitamin d replacement therapy individual cfs have develop vitamin d deficiency follow infection vaccination,"Kodama, Shinichiro,Konishi, Nafuko,Hirai, Yuriko,Fujisawa, Akinori,Nakata, Mitsuko,Teramukai, Satoshi,Fukushima, Masanori",29/09/2024,"Nutrition (Burbank, Los Angeles County, Calif.)"
,role fluoxetine anorexia nervosa,objective to evaluate efficacy fluoxetine treatment anorexia nervosa datum source literature obtain search medline january datum synthesis study conduct efficacy fluoxetine treat anorexia nervosa have conflict result study design methodology should be carefully evaluate conclusion fluoxetine play role reduction symptom obsessive compulsive disorder depression anorexic patient psychotherapy nutritional therapy behavioral therapy should be mainstay treatment fluoxetine should be consider option to prevent relapse to treat associated symptom anorexia nervosa follow adequate weight restoration part maintenance therapy not primary acute therapy fluoxetine appear to be promise treatment patient anorexia nervosa further study need to be perform large sample size well design,"Kim, Sara S",30/05/2003,The Annals of pharmacotherapy
10.1182/blood.2024027038,enhance link sialylation determine extended half life cho rvwf,half life recombinant vwf rvwf express cho cell cho rvwf vonicog alfa vonvendiò veyvondiò be significantly long plasma derive pd vwf concentrate finding be intriguing cho cell do not generate sialylation constitute majority human pdvwf sialylation hypothesize glycan difference might regulate long half life cho rvwf lectin plate bind assay liquid chromatography mass spectrometry analysis confirm cho rvwf lack link sialylation conversely however link sialylation be significantly increase cho rvwf also have reduced expose β gal compare pdvwf consistent human datum cho rvwf clearance be significantly reduce mouse compare pdvwf however clearance asialo pdvwf asialo cho rvwf be identical keep in vivo half life prolongation cho rvwf bind murine macrophage cell be significantly decrease compare pdvwf furthermore cho rvwf binding to purify mgl asgpr receptor be also significantly reduce contrast pdvwf vivo study mouse mouse demonstrate mgl asgpr play significant role regulate cho rvwf clearance together finding demonstrate enhance link sialylation cho rvwf be responsible extended vivo half life,"Byrne, Ciara,Ward, Soracha,O'Sullivan, Jamie M,Chan Kwo Chion, Alain,Lopes, Patricia,Baci, Bogdan,Dowd, Caoimhe,Jordan, Darragh,Baker, Ross Ian,Preston, Roger,Monopoli, Marco,Turecek, Peter L,Kotsias, Maximilianos,Cheeseman, Jack,Moran, Alan,Gardner, Richard A,Spencer, Daniel I R,Atiq, Ferdows,O'Donnell, James S",26/02/2025,Blood
10.1038/s41588-025-02136-y,cross ancestry sex stratify genome wide association analysis amygdala subnucleus volume,amygdala be small critical multi nucleus structure emotion cognition neuropsychiatric disorder genetic association amygdala volumetric trait have be investigate sex combine european population cross ancestry sex stratified analysis be lack here conduct cross ancestry sex stratify genome wide association analyse amygdala volumetric trait chinese european individual identify variant trait association p include new association new loci sex combine univariate analysis seven additional new loci sex combine sex stratify multivariate analysis identify ancestry specific two sex specific association identify genetic variant include fine map causal variant regulate amygdala fetal brain gene expression variant be enrich brain development colocalize mood cognition neuropsychiatric disorder result indicate cross ancestry sex stratify genetic association analysis may provide insight genetic architecture amygdala subnucleus volume,"Ji, Yuan,Liu, Nana,Yang, Yunjun,Wang, Meiyun,Cheng, Jingliang,Zhu, Wenzhen,Qiu, Shijun,Geng, Zuojun,Cui, Guangbin,Yu, Yongqiang,Liao, Weihua,Zhang, Hui,Gao, Bo,Xu, Xiaojun,Han, Tong,Yao, Zhenwei,Zhang, Quan,Qin, Wen,Liu, Feng,Liang, Meng,Wang, Sijia,Xu, Qiang,Xu, Jiayuan,Fu, Jilian,Zhang, Peng,Li, Wei,Shi, Dapeng,Wang, Caihong,Lui, Su,Yan, Zhihan,Chen, Feng,Zhang, Jing,Shen, Wen,Miao, Yanwei,Wang, Dawei,Gao, Jia-Hong,Zhang, Xiaochu,Xu, Kai,Zuo, Xi-Nian,Zhang, Longjiang,Ye, Zhaoxiang,Li, Mulin Jun,Xian, Junfang,Zhang, Bing,Yu, Chunshui",14/11/2023,Nature genetics
10.1158/0008-5472.CAN-24-2553,leverage artificial intelligence neoantigen prediction,neoantigen represent class antigen tumor microenvironment arise diverse somatic mutation aberration specific tumorigenesis hold substantial promise advance tumor immunotherapy however only subset neoantigen effectively elicit anti tumor immune response specific neoantigen recognize individual t cell receptor tcrs remain incompletely characterize therefore substantial research have focus screen immunogenic neoantigen mainly major histocompatibility complex mhc presentation tcr recognition specificity give resource intensiveness inefficiency experimental validation predictive model base artificial intelligence ai have gradually become mainstream method to discover immunogenic neoantigen here provide comprehensive summary current ai methodology predict neoantigen particular focus capability to model peptide mhc pmhc pmhc tcr binding furthermore thorough benchmarke analysis be conduct to assess performance antigen presentation predictor score immunogenicity neoantigen ai model have potential application treatment clinical disease several limitation must first be overcome to realize full potential anticipate advancement datum accessibility algorithmic refinement platform enhancement comprehensive validation immune process be poise to enhance precision utility neoantigen prediction methodology,"Zeng, Jing,Lin, Zhengjun,Zhang, Xianghong,Zheng, Tao,Xu, Haodong,Liu, Tang",12/03/2025,Cancer research
10.1001/jamanetworkopen.2025.0728,donepezil fatigue psychological symptom post condition randomized clinical trial,importance fatigue be most commonly report symptom post condition also know long covid impairs various function one underlie mechanism may be intracerebral inflammation due decrease acetylcholine level objective to examine effect donepezil hydrochloride acetylcholinesterase inhibitor post fatigue psychological symptom design setting participant multicenter double blind randomize clinical trial be perform japan december march adult patient week onset global binary fatigue score great chalder fatigue scale be randomize donepezil placebo group exposure intervention be conduct week period donepezil hydrochloride be administer dosage mg d first week then mg d week main outcome measure primary outcome be change chalder fatigue scale score absolute score week initiation treatment other outcome week such psychological symptom quality life be evaluate secondary outcome result total eligible patient be enrol withdraw be lose to follow up therefore patient group be include efficacy analysis female mean sd age year significant difference be observe baseline characteristic group baseline adjust estimate treatment effect donepezil measure mean difference chalder fatigue scale score week be ci to show significant effect intervention p score hospital anxiety depression scale impact event scale revise euroqol dimension level version patient health questionnaire daily health status week be similar serious adverse event occur group conclusion relevance randomize clinical trial donepezil to treat post condition efficacy fatigue psychological symptom be not confirm general population development effective therapeutic post symptom be need more clinical trial should be conduct future trial registration japan registry clinical trial identifi jrct,"Nakamura, Kensuke,Kondo, Kazuhiro,Oka, Naomi,Yamakawa, Kazuma,Ie, Kenya,Goto, Tadahiro,Fujitani, Shigeki",17/03/2025,JAMA network open
10.1172/JCI185278,target ubiquitin independent proteasome small molecule increase susceptibility pan kras mutant cancer model,advance development direct kra inhibitor kra mutant cancer continue to exhibit resistance currently available therapy here identify regγ mutant kra associate factor enhance regγ transcription kras intermediate suggest regγ proteasome be potential target pan kras inhibitor development elucidate mechanism involve kra regγ regulatory axis link activate kra ubiquitin independent proteasome subsequently develop regγ proteasome inhibitor effectively suppress tumor growth kra mutant cancer model lung cancer organoid notably combination inhibitor exhibit enhance antitumor efficacy cancer cell collectively datum support hypothesis kra mutation enhance capacity regγ proteasome increase regγ expression highlight potential ubiquitin independent proteasome inhibition therapeutic approach pan kras mutant cancer,"Shen, Shihui,Zhang, Qiansen,Wang, Yuhan,Chen, Hui,Gong, Shuangming,Liu, Yun,Gai, Conghao,Chen, Hansen,Zhu, Enhao,Yang, Bo,Liu, Lin,Cao, Siyuan,Zhao, Mengting,Ren, Wenjie,Li, Mengjuan,Peng, Zhuoya,Zhang, Lu,Zhang, Shaoying,Shen, Juwen,Zhang, Bianhong,Lee, Patrick Kh,Li, Kun,Li, Lei,Yang, Huaiyu",25/07/2024,The Journal of clinical investigation
10.1002/ueg2.70011,european consensus malabsorption ueg sige lga spg srgh cgs espcg eagen espen espghan part screening special population nutritional goal supportive care primary care perspective,malabsorption be complex multifaceted condition characterise defective passage nutrient blood lymphatic stream several congenital acquire disorder may cause selective global malabsorption child adult such cystic fibrosis exocrine pancreatic insufficiency epi coeliac disease cd other enteropathy lactase deficiency small intestinal bacterial overgrowth sibo autoimmune atrophic gastritis crohn disease gastric small bowel resection early recognition malabsorption be key tailor proper diagnostic work up identify cause malabsorption patient medical pharmacological history be essential identify risk factor several examination endoscopy small intestinal biopsy non invasive functional test radiologic imaging be useful diagnose malabsorption high prevalence cd should always be look case malabsorption other obvious explanation high risk individual nutritional support be key management patient malabsorption different option be available include oral supplement enteral parenteral nutrition patient short bowel syndrome teduglutide prove effective reduce need parenteral nutrition thus improve quality life patient primary care physician have central role early detection malabsorption should be involve multidisciplinary team improve overall management patient european consensus involve scientific society several expert have dissect issue malabsorption include definition diagnostic testing part high risk category special population nutritional assessment management primary care perspective part,"Lenti, Marco Vincenzo,Hammer, Heinz Florian,Tacheci, Ilja,Burgos, Rosa,Schneider, Stephane,Foteini, Anastasiou,Derovs, Aleksejs,Keller, Jutta,Broekaert, Ilse,Arvanitakis, Marianna,Dumitrascu, Dan Lucian,Segarra-Cantón, Oscar,Krznarić, Željko,Pokrotnieks, Juris,Nunes, Gonçalo,Hammer, Johann,Pironi, Loris,Sonyi, Marc,Sabo, Cristina Maria,Mendive, Juan,Nicolau, Adrien,Dolinsek, Jernej,Kyselova, Denisa,Laterza, Lucrezia,Gasbarrini, Antonio,Surdea-Blaga, Teodora,Fonseca, Jorge,Lionis, Christos,Corazza, Gino Roberto,Di Sabatino, Antonio",14/02/2025,United European gastroenterology journal
10.1016/j.genhosppsych.2025.03.005,association exercise snack cognitive function old adult nhane,background age global population dementia incidence be rapidly increase affect million people worldwide physical activity have be link cognitive enhancement specific effect intermittent short bout exercise term exercise snack es cognitive function cf old adult be not well understand method analyze datum adult age year national health nutrition examination survey cycle cf be assess use standardized test physical activity datum be obtain accelerometer measurement es be define min moderate vigorous physical activity regression analysis smoothed curve fitting threshold effect analysis be conduct adjust relevant covariate result significant positive association be find cf daily average monitor independent movement summary specific es mim es β ci total time spend es time es β ci additional unit mim es minute es daily increase cf score point respectively suggest benefit cognitive health age population inverted u shaped relationship be observe inflection point unit day mim es min day time es indicate diminish cognitive benefit threshold conclusion es be associate high cf practical form physical activity offer effective strategy cognitive health mitigate age relate decline present more accessible alternative traditional continuous exercise,"Wu, Junyu,Wang, Yufei,Qiu, Peng,Li, Youqiang",17/10/2024,General hospital psychiatry
10.1172/JCI183745,activate antiviral immune response potentiate immune checkpoint inhibition glioblastoma model,viral mimicry refer activation innate antiviral immune response induction endogenous retroelement res viral mimicry augment antitumor immune response sensitize solid tumor immunotherapy here find target believe to be novel master epigenetic regulator zinc finger protein induce viral mimicry glioblastoma gbm preclinical model potentiate immune checkpoint inhibition ici recruit hush complex precipitate repressive mark endogenous re gbm be associate marked locoregional immunosuppressive transcriptional signature reduce endogenous expression poor immune cell infiltration target decrease trimethylation increase re activate intracellular dsrna signal cascade furthermore knockdown upregulate antiviral immune program significantly increase pd immune checkpoint expression diverse gbm model importantly target sensitize mouse to ici syngeneic murine orthotopic model innate ifn signal response be recapitulate recurrent gbm rgbm sample radiographic response to checkpoint inhibition widely increase expression dsrna pd perivascular cell infiltration suggest dsrna signal may mediate response immunotherapy finally low expression be biomarker clinical response ici improved survival patient rgbm patient melanoma finding suggest could serve target to potentiate immunotherapy glioma,"Seetharam, Deepa,Chandar, Jay,Ramsoomair, Christian K,Desgraves, Jelisah F,Alvarado Medina, Alexandra,Hudson, Anna Jane,Amidei, Ava,Castro, Jesus R,Govindarajan, Vaidya,Wang, Sarah,Zhang, Yong,Sonabend, Adam M,Mendez Valdez, Mynor J,Maric, Dragan,Govindarajan, Vasundara,Rivas, Sarah R,Lu, Victor M,Tiwari, Ritika,Sharifi, Nima,Thomas, Emmanuel,Alexander, Marcus,DeMarino, Catherine,Johnson, Kory,De La Fuente, Macarena I,Alshiekh Nasany, Ruham,Noviello, Teresa Maria Rosaria,Ivan, Michael E,Komotar, Ricardo J,Iavarone, Antonio,Nath, Avindra,Heiss, John,Ceccarelli, Michele,Chiappinelli, Katherine B,Figueroa, Maria E,Bayik, Defne,Shah, Ashish H",10/06/2024,The Journal of clinical investigation
10.1038/s41541-025-01093-1,highly stable lyophilize mrna vaccine herpe zoster provide potent cellular humoral response,herpe zoster hz be painful vesicular rash occur varicella zoster virus vzv reactivation old adult immunocompromise individual be currently approve vaccine prevention shingle administration be commonly associate high reactogenicity highlight need to develop new vaccine alternative long last immunity improve tolerability administration present study different vaccine candidate design use two different codon optimization target vzv glycoprotein e ge be generate subset mrna construct be formulate lipid nanoparticle assess ability to induce specific cellular humoral immune response follow vaccination mouse notably select mrna vaccine candidate induce high level antibody robust also immune response moreover show alternate lyophilize vaccine provide comparable immunogenicity current liquid frozen formulation be stable long term storage condition,"Munoz-Moreno, Raquel,Allaj, Viola,Gadee, Eddie,Button, Julie M,Diaz, Fernando,Maddur, Mohan S,Chen, Wei,Hu, Cheng Hui,Martinez, Lyndsey,Giannakou, Andreas,Campbell, Adam Lee,Miteva, Yana,Guo, Pengbo,Huang, Bridget,Shi, Shuai,Lotvin, Jason,Tompkins, Kristin,Allen, Pirada Suphaphiphat,Solórzano, Alicia",20/08/2024,NPJ vaccines
10.1038/s41586-025-08721-9,myc ecdna promote intratumour heterogeneity plasticity pdac,intratumour heterogeneity phenotypic plasticity drive tumour progression therapy oncogene dosage variation contribute cell state transition phenotypic thereby provide substrate somatic evolution nonetheless genetic mechanism underlie phenotypic heterogeneity be still poorly understand here show extrachromosomal dna ecdna be major source high level focal amplification key oncogene major contributor myc heterogeneity pancreatic ductal adenocarcinoma pdac demonstrate ecdnas drive vary level myc dosage depend regulatory landscape enable cancer cell to rapidly reversibly adapt microenvironmental change absence selective pressure high ecdna copy number impose substantial fitness cost pdac cell also show myc dosage affect cell morphology dependence cancer cell stromal niche factor work provide detailed analysis ecdnas pdac describe new genetic mechanism drive myc heterogeneity pdac,"Fiorini, Elena,Malinova, Antonia,Schreyer, Daniel,Pasini, Davide,Bevere, Michele,Alessio, Giorgia,Rosa, Diego,D'Agosto, Sabrina,Azzolin, Luca,Milite, Salvatore,Andreani, Silvia,Lupo, Francesca,Veghini, Lisa,Grimaldi, Sonia,Pedron, Serena,Castellucci, Monica,Nourse, Craig,Salvia, Roberto,Malleo, Giuseppe,Ruzzenente, Andrea,Guglielmi, Alfredo,Milella, Michele,Lawlor, Rita T,Luchini, Claudio,Agostini, Antonio,Carbone, Carmine,Pilarsky, Christian,Sottoriva, Andrea,Scarpa, Aldo,Tuveson, David A,Bailey, Peter,Corbo, Vincenzo",06/10/2023,Nature
10.1037/tra0000413,self report mindfulness soldier health follow combat deployment,objective combat exposure have be link health relate challenge associate postcombat adjustment include mental health symptom behavior relate problem physical pain functional impairment mindfulness acceptance present moment reactivity judgment may be associate well mental health follow combat deployment study examine self report mindfulness predict soldier health outcome course postdeployment period method soldier be survey month deployment afghanistan again month later mindfulness be assess use nonreactivity inner experience subscale five facet mindfulness questionnaire hierarchical linear regression examine mindfulness moderate impact combat exposure outcome result control rank interaction combat exposure mindfulness significantly predict posttraumatic stress disorder ptsd symptom depression symptom risk take behavior pain symptom functional impairment interaction term explain to variance health outcome simple slope analysis reveal combat exposure be associate more ptsd symptom depression symptom risk take behavior pain symptom functional impairment soldier report low level mindfulness be effect alcohol misuse sleep difficulty aggressive behavior conclusion nonreactivity inner experience may mitigate detrimental effect high level combat exposure mental physical health outcome finding indicate mindfulness strategy such nonreactivity may be particularly useful employee face potentially traumatic stressor high risk occupational context psycinfo database record c apa right reserve,"Nassif, Thomas H,Start, Amanda R,Toblin, Robin L,Adler, Amy B",06/11/2018,"Psychological trauma : theory, research, practice and policy"
10.1016/j.neuroscience.2025.03.015,enteric nervous system dysfunction driver central nervous system disorder forget brain neurological disease,enteric nervous system ens often call second brain be complex network neuron glial cell gastrointestinal gi tract function autonomously maintain close communication central nervous system cns gut brain axis gba ens dysfunction play crucial role neurodegenerative neurodevelopmental disorder include parkinson disease alzheimer disease autism spectrum disorder disruption such altered neurotransmission gut microbiota imbalance neuroinflammation contribute disease pathogenesis gba enable bidirectional communication vagus nerve gut hormone immune signaling microbial metabolite link gut health neurological function ens dysregulation be implicate condition irritable bowel syndrome ibs inflammatory bowel disease ibd influence systemic cns pathology neuroinflammation impaired barrier integrity review highlight emerge therapeutic strategy target ens dysfunction include prebiotic probiotic fecal microbiota transplantation fmt vagus nerve stimulation offer novel way to modulate gut brain interaction previous perspective view ens passive disease marker review reposition active driver neurological disorder integrate advance ens biomarker therapeutic target gba modulation article present paradigm shift emphasizing ens dysfunction fundamental mechanism neurodegeneration neurodevelopmental disorder perspective pave way innovative diagnostic personalize gut target therapy deep understanding ens role brain health disease,"Hajjeh, Orabi,Rajab, Islam,Bdair, Mohammad,Saife, Sarah,Zahran, Anwar,Nazzal, Iyad,AbuZahra, Mohammad Ibrahem,Jallad, Hammam,Abukhalil, Maram M,Hallak, Mira,Al-Said, Osama S,Al-Braik, Rama,Sawaftah, Zaid,Milhem, Fathi,Almur, Omar,Saife, Sakeena,Aburemaileh, Mohammed,Abuhilal, Anfal",30/01/2025,Neuroscience
10.1186/s12974-025-03406-6,target activation receptor ameliorate neuronal deficit neuroinflammation food bear polystyrene microplastic expose mouse model,impact polystyrene microplastic ps mps nervous system have be document literature numerous study have demonstrate activation epidermal growth factor receptor be crucial neuronal injury regeneration process study investigate role target activation receptor small molecule agonist naphthoic acid mitigate ps mps induce neuronal injury finding reveal target activation receptor significantly ameliorate cognitive behavioral deficit mouse expose ps mps furthermore treatment upregulate expression dedicator cytokinesis sirtuin mitigate mitochondrial synaptic dysfunction hippocampus ps mps expose mouse also diminish activation nf κb signal pathway consequently reduce neuroinflammation vitro experiment demonstrate partially alleviate ps mps induce hippocampal neuronal injury effect microglial inflammation conclusion finding study indicate target activation receptor may mitigate neuronal damage subsequent neuroinflammation thereby alleviate hippocampal neuronal injury induce ps mps exposure ameliorate cognitive dysfunction result offer valuable insight development potential therapeutic strategy,"Liu, Chong,Zhao, Yan,Zhang, Wei,Dao, Ji-Ji,Li, Qian,Huang, Jia,Li, Zhen-Feng,Ma, Yu-Ke,Qiao, Chen-Meng,Cui, Chun,Chen, Shuang-Xi,Yu, Li,Shen, Yan-Qin,Zhao, Wei-Jiang",20/01/2025,Journal of neuroinflammation
10.1158/0008-5472.CAN-24-3023,single cell expression analysis ductal carcinoma situ identify complex genotypic phenotypic relationship alter epithelial composition,ductal carcinoma situ dcis be risk factor subsequent invasive breast cancer to identify event dcis lead invasive cancer perform single cell rna sequence scrna seq dcis lesion match normal breast tissue infer copy number variation cnv be use to identify neoplastic epithelial cell clinical specimen contain mixture dcis normal duct phylogenetic analysis demonstrate intratumoral clonal heterogeneity be associate significant gene expression difference classification epithelial cell mammary cell state reveal subclone contain mixture cell state suggest ongoing pattern differentiation neoplastic transformation cell state proportion be significantly different base estrogen receptor er expression er negative dcis more closely resemble distribution normal breast particularly respect cell basal characteristic specific alteration cell state proportion be associate progression invasive cancer cohort dcis longitudinal outcome ongoing transcription key basement membrane bm gene occur specific subset epithelial cell state include basal myoepithelial be diminish dcis transition invasive breast cancer bm protein laminin not be alter dcis adjacent invasion loss not laminin in vitro dcis model lead invasive phenotype finding suggest process invasion be loss function event imbalance critical cell population essential bm integrity rather gain invasive phenotype neoplastic cell,"Qin, Xiaodi,Strand, Siri H,Lee, Marissa R,Saraswathibhatla, Aashrith,van IJzendoorn, David G P,Zhu, ChunFang,Vennam, Sujay,Varma, Sushama,Hall, Allison,Factor, Rachel E,King, Lorraine,Simpson, Lunden,Luo, Xiaoke,Colditz, Graham A,Jiang, Shu,Chaudhuri, Ovijit,Hwang, E Shelley,Marks, Jeffrey R,Owzar, Kouros,West, Robert B",12/03/2025,Cancer research
10.1001/jama.2025.1983,point care ultrasound sepsis septic shock,,"Kaselitz, Timothy B,Seymour, Christopher W",17/03/2025,JAMA
10.7150/thno.104858,target platinum resistant ovarian cancer disrupt histone lactylation,rationale ovarian cancer be highly lethal gynecological malignancy common platinum resistance lactylation be involve multiple biological process thus explore role histone non histone lactylation platinum resistance provide potential therapeutic target to overcome platinum resistance ovarian cancer method utilize gene set enrichment analysis to investigate lactylation relate pathway alteration platinum resistant platinum sensitive patient tcga cohort differential expression be demonstrate use western blotting immunohistochemistry progression free overall survival be determine use log rank test drug response cisplatin be evaluate apoptosis flow cytometry clonogenic assay vitro chip seq chip qpcr assay be perform to identify downstream target be far confirm qrt pcr lc ms ms be conduct to identify specific lactylation site co ip be use to reveal interaction cell line derive patient derive xenograft pdx model ovarian cancer be construct in vivo experiment result study show elevated histone lactylation especially platinum resistant ovarian cancer moreover high indicate platinum resistance poor prognosis ovarian cancer impair enhance response cisplatin mechanistically directly activate expression to facilitate homologous recombination hr repair furthermore enhance hr repair subsequently confer cisplatin resistance share same upstream regulator notably inhibitor remarkably improve tumor kill ability cisplatin pdx model ovarian cancer conclusion study demonstrate essential role histone lactylation hr repair platinum resistance also identify potential therapeutic strategy to overcome platinum resistance improve prognosis ovarian cancer,"Sun, Chenggong,Li, Xiao,Teng, Qiuli,Liu, Xihan,Song, Li,Schiöth, Helgi B,Wu, Huan,Ma, Xinyue,Zhang, Zhaoyang,Qi, Changjian,Zhang, Haocheng,Song, Kun,Zhang, Qing,Kong, Beihua",08/10/2024,Theranostics
10.1080/19490976.2025.2476561,dysregulation gut microbiota stimulate net drive hcc intrahepatic metastasis therapeutic implication healthy faecal microbiota transplantation,stringent regulation intrahepatic metastasis be essential improve survival outcome patient hepatocellular carcinoma hcc study investigate impact gut microbiota intrahepatic metastasis hcc evaluate therapeutic potential healthy fecal microbiota transplantation fmt dysregulation gut microbiota characterize significant reduction abundance beneficial bacteria such anaerotruncus colihomini dysosmobacter welbionis be observe patient intrahepatic metastatic hcc human flora associate hfa intrahepatic metastatic hcc mouse model be successfully establish consecutive week human mouse fmt dysregulation gut microbiota promote intrahepatic metastasis mouse model primarily enhance neutrophil mediate inflammatory response lead excessive formation neutrophil extracellular trap net consequently promote tumor vascular growth tissue necrosis result intrahepatic metastasis hcc notably fmt healthy donor mitigate pathological process study elucidate role mechanism dysregulate gut microbiota promote intrahepatic metastasis hcc healthy fmt emerge promising novel therapeutic strategy prevent treat intrahepatic metastasis hcc,"Deng, Zhe,Mei, Si,Ouyang, Zhaoguang,Wang, Ruoyu,Wang, Lihuai,Zou, Bo,Dai, Jingjing,Mao, Kexin,Li, Qian,Guo, Qianqian,Yi, Chun,Meng, Fanying,Xie, Mingxia,Zhang, Xue,Wang, Rongrong,Deng, Tianhao,Wang, Zhenyu,Li, Xiaozheng,Wang, Qing,Liu, Bin,Tian, Xuefei",18/03/2025,Gut microbes
10.1111/irv.70073,mortality risk patient influenza illness admit icu systematic review meta analysis,background vaccination program available treatment seasonal influenza carry large mortality burden especially intensive care unit icu setting understand influenza mortality burden icu setting can inform treatment planning resource allocation nonetheless surveillance datum mortality icu admit patient be scarce estimate vary greatly systematic literature review slr meta analysis investigate cause mortality risk icu admit patient influenza europe method include observational study conduct europe report mortality patient month age influenza admit icu study publish be include quality be assess use modify newcastle ottawa scale pool cause mortality risk be calculate proportion use random effect model inverse variance method sensitivity analysis be also conduct include only study identify have low risk bias result thirty seven study report patient be include cause mortality range to overall pool mortality risk estimate be ci study heterogeneity be high cochran q test p sensitivity analysis use only study identify have low risk bias produce pool mortality risk conclusion result indicate approximately quarter patient influenza admit icu die reinforce need effective vaccination program treatment optimization,"Suárez-Sánchez, Pablo,Majuelos-Melguizo, Jara,Hinojosa-Campos, Marina,Podmore, Bélène,Gillespie, Iain A,Han, Jennifer,Sloot, Rosa,Christensen, Dina",27/12/2024,Influenza and other respiratory viruses
10.1038/s41467-025-57760-3,potentially causal association placental dna methylation schizophrenia other neuropsychiatric disorder,increase evidence support role placenta neurodevelopment onset neuropsychiatric disorder recently mqtl iqtl map have prove useful understand relationship snps gwa be not capture eqtl context propose part genetic predisposition complex neuropsychiatric disorder act placental dna methylation construct public placental cis mqtl database include cpg site calculate fetal placenta dna sample inma project run cell gestational sex imqtl model combine datum summary statistic gwas ten neuropsychiatric disorder use summary base mendelian randomization colocalization also evaluate influence identify dna methylation site placental gene expression richs cohort find placental cis mqtls be enrich placenta specific active chromatin region establish part genetic burden schizophrenia bipolar disorder major depressive disorder confer risk placental dna methylation potential causality several observed association be reinforce secondary association signal identify conditional analysis involvement cell type imqtls correlation identify dna methylation site expression level relevant gene placenta,"Cilleros-Portet, Ariadna,Lesseur, Corina,Marí, Sergi,Cosin-Tomas, Marta,Lozano, Manuel,Irizar, Amaia,Burt, Amber,García-Santisteban, Iraia,Garrido-Martín, Diego,Escaramís, Geòrgia,Hernangomez-Laderas, Alba,Soler-Blasco, Raquel,Breeze, Charles E,Gonzalez-Garcia, Bárbara P,Santa-Marina, Loreto,Chen, Jia,Llop, Sabrina,Fernández, Mariana F,Vrijheid, Martine,Ibarluzea, Jesús,Guxens, Mònica,Marsit, Carmen,Bustamante, Mariona,Bilbao, Jose Ramon,Fernandez-Jimenez, Nora",14/03/2023,Nature communications
10.2147/DDDT.S512872,enhance diabete treatment compare pioglitazone metformin dapagliflozin basal insulin metformin type diabetes,aim aim study be to compare efficacy safety fix dose combination fdc pioglitazone metformin supplement dapagliflozin test group basal insulin supplement metformin control group patient inadequately control type diabetes mellitus dm method week prospective randomize open label study enrol patient age year glycated hemoglobin level primary endpoint be proportion patient achieve week hypoglycemia weight gain secondary endpoint include blood glucose lipid profile body weight body mass index inflammatory marker bone gla protein liver enzyme patient satisfaction result full analysis set participant significant difference be observe primary endpoint test group control group however test group have high percentage patient achieve week hypoglycemia experience weight loss patient test group kg also achieve substantial achievement rate test group also exhibit great reduction body weight improvement hour postprandial glucose level systolic blood pressure lipid profile notably combination therapy do not increase risk hypoglycemia weight gain patient test group be more satisfied control group continue to accept pioglitazone metformin fdc combine dapagliflozin conclusion absence contraindication pioglitazone metformin fdc supplement dapagliflozin may serve safe effective alternative basal insulin combine metformin rectify inadequate glucose control former enable metabolic improvement compromise safety chinese clinical trial registry number,"Lin, Yi,Shi, Jianxia,Yu, Xuemei,Sun, Jiao,Lixia, Suo,Dou, Jiaqing,Zhang, Min,Li, Xiaohua,Tian, Zhufang,Deng, Hongyan,Feng, Bo,Su, Qing,Peng, Yongde",17/12/2024,"Drug design, development and therapy"
10.1161/CIRCULATIONAHA.124.072855,withdrawal guideline direct medical therapy patient heart failure improved ejection fraction,background limited evidence exist prognostic role continue medical therapy patient heart failure hf ejection fraction ef have improve time study assess rate patient profile association morbidity mortality renin angiotensin inhibitor rasi angiotensin receptor neprilysin inhibitor arni beta blocker bbl mineralocorticoid receptor antagonist mra withdrawal patient hf improved ef method patient first record ef late ef swedish hf registry june december be include retrospective observational study withdrawal be define patient treatment first reduced not second improve registration association withdrawal time first cardiovascular mortality hospitalization hf censor year be assess cox regression model use overlap weighting result patient hf improved ef median age year percentile woman receive rasi arni bbl mra respectively ef be withdrawal rate time improved ef registration be rasi arni bbl mra predictor withdrawal include low use other hf medication high ef later ef registration long time ef assessment weighting withdrawal be independently associate high risk cardiovascular mortality hospitalization hf rasi arni mra not bbl withdrawal bbl be associate high risk primary outcome subgroup patient improved ef to p interaction conclusion patient hf improved ef hf therapy withdrawal be rare withdraw rasi arni mra be associate high mortality morbidity year association be find bbl withdrawal significant heterogeneity ef improvement suggest well outcome continue bbl only ef improve up to result be hypothesis generating highlight need randomize control trial test bbl withdrawal patient hf improved ef,"Basile, Christian,Lindberg, Felix,Benson, Lina,Guidetti, Federica,Dahlström, Ulf,Piepoli, Massimo Francesco,Mol, Peter,Scorza, Raffaele,Maggioni, Aldo Pietro,Lund, Lars H,Savarese, Gianluigi",17/03/2025,Circulation
10.1186/s12951-025-03284-3,functional nanozyme system synergistic tumor immunotherapy cuproptosis ferroptosis activation,elevated copper level induce tumor cuproptosis ferroptosis lead immunogenic cell death subsequent antitumor immune response however dysregulate copper metabolism tumor cell maintain homeostatic copper balance hypoxic microenvironment hinder therapeutic efficacy study present nanozyme system termed cussomep comprise copper base nanovector cussnv be pegylate load omeprazole copper transporter inhibitor to enhance tumor synergistic immunotherapy promote cuproptosis ferroptosis cussnv be assemble dithiodiglycolic acid copper ion exhibit peroxidase glutathione oxidase catalase like activity responsive degradability nanozyme alleviate tumor hypoxia produce oxygen induce ferroptosis generation lethal hydroxyl radical deplete glutathione additionally omeprazole increase cellular copper concentration oxidative stress inhibit intracellular copper transport atpase enhance lipoylate protein oligomerization cuproptosis breast tumor mouse model cussomep elicit robust antitumor immune response include dendritic cell maturation t cell proliferation combine antibody cussomep significantly inhibit tumor metastasis bilateral lung metastatic model work present functional nanozyme system promising strategy synergistic tumor immunotherapy leverage ferroptosis cuproptosis,"Gu, Lina,Sun, Ying,Bai, Tingjie,Shao, Sijie,Tang, Shumin,Xue, Panpan,Cai, Wanlin,Qin, Xian,Zeng, Xuemei,Yan, Shuangqian",14/12/2024,Journal of nanobiotechnology
10.1007/s12035-025-04829-1,dna methylation regulate promote progression parkinson disease,recent study suggest palmitoylation may influence protein involve neurotransmission neurodegenerative change such pathological α synuclein however role palmitoylation parkinson disease pd have not be systematically investigate additionally finding dna methylation change pd associate gene expression remain inconsistent study aim to explore causal relationship mechanism palmitoylation gene dna methylation pd use mendelian randomization mr study employ two sample mr analysis summary data base mendelian randomization smr analysis mediation analysis utilize pd gwa datum finngen database palmitoylation gene datum eqtlgen database dna methylation datum godmc database first two sample mr analysis be use to evaluate causal relationship palmitoylation gene pd then smr method be apply to validate association gene expression pd finally mediation analysis be conduct to explore mediating effect dna methylation relationship expression palmitoylation gene pd study find significant positive correlation high expression gene increase pd risk standard deviation increase expression be associate increase pd risk far dna methylation analysis identify two key methylation site indirectly influence occurrence pd regulate expression gene mediation effect analysis reveal methylation site indirectly promote development pd regulate expression gene mediation effect gene expression account total effect respectively sensitivity analysis smr analysis support finding indicate high statistical robustness study highlight role dna methylation regulating pd progression suggest potential clinical application such biomarker therapeutic target early pd diagnosis treatment,"Liao, Jing,Bei, Liyuan,Nie, Pengbing,Liu, Pinjing,Zhang, Yongquan",09/01/2025,Molecular neurobiology
10.1016/j.jaci.2025.02.034,cigarette smoke induce epithelial cell ferroptosis promote neutrophilic inflammation patient nasal polyp,background regulation epithelial cell death have emerge key mechanism maintain immune homeostasis airway however mechanism govern epithelial cell survival nasal polyp nps remain poorly understand objective to investigate ferroptosis nasal epithelial cell implication pathogenesis nps method cell death lipid peroxidation ferrous iron level nasal epithelial cell be determine flow cytometry biomarker signal pathway associate ferroptosis be evaluate quantitative rt pcr single cell bulk rna sequence immunofluorescence stain western blotting human nasal epithelial cell hnecs cell be stimulate different agent mitochondrial ultrastructure hnec be visualize transmission electron microscopy cytokine level be quantify use elisa cigarette smoke extract mouse model be establish treat deferoxamine result nasal epithelial cell eosinophilic noneosinophilic nps show intensify lipid peroxidation alter mitochondrial morphology resemble feature ferroptosis ferroptosis trigger c x c motif ligand production cell hnec activation mitogen activate protein kinase pathway cse exposure elevate ferrous iron level upregulate transferrin receptor lead to ferroptosis subsequent production hnecs deferoxamine treatment inhibit nasal epithelial cell ferroptosis level neutrophilic number cse induce mice model smoking burden be correlate level neutrophil infiltration patient nps analysis uk biobank participant reveal smoking risk factor nps odd ratio confidence interval p conclusion smoking induce ferroptosis promote production nasal epithelial cell thus potentially exacerbate neutrophilic inflammation nps,"Pan, Li,Yu, Ze,Xiang, Wen-Xuan,Sun, Shi-Ran,Li, Jing-Xian,Deng, Yi-Ke,Wang, Meng-Chen,Zhong, Ji-Xin,Huang, Kun,Gao, Pei-Song,Zhu, Li-Ping,Yao, Yin,Liu, Zheng",02/09/2024,The Journal of allergy and clinical immunology
10.1038/s41591-025-03515-y,hospital admission attributable reduce air pollution clean air policy china,air pollution prevention control action plan appcap be consider to be most stringent air pollution control policy china implement policy be milestone china to mitigate serious air pollution however health benefit attributable reduce fine particulate air pollution implementation appcap have not be quantitatively estimate constituent specific morbidity cause specific basis here conduct nationwide case crossover study base hospital admission record chinese city compare annual average concentration black carbon bc decrease respectively result average relative reduction annual attributable fraction nine major cause specific hospital admission associate bc be respectively annual attributable fraction depression show large reduction nationally city high reduction bc be find to have high absolute reduction annual hospital admission attributable fraction associate bc geographic inequality health benefit still exist study highlight substantial wide range health benefit reduce bc level follow nationwide implementation appcap china,"Liu, Huimeng,Lei, Jian,Liu, Yuewei,Zhu, Tong,Chan, Kahung,Chen, Xi,Wei, Jing,Deng, Furong,Li, Ge,Jiang, Yunxing,Bai, Lijun,Wang, Kai,Chen, Juan,Lan, Yang,Xia, Xi,Wang, Jinxi,Wei, Chen,Li, Yinxiang,Chen, Renjie,Gong, Jicheng,Duan, Xiaoli,Zhang, Kai,Kan, Haidong,Shi, Xiaoming,Guo, Xinbiao,Wu, Shaowei",08/07/2024,Nature medicine
10.1016/j.waojou.2025.101034,wao aria consensus chronic cough executive summary,acute cough be highly prevalent symptom clinical practice chronic cough be complex disease significant impact quality life mechanistic pathway chronic cough cough comorbid clinical phenotype be elusive mount evidence suggest presence hypersensitive cough reflex implication transient receptor potential channel receptor cough neuronal pathway previously world allergy organization rhinitis impact asthma aria joint committee chronic cough publish update experimental clinical datum chronic cough addition multidisciplinary care pathway approach management goal manuscript be to provide clinician succinct summary chronic cough pathophysiology clinical phenotype management strategy primary cough specialty care executive summary be primer clinician chronic cough increase awareness topic primary care physician will improve outcome management patient chronic cough,"Rouadi, Philip W,Idriss, Samar A,Bousquet, Jean,Morais-Almeida, Mario,Azar, Cecilio R,Al-Ahmad, Mona Sulaiman,Yáñez, Anahí,Ali Y Al-Nesf, Maryam,Nsouli, Talal M,Bahna, Sami L,Abou-Jaoude, Eliane,Zaitoun, Fares H,Hadi, Usamah M,Scadding, Glenis K,Smith, Peter K,Gómez, René Maximiliano,González-Díaz, Sandra N,Klimek, Ludger,Juvelekian, Georges S,Riachy, Moussa A,Canonica, Giorgio Walter,Peden, David,Wong, Gary W K,Sublett, James,Bernstein, Jonathan A,Wang, Lianglu,Tanno, Luciana Kase,Chikhladze, Manana,Levin, Michael,Chang, Yoon-Seok,Martin, Bryan L,Caraballo, Luis,Custovic, Adnan,Ortega-Martell, José Antonio,Ly Lesslar, Olivia J,Giavina-Bianchi, Pedro,Papadopoulos, Nikolaos,Hossny, Elham,Ebisawa, Motohiro,Fiocchi, Alessandro,Ansotegui, Ignacio J",29/08/2024,The World Allergy Organization journal
10.1182/blood.2024026588,loss permit transcriptional activity cellular growth multiple myeloma,multiple myeloma mm be complex hematological malignancy characterize genomic change transcriptomic dysregulation initial exome sequence approach have fail to identify single frequent mutation code genome however use whole genome sequencing wgs find one genomic region most frequently mutate mm patient be untranslated utr region intron gene rna seq datum large cohort suggest loss expression large majority mm patient compare normal plasma cell loss function panel mm cell line lead highly proliferative phenotype vitro vivo ectopic expression significantly reduce cell viability suggest tumor suppressor function mm study cellular molecular effect loss observe endow myeloma cell proliferative potential cooperation plasma cell define transcription factor be involve direct protein protein interaction limit dna bind activity loss thus enhance expression associate cytokine reduce mitochondrial metabolism ro level study therefore suggest loss provide necessary molecular change to allow mediate transcriptional activity mm cell growth survival,"Chakraborty, Chandraditya,Talluri, Srikanth,Binder, Moritz,Morelli, Eugenio,Mayoral, Jessica Encinas,Derebail, Sanika,Aktas Samur, Anil,Epstein, Charles B,Anderson, Kenneth C,Shammas, Masood A,Samur, Mehmet K,Fulciniti, Mariateresa,Munshi, Nikhil C",24/01/2025,Blood
10.1016/j.biortech.2011.11.059,novel efficient method immobilization thermolysin use sodium chloride salting in consecutive microwave irradiation,sodium chloride salting microwave irradiation be combine to drive thermolysin molecule mesoporous support to obtain efficiently immobilized enzyme concentration sodium chloride be m microwave power be w enzyme be couple support min maximum specific activity immobilized enzyme be u be fold increase activity enzyme immobilize use conventional technique fold increase free enzyme additionally thermal stability immobilize thermolysin be significantly improve incubate c be reduction activity free thermolysin lose most activity immobilization also protect thermolysin organic solvent denaturation microwave assist immobilization technique combine sodium chloride salting could be apply other sparsely soluble enzyme immobilization simplicity high efficiency,"Chen, Feifei,Zhang, Fangkai,Du, Fangchuan,Wang, Anming,Gao, Weifang,Wang, Qiuyan,Yin, Xiaopu,Xie, Tian",29/08/2011,Bioresource technology
10.1186/s12974-025-03405-7,unlock therapeutic potential tumor derive evs ischemia reperfusion breakthrough perspective glioma stroke,clinical study have reveal bidirectional relationship glioma ischemic stroke evidence spatial overlap two condition connection arise significant similarity pathological process include regulation cellular metabolism inflammation coagulation hypoxia angiogenesis neural repair involve common biological factor significant share feature disease be crucial role extracellular vesicle evs mediate intercellular communication extracellular vesicle characteristic bilayer structure encapsulate protein lipid nucleic acid shield enzymatic degradation ribonuclease deoxyribonuclease protease structural protection facilitate long distance intercellular communication multicellular organism glioma evs be pivotal intracranial signal shape tumor microenvironment importantly cargo carry glioma derive evs closely align biological factor involve ischemic stroke underscore substantial impact glioma stroke pathology particularly crucial role evs key mediator interaction review explore pathological interplay glioma ischemic stroke address clinical manifestation pathophysiological process stage hypoxia stroke onset progression recovery particular focus crucial role evs cargo interaction,"Hao, Zhongnan,Guan, Wenxin,Wei, Wei,Li, Meihua,Xiao, Zhipeng,Sun, Qinjian,Pan, Yongli,Xin, Wenqiang",12/01/2025,Journal of neuroinflammation
10.1073/pnas.2420466122,atlas early human mandibular endochondral osteogenic paracrine signal region meckel cartilage,mandible also know low jaw be only bone skull can move be essential speak chew meckel cartilage mc be temporary structure support formation mandible mc be involve ossification mandible be poorly understand use single cell rna sequence single cell spatial transcriptomic analysis spatiotemporal atla mc human fetus to wk postconception be establish highlight role mc ossification mandible importantly reveal two population mc contribute mandibular ossification different mechanism anterior mc can differentiate osteolineage cell show vivo lineage trace mouse model intermediate mc facilitate intramembranous ossification cell cell communication possibly signal ligand pdgfc study suggest mc play crucial role mediate mandibular ossification distinct mechanism provide valuable insight understand oral craniofacial disease disorder future,"Shen, Zongshan,Zhang, Ran,Chen, Xinyue,Yang, Guan,Si, Yuanchun,Yan, Tianxing,Chen, Suwen,Cheng, Bin,Wu, Xiaoshan,Chen, Di,Zhang, Dong,Xiao, Guozhi,Zhu, Jian-Kang,Wang, Songlin",17/03/2025,Proceedings of the National Academy of Sciences of the United States of America
10.1016/j.jaci.2025.02.038,deficiency important form common variable immunodeficiency inflammation,background interferon regulatory bind be transcription factor play important role regulate immune pathway angiogenesis apoptosis cell differentiation defect gene have be implicate immunodeficiency objective to deepen understanding clinical implication variant seek to clinically characterize functionally test thirty four individual variant method collect subject family mutation record be abstract clinical phenotype functional testing be perform peripheral blood mononuclear cell pbmcs nuclear factor activate t cell nfat luciferase gene reporter construct quantitative cdna determination be use to evaluate repressor activity associate ectopic expression various mutant construct jurkat cell result most subject have immunodeficiency variable gastrointestinal inflammatory autoimmune feature include chronic abdominal pain colitis diarrhea constipation vitiligo alopecia migratory rash be reduce frequency memory b cell poor immunoglobulin production reduce calcium flux response b cell receptor stimulus pbmcs have increase apoptosis vitro compare healthy control impair repression nfat activation be observe use patient derive mutant construct compare wild type similarly tnf α transcript level be high use patient derive mutation compare wild type construct conclusion deficiency cause complex immunodeficiency include gastrointestinal inflammatory disorder as well impair b cell maturation impaired repression nfat pathway appear to enhance proinflammatory signal proinflammatory cytokine expression,"Udemgba, Chioma,Pillay, Bethany,Shafer, Samantha,Alberstadt, Angelika,Abers, Michael,Gilliaux, Olivier,Chen, Karin,Rae, William,Hanitsch, Leif,Von Bernuth, Horst,Neves, Joao Farela,Raje, Nikita,Moens, Leen,van Hagen, P Martin,Bergerson, Jenna,Hartog, Nicholas,Niehues, Tim,Dückers, Gregor,Falcone, Emilia,Keller, Michael,Hsu, Amy,Meyts, Isabelle,Holland, Steven M",30/11/2023,The Journal of allergy and clinical immunology
10.1016/j.ccell.2025.02.014,target tumor monocyte intrinsic pd rewire sting signal enhance ste agonist therapy,sting be important dna sense machinery initiate immune response therapy target sting have show poor outcome clinical trial here reveal sting signal induce pd tumor monocyte dominate resistance sting agonist therapy cell intrinsic pd induce sting ifn axis be identify drive factor protumoral pd notably activate resist sting induce upregulation cell intrinsic pd associate protumoral function mechanistically stimulation remodel sting signal facilitate sting interaction suppress ifn response enhance nf κb activation moreover demonstrate combine sting agonist agonist pretreatment significantly improve antitumor efficacy murine syngeneic humanize model finding uncover protumoral aspect sting activation mediate cell intrinsic pd propose promising strategy to boost antitumor immunity fine tune sting signal output,"Song, Huan,Chen, Lin,Pan, Xuanxuan,Shen, Yuru,Ye, Maolin,Wang, Guohong,Cui, Can,Zhou, Qi,Tseng, Yujen,Gong, Zheng,Zhong, Bin,Cui, Haoshu,Mo, Shaocong,Zheng, Jiayue,Jin, Bryan,Zheng, Wanwei,Luo, Feifei,Liu, Jie",30/07/2024,Cancer cell
10.1038/s41573-025-01158-9,fibrosis cross organ biology pathway development innovative drug,fibrosis be pathophysiological mechanism involve chronic progressive disease result excessive tissue scarring disease associate fibrosis include metabolic dysfunction associate steatohepatitis mash inflammatory bowel disease ibds chronic kidney disease ckd idiopathic pulmonary fibrosis ipf systemic sclerosis ssc be collectively responsible substantial morbidity mortality few drug direct antifibrotic activity be approve pulmonary fibrosis considerable progress have be make understanding mechanism fibrosis translation knowledge effective therapy continue to be limited challenging aim assist developer novel antifibrotic drug review integrate viewpoint biologist physician scientist core pathway involve fibrosis organ as well specific characteristic approach to assess therapeutic intervention fibrotic disease lung gut kidney skin liver discussion be use basis to propose strategy to improve translation potential antifibrotic therapy,"Rieder, Florian,Nagy, Laura E,Maher, Toby M,Distler, Jörg H W,Kramann, Rafael,Hinz, Boris,Prunotto, Marco",10/02/2025,Nature reviews. Drug discovery
10.1038/s43018-025-00933-2,gremlin express splenic niche cell population restrain chronic myeloid leukemia antagonize bmp pathway,spleen play critical role pathogenesis leukemia however understanding splenic niche be very limited herein report induce expression secrete protein gremlin mouse model restrain chronic myeloid leukemia cml progression synergize tyrosine kinase inhibitor treatment blockade gremlin promote cml development intriguingly effect gremlin be most evident spleen not bone marrow gremlin induce apoptosis leukemic stem cell antagonize bmp pathway single cell rna sequence experimental validation together show gremlin mark unique stromal cell population spleen mouse human genetic ablation gremlin cell lead to accelerate cml progression collectively gremlin gremlin cell be key defensive niche component spleen limit cml progression reveal unprecedented mechanism body to fight leukemia,"Wang, Jinming,Xu, Penghui,Ji, Zhongzhong,Cheng, Chaping,Liu, Yiyun,Du, Genyu,Zhang, Shilei,Miao, Juju,Wang, Deng,Chen, Ruoyang,Li, Dawei,Zhang, Kai,Zhao, Huifang,Sun, Yujiao,Chen, Xinyu,Jing, Na,Liu, Kaiyuan,He, Yuman,Xi, Xialian,Zhang, Yingchao,Wang, Nan,Xu, Longmei,Yao, Jufang,Gao, Xiaomei,Zhou, Jianhua,Fan, Songqing,Wang, Xiaorui,Dong, Shuxian,Chen, Fangli,Hou, Jian,Zhang, Ming,Gao, Wei-Qiang,Shen, Lijing,Zhang, Pengcheng,Zhu, Helen He",09/04/2024,Nature cancer
10.1016/j.celrep.2025.115426,macrophage specific phgdh protect mafld suppress,metabolic dysfunction associate fatty liver disease mafld be progressive disease only one approve treatment currently available hepatic phosphoglycerate dehydrogenase phgdh rate limit enzyme serine biosynthesis pathway regulate mafld development however role macrophage phgdh mafld progression remain unclear here demonstrate lipotoxicity inducer palmitic acid pa significantly increase macrophage phgdh expression phgdh deficiency macrophage promote pa induce inflammatory response myeloid specific phgdh deficiency exacerbate mafld mouse mechanistically tetrameric phgdh bind transform growth factor β activate kinase to inhibit interaction bind protein sequentially suppress activation downstream nf κb mapk signal inhibition activation slow development metabolic dysfunction associate steatohepatitis mash cause myeloid phgdh knockout importantly adeno associate virus mediate phgdh overexpression liver macrophage alleviate mafld mouse collectively result identify macrophage phgdh promising therapeutic agent mafld,"Hu, Penghui,Shan, Xiao,Dong, Hongyuan,Yu, Sujun,Wang, Baochen,Xiong, Hui,Ji, Zemin,Jing, Weijia,Cui, Yan,Li, Zihan,Zhou, Yanzhao,Wang, Zhe,Wang, Jinrong,Tang, Jiuzhou,Wang, Ting,Xie, Keliang,Yu, Qiujing",23/07/2024,Cell reports
10.1182/blood.2024026139,ruxolitinib combine dexamethasone adult patient newly diagnose hemophagocytic lymphohistiocytosis china,hemophagocytic lymphohistiocytosis hlh be severe hyperinflammatory syndrome overall survival adult patient be poor ruxolitinib janus kinase jak inhibitor have show promise treat hlh exert synergistic effect combine dexamethasone pilot study preliminarily demonstrate combination ruxolitinib dexamethasone ru d regimen have high response rate lead favorable short term survival outcome adult hlh patient prospective phase clinical trial propose ru d regimen first line treatment adult newly diagnose hlh unknown trigger identifi total chinese patient be enrol median follow time be month range month os rate primary endpoint be exceed expect month os rate month year os rate be respectively median os lymphoma associate hlh lahs patient be month most patient have nk t cell lymphoma contrast year os rate non lahs patient be overall response rate orr be patient achieve complete response cr ru d regimen overall ru d regimen be well tolerate hlh patient study demonstrate efficacy safety ru d regimen adult newly diagnose hlh unknown trigger warrant phase randomize control study,"Zhou, De,Huang, Xianbo,Zhu, Lixia,Hu, Xuelian,Yang, Xiudi,Xie, Mixue,Huang, Xin,Yu, Fang,Wei, Juying,Ma, Liya,Zhu, Jingjing,Zhao, Shuqi,Xie, Wanzhuo,Tong, Hongyan,Jin, Jie,Ye, Xiujin",27/02/2025,Blood
10.1002/cac2.70016,block potentiate efficacy anti therapy glioblastoma remodel tumor associate macrophage,background glioblastoma gbm be largely refractory to antibody program cell death anti therapy fully understand cellular heterogeneity immune adaptation response anti therapy be necessary to design more effective immunotherapy gbm study aim to dissect molecular mechanism specific immunosuppressive subpopulation to drive anti resistance gbm method systematically analyse single cell rna sequence spatial transcriptomic datum gbm tissue receive anti therapy to characterize microenvironment alteration biological function novel circular rna circrna be validate vitro vivo mechanically co immunoprecipitation rna immunoprecipitation pull assay be conduct result mesenchymal gbm me gbm cell be associate poor prognosis secrete phosphoprotein myeloid derive macrophage mdm unique subpopulation mdm complex function preferentially accumulate non responder anti therapy indicate me gbm cell mdm be main anti resistant cell subpopulation functionally determine circular rna succinate dehydrogenase complex assembly factor be positively associate abundance two anti resistant cell subpopulation facilitate formation regional me gbm mdm cell interaction loop result spatially specific adaptive immunosuppressive microenvironment mechanically find promote mes gbm cell formation stabilize integrin alpha protein n glycosylation meanwhile n glycosylation protein facilitate translocation exosome subsequent delivery mdm to induce formation mdm turn maintain mes gbm cell status induce t cell dysfunction pathway ultimately promote gbm immune escape importantly finding demonstrate antibody mediate blockade enhance anti mediate antitumor immunity conclusion work elucidate potential tissue adaptation mechanism intratumoral dynamic interaction me gbm cell mdm t cell anti non responder identify therapeutic potential target to reduce anti resistance gbm,"Zhao, Rongrong,Pan, Ziwen,Qiu, Jiawei,Li, Boyan,Qi, Yanhua,Gao, Zijie,Qiu, Wei,Tang, Weijie,Guo, Xiaofan,Deng, Lin,Li, Gang,Xue, Hao",27/02/2025,"Cancer communications (London, England)"
10.1002/gps.70069,change disease burden depressive disorder middle aged old adult aged china year insight global burden disease study,objective china depressive disorder dd middle aged old adult be significant public health concern research utilize late global burden disease study gbd database to evaluate evolve disease burden dd demographic past decade method datum incidence disability adjust life year daly dd people age china be collect gbd age period cohort apc model be apply to determine effect age period cohort incidence daly rate dd result last year be increase overall age standardize incidence rate asir increase age standardize daly rate asdr dd middle aged old adult china female consistently exhibit high asir asdr male significantly increase asir asdr dd population especially female apc analysis reveal annual net drift incidence daly rate gender local drift incidence be negative age group positive age group daly rate show negative local drift age group positive age group incidence daly rate increase age display trend initial decline follow increase period effect trend initial increase follow decrease cohort effect moreover impact age period cohort exhibit gender difference conclusion finding provide comprehensive depth perspective study change trend dd burden china identify target prevention treatment policy dd different aspect,"Xiao, Yu,Chen, Ting-Ting,Zhang, Zhou,Liu, Liang,Du, Na",29/01/2025,International journal of geriatric psychiatry
10.1111/cpr.70021,target to inhibit age rage nf κb signalling effectively ameliorate nucleus pulposus dysfunction angiogenesis obesity relate intervertebral disc degeneration,intervertebral disc degeneration ivdd be primary contributor to low back pain pose significant social economic burden increase evidence show obesity contribute to ivdd underlie mechanism remain elusive here firstly reveal causal correlation obesity ivdd two sample mendelian randomization analysis identify fatty acid bind protein potential regulator to associate ivdd obesity elevated expression promote extracellular matrix ecm disequilibrium angiogenesis to exacerbate ivdd progression genetically knock pharmacologically inhibit high fat diet induce mouse alleviate ivdd mechanistically obesity activate mammalian target rapamycin complex upregulate expression lead accumulation advanced glycation end product age intervertebral disc tissue age far activate nf κb signal pathway exacerbate ecm degradation neovascularization conversely rapamycin mediate inhibition suppress expression nucleus pulposus cell npc alleviate ivdd vivo collectively finding reveal critical role obesity induce axis ecm degradation angiogenesis ivdd progression target may represent promising therapeutic strategy ivdd obese individual,"Han, Lin,Li, Fudong,Wu, Huiqiao,Wang, Weiheng,Chen, Peiwen,Xia, Weicheng,Liu, Yang,Sun, Kaiqiang,Lin, Wenbo",16/02/2025,Cell proliferation
10.1136/bmjopen-2017-019350,randomise control trial rhinothermy treatment common cold feasibility study,objective to determine feasibility randomised control trial rct rhinothermy common cold design open label randomise control feasibility study set single centre research institute new zealand recruiting participant community participant adult participant symptom common cold present hour onset symptom intervention participant be randomly assign to receive l min humidified air c high flow nasal cannulae hour day to day rhinothermy vitamin c mg daily day control primary secondary outcome measure primary outcome be proportion screen candidate be randomise secondary outcome include proportion randomise participant complete study modify jackson score randomisation day initiation randomised regimen time feel lot well compare study entry time resolution symptom symptom score day postrandomisation proportion organism identify pcr analysis nasal swab take baseline pattern use rhinothermy device estimate adherence control group rhinothermy device tolerability result ci to potential participant screen eligibility be randomise rhinothermy be well tolerate randomised participant complete study ci to reduction baseline modify jackson score be great rhinothermy compare control day maximum difference day ci substantial clinical benefit threshold modify jackson score be unit change conclusion study show rct rhinothermy compare low dose vitamin c treatment common cold be feasible trial registration number result,"Hei, Susanne van de,McKinstry, Steven,Bardsley, George,Weatherall, Mark,Beasley, Richard,Fingleton, James",30/03/2018,BMJ open
10.1007/s00401-025-02863-w,biofluid base staging alzheimer disease,recently conceptual system in vivo staging alzheimer disease ad use fluid biomarker have be suggest thus be important to assess available fluid biomarker can successfully stage ad clinically biologically relevant category triad cohort explore p p nta tau biomarker early intermediate late ad pathology respectively have potential biofluid base staging cerebrospinal fluid csf plasma compare paired csf plasma subset finding suggest good concordance biofluid staging underlie pathology classify amyloid positivity three category base neurofibrillary pathology minimal non existent p positive early intermediate p p positivity advanced tau tangle deposition p p nta tau positive index tau pet discordant case account csf plasma measurement respectively paired sample notably plasma base staging match one case approximately remain participant be one to three biofluid stage high csf compare to plasma overall exploratory result suggest biofluid staging ad hold potential offer valuable insight underlie ad hallmark disease severity however applicability molecular characterization research setting have yet to be demonstrate,"Lantero-Rodriguez, Juan,Montoliu-Gaya, Laia,Ashton, Nicholas J,Pola, Ilaria,Therriault, Joseph,Rahmouni, Nesrine,Brum, Wagner S,Servaes, Stijn,Stevenson, Jenna,Di Molfetta, Guglielmo,Arslan, Burak,Klostranec, Jesse,Vitali, Paolo,Montembeault, Maxime,Gauthier, Serge,Tissot, Cecile,Macedo, Arthur C,Pascoal, Tharick A,Jeromin, Andreas,Gobom, Johan,Blennow, Kaj,Zetterberg, Henrik,Rosa-Neto, Pedro,Benedet, Andrea L",06/11/2024,Acta neuropathologica
10.1146/annurev-immunol-101721-032910,regulation cgas sting pathway,cgas cgamp ste pathway be essential immune defense pathogen bind dna cgas synthesize cgamp activate sting lead potent innate immune effector response however lack specific feature to distinguish self dna cgas ste immunity require precise regulation to prevent aberrant activation several safeguard mechanism act different level have evolve to maintain tolerance self dna ensure immune homeostasis normal condition disruption safeguard can lead erroneous activation self dna result inflammatory condition also favorable antitumor immunity insight structural cellular checkpoint control terminate cgas sting signaling be essential comprehend manipulate dna trigger innate immunity health disease,"Zhang, Bing,Xu, Pengbiao,Ablasser, Andrea",14/03/2025,Annual review of immunology
10.1002/advs.202417827,flavonifractor plautii metabolite desaminotyrosine prophylactic agent alleviate myocardial ischemia reperfusion injury,myocardial ischemia reperfusion i r injury be major contributor myocardial damage lead adverse cardiac remodeling dysfunction recent study have highlight potential gut microbiota derive metabolite modulate cardiac outcome here cardioprotective effect commensal bacterium flavonifractor plautii plautii metabolite desaminotyrosine dat myocardial i r injury be investigate show prophylactic gavage plautii attenuate myocardial i r injury evidence improve cardiac function reduce cardiac injury also find metabolite dat recapitulate cardioprotective effect myocardial i r injury transcriptomic analysis have reveal dat preserve cardiac tissue attenuate immune response myocardial i r injury mechanistically dat promote cardiomyocyte survival modulation nicotinamide adenine dinucleotide phosphate ratio far dat suppress macrophage proinflammatory activity cardiac inflammation reduction production take together finding indicate plautii metabolite dat exert pleiotropic cardioprotective effect myocardial i r injury suggest potential prophylactic therapeutic option alleviate myocardial i r injury,"Du, Heng,Liu, Xu,Shen, Jianghua,Yuan, Hailong,Zhang, Hao,Xi, Gan,Li, Yujing,Wang, Yuhan,Zhang, Jiahe,Yang, Chaofan,Xu, Pengfei,Wang, Jiawan,Wang, Fang,Liu, Siqi,Zhou, Yanan,Gu, Qi,Lu, Jingjing,Wei, Tuo,Gao, Zeyu,Zang, Jingyi,Wang, Jun,Song, Moshi",12/02/2025,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"
10.1097/HEP.0000000000001302,pre b cell leukemia transcription factor contribute to liver fibrosis enable signaling hepatic stellate cell,background aim liver fibrosis dysregulate contribute irreversible loss hepatic structure function herald end stage liver disease include cirrhosis hepatocellular carcinoma hepatic stellate cell hsc represent common progenitor myofibroblast produce extracellular matrix ecm protein to mediate liver fibrosis present study investigate role pre b cell leukemia transcription factor process method liver fibrosis be induce injection bile duct ligation bdl cellular transcriptome be examine rna seq seq result be screen mining liver fibrosis relate single cell rna seq dataset most prominently up regulate transcription factor hsc activation ingenuity pathway analysis ipa couple reporter assay chip assay demonstrate mediate elevation expression transcriptional level hsc knockdown attenuate hsc myofibroblast transition vitro liver fibrosis mouse integrate transcriptomic analysis suggest contribute hsc activation activate host pro fibrogenic molecule include interleukin receptor consistently exposure recombinant promote hsc activation knockdown hamper hsc activation mechanistically interact tgf β receptor tβri ii to trigger pro fibrogenic signal cascade importantly blockade signal neutralize antibody markedly ameliorate liver fibrosis mouse finally positive correlation hsc activation be identify cirrhotic patient conclusion datum uncover previously unappreciated role hsc activation provide proof concept target signal intervention liver fibrosis,"Zhao, Qianwen,Liu, Hong,Yang, Zhen,Han, Xingxing,Kang, Aoqi,Li, Hao,Ren, Wenjing,Chen, Qianqian,Huan, Yue,Xu, Yong,Li, Jie,Kong, Ming,Li, Zilong",15/10/2024,"Hepatology (Baltimore, Md.)"
10.7150/ijbs.103343,role thrombospondin osteoarthritis molecular mechanism therapeutic potential,osteoarthritis oa be prevalent chronic degenerative joint disorder characterize cartilage degeneration joint inflammation pain pathogenesis oa still remain unclear various factor contribute oa role extracellular matrix ecm protein particularly thrombospondin tsp have garner significant attention tsp family multifunctional extracellular matrix glycoprotein be know to participate numerous physiological pathological process include cell adhesion migration differentiation angiogenesis synaptogenesis cell cell cell matrix interaction review provide summary current understanding tsp protein pathogenesis oa include effect cartilage homeostasis synovial inflammation subchondral bone remodeling arthritic pain also review evidence support potential tsp protein diagnostic biomarker therapeutic target focus recent advance cartilage regeneration gene delivery therapy pain management consider multifaceted role tsp protein maintain articular homeostasis tsp protein emerge promise therapeutic target oa,"Aihaiti, Yirixiati,Yu, Hui,Xu, Peng",06/09/2024,International journal of biological sciences
10.3389/fendo.2025.1509752,association non high density lipoprotein cholesterol high density lipoprotein cholesterol ratio cardiovascular disease mortality patient type diabete mellitus diabetic kidney disease,purpose non high density lipoprotein cholesterol high density lipoprotein cholesterol ratio nhhr represent essential lipid index be closely related occurrence development diabete cardiovascular disease cvds therefore study be intend to far investigate association nhhr index mortality rate cvds patient type diabetes mellitus dm diabetic kidney disease dkd method research sample be select nhane national health nutrition examination survey database individual be categorize base quartile nhhr index restrict cubic plot cox regression model be utilize to examine threshold pattern nhhr index relation risk cvds mortality dm patient as well dkd subgroup analysis p value be use to evaluate interaction different variable result nhhr index show nonlinear association cardiovascular mortality two patient group follow l shape pattern individual dm low nhhr index correlate increase risk death demonstrate reduction mortality risk unit increase nhhr threshold similarly patient dkd low nhhr index be associate heighten cardiovascular mortality risk indicate reduction death risk unit increase nhhr specify threshold patient diagnose dm third quartile nhhr index be significantly link reduce mortality risk association remain consistent even additional variable be consider hazard ratio hr confidence interval ci patient dkd cardiovascular mortality be notably high third fourth quartile nhhr index hr ci hr ci conclusion nhhr be increase nhhr index be associate reduce risk cvd mortality patient dm similarly nhhr fall elevation nhhr index correlate decrease risk cvd mortality patient dkd,"Li, Zhiyu,Xu, Hongyang",11/10/2024,Frontiers in endocrinology
10.1038/s41467-025-57823-5,identification non inhibitory aptameric ligand ligase target protein degradation,crucial element proteolysis target chimera protacs choice ubiquitin ligase significantly influence degradation efficacy selectivity however available arsenal ligase protac development remain underexplored severely limit scope target protein degradation study identify non inhibitory aptamer target substrate receptor cullin ring ligase complex warhead targeted protein degradation aptamer base protac platform term zatac be facilely produce bioorthogonal chemistry self assembly show promise eliminate several undruggable target protein include nucleolin ncl sry box transcription factor mutant underscore universality versatility to specifically deliver zatac cancer cell far develop dna three way junction base zatac zatacs integrate additional aptamer selectively recognize protein overexpresse surface cancer cell zatacs demonstrate vivo tumor specific distribution achieve dual target degradation thereby suppress tumor growth cause noticeable toxicity summary zatac represent general modular straightforward platform target protein degradation offer insight potential other untapped ligase,"Yang, Zhihao,Chen, Miao,Ge, Ruixin,Zhou, Ping,Pan, Wei,Song, Jiayi,Ma, Shuwen,Chen, Song,Xu, Chenyu,Zhou, Mengyu,Mi, Wenyi,Ni, Hua,Chen, He,Yao, Xue,Dong, Xifeng,Chen, Yan,Zhou, Jun,Xuan, Chenghao,Dong, Cheng,Yan, Hua,Xie, Songbo",26/08/2024,Nature communications
10.1038/s43018-025-00928-z,target histone reader inhibits antiandrogen induce neuroendocrine tumor transdifferentiation prostate cancer,transdifferentiation adenocarcinoma to neuroendocrine prostate cancer nepc man confer antiandrogen therapy resistance here analysis combine screening single cell rna sequence tracking tumor transition demonstrate antiandrogen induce zinc finger mynd type contain epigenetic programming orchestrate nepc transdifferentiation ablation prevent nepc development upregulation mediate achaete scute homolog promote nepc differentiation show forkhead box protein stabilize bind chromatin region characterize modification target antiandrogen therapy release swi snf chromatin remodeling complex androgen receptor facilitate interaction to upregulate critical neuroendocrine lineage regulator develop small molecule design to inhibit histone recognition effectively block nepc development finding reveal critical role dependent epigenetic programming induce androgen deprivation therapy orchestrate lineage fate target emerge promising strategy impede nepc development,"Wang, Hanling,Zhang, Sulin,Pan, Qiang,Guo, Jiacheng,Li, Ni,Chen, Lifan,Xu, Junyu,Zhou, Jingyi,Gu, Yongqiang,Wang, Xuege,Zhang, Guoying,Lian, Yannan,Zhang, Wei,Lin, Naiheng,Jin, Zige,Zang, Yi,Lan, Weihua,Cheng, Xiaoyan,Tan, Minjia,Chen, Fei Xavier,Jiang, Jun,Liu, Qiuli,Zheng, Mingyue,Qin, Jun",01/02/2024,Nature cancer
10.1038/s41571-025-01011-3,utilize ctdna to discover mechanism resistance target therapy patient metastatic nsclc more informative trial,advance target therapy patient non small cell lung cancer have substantially improve outcome actionable alteration certain oncogenic driver gene however acquire resistance target therapy remain major challenge understand mechanism underlie acquire resistance will be crucial development strategy might overcome effect delay onset circulate tumour dna owe need only minimally invasive sampling potential role prognostic predictive biomarker be increasingly be use research clinical practice several study have explore landscape acquire resistance target therapy use approach however methodology publish study vary widely several major challenge remain address practical difficulty associate method challenge currently limit depth research insight provide available datum perspective review clinical report describe use circulate tumour dna to detect mechanism acquire resistance target therapy predominantly patient advanced stage non small cell lung cancer highlight key unresolved question aim move more informative research study,"Ernst, Sophie M,Aldea, Mihaela,von der Thüsen, Jan H,de Langen, Adrianus J,Smit, Egbert F,Paats, Marthe S,Aerts, Joachim G J V,Mezquita, Laura,Popat, Sanjay,Besse, Benjamin,Remon, Jordi,Rolfo, Christian,Dubbink, Hendrikus J,Dingemans, Anne-Marie C",27/02/2025,Nature reviews. Clinical oncology
10.1038/s43587-025-00816-2,signal drive alzheimer disease pathology disrupt neuronal oligodendrocyte homeostasis,neuroinflammation include interleukin signal be central alzheimer disease ad pathology inhibition subunit attenuate pathology ad like mouse however signal mechanism expression pattern remain elusive here show receptor be predominantly express neuron oligodendrocyte ad like mouse patient ad receptor transcript be barely detectable consistently deletion receptor neuroectodermal cell ameliorate ad pathology mouse removal receptor have effect genetic ablation signal alone revert loss mature oligodendrocyte restore myelin homeostasis rescue amyloid β dependent reduction parvalbumin positive interneuron restore phagocytosis relate change microglia mouse furthermore protein expression be increase human ad brain compare healthy age match control human oligodendrocyte like cell respond profoundly stimulation conclude oligodendroglial neuronal signal not signal be key orchestrate ad relate neuroimmune crosstalk represent attractive therapeutic target ad,"Schneeberger, Shirin,Kim, Seung Joon,Geesdorf, Maria N,Friebel, Ekaterina,Eede, Pascale,Jendrach, Marina,Boltengagen, Anastasiya,Braeuning, Caroline,Ruhwedel, Torben,Hülsmeier, Andreas J,Gimber, Niclas,Foerster, Marlene,Obst, Juliane,Andreadou, Myrto,Mundt, Sarah,Schmoranzer, Jan,Prokop, Stefan,Kessler, Wiebke,Kuhlmann, Tanja,Möbius, Wiebke,Nave, Klaus-Armin,Hornemann, Thorsten,Becher, Burkhard,Edgar, Julia M,Karaiskos, Nikos,Kocks, Christine,Rajewsky, Nikolaus,Heppner, Frank L",12/04/2024,Nature aging
10.1038/s41467-025-57651-7,axonal rna localization be essential long term memory,localization mrnas neuronal terminal couple local translation have emerge prevalent mechanism control synaptic proteome however physiological regulation function process context mature vivo memory circuit have remain unclear here combine synaptosome rna profiling whole brain high resolution imaging to uncover mrnas different localization pattern axon drosophila mushroom body memory neuron exhibit regionalize input dependent recruitment axon integrate transcriptome wide bind approach functional assay show conserve imp rna bind protein control transport mrnas to mushroom body axon characterize mutant transport be selectively impaired use unique mutant demonstrate axonal mrna localization be require long term not short term behavioral memory work uncover circuit dependent mrna target vivo demonstrate importance local rna regulation memory consolidation,"de Queiroz, Bruna R,Laghrissi, Hiba,Rajeev, Seetha,Blot, Lauren,De Graeve, Fabienne,Dehecq, Marine,Hallegger, Martina,Dag, Ugur,Dunoyer de Segonzac, Marion,Ramialison, Mirana,Cazevieille, Chantal,Keleman, Krystyna,Ule, Jernej,Hubstenberger, Arnaud,Besse, Florence",11/02/2024,Nature communications
10.1016/j.dsx.2025.103212,comparative efficacy safety semaglutide mg tirzepatide mg obesity type diabetes systematic review phase clinical trial,background aim semaglutide mg tirzepatide have be recently approve chronic use obesity be lack literature compare efficacy safety agent people obesity overweight type diabetes systematically review phase randomize control trial rct conduct two agent to synthesize comparative efficacy safety outcome method systematically search pubme electronic database december use select keyword boolean subsequently compare most closely match trial conduct semaglutide mg tirzepatide adjusted baseline imbalance treatment outcome modifier present unadjuste absence baseline imbalance indirect treatment comparison method result identify one trial semaglutide mg tirzepatide mg obese overweight people one trial semaglutide mg tirzepatide mg overweight people be almost entirely comparable concern baseline outcome modifier characteristic unadjusted analysis individual patient datum find relatively high additional weight loss additional reduction few gastrointestinal side effect gi s e tirzepatide mg respectively semaglutide mg intention to treat analysis conclusion tirzepatide mg be more effective have few gi e semaglutide mg well power head head rct be currently need to confirm finding,"Singh, Akriti,Singh, Awadhesh Kumar,Singh, Ritu,Misra, Anoop",27/01/2025,Diabetes & metabolic syndrome
10.1080/19490976.2025.2477816,microbial micronutrient sharing gut redox balance keystone taxa basis new perspective solution target health gut,health gut microbiome function stable ecosystem maintain overall balance ensure own survival environmental stressor complex microbial interaction balance protection stressor be maintain interaction bacterial ecosystem as well host consequence gut microbiome play critical role various physiological process include maintain structure function gut barrier educate gut immune system modulate gut motor digestive absorptive as well neuroendocrine system be crucial human health disease pathogenesis probiotic widely available clinically establish offer various health benefit primarily beneficially modulate gut microbiome however clinical outcome can vary significantly difference host physiology diet individual microbiome composition other environmental factor perspective paper highlight emerge scientific insight importance microbial micronutrient sharing gut redox balance keystone specie gut barrier maintain diverse functional microbial ecosystem relevance human health propose novel approach target microbial ecosystem keystone taxa performance supply microbial micronutrient form colon deliver vitamin precision prebiotic human milk oligosaccharide hmos synthetic glycan component precisely tailor ingredient combination to optimize human health strategy may effectively support stabilize microbial ecosystem provide more robust consistent approach various individual environmental condition thus overcome limitation current single biotic solution,"Steinert, Robert E,Rehman, Ateequr,Sadabad, Mehdi Sadaghian,Milanese, Alessio,Wittwer-Schegg, Jonas,Burton, Jeremy P,Spooren, Anneleen",17/03/2025,Gut microbes
10.1093/brain/awaf096,activate reduce mucosa associate invariant t cell encephalitis,anti leucine rich glioma anti contactin associate autoimmune encephalitis aie be common characterize pathogenic antibody target neuronal autoantigen however driver antibody secrete cell asc involvement t cell remain unresolved perform single cell rna sequence fresh cerebrospinal fluid csf parallel blood sample patient aie compare to control patient multiple sclerosis ms idiopathic intracranial hypertension iih validate observation independent cohort use flow cytometry csf blood confirm autoantibody specificity use recombinant human monoclonal antibodie compare iih ms control observe clonal csf specific asc expansion aie mostly normal csf finding asc be dominantly plasmablast transcribed heavy chain expand clone show sign affinity maturation bind respective neuronal autoantigen t cell cluster central memory t cell be activate clonally restrict expand t cell clone be often share csf blood also observe shift nk cell loss mucosa associate invariant t mait cell csf blood aie compare iih ms control indeed mait like t cell be detect autopsy brain aie patient mouse lack mait cell display increase antibody seroconversion high titer follow active immunization datum confirm intrathecal antigen specific plasma cell expansion aie large cohort untreated aie patient suggest activate expand central memory t cell csf participate disease pathogenesis first time implicate invariant t cell receptor express lymphocyte brain csf blood disease pathogenesis,"Esser, Daniela,Müller-Miny, Louisa,Heming, Michael,Paunovic, Manuela,van Duijn, Martijn,Abrante Cabrera, Ligia,Mair, Katharina M,Strippel, Christine,Räuber, Saskia,Dargvainiene, Justina,Kovac, Stjepana,Gross, Catharina C,Fransen, Nina,van Steenhoven, Robin,Körtvélyessy, Péter,Stenzel, Werner,Höftberger, Romana,Bindels, Eric,Bien, Christian G,Wiendl, Heinz,Meuth, Sven G,Bauer, Jan,Melzer, Nico,Titulaer, Maarten J,Leypoldt, Frank,Meyer Zu Hörste, Gerd",23/03/2024,Brain : a journal of neurology
10.1186/s12943-025-02276-z,mediate downregulation be dominant reversible mechanism immune evasion immunotherapy resistance non small cell lung cancer,background resistance naturally occur anti cancer immunity immunotherapy be common patient aggressive non small cell lung cancer nsclc recent study indicate role loss hla class i antigen presentation machinery apm protein microglobulin acquire resistance immune checkpoint blocker however mechanism functional consequence therapeutic potential apm defect nsclc remain poorly understand method use multiplexed immunofluorescence spatially map effector tumor infiltrate lymphocyte til apm component baseline pre treatment nsclcs patient treat axis blocker independent cohort impact silence lung cancer cell use sirnas crispr be study use transcriptomic analysis phosphoprotein array atac sequence measurement surface hla peptide complex vitro tumor antigen specific t cell killing establish autologous co culture tumor immune cell primary human nsclcs to study functional impact blockade use monoclonal antibody high throughput drug screen support identification compound able to increase expression nsclc cell result identify cancer cell selective protein downregulation treatment naïve nsclcs associate reduce sensitivity immune checkpoint blocker downregulation occur lung tumor survival impact silence lung cancer cell alter key intracellular immunomodulatory pathway limited sensitivity proinflammatory cytokine reduce level surface peptide hla complex protect malignant cell tumor antigen specific t cell killing upregulation loss human nsclcs be associate reduce promoter chromatin accessibility elevated expression treatment reduce level chromatin accessibility gene promoter nsclc cell reproduce functional consequence loss intact human nsclc transcript be detect intratumoral myeloid cell blockade increase human nsclc cell killing autologous til epigenetic modulator other drug known anti cancer activity increase expression function lung cancer cell conclusion study reveal previously unrecognized function antigen presentation establish reversible multi cellular axis mediating adaptive immune evasion immunotherapy resistance clinical potential,"Ranjan, Kishu,Rajendran, Barani Kumar,Deen, Imad Ud,Costantini, Adrien,de Rodas, Miguel Lopez,Desai, Shruti S,Scallo, Frankie,Gianino, Nicole,Ferrone, Soldano,Schalper, Kurt A",05/11/2024,Molecular cancer
10.1186/s12943-025-02276-z,mediate downregulation be dominant reversible mechanism immune evasion immunotherapy resistance non small cell lung cancer,background resistance naturally occur anti cancer immunity immunotherapy be common patient aggressive non small cell lung cancer nsclc recent study indicate role loss hla class i antigen presentation machinery apm protein microglobulin acquire resistance immune checkpoint blocker however mechanism functional consequence therapeutic potential apm defect nsclc remain poorly understand method use multiplexed immunofluorescence spatially map effector tumor infiltrate lymphocyte til apm component baseline pre treatment nsclcs patient treat axis blocker independent cohort impact silence lung cancer cell use sirnas crispr be study use transcriptomic analysis phosphoprotein array atac sequence measurement surface hla peptide complex vitro tumor antigen specific t cell killing establish autologous co culture tumor immune cell primary human nsclcs to study functional impact blockade use monoclonal antibody high throughput drug screen support identification compound able to increase expression nsclc cell result identify cancer cell selective protein downregulation treatment naïve nsclcs associate reduce sensitivity immune checkpoint blocker downregulation occur lung tumor survival impact silence lung cancer cell alter key intracellular immunomodulatory pathway limited sensitivity proinflammatory cytokine reduce level surface peptide hla complex protect malignant cell tumor antigen specific t cell killing upregulation loss human nsclcs be associate reduce promoter chromatin accessibility elevated expression treatment reduce level chromatin accessibility gene promoter nsclc cell reproduce functional consequence loss intact human nsclc transcript be detect intratumoral myeloid cell blockade increase human nsclc cell killing autologous til epigenetic modulator other drug known anti cancer activity increase expression function lung cancer cell conclusion study reveal previously unrecognized function antigen presentation establish reversible multi cellular axis mediating adaptive immune evasion immunotherapy resistance clinical potential,"Ranjan, Kishu,Rajendran, Barani Kumar,Deen, Imad Ud,Costantini, Adrien,de Rodas, Miguel Lopez,Desai, Shruti S,Scallo, Frankie,Gianino, Nicole,Ferrone, Soldano,Schalper, Kurt A",05/11/2024,Molecular cancer
10.1136/jitc-2024-010639,protein arginine methyltransferase enhance immune checkpoint blockade efficacy sting pathway mmr proficient colorectal cancer,background emergence immunotherapy have revolutionize paradigm cancer treatment immune checkpoint blockade icb solid cancer include colorectal cancer crc however only small subset crc patient harbor deficient mismatch repair dmmr microsatellite instability high msi h benefit icb therapy very limited response icb therapy have be achieve mmr proficient crc represent significant challenge limit clinical application immunotherapy mmr be critical dna repair pathway maintain genomic integrity correct dna mismatch be mediate mutsα mutsβ complex consist respectively give mmr status direct effective immune response seek to determine target mmr capacity boost icb efficacy method azoxymethane dextran sodium sulfate aom crc xenograft model be use to evaluate function response inhibitor combination therapy biochemical assay be perform to elucidate underlying mechanism mediate methylation immune evasion result have identify crucial regulator mmr capacity dimethylation modification abrogate mmr capacity prevent recruitment loss inhibition trigger cytosolic dna accumulation cgas sting signal activation lead enhance immune response deficient colon tumor xenograft pharmacological inhibition use promote mutagenesis destabilize mutsα mutsβ assembly prolong exposure maintain msi like phenotype microsatellite stability mss cell treatment sensitize icb efficacy mss cell not msi cell vivo similar effect have be observe mss colon tumor induce aom dss conclusion study provide preclinical proof concept to overcome resistance immunotherapy target crc mss,"Duan, Jinlin,Chen, Tao,Li, Qiwei,Zhang, Yu,Lu, Ting,Xue, Junyan,Sun, Yang,Gao, Ling,Zhang, Yonglong",26/02/2025,Journal for immunotherapy of cancer
10.1007/s12264-025-01384-6,comprehensive brain wide mapping afferent efferent nucleus associate heart mouse,normal heart function depend complex regulation brain abnormality axis affect various disease such myocardial infarction anxiety disorder however systematic tracking brain region associate input output heart be lack study inject retrograde transsynaptic pseudorabie virus prv anterograde transsynaptic herpe simplex virus hsv left ventricular wall mouse to identify whole brain region associate input output heart successfully detect prv hsv expression at least brain subregion male female mouse sex difference be discover mainly hypothalamus medulla male mouse exhibit great correlation hierarchical clustering female mouse indicate reduced similarity increase modularity virus expression pattern male mouse further graph theory multiple linear regression analysis different injection timeline reveal hub region prv have highly similar cluster different brain level suggest top down hierarchically transmit neural control pattern heart hub region hsv have scatter cluster brain region gather cortex brainstem suggest bottom up leapfrog multipoint neural sense pattern heart pattern contain many hub brain region have be previously overlook axis study result provide brain target future research will lead deep insight brain mechanism involve specific heart condition,"Liu, Haiying,Huang, Xin,Xia, Ruixin,Zhao, Xin,Li, Zimeng,Liu, Qian,Li, Congye,Mao, Honghui,Wang, Wenting,Wu, Shengxi",04/11/2024,Neuroscience bulletin
10.1016/j.drup.2025.101237,blockade restore osimertinib sensitivity drug resistant egfr mutant non small cell lung cancer,aim to investigate role mediate drug resistance egfr target therapy non small cell lung cancer nsclc method image mass cytometry be conduct nsclc tumor have egfr mutation correlate clinical variable include overall survival endoglin expression co receptor bone morphogenetic protein bmp signal two osimertinib resistant egfr mutant cell line be develop to study effect egfr disruption single cell rna sequence isogenic parental osimertinib resistant line be perform additionally atac sequence single cell energetic metabolism profile translation inhibition analysis scenith be use to assess promoter chromatin status glycolytic state result find negative correlation expression overall survival patient treatment osimertinib egfr knockdown significantly elevate expression egfr mutant cell line single cell rna sequencing identify subset cell heighten endothelial characteristic alter pyrimidine metabolism associate osimertinib resistance cell exhibit slow cycling behavior characterize elevated chromatin condensation reduce glycolysis combine osimertinib carotuximab neutralize antibody significantly reduce slow cycle transcriptomic signature increase chromatin accessibility restore glycolysis compare osimertinib treatment alone mass spectrometry confirm carotuximab re engage egfr signal couple consequently carotuximab re sensitized resistant tumor osimertinib increase mitotic index erk signal mouse model conclusion carotuximab effectively reduce slow cycle cell population restore osimertinib sensitivity offer promising strategy manage refractory nsclc,"Thiruvalluvan, Manish,Billet, Sandrine,Liu, Zhenqiu,Lownik, Joseph,Waissengrin, Barliz,Kim, Hyoyoung,Villamejor, Anton L,Milshteyn, Larry,Li, Xiamo,Gayhart, Matthew,Araña, Manuel,Sankar, Kamya,Posadas, Edwin M,Lopategui, Jean,You, Sungyong,Reckamp, Karen L,Bhowmick, Neil A",06/11/2024,Drug resistance updates : reviews and commentaries in antimicrobial and        anticancer chemotherapy
10.1016/j.phymed.2025.156484,fangchinoline suppresses nasopharyngeal carcinoma progression inhibit sqle to regulate akt pathway dysregulation,background purpose squalene epoxidase sqle key enzyme cholesterol metabolism remain underexplored nasopharyngeal carcinoma npc additionally therapeutic potential fangchinoline alkaloid anticancer property have yet to be systematically evaluate research investigate fangchinoline efficacy npc treatment sqle relate mechanism method drug screening npc cell line identify potential candidate value be determine use assay apoptosis proliferation invasion be assess annexin v pi stain edu staining transwell assay cholesterol level be quantify use tg kit rna sequence go kegg analysis identify key pathway correlation analysis be perform cbioportal database protein interaction network string cytoscape survival analysis kaplan meier curve gene protein expression be validate qpcr western blot npc mouse model confirm vivo efficacy result fangchinoline inhibit npc cell proliferation induce apoptosis reduce cholesterol accumulation rna sequencing reveal fangchinoline downregulate sqle expression suppress akt pathway correlation protein interaction analyse highlight sqle role npc progression survival analysis confirm clinical relevance target sqle disrupt cholesterol metabolism fangchinoline suppress tumor growth vitro vivo conclusion study demonstrate fangchinoline inhibit npc growth target sqle disrupt akt pathway provide new insight sqle therapeutic target npc,"Xie, Jieyun,Shi, Zexian,Sun, Lingling,Wu, Yihong,Feng, Jiuhuan,Wang, Han,Lai, Haifeng",24/08/2024,Phytomedicine : international journal of phytotherapy and phytopharmacology
10.1161/CIRCRESAHA.124.325049,alleviate aortic aneurysm dissection regulate polymerization,background aortic aneurysm dissection aad be life threaten disease lack effective pharmacological treatment protein ubiquitination play pivotal role cardiovascular disease however possible contribution ubiquitin ligase membrane associate ring finger protein cause aad remain elusive method integrate single cell rna sequence analysis be conduct human aad tissue base screening result generate mouse line smooth muscle cell specific knockout β aminopropionitrile monofumarate be use to establish aad cleavage target tagmentation cleavage target tagmentation quantitative polymerase chain reaction be perform to identify possible target gene histone lactylation result expression be downregulate aorta patient aad β aminopropionitrile monofumarate induce aad mouse β aminopropionitrile monofumarate induced aad be significantly accentuate global vascular smooth muscle cell specific deletion fl mouse aad pathology be rescue recombinant adeno associate virus serotype express flag tag promoter interact pyruvate kinase to promote link polyubiquitination deficiency lessen dimer tetramer conversion aad overtly exacerbate aad induce histone lactylation vascular smooth muscle cell foster glucose metabolism reprogramme thereby promote drive apoptotic transcriptional response hallmark aad pathogenesis specific activator pronouncedly alleviated deficiency deteriorate aad pathology conclusion finding demonstrate be novel endogenous defender prevent aad inhibit vascular smooth muscle cell apoptosis suggest represent potential therapeutic target aad,"Li, Yiran E,Liu, Shuolin,Wang, Litao,Du, Yuxin,Wu, Lin,Chen, Haoran,Zhu, Tingfang,Lin, Jie,Xiong, Shengjun,Wang, Yayu,Zheng, Qijun,Zou, Rongjun,Lin, Ling,Li, Zheyun,Wang, Lixin,Ge, Junbo,Ren, Jun,Zhang, Yingmei",13/03/2025,Circulation research
10.1186/s12872-025-04574-2,effect diltiazem metoprolol level high sensitivity troponin patient permanent atrial fibrillation randomized trial,background high sensitive cardiac troponin assay provide prognostic information atrial fibrillation af patient few study have explore impact long term rate control therapy level troponin patient coronary heart disease heart failure substudy rate control atrial fibrillation rataf ii study aim to compare effect six month treatment diltiazem metoprolol hs troponin tni level rest exercise testing patient permanent af method be parallel group randomize investigator blind clinical trial cohort consist patient woman mean age year symptomatic permanent af preserve left ventricular systolic function coronary heart disease participant be randomize ratio to receive diltiazem mg metoprolol mg once daily six month blood test be draw rest peak exercise testing baseline one month six month treatment research have be support grant south eastern norway regional health authority vestre viken hospital trust result six month treatment diltiazem metoprolol significantly lower heart rate rest peak exercise treatment group exhibit decrease hs tni level rest diltiazem p metoprolol p peak exercise diltiazem p metoprolol p six month compare baseline level significant difference observe group conclusion patient permanent af six month rate control therapy diltiazem metoprolol lower level hs tni further research be warrant to determine reduction translate improved prognosis trial registration registration date,"Enge, Katrine,Ulimoen, Sara Reinvik,Enger, Steve,Onarheim, Sophia,Olufsen, Mona,Pripp, Are Hugo,Steinsvik, Trude,Hall, Christian,Hetland, Mathias,Tveit, Arnljot",25/10/2024,BMC cardiovascular disorders
10.7326/ANNALS-24-01917,acute pain management people opioid use disorder systematic review,background guidance acute pain management people opioid use disorder oud be limited purpose to synthesize evidence benefit harm acute pain intervention people oud datum source apa psycarticle apa psycinfo apa psycextra allied complementary medicine database cinahl cochrane library google scholar ovid embase ovid medline pubmed scopus web science core collection july study selection study design evaluate acute pain intervention adult oud include pain oud outcome datum extraction independent dual screening single investigator datum extraction verification dual quality strength evidence assessment datum synthesis seventeen trial control observational study uncontrolle observational study meet eligibility criterion continue use buprenorphine acute pain episode may be associate similar improved pain relate outcome discontinuing base cohort study conduct primarily perioperative setting single well conduct randomize control trial emergency department ed perioperative setting adult not prescribe medication oud suggest oral clonidine intramuscular haloperidol midazolam intravenous morphine intraoperative iv lidocaine may improve pain outcome warrant study diverse patient population few study evaluate methadone effect intervention oud outcome limitation most evidence be observational risk bias confound study be conduct ed hospital setting most widespread use high potency synthetic opioid non population use opium conclusion overall evidence pain outcome people oud be low effect pain intervention oud outcome be important evidence gap primary funding source none protocol register priori open science framework,"Buonora, Michele J,Mackey, Katherine,Khalid, Laila,Hickey, Thomas R,Grimshaw, Alyssa A,Moss, Max,Starrels, Joanna L,Alford, Daniel P,Becker, William C,Weimer, Melissa B",17/03/2025,Annals of internal medicine
10.1186/s13059-025-03499-5,single nucleus spatial transcriptomic atlas liver reveal topological functional regenerative organ disruption patient,background molecular underpinning organ dysfunction severe potential long term sequelae be intense investigation to shed light context liver function perform single nucleus rna seq spatial transcriptomic profiling liver decedent result identify hepatocyte positive sar rna expression phenotype resemble infected lung epithelial cell central role pro fibrotic tgfβ signal cell cell communication network integrate analysis comparison healthy control reveal extensive change cellular composition expression state liver provide underpinning hepatocellular injury ductular reaction pathologic vascular expansion fibrogenesis characteristic cholangiopathy also observe kupffer cell proliferation erythrocyte progenitor first time human liver single cell atla absence clinical acute liver injury phenotype endothelial cell composition be dramatically impact concomitantly extensive alteration profibrogenic activation reactive cholangiocyte mesenchymal cell conclusion atla provide novel insight liver physiology pathology form foundational resource investigation understanding,"Pita-Juarez, Yered,Karagkouni, Dimitra,Kalavros, Nikolaos,Melms, Johannes C,Niezen, Sebastian,Delorey, Toni M,Essene, Adam L,Brook, Olga R,Pant, Deepti,Skelton-Badlani, Disha,Naderi, Pourya,Huang, Pinzhu,Pan, Liuliu,Hether, Tyler,Andrews, Tallulah S,Ziegler, Carly G K,Reeves, Jason,Myloserdnyy, Andriy,Chen, Rachel,Nam, Andy,Phelan, Stefan,Liang, Yan,Gregory, Mark,He, Shanshan,Patrick, Michael,Rane, Tushar,Wardhani, Aster,Amin, Amit Dipak,Biermann, Jana,Hibshoosh, Hanina,Veregge, Molly,Kramer, Zachary,Jacobs, Christopher,Yalcin, Yusuf,Phillips, Devan,Slyper, Michal,Subramanian, Ayshwarya,Ashenberg, Orr,Bloom-Ackermann, Zohar,Tran, Victoria M,Gomez, James,Sturm, Alexander,Zhang, Shuting,Fleming, Stephen J,Warren, Sarah,Beechem, Joseph,Hung, Deborah,Babadi, Mehrtash,Padera, Robert F Jr,MacParland, Sonya A,Bader, Gary D,Imad, Nasser,Solomon, Isaac H,Miller, Eric,Riedel, Stefan,Porter, Caroline B M,Villani, Alexandra-Chloé,Tsai, Linus T-Y,Hide, Winston,Szabo, Gyongyi,Hecht, Jonathan,Rozenblatt-Rosen, Orit,Shalek, Alex K,Izar, Benjamin,Regev, Aviv,Popov, Yury V,Jiang, Z Gordon,Vlachos, Ioannis S",04/07/2023,Genome biology
10.1186/s12889-025-21910-5,long term exposure air pollution gastrointestinal disease finding nationwide cohort study china,background aim air pollution pose significant risk human health impact gastrointestinal gi health remain underexplored study assess long term effect air pollution gi disease use datum china health retirement longitudinal study charls method nationwide cohort study utilize charl datum participant recruit follow survey long term exposure co be assess use geocode residential address link air quality datum cox proportional hazard model subgroup interaction analysis be use to evaluate association pollutant gi disease incidence adjust demographic behavioral confounder result incidence gi disease be participant long term exposure hr ci hr ci hr ci hr ci co hr ci hr ci be significantly associate gi disease interaction analysis show effect pollutant vary region residence smoking alcohol use urban resident live specific region experience strong association likely high pollution level different environmental factor smoker alcohol user be also more susceptible adverse effect pollutant conclusion long term exposure multiple air pollutant increase risk gi disease ozone may potentially offer protective effect public health measure to reduce air pollution especially urban area to protect high risk group be urgently need,"Kou, Yanqi,Ye, Shicai,Du, Weimin,Lu, Zhuoyan,Yang, Ke,Zhan, Liping,Huang, Yujie,Qin, Ling,Yang, Yuping",27/06/2024,BMC public health
10.1111/wvn.70008,effectiveness mind body exercise health relate quality life mental health breast cancer treatment umbrella review meta analysis randomized control trial,background previous study regard mind body exercise people breast cancer mostly focus one type mind body exercise provide conflict result aim paper aim to systematically synthesize evidence hierarchy examine credibility previous meta analysis different type mind body exercise method search pubmed embase cochrane library web science epitemonikos database inception february meta analysis randomized control trial include meta analysis examine effect mind body exercise at least one outcome health relate quality life cancer relate fatigue depression anxiety sleep quality breast cancer patient random effect estimate prediction interval small study effect excess significance bias be calculate furthermore categorize meta analysis base evidence credibility criterion assess quality use measurement tool to assess systematic review result umbrella review include re analysis meta analysis article include randomize control trial involve breast cancer patient survivor identify article low quality article critically low quality convincing evidence support effectiveness yoga intervention reduce depression symptom g confidence interval however meta analysis be support weak evidence qigong alleviate depression qigong baduanjin tai chi chuan yoga improve health relate quality life multiple mind body exercise tai chi chuan yoga reduce cancer relate fatigue baduanjin yoga reduce anxiety as well yoga improve sleep quality link evidence action mind body exercise especially yoga may be beneficial improve health relate quality life mental health breast cancer patient further high quality intervention investigate diverse mind body exercise intervention be warrant to ascertain effectiveness health relate quality life mental health outcome,"Wen, Jingsi,Hui, Stanley Sai-Chuen,Chin, Edwin Chun-Yip,Yang, Yijian,Sit, Cindy Hui-Ping",01/12/2024,Worldviews on evidence-based nursing
10.1016/j.neuron.2025.02.003,population coding predator imminence hypothalamus,hypothalamic neuron be activate predator cue be necessary sufficient instinctive defensive response however such datum do not distinguish feature predator encounter be encode neural activity to address issue image neuron single cell resolution freely behave mouse expose natural predator vary contexts result reveal neuron do not encode different defensive behavior rather represent predator identity multiple predator evoke internal state include threat evoke fear anxiety arousal neophobia predator imminence safety notably threat safety be encode bi directionally anti correlated subpopulation strikingly individual difference predator defensiveness be correlate individual difference response dynamic thus different threat relate internal state variable be encode distinct neuronal subpopulation genetically define anatomically restrict hypothalamic cell class,"Cheung, Kathy Y M,Nair, Aditya,Li, Ling-Yun,Shapiro, Mikhail G,Anderson, David J",25/06/2024,Neuron
10.1016/j.ymthe.2025.03.018,peptide cloak lipid nanoparticle promote cell specific mrna delivery,mrna base therapeutic deliver lipid nanoparticle lnp mrna hold great promise treat diverse disease however further improvement be need to refine outcome non vaccine extrahepatic application such minimize mononuclear phagocyte system mps rapid clearance target toxicity undesired tissue propose modify lnp surface phagocytic cell do not eat signal combination previously establish antibody base targeted lnp tlnp to create tlnp platform reduce phagocytic clearance target effect improve efficiency cell specific delivery show modification decrease macrophage hepatic uptake vitro vivo combine modification antibody target endothelial cell t cell hematopoietic stem cell hsc increase target efficiency to fold compare tlnp alone enhance target tlnp hsc reduce off targeting enable delivery pro apoptotic mrna hsc depletion precondition strategy prior bone marrow transplant additionally modify lnps show diminished inflammatory effect hepatic tissue altered protein corona tlnp mrna platform reduce phagocytic clearance mitigate inflammatory effect enhance target delivery should far facilitate development vivo mrna therapeutic,"Papp, Tyler Ellis,Zeng, Jianhao,Shahnawaz, Hamna,Akyianu, Awurama,Breda, Laura,Yadegari, Amir,Steward, Joseph,Shi, Ruiqi,Li, Qin,Mui, Barbara L,Tam, Ying K,Weissman, Drew,Rivella, Stefano,Shuvaev, Vladimir,Muzykantov, Vladimir R,Parhiz, Hamideh",08/07/2024,Molecular therapy : the journal of the American Society of Gene Therapy
,cytogenetic analysis recombination male drosophila ananassae,cytogenetic study recombination male drosophila ananassae be carry examine male derive mating marker female b se bri ru bs stock male two wild stran tng male recombination value section b se chromosome bri ru chromosome be high tng extremely low demonstrate presence chiasmata tng male frequency capable account observed recombination value unique series iso site aberration be also observe tng male parallelism distribution pattern chiasmata iso site aberration propose recombination male ananassae be meiotic origin iso site aberration be relate chiasma formation,"Matsuda, M,Imai, H,Tobari, Y N",01/01/1983,Chromosoma
10.1038/s41589-025-01864-w,post translational modification orchestrate intrinsic signal bias,recent advance g protein couple receptor gpcr biology regulation gpcr activation signal function post translational modification ptms remain largely unexplored study orphan gpcr exceedingly high constitutive g protein activity be emerge neurotherapeutic target discover disproportionately low arrestin recruitment activity profile n glycosylation phosphorylation pattern find two type ptms differentially shape intrinsic signal bias n terminal n glycosylation promote constitutive signal possibly favor self activate conformation phosphorylation helix great surprise suppress arrestin recruitment attenuate receptor internalization addition uncover counteracting role n glycosylation phosphorylation modulate dependent accumulation huntingtin protein brain striatal cell study provide new insight regulation intrinsic signal bias cellular function orphan gpcr distinct ptms different motif,"Zhang, Bingjie,Ge, Wei,Ma, Mengna,Li, Shanshan,Yu, Jie,Yang, Guang,Wang, Huilan,Li, Jingwen,Li, Qingrun,Zeng, Rong,Lu, Boxun,Shui, Wenqing",29/05/2024,Nature chemical biology
10.1016/j.cct.2025.107883,pirfenidone to prevent fibrosis acute respiratory distress syndrome pioneer study protocol,background pulmonary fibrosis be major complication acute respiratory distress syndrome ard pirfenidone be approve treatment idiopathic pulmonary fibrosis may attenuate ards relate fibrosis decrease need prolonged ventilation accordingly aim to evaluate effect pirfenidone ventilator free day patient ard method multi center randomize double blind placebo control trial plan to randomly assign adult invasively ventilate ard to receive pirfenidone placebo to day primary outcome be day alive ventilator free day secondary outcome include icu free day hospital free day all day icu mortality hospital mortality will also assess fibroproliferative change high resolution ct scan icu discharge quality life datum analysis will be intention treat basis discussion trial be ongoing currently recruit will be first randomize control study to investigate compare placebo pirfenidone reduce number day alive ventilator free patient ard double blind multicenter design will provide internal validity minimal bias degree external validity hypothesis be confirm treatment would justify large trial intervention trial registration trial be register trial identification,"Monti, Giacomo,Marzaroli, Matteo,Tucciariello, Maria Teresa,Ferrara, Brian,Meroi, Francesco,Nakhnoukh, Cristina,Zambon, Massimo,Borghi, Giovanni,Guarracino, Fabio,Manazza, Marco,Ajello, Valentina,Belletti, Alessandro,Biuzzi, Cesare,Plumari, Valentina,Filippini, Matteo,Cuffaro, Raffaele,Racanelli, Gabriele,Pontillo, Domenico,Rauch, Simon,Oliva, Federico Mattia,Tescione, Marco,Redaelli, Martina Baiardo,Melegari, Gabriele,Maj, Giulia,Navalesi, Paolo,Gerardi, Michele,Caccioppola, Alessio,Bruni, Andrea,Ballotta, Andrea,Ferri, Camilla,Orso, Daniele,Di Benedetto, Vincenzo,Baldassarri, Rubia,Franceschini, Giulia,Alamami, Ans,Pasin, Laura,Putzu, Alessandro,Garcia, Carolina Soledad Romero,Chen, Yih-Sharng,Noto, Alberto,Yavorovskiy, Andrey,Hajjar, Ludhmila Abrahao,Cortegiani, Andrea,Likhvantsev, Valery,Konkayev, Aidos,Finco, Gabriele,Sales, Gabriele,Brazzi, Luca,Paternoster, Gianluca,Bellomo, Rinaldo,Zangrillo, Alberto,Landoni, Giovanni,Di Tomasso, Nora",28/12/2024,Contemporary clinical trials
10.1186/s12974-025-03401-x,do microglia metabolize fructose alzheimer disease,alzheimer disease ad be age associate neurodegenerative disorder complex etiology emerge ad therapeutic can slow cognitive decline may worsen dementia certain group individual therefore alternative treatment be much need microglia brain resident macrophage have potential to be novel therapeutic target regulate many facet ad include lipid droplet ld accumulation amyloid beta aβ clearance neuroinflammation to carry such function microglia undergo phenotypic change be link shift metabolism substrate utilization homeostatic microglia be drive oxidative phosphorylation oxphos glycolysis aging ad microglia shift far glycolysis interestingly metabolic reprogramming may be link increase fructose metabolism brain microglia predominantly express fructose transporter enzyme involve fructolysis endogenous fructose production expression be upregulate aging disease here review evidence fructose uptake breakdown production microglia also evaluate emerge literature target fructose metabolism brain periphery to assess ability to modulate microglial function ad ability microglia to transport utilize fructose couple well establish role fructose metabolic dysfunction support notion microglial fructose metabolism may be novel potential therapeutic target ad,"Sturno, Annalise M,Hassell, James E Jr,Lanaspa, Miguel A,Bruce, Kimberley D",07/01/2025,Journal of neuroinflammation
10.1186/s12916-025-03989-0,lenvatinib pembrolizumab compare carboplatin paclitaxel carboplatin paclitaxel pretreate recurrent advanced endometrial cancer,background lenvatinib pembrolizumab have demonstrate improved survival compare doxorubicin paclitaxel monotherapy patient advanced recurrent endometrial cancer ecs however response rate monotherapy be poor recurrent setting herein perform retrospective analysis use real world datum to compare outcome lenvatinib pembrolizumab carboplatin paclitaxel pt doxorubicin patient pt pretreate advanced recurrent ec method perform multi institutional retrospective analysis use de identified electronic health record database trinetx to compare lenvatinib pembrolizumab carboplatin paclitaxel pt doxorubicin outcome patient pt pretreate advanced recurrent ec propensity score matching psm be conduct primary outcome be overall survival os treatment group secondary outcome be adverse event profile result january september identify patient pt treat advanced recurrent ec receive lenvatinib pembrolizumab patient receive pt platinum free interval month follow psm significant difference median os be observe lenvatinib pembrolizumab re challenge pt group month p hazard ratio confidence interval however lenvatinib pembrolizumab provide well survival benefit doxorubicin adverse event analysis show more hypothyroidism hypertension proteinuria lenvatinib pembrolizumab more hematologic toxicity chemotherapy group conclusion lenvatinib pembrolizumab be not associate improved survival compare re challenge pt patient platinum free interval month re challenge pt remain valid option pt treat recurrent advanced ec especially patient substantially long platinum free interval,"Wang, Shao-Jing,Sun, Lou,Shih, Yu-Hsiang,Lu, Ting-Fang,Chen, Yen-Fu,Hsu, Shih-Tien,Liu, Chin-Ku,Hwang, Sheau-Feng,Chen, Jem-Kun,Chen, Hsin-Hua,Lu, Chien-Hsing",08/05/2024,BMC medicine
10.1016/j.molcel.2025.02.016,spatial control deposition enhancer promoter rna co acetylation chromatin,interaction methyltransferase be critical to deposit various type rnas remain to be uncover be spatial control deposition different type rnas here genome wide crispr screening cell line find acetylase mediate acetylation suppress binding mark chromatin inhibit interaction consistently catalyze acetylation specifically occur mark chromatin disruptive mutation acetylation site selectively promote chromatin associate rna bind enhancer promoter mark result transcription inhibition ferroptosis inhibition relate gene addition promote acetylation phosphorylate inhibition promote ferroptosis manner depend acetylation study reveal spatial selective way to specifically regulate deposition enhancer promoter rna,"Huang, Xiang,Zhang, Jie,Cun, Yixian,Ye, Meijun,Ren, Zhijun,Guo, Wenbing,Ma, Xiaojun,Liu, Jiayin,Luo, Weiwei,Sun, Xiang,Shao, Jingwen,Wu, Zehong,Zhu, Xiaofeng,Wang, Jinkai",23/08/2024,Molecular cell
10.1016/j.canlet.2025.217639,enhance warburg effect immune evasion non small cell lung cancer pathway,non small cell lung cancer nsclc be acknowledge primary subtype lung cancer warburg effect mark elevated glucose consumption lactate fermentation be prevalent characteristic nsclc mechanism circrna mediate regulation warburg effect immune evasion nsclc remain unclear study find elevated circrna whiche promote glycolysis lactate generation result infiltration regulatory t cell treg nsclc act sponge inhibit negative regulation target gene therefore facilitate glycolysis lactate generation accumulation lactic acid tumor microenvironment promote treg cell proliferation aid immune evasion functionally suppression significantly impede tumor development vitro vivo finding collectively clarity previously unexamined mechanism link axis regulation warburg effect immune evasion nsclc,"Li, Jinyou,Xu, Shiwei,Zhan, Yangyang,Lv, Xinyi,Sun, Zhenyu,Man, Li,Yang, Donghua,Sun, Yahong,Ding, Shengguang",19/11/2024,Cancer letters
10.1016/j.molcel.2025.02.016,spatial control deposition enhancer promoter rna co acetylation chromatin,interaction methyltransferase be critical to deposit various type rnas remain to be uncover be spatial control deposition different type rnas here genome wide crispr screening cell line find acetylase mediate acetylation suppress binding mark chromatin inhibit interaction consistently catalyze acetylation specifically occur mark chromatin disruptive mutation acetylation site selectively promote chromatin associate rna bind enhancer promoter mark result transcription inhibition ferroptosis inhibition relate gene addition promote acetylation phosphorylate inhibition promote ferroptosis manner depend acetylation study reveal spatial selective way to specifically regulate deposition enhancer promoter rna,"Huang, Xiang,Zhang, Jie,Cun, Yixian,Ye, Meijun,Ren, Zhijun,Guo, Wenbing,Ma, Xiaojun,Liu, Jiayin,Luo, Weiwei,Sun, Xiang,Shao, Jingwen,Wu, Zehong,Zhu, Xiaofeng,Wang, Jinkai",23/08/2024,Molecular cell
10.1038/s43018-025-00921-6,odronextamab monotherapy patient relapse refractory diffuse large b cell lymphoma primary efficacy safety analysis phase trial,phase multicohort ongoing study evaluate odronextamab bispecific antibody patient relapse refractory r r b cell non hodgkin lymphoma line therapy here primary analysis diffuse large b cell lymphoma dlbcl cohort be report patient receive intravenous odronextamab day cycle progression unacceptable toxicity cycle step up dosing to mitigate cytokine release syndrome crs risk primary endpoint be objective response rate orr secondary endpoint include complete response cr rate duration response progression free survival pfs overall survival total patient be enrol month efficacy follow up orr be cr rate be median duration response cr be month respectively undetectable minimal residual disease cycle day be associate pfs benefit step up to to mg crs be most common treatment emergent adverse event grade immune effector cell associate neurotoxicity syndrome be report infection be report patient grade coronavirus disease grade conclusion odronextamab show encourage efficacy heavily pretreate r r dlbcl generally manageable safety supportive care clinical trial registration,"Kim, Won Seog,Kim, Tae Min,Cho, Seok-Goo,Jarque, Isidro,Iskierka-Jażdżewska, Elżbieta,Poon, Li Mei,Prince, H Miles,Zhang, Huilai,Cao, Junning,Zhang, Mingzhi,Tessoulin, Benoît,Oh, Sung Yong,Lim, Francesca,Carpio, Cecilia,Tan, Tran-Der,Ayyappan, Sabarish,Gutierrez, Antonio,Cai, Jingxian,Ufkin, Melanie,Shariff, Saleem,Brouwer-Visser, Jurriaan,Chaudhry, Aafia,Mohamed, Hesham,Ambati, Srikanth,Walewski, Jan",14/08/2024,Nature cancer
10.1177/14230380251316788,external validation serum tumor marker algorithm early prediction durable benefit to immunotherapy metastastic non small cell lung carcinoma,backgroundimmune checkpoint inhibitor icis provide significant survival benefit non small cell lung cancer nsclc patient however accurately predict patient will benefit remain challenge previously show stop model machine learning model base serum tumor marker be capable identify non responder week study aim to externally validate model to assess predictive value combination radiological response assessment use recist cohort metastatic nsclc patient cyfra cea nse be measure start week ici treatment ability stop model to predict durable benefit ndb progressive disease death month disease control less month be assess use specificity positive predictive value ppv moreover combination stop model recist week icis be stop model achieve specificity ci ppv predict ndb ci combine stop model recist improve specificity ppv predict ndb average week iqr week prior develop radiologically define week icis blood base stop model be capable accurately predict ndb metastatic nsclc patient early conventional radiological assessment combine serological radiological response assessment create early opportunity to safely stop ici treatment patient will not benefit clinical utility assay be limit high specificity come cost low sensitivity,"Schuurbiers, Milou M F,van Delft, Freek A,Koffijberg, Hendrik,IJzerman, Maarten J,Monkhorst, Kim,Ligtenberg, Marjolijn J L,van den Broek, Daan,van Rossum, Huub H,van den Heuvel, Michel M",18/03/2025,Tumour biology : the journal of the International Society for Oncodevelopmental        Biology and Medicine
10.1016/j.pan.2025.02.015,recommendation european guideline diagnosis therapy pancreatic exocrine insufficiency,background pancreatic exocrine insufficiency pei be define reduction pancreatic exocrine secretion level allow normal digestion nutrient pancreatic disease pancreatic surgery be main cause pei other condition can affect digestive function pancrea method collaboration european digestive surgery ed european society pediatric gastroenterology hepatology nutrition espghan european society clinical nutrition metabolism espen european society digestive oncology esdo european society primary care gastroenterology espcg work group develop european guideline diagnosis therapy pei united european gastroenterology ueg provide endorsement financial support development guideline result recommendation cover topic relate clinical management pei concept pathogenesis clinical relevance general diagnostic approach general therapeutic approach pei secondary chronic pancreatitis pei acute pancreatitis pei associate pancreatic cancer pei secondary cystic fibrosis pei pancreatic surgery pei esophageal gastric bariatric surgery pei patient type type diabetes pei other condition conclusion european guideline diagnosis therapy pei provide evidence base recommendation concern key aspect etiology diagnosis therapy follow up base current available evidence recommendation should serve reference standard exist management pei guide future clinical research article summarize recommendation statement,"Vujasinovic, Miroslav,Iglesia, Daniel de la,Dominguez-Muñoz, J Enrique,Löhr, J Matthias",21/12/2024,Pancreatology : official journal of the International Association of        Pancreatology (IAP) ... [et al.]
10.7554/eLife.91329,inhibit dependent plasma membrane rupture protect inflammasome induce blood coagulation inflammation,systemic blood coagulation accompany inflammation severe infection sepsis covid previously establish link coagulopathy pyroptosis vital defense mechanism infection pyroptosis formation gasdermin d gsdmd pore plasma membrane lead release tissue factor microvesicle mvs be procoagulant mouse lack gsdmd release few procoagulant mvs however specific mechanism couple activation gsdmd mv release remain unclear plasma membrane rupture pmr pyroptosis be recently report to be actively mediate transmembrane protein here show promote procoagulant mv release pyroptosis haploinsufficiency glycine inhibition limit release procoagulant mvs inflammatory cytokine partially protect blood coagulation lethality trigger bacterial flagellin finding suggest crucial role dependent pmr inflammasome induce blood coagulation inflammation,"Cui, Jian,Li, Hua,Ye, Dien,Zhang, Guoying,Zhang, Yan,Yang, Ling,Sim, Martha M S,Wood, Jeremy P,Wei, Yinan,Li, Zhenyu,Wu, Congqing",17/03/2025,eLife
10.1016/j.eclinm.2025.103131,performance ai prediction tool new onset atrial fibrillation coronary artery bypass grafting,background be lack tool to predict new onset postoperative atrial fibrillation noaf coronary artery bypass grafting cabg aim to develop validate novel ai base bedside tool accurately predict predict noaf cabg method datum patient undergo cabg march july two tertiary hospital china be retrospectively analyze patient one hospital form derivation cohort split training test set patient separate hospital form external validation cohort stacking model integrate base learner be develop evaluate use accuracy precision recall score area curve auc shapley additive explanation shap value be calculate plot to interpret contribution individual characteristic model prediction finding seventy seven predictive characteristic be analyze stacking model achieve superior performance aucs score independent external validation outperform vasc hatch poaf score auc p shap value indicate importance predictive feature noaf descend order include brain natriuretic peptide leave ventricular end diastolic diameter ejection fraction bmi β receptor blocker duration surgery age neutrophil percentage albumin ratio myocardial infarction leave atrial diameter hypertension smoking status subsequently construct easy to use bedside clinical tool noaf risk assessment leverage characteristic interpretation ai base tool offer superior prediction noaf outperform three exist predictive tool future study should far explore various patient characteristic influence timing noaf onset early late funding work be fund lingnan nightingale nursing research institute guangdong province guangdong nursing society,"Ma, Hualong,Chen, Dalong,Lv, Weitao,Liao, Qiuying,Li, Jingyi,Zhu, Qinai,Zhang, Ying,Deng, Lizhen,Liu, Xiaoge,Wu, Qinyang,Liu, Xianliang,Yang, Qiaohong",30/11/2024,EClinicalMedicine
10.7150/thno.102014,plasma extracellular vesicle recurrent gbms carry ldha to activate glioblastoma stemness enhance glycolysis,rationale glioblastoma multiforme gbm be most aggressive primary malignant brain tumor adult characterize high invasiveness poor prognosis glioma stem cell gsc drive gbm treatment resistance recurrence however molecular mechanism activate intracranial gsc remain unclear extracellular vesicle evs be crucial signal mediator regulate cell metabolism can cross blood brain barrier bbb study aim to elucidate cargo contribute intracranial gsc state validate non invasive diagnostic strategy gbm relapse method isolate plasma extracellular vesicle pl evs three group recurrent gbm patient post resection non recurrent gbm patient post resection healthy individual newly diagnose gbm patient serve additional control evs be characterize co cultured primary gbm cell line to assess effect tumor stemness cargo be analyze use proteomic to investigate specific subpopulation contribute gbm relapse base finding generate engineer ldha enrich evs ldha evs co cultured patient derive organoid pdo metabolomic be perform to elucidate underlie signal transduction pathway result study demonstrate pl evs recurrent gbm patient enhance aerobic glycolysis stemness gbm cell proteomic analysis reveal plasma evs recurrent gbms encapsulate considerable amount enzyme lactate dehydrogenase ldha mechanistically ldha load evs promote glycolysis induce camp atp cycling accelerate lactate production thereby maintain gsc phenotype concurrently post surgical therapy induce stress modulate hypoxia residual tumor promote ldha enrich release clinically high level circulate ldha positive evs correlate increase glycolysis poor therapeutic response short survival recurrent gbm patient conclusion study highlight ldha load evs key mediator promote gsc property metabolic reprogramme gbm finding provide insight recurrence mechanism suggest potential liquid biopsy approach monitoring prevent gbm relapse,"Zhang, Xin,Li, JunJie,Huang, Yiyao,Yang, Anming,Liu, Xiaoliu,Luo, Yunhao,Tian, Hao,Wen, Minghui,Zhong, Chengzong,Peng, Bin,Sun, Haitao,Zheng, Lei",06/08/2024,Theranostics
10.1016/j.ccell.2025.02.018,effective target pdgfra alter high grade glioma avapritinib,pdgfra be crucial tumorigenesis frequently genomically alter high grade glioma hgg comprehensive dataset pediatric hgg detect pdgfra mutation amplification case suggest pdgfra therapeutic target reveal pdgfra kit inhibitor avapritinib show selectivity pdgfra inhibition distinct pattern subcellular effect vitro vivo activity patient derive hgg model effective blood brain barrier penetration mouse human furthermore report preliminary clinical real world experience use avapritinib pediatric young adult patient predominantly recurrent refractory pdgfra altered hgg early datum demonstrate avapritinib be well tolerated result radiographic response case suggest potential role avapritinib treatment hgg specific pdgfra alteration overall translational result underscore therapeutic potential pdgfra inhibition avapritinib hgg,"Mayr, Lisa,Neyazi, Sina,Schwark, Kallen,Trissal, Maria,Beck, Alexander,Labelle, Jenna,Eder, Sebastian K,Weiler-Wichtl, Liesa,Marques, Joana G,de Biagi-Junior, Carlos A O,Lo Cascio, Costanza,Chapman, Owen,Sridhar, Sunita,Kenkre, Rishaan,Dutta, Aditi,Wang, Shanqing,Wang, Jessica,Hack, Olivia,Nascimento, Andrezza,Nguyen, Cuong M,Castellani, Sophia,Rozowsky, Jacob S,Groves, Andrew,Panditharatna, Eshini,Cruzeiro, Gustavo Alencastro Veiga,Haase, Rebecca D,Tabatabai, Kuscha,Madlener, Sibylle,Wadden, Jack,Adam, Tiffany,Kong, Seongbae,Miclea, Madeline,Patel, Tirth,Bruckner, Katharina,Senfter, Daniel,Lämmerer, Anna,Supko, Jeffrey,Guntner, Armin S,Palova, Hana,Neradil, Jakub,Stepien, Natalia,Lötsch-Gojo, Daniela,Berger, Walter,Leiss, Ulrike,Rosenmayr, Verena,Dorfer, Christian,Dieckmann, Karin,Peyrl, Andreas,Azizi, Amedeo A,Baumgartner, Alicia,Slaby, Ondrej,Pokorna, Petra,Clark, Louise M,Cameron, Amy,Nguyen, Quang-De,Wakimoto, Hiroaki,Dubois, Frank,Greenwald, Noah F,Bandopadhayay, Pratiti,Beroukhim, Rameen,Ligon, Keith,Kramm, Christof,Bronsema, Annika,Bailey, Simon,Stucklin, Ana Guerreiro,Mueller, Sabine,Skrypek, Mary,Martinez, Nina,Bowers, Daniel C,Jones, David T W,Jones, Chris,Jäger, Natalie,Sterba, Jaroslav,Müllauer, Leonhard,Haberler, Christine,Kumar-Sinha, Chandan,Chinnaiyan, Arul,Mody, Rajen,Chavez, Lukas,Furtner, Julia,Koschmann, Carl,Gojo, Johannes,Filbin, Mariella G",30/07/2024,Cancer cell
10.1186/s12967-025-06356-y,f box protein overexpression inhibit proliferation metastasis clear cell renal cell carcinoma be closely related creb pathway tumor immune cell infiltration,background many study have show f box protein regulate epithelial mesenchymal transition be closely relate tumor metastasis however be still limited research role f box protein renal cell carcinoma rcc method public database be use to screen differentially express gene f box protein clear cell rcc ccrcc expression differential gene prognostic value be verify rt qpcr immunohistochemistry pyrosequencing be use to detect regulatory effect dna methylation expression effect expression cell proliferation metastasis be clarify cell phenotype experiment animal model relationship expression infiltration level tumor immune cell be also analyze gsea western blot be use to identify downstream molecular pathway associate expression result result reveal be significantly underexpresse ccrcc increase expression predict well patient prognosis promoter region exhibit dna hypermethylation expression be significantly restore demethylation addition overexpression significantly inhibit proliferation metastasis ccrcc cell vitro vivo mechanistically expression be relate stroma score infiltration level immune infiltrate cell associate prognosis moreover overexpression increase expression key molecule creb pathway conclusion result suggest be novel prognostic biomarker ccrcc patient function tumor suppressor gene moreover may regulate creb pathway be closely relate tumor immune cell infiltration ccrcc,"Yang, Wuping,Jing, Taile,Wu, Cunjin,Lu, Minghao,Yao, Xiaolin,Xia, Dan,Peng, Ding",04/11/2024,Journal of translational medicine
10.1586/erv.11.128,hpv vaccine remain to be do interview lauren constable,,"Zur Hausen, Harald",03/11/2011,Expert review of vaccines
10.1016/j.cels.2025.101205,proliferation history transcription factor level drive direct conversion motor neuron,sparse stochastic nature conversion have obscure understanding transcription factor tfs drive cell new identity to overcome limit develop tailor high efficiency conversion system increase direct conversion fibroblast motor neuron fold tailor cocktail minimal set transcript reduce extrinsic variation allow to examine proliferation tfs synergistically drive conversion show cell state set proliferation history define cell interpret level tfs control proliferation history titrate tf find conversion correlate level pioneer tf isolate cell proliferation history level demonstrate level expression alone be insufficient to predict conversion rate rather proliferation history level combine to drive direct conversion finally increase proliferation rate adult human fibroblast generate morphologically mature induce human motor neuron high rate,"Wang, Nathan B,Lende-Dorn, Brittany A,Beitz, Adam M,Han, Patrick,Adewumi, Honour O,O'Shea, Timothy M,Galloway, Kate E",28/12/2023,Cell systems
10.1177/15333175251325091,automatic detection cognitive impairment patient white matter hyperintensity use deep learning radiomic,white matter hyperintensity wmh be associate cognitive impairment study patient wmh hospital be randomly divide training set patient internal validation set patient addition wmh patient hospital be use external validation set cognitive status be determine base neuropsychological assessment result deep learn convolutional neural network vb net be use to automatically identify segment whole brain subregion wmh pyradiomic package python be use to automatically extract radiomic feature wmh bilateral hippocampi delong test reveal random forest model base combined feature have good performance detection cognitive impairment wmh patient auc external validation set result provide clinical doctor reliable tool early diagnosis cognitive impairment wmh patient,"Feng, Junbang,Le, Xingyan,Li, Li,Tang, Lin,Xia, Yuwei,Shi, Feng,Guo, Yi,Zhou, Yueqin,Li, Chuanming",15/03/2025,American journal of Alzheimer's disease and other dementias
10.1136/jitc-2024-011149,voxel level radiomic deep learning predict pathologic complete response esophageal squamous cell carcinoma neoadjuvant immunotherapy chemotherapy,background accurate prediction pathologic complete response pcr follow neoadjuvant immunotherapy combine chemotherapy nict be crucial tailor patient care esophageal squamous cell carcinoma escc study aim to develop validate deep learning model use novel voxel level radiomic approach to predict pcr base preoperative ct image method multicenter retrospective study patient escc undergo nict follow radical esophagectomy be enrol three institution patient one center be divide training set patient internal validation set patient datum other two center be use external validation set patient respectively deep learning model vision mamba integrate voxel level radiomic feature map ct image pcr prediction additionally other commonly use deep learning model include resnet vision transformer as well traditional radiomic method be develop comparison model performance be evaluate use accuracy area curve auc sensitivity specificity prognostic stratification capability shapley additive explanation analysis be employ to interpret model prediction result vision mamba model demonstrate robust predictive performance training set accuracy auc sensitivity specificity validation set accuracy auc sensitivity specificity model outperform other deep learning model traditional radiomic method model ability to stratify patient high low risk group be validate show superior prognostic stratification compare traditional method shap provide quantitative visual model interpretation conclusion present voxel level radiomic base deep learning model to predict pcr neoadjuvant immunotherapy combine chemotherapy base pretreatment diagnostic ct image high accuracy robustness model could provide promising tool individualized management patient escc,"Zhang, Zhen,Luo, Tianchen,Yan, Meng,Shen, Haixia,Tao, Kaiyi,Zeng, Jian,Yuan, Jingping,Fang, Min,Zheng, Jian,Bermejo, Inigo,Dekker, Andre,Ruysscher, Dirk De,Wee, Leonard,Zhang, Wencheng,Jiang, Youhua,Ji, Yongling",04/03/2025,Journal for immunotherapy of cancer
10.1186/s40560-025-00776-0,japanese clinical practice guideline management sepsis septic shock,revise edition japanese clinical practice guideline management sepsis septic shock j sscg be publish japanese society intensive care medicine japanese association acute medicine be fourth revision first edition be publish purpose guideline be to assist healthcare provider make appropriate decision treatment sepsis septic shock lead improve patient outcome aim to create guideline be easy to understand use physician recognize sepsis provide initial management specialized physician take treatment multidisciplinary healthcare provider include nurse physical therapist clinical engineer pharmacist j sscg cover follow nine area diagnosis sepsis source control antimicrobial therapy initial resuscitation blood purification disseminate intravascular coagulation adjunctive therapy post intensive care syndrome patient family care pediatric area extract important clinical issue grade grading recommendation assessment development evaluation method be adopt make recommendation modify delphi method be use to determine recommendation vote committee member result grade base recommendation good practice statement information background question be create response clinical question also describe future research question,"Shime, Nobuaki,Nakada, Taka-Aki,Yatabe, Tomoaki,Yamakawa, Kazuma,Aoki, Yoshitaka,Inoue, Shigeaki,Iba, Toshiaki,Ogura, Hiroshi,Kawai, Yusuke,Kawaguchi, Atsushi,Kawasaki, Tatsuya,Kondo, Yutaka,Sakuraya, Masaaki,Taito, Shunsuke,Doi, Kent,Hashimoto, Hideki,Hara, Yoshitaka,Fukuda, Tatsuma,Matsushima, Asako,Egi, Moritoki,Kushimoto, Shigeki,Oami, Takehiko,Kikutani, Kazuya,Kotani, Yuki,Aikawa, Gen,Aoki, Makoto,Akatsuka, Masayuki,Asai, Hideki,Abe, Toshikazu,Amemiya, Yu,Ishizawa, Ryo,Ishihara, Tadashi,Ishimaru, Tadayoshi,Itosu, Yusuke,Inoue, Hiroyasu,Imahase, Hisashi,Imura, Haruki,Iwasaki, Naoya,Ushio, Noritaka,Uchida, Masatoshi,Uchi, Michiko,Umegaki, Takeshi,Umemura, Yutaka,Endo, Akira,Oi, Marina,Ouchi, Akira,Osawa, Itsuki,Oshima, Yoshiyasu,Ota, Kohei,Ohno, Takanori,Okada, Yohei,Okano, Hiromu,Ogawa, Yoshihito,Kashiura, Masahiro,Kasugai, Daisuke,Kano, Ken-Ichi,Kamidani, Ryo,Kawauchi, Akira,Kawakami, Sadatoshi,Kawakami, Daisuke,Kawamura, Yusuke,Kandori, Kenji,Kishihara, Yuki,Kimura, Sho,Kubo, Kenji,Kuribara, Tomoki,Koami, Hiroyuki,Koba, Shigeru,Sato, Takehito,Sato, Ren,Sawada, Yusuke,Shida, Haruka,Shimada, Tadanaga,Shimizu, Motohiro,Shimizu, Kazushige,Shiraishi, Takuto,Shinkai, Toru,Tampo, Akihito,Sugiura, Gaku,Sugimoto, Kensuke,Sugimoto, Hiroshi,Suhara, Tomohiro,Sekino, Motohiro,Sonota, Kenji,Taito, Mahoko,Takahashi, Nozomi,Takeshita, Jun,Takeda, Chikashi,Tatsuno, Junko,Tanaka, Aiko,Tani, Masanori,Tanikawa, Atsushi,Chen, Hao,Tsuchida, Takumi,Tsutsumi, Yusuke,Tsunemitsu, Takefumi,Deguchi, Ryo,Tetsuhara, Kenichi,Terayama, Takero,Togami, Yuki,Totoki, Takaaki,Tomoda, Yoshinori,Nakao, Shunichiro,Nagasawa, Hiroki,Nakatani, Yasuhisa,Nakanishi, Nobuto,Nishioka, Norihiro,Nishikimi, Mitsuaki,Noguchi, Satoko,Nonami, Suguru,Nomura, Osamu,Hashimoto, Katsuhiko,Hatakeyama, Junji,Hamai, Yasutaka,Hikone, Mayu,Hisamune, Ryo,Hirose, Tomoya,Fuke, Ryota,Fujii, Ryo,Fujie, Naoki,Fujinaga, Jun,Fujinami, Yoshihisa,Fujiwara, Sho,Funakoshi, Hiraku,Homma, Koichiro,Makino, Yuto,Matsuura, Hiroshi,Matsuoka, Ayaka,Matsuoka, Tadashi,Matsumura, Yosuke,Mizuno, Akito,Miyamoto, Sohma,Miyoshi, Yukari,Murata, Satoshi,Murata, Teppei,Yakushiji, Hiromasa,Yasuo, Shunsuke,Yamada, Kohei,Yamada, Hiroyuki,Yamamoto, Ryo,Yamamoto, Ryohei,Yumoto, Tetsuya,Yoshida, Yuji,Yoshihiro, Shodai,Yoshimura, Satoshi,Yoshimura, Jumpei,Yonekura, Hiroshi,Wakabayashi, Yuki,Wada, Takeshi,Watanabe, Shinichi,Ijiri, Atsuhiro,Ugata, Kei,Uda, Shuji,Onodera, Ryuta,Takahashi, Masaki,Nakajima, Satoshi,Honda, Junta,Matsumoto, Tsuguhiro",13/12/2024,Journal of intensive care
10.1302/2046-3758.143.BJR-2024-0207.R1,evaluation causal relationship circulate biomarker osteoarthritis bidirectional mendelian randomization study,aim circulate biochemistry marker be commonly use to monitor detect disease induce dysfunction include osteoarthritis oa however causal nature relationship be nevertheless largely unknown due unmeasured confound factor observational study aim to reveal causal relationship circulate biochemistry marker oa pathogenesis method conduct comprehensive bidirectional two sample mendelian randomization mr study circulate biomarker six oa type use large scale genome wide association study gwas summary statistic datum uk biobank cohort late meta analysis replicate significant result low density lipoprotein cholesterol ldl c total cholesterol tc independent large gwas dataset obtain global lipids genetics consortium glgc result use to instrumental variable biomarker large mr analysis identify causal association bonferroni correct significance level involve seven biomarker five oa type ldl c odd ratio sd increase ci apolipoprotein b ci tc ci to calcium ci glucose ci to be causally associate reduce risk oa phosphate ci aspartate aminotransferase ci be causally associate increase risk analysis glgc summary statistic successfully replicate ldl c ci tc ci conclusion comprehensive bidirectional mr analysis provide new insight prevention treatment oa as well understand biological mechanism underlie oa pathogenesis,"Zhu, Xiao-Wei,Zheng, Xiao,Wang, Lu,Liu, Jia,Yang, Man,Liu, Ya-Qi,Qian, Yun,Luo, Yuan,Zhang, Lei",17/03/2025,Bone & joint research
10.1038/s41392-025-02168-0,systemic lupus erythematosus update insight pathogenesis diagnosis prevention therapeutic,systemic lupus erythematosus sle be chronic inflammatory illness heterogeneous clinical manifestation cover multiple organ diversified type medication have be show effective alleviate sle syndrome range cytokine antibodie hormone molecular inhibitor antagonist to cell transfusion drug develop treat other disease may benefit sle patient agent establish sle therapeutic may be sle inductive complexity regard sle therapeutic render essential urgent to identify mechanism action pivotal signal axis drive sle pathogenesis to establish innovative sle target approach desirable therapeutic outcome safety introduce research history sle epidemiology categorize primary determinant drive sle pathogenesis mechanism comb current knowledge sle diagnosis group disease onset activity comorbidity introduce genetic epigenetic hormonal environmental factor predispose sle comprehensively categorize preventive strategy available sle therapeutic accord function mechanism summary propose three mechanism determinant role sle initiation progression attenuate immune system restore cytokine microenvironment homeostasis rescue impair debris clearance machinery provide update insight current understanding sle regard pathogenesis diagnosis prevention therapeutic may open innovative avenue field sle management,"Dai, Xiaofeng,Fan, Yuting,Zhao, Xing",04/09/2024,Signal transduction and targeted therapy
10.1016/j.canlet.2025.217642,fibrinogen like tumor associate macrophage derive extracellular vesicle shape immunosuppressive microenvironment colorectal liver metastasis promote tumor stemness neutrophil extracellular trap formation,investigate mechanism underlie development immunosuppressive microenvironment colorectal liver metastasis crlm be important identify synergistic target immunotherapy regulatory role tumor associate macrophage derive extracellular vesicle tam evs immune microenvironment crlm have not yet be fully explore here find tam evs shape immunosuppressive microenvironment invasive front murine crlm model thus dampen anti immunotherapy environment be characterize increase tumor stemness potential abundant neutrophil extracellular trap net formation mechanistically tam evs derive fibrinogen like interact receptor tumor cell far activate p positive feedback loop to increase stemness potential cancer cell mediate communication cancer cell neutrophil use anti monoclonal antibody can reduce net production synergize anti immunotherapy offer clinical translational significance crlm therapy p loop correlate immunosuppressive microenvironment poor prognosis human patient crlm result reveal potential enhance efficacy immunotherapy target clearance net use anti monoclonal antibodie have significant clinical translational value treatment crlm,"Zhou, Menghua,Guan, Bingjie,Liu, Youdong,Gu, Qi,Chen, Weiwei,Xie, Bowen,Zhou, Mantang,Xiang, Jianjun,Zhao, Senlin,Zhao, Qian,Yan, Dongwang",03/10/2024,Cancer letters
10.1007/s40265-025-02162-4,safety anti osteoarthritis medication systematic literature review post marketing surveillance study,background several meta analysis phase randomize control trial rct be publish reassess safety most anti osteoarthritis oa medication mainly basis datum full safety report current systematic review sr intend to provide complementary insight safety anti oa medication use evidence post marketing safety surveillance study method review protocol be register prospero database registration no follow cochrane methodology srs intervention comprehensively search medline central scopus toxline database inception november to include post marketing safety surveillance study anti oa medication outcome sr be adverse event aes report include study result literature search yield study article be ultimately include review most study investigate non steroidal anti inflammatory drug nsaid study report intra articular hyaluronic acid iaha study symptomatic slow act drug osteoarthritis sysadoas be assess seven study one also assess nsaid corticosteroid injection four study opioid herbal mixture other compound be investigate respectively three two study most study be cohort study other be case report case series rct report same trial case control study most commonly report aes nsaid cohort sample size vary patient rct patient oa case control case control patient oa study be gastrointestinal gi cardiovascular cv ae specific aes varying individual nsaid comparison nsaid be make overall literature show well similar safety profile celecoxib daily dose mg dosage be report compare other nsaid regard gi cv renal event other anti oa medication most common ae report cohort study be iaha injection site pain diacerein gi aes reddish urine avocado soybean unsaponifiable gi aes non pharmaceutical grade glucosamine chondroitin allergic reaction gi disorder opioid hip fracture associate long term tramadol use old adult gi nervous system disorder hydrocodone corticosteroid injection increase risk oa progression herbal mixture other compound gi aes be case report case series specific aes various anti oa medication require further investigation well design cohort study definitive conclusion can be reach conclusion sr confirm previous evidence safety anti oa medication meta analysis phase rct evidence here report limitation research highlight urgent need reporting guideline post marketing safety surveillance study importantly real life safety surveillance anti oa medication should be strengthen large cohort study control group result should be disaggregate disease population drug common several condition,"Honvo, Germain,Lengelé, Laetitia,Alokail, Majed,Al-Daghri, Nasser,Reginster, Jean-Yves,Bruyère, Olivier",10/02/2025,Drugs
10.1080/07853890.2025.2477295,improvement endocrine metabolic condition patient polycystic ovary syndrome acupuncture combined therapy systematic review meta analysis,background polycystic ovary syndrome pcos be common endocrine disorder woman reproductive age significantly impact reproductive health acupuncture combined therapy may have beneficial effect endocrine metabolic state woman pcos systematic review meta analysis evaluate treatment effect potential mechanism acupuncture combined therapy compare oral metformin treat pcos patient method evaluation focus three set outcome hormonal indicator metabolic indicator body weight indicator study involve additional therapy specify intervention include patient other disease be exclude additionally datum mining method be use include frequency statistic to analyze frequency acupuncture point meridian involve apriori algorithm to perform association rule analysis most effective intervention result study include article study involve six intervention acupuncture combine metformin acupuncture treatment acupuncture chinese herbal medicine metformin acupuncture chinese herbal medicine acupuncture combine cupping auricular acupuncture combine metformin show significant improvement evaluated indicator datum mining reveal stomach meridian foot yangme be most frequently use most commonly use combination point include conclusion study suggest acupuncture combined therapy may benefit pcos however risk bias heterogeneity observe be note future high quality rigorously design randomize control trial be need to confirm finding provide strong clinical recommendation acupuncture pcos treatment,"Wu, Tianyu,Liu, Yiwei,Kong, Fanjing,Hu, Jinqun,Liu, Yu,Yang, Jie,Chen, Jiao",17/03/2025,Annals of medicine
,dominant mutation arabidopsis confer resistance auxin ethylene abscisic acid,have screen large population seed arabidopsis thaliana plant be resistant to exogenously apply indole acetic acid iaa one resistant line identify screen carry dominant mutation have name linkage analysis indicate gene lie chromosome plant carry mutation be severe dwarf display defect growth orientation shoot root suggest mutation affect aspect gravitropic growth addition root plant lack root hair growth inhibition experiment indicate root plant be resistant ethylene abscisic acid as well auxin,"Wilson, A K,Pickett, F B,Turner, J C,Estelle, M",01/07/1990,Molecular & general genetics : MGG
,dominant mutation arabidopsis confer resistance auxin ethylene abscisic acid,have screen large population seed arabidopsis thaliana plant be resistant to exogenously apply indole acetic acid iaa one resistant line identify screen carry dominant mutation have name linkage analysis indicate gene lie chromosome plant carry mutation be severe dwarf display defect growth orientation shoot root suggest mutation affect aspect gravitropic growth addition root plant lack root hair growth inhibition experiment indicate root plant be resistant ethylene abscisic acid as well auxin,"Wilson, A K,Pickett, F B,Turner, J C,Estelle, M",01/07/1990,Molecular & general genetics : MGG
10.1186/s12967-025-06301-z,multidimensional bioinformatics perspective smoking link driver gene immune regulatory mechanism non small cell lung cancer,background lung cancer one lead cause cancer relate morbidity mortality worldwide be strongly associate smoking primary carcinogenic factor however strong link smoking lung cancer not smoker develop disease suggest individual genetic susceptibility molecular mechanism may play critical role onset lung cancer understand gene drive mechanism immune regulatory pathway involve smoking relate lung cancer remain one key challenge current lung cancer research method study employ integrative bioinformatics approach to explore gene expression difference immune microenvironment characteristic smoker non small cell lung cancer nsclc normal individual first smoking link lung cancer driver gene sldcgs be identify follow mendelian randomization mr summary base mendelian randomization smr analysis to far validate causal relationship next public database include tcga geo gtex be use to systematically analyze expression difference sldcgs various clinical subgroup immune infiltration analysis be conduct to explore potential role immune microenvironment nsclc result study identify hla j core driver gene smoking associate nsclc mr analysis confirm potential causal relationship hla j development nsclc specifically high expression be closely associate occurrence nsclc low expression hla j be implicate immune evasion mechanism nsclc additionally immune microenvironment analysis reveal hla j enhance activity immune cell particularly t cell to promote tumor immune recognition suppress immune cell function weaken immune surveillance facilitate immune evasion conclusion study systematically reveal molecular mechanism smoking link nsclc multidimensional bioinformatics analysis highlight key role sldcgs immune evasion discovery hla j provide new theoretical foundation targeted immunotherapy significant potential early diagnosis personalized treatment smoking induce nsclc future research should focus validate gene clinical sample explore potential immunotherapy,"Ouyang, Can,Yu, Xiaopeng,Wang, Huazhong,Zeng, Puhua",23/12/2024,Journal of translational medicine
10.1016/j.ebiom.2025.105646,confer ferroptosis resistance epithelial ovarian cancer export,background high mortality rate associate epithelial ovarian cancer eoc be primarily due to recurrence chemoresistance underscore urgent need innovative therapeutic approach leverage newly identify vulnerability cancer cell conventional chemotherapy induce apoptosis target dna mitotic machinery ferroptosis represent new distinct form program cell death characterise accumulation lipid peroxide method sensitivity different eoc cell line to ferroptosis inducer be evaluate use cell viability assay lipid peroxidation measurement live cell imaging ph sensitive phuji reporter be perform to track extracellular export acyl coa synthetase long chain family member exosome upstream regulator be identify immunoprecipitation mass spectrometry ip ms validate use protein bind assay finally cell derive xenograft cdx patient derive xenograft pdx model be utilise to evaluate therapeutic potential overcome ferroptosis resistance finding study find interferon combine arachidonic acid aa be endogenous ferroptosis inducer could initiate ferroptosis most eoc cell however eoc cell display significant resistance contrary typical increase protein observe ferroptosis sensitive cell resistant eoc cell exhibit surprisingly low level pro ferroptotic lipid metabolic protein intriguingly reduction be attribute exosomal expulsion protein reveal distinct cellular mechanism to evade ferroptosis far identify pivotal regulator sort late endosome thereby facilitate subsequent release exosome notably target not only overcome resistance ferroptotic cell death also markedly suppress tumour growth interpretation finding uncover crucial role ferroptosis evasion facilitate exporting protein exosome highlight promising target ferroptosis base anti cancer therapy funding fund beijing municipal natural science foundation key program national natural science foundation china nsfc peke university medicine youth science technology innovation sail plan project type b medical interdisciplinary seed fund guangdong basic apply basic research foundation special fund national clinical key speciality construction program china,"Jiang, Yuening,Li, Jie,Wang, Tianzhen,Gu, Xiaoyang,Li, Xinyu,Liu, Zhaofei,Yue, Wei,Li, Mo",24/09/2024,EBioMedicine
10.1038/s41572-025-00600-x,primary sclerose cholangitis,primary sclerose cholangitis psc be chronic biliary inflammation associate periductular fibrosis intrahepatic extrahepatic bile duct lead stricture bacterial cholangitis decompensate liver disease need liver transplantation rare focal liver disease affect race age predominance young male be to association inflammatory bowel disease aetiology be unknown pathophysiology be poorly understand psc be regard autoimmune liver disease base strong immunogenetic background far associated risk various malignancy particularly cholangiocellular carcinoma be also poorly understand medical therapy have be approve so far have be show to improve transplant free survival however ursodeoxycholic acid be widely use improve biochemical parameter cholestasis be safe low dose mri biliary tract be primary imaging technology diagnosis endoscopic intervention bile duct should be limit clinically relevant stricture balloon dilatation biopsy brush cytology end stage liver disease decompensation be indication liver transplantation recurrent psc in to patient several novel therapeutic strategy be various stage development include apical sodium dependent bile acid transporter ileal bile acid transporter inhibitor integrin inhibitor peroxisome proliferator activate receptor agonist blocker recombinant inhibitor farnesoid x receptor bile acid receptor agonist ursodeoxycholic acid manipulation gut microbiome include faecal microbiota transplantation article summarize present knowledge define unmet medical need to improve quality life survival,"Manns, Michael P,Bergquist, Annika,Karlsen, Tom H,Levy, Cynthia,Muir, Andrew J,Ponsioen, Cyriel,Trauner, Michael,Wong, Grace,Younossi, Zobair M",07/02/2025,Nature reviews. Disease primers
10.1126/sciadv.adr3757,genetically support target drug repurpose brain aging systematic study uk biobank,brain age gap bag deviation estimate brain age chronological age be promising marker brain health however genetic architecture reliable target brain aging remains poorly understand study estimate magnetic resonance imaging brain age use deep learning model train uk biobank validate three external dataset genome wide association study bag identify two unreported loci seven previously report loci integrate mendelian randomization mr colocalization analysis eqtl pqtl datum prioritize seven genetically support druggable gene include mapt gzmb gnly nmb promise target brain aging rediscover potential drug evidence clinical trial aging prioritize several drug strong genetic support study provide insight genetic basis brain aging potentially facilitate drug development brain aging to extend health span,"Yi, Fan,Yuan, Jing,Somekh, Judith,Peleg, Mor,Zhu, Yi-Cheng,Jia, Zhilong,Wu, Fei,Huang, Zhengxing",12/03/2025,Science advances
10.1681/ASN.0000000681,deficiency r loop pathway kidney injury diabetic nephropathy,background diabetic nephropathy be primary cause kidney failure persistent hyperglycemia cause metabolic perturbation epigenetically dysregulate gene expression renal cell thereby lead diabetic nephropathy pathogenesis analyze geo database use machine learning algorithm preliminary result demonstrate growth arrest dna damage inducible might serve key regulator diabetic nephropathy furthermore emerge evidence have show r loop three strand dna rna structure be crucial gene expression diabetic nephropathy therefore study aim to investigate role diabetic nephropathy modulate epigenetic alteration interaction r loop method diabetic mouse model be establish inject streptozotocin intraperitoneally mouse kidney histology biochemical marker be analyze wild type knockout renal tubule specific overexpresse mouse lentivirus be use to induce overexpression cell high glucose treatment be apply to verify mechanism vitro result expression be reduce kidney diabetic nephropathy correlate kidney dysfunction knockout worsen kidney injury overexpression mitigate mechanistically interact r loop promoter recruit to activate transcription deficiency r loop pathway exacerbate mitochondrial injury disrupt lipid metabolism increase oxidative stress diabetic nephropathy conclusion deficiency exacerbate diabetic nephropathy interact r loop inhibit promoter demethylation target r loop pathway offer therapeutic potential diabetic nephropathy,"Li, Xue Qi,Zhang, Jia Xiu,Li, Liang,Wu, Qin Yi,Ruan, Xiong Zhong,Chen, Pei Pei,Ma, Kun Ling",09/10/2024,Journal of the American Society of Nephrology : JASN
10.1001/jamasurg.2025.0220,neoadjuvant chemoradiotherapy chemoimmunotherapy esophageal squamous cell carcinoma,importance association neoadjuvant chemoimmunotherapy ncit chemoradiotherapy ncrt tumor downstaging survival locally advanced esophageal squamous cell carcinoma escc remain unclear limited evidence objective to compare association ncit ncrt tumor regression long term survival patient locally advanced escc design setting participant comparative effectiveness research study january march patient locally advanced escc undergo esophagectomy follow ncrt ncit be identify prospective database high volume esophageal surgery center china follow up begin date surgery continue last record contact march occur first datum be analyze april september main outcome measure primary end point be year overall survival os disease free survival dfs secondary end point include major pathologic response mpr pathologic complete response pcr cox proportional hazard regression analysis be use to investigate risk factor os dfs result study include patient median iqr age year man patient ncrt group patient ncit group propensity score matching be patient group year os hazard ratio ci p hazard ratio ci p rate be significantly high ncit group ncrt group ncrt group have high mpr rate ncit group pcr rate be similar multivariable cox analysis demonstrate ncit mpr be independently associate os dfs ncit group exhibit low overall recurrence rate patient patient distant metastasis rate patient patient locoregional metastasis rate be similar patient patient well os dfs be obtain ncit group ncrt group regardless adjuvant immunotherapy be give conclusion relevance compare ncrt patient locally advanced escc receiving ncit have well year os dfs decrease distant metastasis may be main reason far prospective randomized clinical trial be need to verify finding,"Guo, Xufeng,Chen, Chunji,Zhao, Jinbo,Wang, Changchun,Mei, Xinyu,Shen, Jianfei,Lv, Huilai,Han, Yongtao,Wang, Qifeng,Lv, Jiahua,Chen, Hainan,Yan, Xiaolong,Liu, Zhichao,Zhang, Zhengyang,Zhong, Qihong,Jiang, Youhua,Xu, Liwei,Li, Xiaoyang,Qian, Dong,Ma, Dehua,Ye, Minhua,Wang, Chunguo,Wang, Zimin,Lin, Jiangbo,Tian, Ziqiang,Leng, Xuefeng,Li, Zhigang",19/03/2025,JAMA surgery
10.1172/JCI184740,atgl link insulin dysregulation insulin resistance adolescent obesity hepatosteatosis,study examine underlie cellular mechanism associate insulin resistance ir metabolic disease risk subcutaneous adipose tissue sit youth obesity ir compare adolescent be insulin sensitive be adolescent ir obesity undergo hour oral glucose tolerance test mri to measure abdominal fat distribution liver fat content lipolysis be determine glycerol turnover infusion adipose triglyceride lipase atgl phosphorylation western blot sit sample biopsie prior minute follow insulin infusion hyperinsulinemic euglycemic clamp turnover suppression hec first step be low participant ir compare be prior insulin infusion activate atgl reflect p atgl atgl ratio be great participant ir compare be suppress response minute insulin exposure participant be not ir lastly great atgl inactivation be associate great glycerol suppression low liver mediate inhibition adipose tissue lipolysis atgl be dysregulate adolescent ir compare be thereby serve vital mechanism link glucose insulin dysregulation ectopic lipid storage work be support fund nih robert leet clara guthrie patterson trust mentor research award,"Slusher, Aaron L,Santoro, Nicola,Vash-Margita, Alla,Galderisi, Alfonso,Hu, Pamela,Tokoglu, Fuyuze,Li, Zhongyao,Tarabra, Elena,Strober, Jordan,Vatner, Daniel F,Shulman, Gerald I,Caprio, Sonia",12/07/2024,The Journal of clinical investigation
10.1016/j.jare.2025.03.017,probiotic enhance donor microbiota stability improve efficacy fecal microbiota transplantation treat colitis,introduction stability metabolic functionality donor microbiota be critical determinant fecal microbiota transplantation fmt efficacy inflammatory bowel disease ibd probiotic show potential to enhance microbiota resilience role optimize donor microbiota fmt remain underexplored objective study investigate pretreatment donor microbiota plantarum could improve fmt outcome dss induce colitis model modulate microbial stability metabolic activity host microbiome interaction method donor mouse receive plantarum week to generate modify fmt mfmt dss colitis mouse be treat mfmt conventional fmt aminosalicylic acid asa multi omics analysis functional assay stress resistance engraftment efficiency be use to evaluate therapeutic mechanism result pretreatment confer three key advantage to donor microbiota ecological stabilization drive acidification ph lgg p enrich butyrogenic butyricicoccus butyrate increase p improve stress resistance bile acid gastric condition survival fmt metabolic reprogramming metabolize tryptophan lgg to generate immunomodulatory indole ila iaa activate aryl hydrocarbon receptor ahr signal upregulate anti inflammatory bile acid remodeling mfmt restore sulfolithocholic acid β mca level outperform fmt resolve dss induce dysregulation mfmt achieve remission rate fmt enhance gut barrier integrity reverse colitis associate metabolic dysregulation elevated spermidine sulfocholic acid probiotic preconditioning improve donor engraftment enrich success associate taxa sporobacter butyricimonas suppress pathogen clostridium papyrosolven conclusion plantarum optimize donor microbiota ph drive niche engineering immunometabolic reprogramming bile acid modulation address key limitation conventional fmt multi targeted efficacy mfmt evidence superior remission rate metabolic restoration establish approach translatable strategy ibd therapy study establish probiotic enhance fmt paradigm precision microbiome intervention,"Fan, Jingjing,Wu, Ying,Wang, Xing,Ullah, Habib,Ling, Zhenmin,Liu, Pu,Wang, Yu,Feng, Pengya,Ji, Jing,Li, Xiangkai",16/12/2024,Journal of advanced research
10.1001/jamanetworkopen.2025.0669,probiotic fever duration child upper respiratory tract infection randomized clinical trial,importance upper respiratory tract infection urtis be prevalent child prompt frequent health care consultation especially fever probiotic show potential adjuvant treatment urtis evidence child be limited objective to evaluate efficacy probiotic mixture contain bifidobacterium breve bifidobacterium lactis lactobacillus rhamnosus shorten fever duration child urtis design setting participant randomize clinical trial be conduct november june pediatric emergency department ca granda ospedale maggiore policlinico milan italy patient day year age fever c urti be eligible exclusion criterion include recent probiotic use chronic autoimmune disease immunosuppressive treatment requirement hospitalization randomization be computer generate assign participant intervention probiotic control placebo group participant parent caregiver investigator be mask group assignments primary analysis follow intention treat approach intervention probiotic group receive daily single dose ml probiotic mixture contain bifidobacterium breve bifidobacterium lactis lactobacillus rhamnosus day placebo group receive daily single dose ml placebo day main outcome measure primary outcome be fever duration define number day first last day fever result patient enrol male mean sd age year be randomly assign to receive placebo to receive probiotic median iqr fever duration be short probiotic group placebo group median iqr day day adjusted risk ratio ci few mild adverse event be report do not significantly differ probiotic placebo group include constipation p abdominal pain p conclusion relevance randomize clinical trial administer probiotic mixture reduce fever duration day compare placebo meaningful safety concern probiotic mixture investigation could be effective adjuvant shorten fever duration child urtis trial registration identifi,"Bettocchi, Silvia,Comotti, Anna,Elli, Marina,De Cosmi, Valentina,Berti, Cristiana,Alberti, Ilaria,Mazzocchi, Alessandra,Rosazza, Chiara,Agostoni, Carlo,Milani, Gregorio Paolo",14/03/2025,JAMA network open
10.1016/j.jhep.2024.11.007,easl ern clinical practice guideline wilson disease,wilson disease be autosomal recessive disorder copper metabolism affect liver brain other organ diagnosis be base clinical feature biochemical test include plasma ceruloplasmin concentration h urinary copper excretion copper content liver molecular analysis leipzig score additionally relative exchangeable copper determination be recommend diagnosis pharmacological therapy comprise chelate agent penicillamine trientine zinc salt only chelator be recommend significant liver disease monitoring be base clinical symptom liver test copper metabolism urinary copper excretion exchangeable copper to detect poor compliance under treatment acute liver failure be challenge make diagnosis be difficult pharmacological therapy may not be sufficient to save life liver transplantation have well define role wilsonian acute hepatic failure may also be consider neurological disease,,08/11/2024,Journal of hepatology
10.1016/j.ygyno.2015.01.552,detection endometrial cancer molecular analysis dna collect vaginal tampon,objective demonstrate feasibility detect ec combine minimally invasive specimen collection technique sensitive molecular testing method prior to hysterectomy ec benign indication woman collect vaginal pool sample intravaginal tampon underwent endometrial brushing specimen underwent pyrosequencing dna methylation gene report to be hypermethylate gynecologic cancer recently identify marker discover profile ec methylation be evaluate individually cpgs average gene difference ec benign endometrium be be assess use two sample t test area curve auc result thirty eight ec bes be include evaluate cpgs gene include previously report marker haao identify discovery work npy mme additional cpg site mean methylation be high tampon specimen ec be gene mme haao gene relative hypermethylation be observe ec be cpgs endometrial brush tampon result be similar tampon specimen auc be high be first report hypermethylation ec conclusion dna hypermethylation ec tissue can also be identify vaginal pool dna collect intravaginal tampon identification additional ec biomarker refined collection method be need to develop early detection tool ec,"Bakkum-Gamez, Jamie N,Wentzensen, Nicolas,Maurer, Matthew J,Hawthorne, Kieran M,Voss, Jesse S,Kroneman, Trynda N,Famuyide, Abimbola O,Clayton, Amy C,Halling, Kevin C,Kerr, Sarah E,Cliby, William A,Dowdy, Sean C,Kipp, Benjamin R,Mariani, Andrea,Oberg, Ann L,Podratz, Karl C,Shridhar, Viji,Sherman, Mark E",17/12/2014,Gynecologic oncology
10.1093/jimmun/vkaf005,sustained activation induce cytidine deaminase aid expression b cell follow plasmodium malaria infection kenyan child,burkitt lymphoma bl be characterize elevated level enzyme activation induce cytidine deaminase aid enzyme critical myc translocation be hallmark bl ebv plasmodium malaria be cofactor etiology bl however pathogen drive bl pathogenesis be not yet understand study test hypothesis falciparum ebv synergize to induce dysregulate expression aid use flow cytometry intracellular aid expression be measure pbmcs cohort child western kenya uncomplicated malaria community control child uncomplicated malaria have elevated level b cell compare control high level aid be sustain to week parasite clearance use imagestream flow cytometry find aid be localize nucleus b cell child malaria to test ebv falciparum synergize to drive expression aid stimulate b cell ebv cpg to mimic dna baff induce falciparum infection combination individually ebv baff cpg induce aid expression however combine be significant increase frequency cell cell treat ebv baff cpg individually collectively datum suggest malaria ebv coinfection result sustained aid expression potentially influence myc translocation be characteristic bl,"Ariera, Bonface,Guyah, Bernard,Rahkola, Jeremy,Arao, Ian,Waomba, Kevin,Koech, Emmily,Samayoa-Reyes, Gabriela,Sabourin, Katherine R,Ogolla, Sidney,Rochford, Rosemary",26/08/2024,"Journal of immunology (Baltimore, Md. : 1950)"
10.1136/bmjebm-2024-112974,analgesic effect non surgical non interventional treatment low back pain systematic review meta analysis placebo control randomised trial,objective to investigate efficacy non surgical non interventional treatment adult low back pain compare placebo eligibility criterion randomise control trial evaluate non surgical non interventional treatment compare placebo sham adult year report non specific low back pain information source medline cinahl embase psychinfo cochrane central register control trial be search inception april risk bias risk bias include study be assess use to pedro scale synthesis result random effect meta analysis be use to estimate pool effect correspond confidence interval outcome pain intensity to scale first assessment post treatment treatment type duration low back week chronic week certainty evidence be assess use grading recommendation assessment grade approach result total trial comparison provide datum different treatment treatment combination one treatment acute low back pain non steroidal anti inflammatory drug nsaid five treatment chronic low back pain exercise spinal manipulative therapy taping antidepressant transient receptor potential vanilloid agonist be efficacious effect size be small moderate certainty three treatment acute low back pain exercise glucocorticoid injection paracetamol two treatment chronic low back pain antibiotic anaesthetic be not efficacious be unlikely to be suitable treatment option moderate certainty evidence evidence be inconclusive remain treatment small sample imprecision low very low certainty evidence conclusion current evidence show one non surgical non interventional treatment low back pain be efficacious provide only small analgesic effect placebo efficacy majority treatment be uncertain limited number randomised participant poor study quality further high quality placebo control trial be warrant to address remain uncertainty treatment efficacy great consideration placebo control design non surgical non interventional treatment trial registration number osf registry,"Cashin, Aidan G,Furlong, Bradley M,Kamper, Steven J,De Carvalho, Diana,Machado, Luciana Ac,Davidson, Simon Re,Bursey, Krystal K,Abdel Shaheed, Christina,Hall, Amanda M",10/11/2024,BMJ evidence-based medicine
10.1016/j.ajcnut.2025.03.006,individualized nutritional intervention routine care gestational diabetes prevention randomized control trial,background gestational diabetes mellitus gdm affect million female child effective dietary strategy early prevention be controversial objective to investigate individualized nutritional intervention reduce gdm incidence high risk female method randomized trial be conduct three tertiary hospital shanghai china randomly assign pregnant woman first trimester be identify to be high risk gdm prediction model individualized nutritional intervention usual care intervention consist three dietary consultation dietitian base chinese dietary guideline oral glucose tolerance test ogtt gestational week control group receive usual care participant provide day food record follow up primary outcome be gdm incidence use international association diabete pregnancy study group criterion key secondary outcome be dietary alteration gestational weight gain gwg maternal metabolic profile perinatal pregnancy outcome intention to treat analysis be conduct result total female be enrol be assign intervention usual care gdm be diagnose female intervention group compare control group adjust relative risk ci more female intervention group have appropriate gwg control group low level fast hour insulin ogtt observe reduction rate small gestational age intervention group compare control group neonatal hypoglycemia conclusion female risk gdm individualized nutritional intervention base chinese dietary guideline provide ogtt do not prevent gdm help to manage gwg appropriately improve pregnancy outcome trial registration chictr register oct initial participant enrollment may note url,"Wang, Lulu,Wang, Xipeng,Zhang, Rong,Sun, Wenguang,Zhang, Chenjie,Zhang, Chen,Qin, Guoyou,Peng, Jiahuan,Li, Hong,Fan, Jianxia,Qu, Lei,Ma, Liying,Chen, Lei,Wu, Jiaying,Hao, Yanhui,Ruan, Huijuan,Zheng, Tao,Wu, Dongling,Li, Shaojing,Liu, Yanyan,Wang, Man,Lu, Huan,Dennis, Cindy-Lee,Mol, Ben W,Huang, Hefeng,Wu, Yanting",25/08/2024,The American journal of clinical nutrition
10.1002/ajh.27666,waldenström macroglobulinemia update diagnosis risk stratification management,disease overview waldenström macroglobulinemia wm be lymphoplasmacytic lymphoma immunoglobulin m igm monoclonal protein clinical feature include anemia thrombocytopenia hepatosplenomegaly lymphadenopathy rarely hyperviscosity diagnosis presence igm monoclonal protein associate clonal lymphoplasmacytic cell bone marrow confirm diagnosis mutation be detectable more patient be find most igm mgus patient be not require diagnosis risk stratification age albumin hemoglobin level platelet count microglobulin lactate dehydrogenase ldh monoclonal igm concentration be characteristic be predictive outcome risk adapt therapy not patient fulfill wm criterion require therapy patient can be observe symptom develop rituximab monotherapy be inferior combination regimen recommend first line therapy can be chemoimmunotherapy covalent bruton tyrosine kinase inhibitor preferred mayo clinic induction be rituximab bendamustine rituximab maintenance zanubrutinib management refractory disease bortezomib cyclophosphamide fludarabine thalidomide everolimus pirtobrutinib carfilzomib lenalidomide bendamustine venetoclax have all be show to have activity relapse wm give wm natural history reduction therapy toxicity be important part treatment selection most patient succumb cause unrelated macroglobulinemia,"Gertz, Morie A",26/02/2025,American journal of hematology
10.1172/JCI190957,macrophage key conductor perivascular inflammation vascular remodeling hypoxia induce pulmonary hypertension,pulmonary hypertension ph encompass heterogenous group disorder common feature increase pulmonary arterial pressure patient ph associate lung disease hypoxia undergo immune mediate vascular remodeling include thickening muscular layer surround artery arteriole issue jci kumar colleague examine role interstitial macrophage model high altitude ph resident interstitial macrophage increase proliferated express monocyte chemoattractant ligand be also rise macrophage express be know to activate vascular remodeling tgf β block monocyte recruitment partially reduce hypoxic ph corticosteroid treatment effectively reduce expression monocyte recruitment far plasma sample collect individual ascend low high altitude show increase tgf β level be reduce dexamethasone finding reveal interstitial macrophage population potential therapeutic target hypoxic ph,"Spiekerkoetter, Edda",17/03/2025,The Journal of clinical investigation
10.1111/epi.18357,effectiveness safety adjunctive cenobamate people focal onset epilepsy interim result week observational period bless study,objective cenobamate be antiseizure medication asm dual mechanism action be recently approve treatment focal seizure adult analysis aim to describe outcome week start cenobamate therapy real world setting method bless be ongoing observational retrospective prospective cohort study to evaluate real world effectiveness safety adjunctive cenobamate adult uncontrolled focal epilepsy subgroup analysis be perform subject to previous asm early user previous asm late user result second interim analysis bless study include participant median interquartile range age year have median prior asm median monthly seizure baseline median monthly seizure frequency be reduce baseline week subject have seizure frequency reduction show sustained seizure freedom proportion participant take concomitant asm increase baseline week early user median reduction monthly seizure frequency week be subject have response rate frequency adverse drug reaction adrs be early late user most frequent adr be somnolence dizziness balance disorder occurrence adr participant maintain prescribed dose permanently discontinue treatment significance cenobamate be effective reduce seizure frequency real world setting show manageable safety profile treatment cenobamate also reduce burden concomitant asm early late user,"Lattanzi, Simona,Dono, Fedele,d'Orsi, Giuseppe,D'Aniello, Alfredo,Panebianco, Mariangela,Bonanni, Paolo,Di Bonaventura, Carlo,Montalenti, Elisa,Gambardella, Antonio,Ranzato, Federica,Pauletto, Giada,Tartara, Elena,La Neve, Angela,Bisulli, Francesca,Vatti, Giampaolo,Pulitano, Patrizia,Liguori, Claudio,Assenza, Giovanni,Giordano, Alfonso,Pignatta, Pietro,Belcastro, Vincenzo,Cecconi, Michela,Beretta, Simone,Pizzanelli, Chiara,Pezzella, Marianna,Gangitano, Massimo,Elia, Maurizio,Renna, Rosaria,Vollono, Catello,Pascarella, Angelo,Tramacere, Luciana,De Maria, Giovanni,Audenino, Daniela,Pasolini, Maria Pia,Giuliano, Loretta,Galli, Rosita,Strigaro, Gionata,Puligheddu, Monica,Labate, Angelo,Penza, Pietro,Quadri, Stefano,Stokelj, David,Boero, Giovanni,Fallica, Elisa,Santo Sabato, Monica,Falcicchio, Giovanni,Foschi, Nicoletta,Procaccini, Michela,Villano, Valentina,Camattari, Gabriele,Mele, Fabiano,Roncari, Barbara,Di Gennaro, Giancarlo",13/02/2025,Epilepsia
10.1038/s41563-025-02164-3,de novo design self assemble peptide antimicrobial activity guide deep learning,bioinspire material base self assemble peptide be promise tackle various challenge biomedical engineering contemporary data drive approach have lead discovery self assemble peptide various structure property predict functionality material be still challenge here describe deep learning guide de novo design antimicrobial material base self assemble peptide target bacterial membrane to address emerge problem bacterial drug resistance approach integrate non natural amino acid enhanced peptide self assembly effectively predict functional activity self assemble peptide material minimal experimental annotation design self assemble peptide leader display excellent vivo therapeutic efficacy intestinal bacterial infection mouse moreover exhibit enhance biofilm eradication capability do not induce acquire drug resistance mechanistic study reveal design peptide can self assemble bacterial membrane to form nanofibrous structure kill multidrug resistant bacteria work thus provide strategy to discover functional peptide material customize design,"Liu, Huayang,Song, Zilin,Zhang, Yu,Wu, Bihan,Chen, Dinghao,Zhou, Ziao,Zhang, Hongyue,Li, Sangshuang,Feng, Xinping,Huang, Jing,Wang, Huaimin",11/04/2024,Nature materials
10.1182/blood.2024027516,therapeutic switch plasma recombinant patient congenital ttp japanese real world datum,congenital thrombotic thrombocytopenic purpura cttp be ultra rare disorder characterize thrombocytopenia microangiopathic hemolytic anemia ischemic organ damage cause pathogenic variant contain product include fresh frozen plasma ffp plasma derive factor viii concentrate be commonly use to supply however frequent hospital visit allergic reaction be major drawback recombinant be recently develop to address issue however real world evidence have not be report owe rarity condition study compare efficacy safety ffp japanese patient include five patient end stage renal disease be exclude phase iii trial median peak level activity min administration be significantly high ffp activity week administration be well maintain compare ffp infusion patient report allergic reaction administration appreciate convenience single infusion suggest be safe effective alternative to ffp patient cttp be first publication patient cttp switch ffp to novel japanese real world data,"Sakai, Kazuya,Hamamura, Atsushi,Yoshimura, Yoshiko,Abe, Miyuki,Ogawa, Yoshiyuki,Tanaka, Kazuki,Hattori, Norimichi,Tokugawa, Tazuko,Kanai, Rie,Ikejiri, Fumiyoshi,Takeyama, Masahiro,Taoka, Teruhisa,Fujita, Naoki,Kanaya, Minoru,Koh, Katsuyoshi,Shiragami, Hiroshi,Azumi, Hidekazu,Saito, Kenki,Matsumoto, Masanori",18/02/2025,Blood
10.1016/j.jacep.2025.01.009,pulse field thermal catheter ablation atrial fibrillation patient hypertrophic cardiomyopathy,background pulse field ablation pfa may be beneficial treatment atrial fibrillation af patient hypertrophic cardiomyopathy hcm objective goal study be to compare safety efficacy pfa thermal ablation patient hcm af method patient hcm undergo first af ablation use pfa thermal ablation cryoballoon radiofrequency be retrospectively include french swiss center freedom atrial arrhythmia aa recurrence month follow up be assess result overall patient median age year male paroxysmal af hcm underwent pfa thermal ablation af addition pulmonary vein pv isolation extra pv ablation be perform pfa case thermal case pfa be associate short median procedure time thermal ablation minute minute minute minute p less postprocedural heart failure vs n p freedom aa recurrence be ci month pfa be associate less aa recurrence thermal ablation adjust hr ci p extra pv ablation be associate more sustained aa recurrence thermal ablation hr ci p not pfa hr ci p conclusion patient hcm af pfa seem to be associate well safety efficacy outcome thermal ablation,"Gribissa, Samy,Kueffer, Thomas,Knecht, Sven,Waintraub, Xavier,Badenco, Nicolas,Charron, Philippe,Pinon, Pauline,King, Raphael,Gandjbakhch, Estelle,Duthoit, Guillaume,Sticherling, Christian,Reichlin, Tobias,Laredo, Mikael",15/11/2024,JACC. Clinical electrophysiology
10.1016/j.annonc.2025.03.005,redefine clinical trial strategic design to support drug approval medical oncology,randomize clinical trial represent gold standard introduction innovative therapy medical oncology provide high level evidence to ascertain clinical activity new drug novel combination however current infrastructure clinical trial support innovative drug approval be challenge increase body knowledge concern tumor biology therapy resistance fast grow armamentarium novel anti cancer compound impressively upscaled datum analysis capacity as well increase cost relate clinical trial management scenario modern clinical trial design need to evolve to expedite new drug approval tailor patient treatment strategy accord medical need balanced patient orient clinical trial design be eagerly warrant to increase efficiency to include fast pace technological innovation scientific discovery ultimately to face challenge modern medical oncology field,"Antonarelli, G,Pérez-García, J M,Gion, M,Rugo, H,Schmid, P,Bardia, A,Hurvitz, S,Harbeck, N,Tolaney, S M,Curigliano, G,Llombart-Cussac, A,Cortés, J",27/01/2025,Annals of oncology : official journal of the European Society for Medical        Oncology
10.1093/nar/gkaf177,rapid dynamic allow low abundance helicase to promote telomere replication,regulator telomere length helicase facilitate telomere replication disassemble dna secondary structure such g quadruplexe telomeric loop t loop end chromosome recruitment telomere occur s phase cell cycle dynamic process have not be study here utilize crispr genome editing single molecule imaging to monitor movement human cell nucleus utilize rapid three dimensional diffusion to search telomere other nuclear target only chromatin bind be associate telomere time s phase telomere bind have much more extended association binding be enhance interaction telomeric protein be largely independent atpase activity absence catalytic activity lead severe defect cell proliferation slow progression s phase chromosome end end fusion event propose rapid diffusion allow low abundance protein to explore nucleus bind be recruit telomere,"Wu, Guanhui,Taylor, Erin,Youmans, Daniel T,Arnoult, Nausica,Cech, Thomas R",21/02/2025,Nucleic acids research
10.1186/s12943-025-02295-w,lactate accumulation induce to activate super enhancer drive expression promote niraparib resistance ovarian cancer,ovarian cancer be gynecological malignancy high recurrence mortality rate niraparib can effectively affect progression challenge drug resistance remain herein niraparib resistant ovarian cancer cell line be construct to identify abnormally activate enhancer associate target gene rna situ conformation sequence notably target gene be markedly upregulate niraparib resistant cell inhibit restore sensitivity additionally abnormal activation glycolysis niraparib resistant cell induce lactate accumulation promote lactylation histone lysine residue correlation analysis show key glycolysis enzyme such pyruvate kinase m lactate dehydrogenase be significantly positively correlate expression ovarian cancer additionally activate super enhancer se niraparib expression myc transcription factor thereby enhance dna damage repair ability promote drug resistance ovarian cancer cell overall finding study indicate lactic acid accumulation lead lactylation histone thereby upregulate se mediate abnormal expression promote niraparib resistance ovarian cancer cell suggest potential therapeutic target niraparib resistant ovarian cancer,"Lu, Bingfeng,Chen, Shuo,Guan, Xue,Chen, Xi,Du, Yuping,Yuan, Jing,Wang, Jielin,Wu, Qinghua,Zhou, Lingfeng,Huang, Xiangchun,Zhao, Yang",24/09/2024,Molecular cancer
10.1182/blood.2025028566,mediate interferon signature associate preclinical jak inhibitor sensitivity t cell acute lymphoblastic leukemia,utilize single cell genomic to characterize t patient treat cog poor clinical outcome favorable genomic feature identify mediate interferon relate transcriptional signature inflammatory microenvironment be associate sensitivity small molecule jak inhibition,"Xu, Jason,Sussman, Jonathan H,Yang, Austin,Yoshimura, Satoshi,Hu, Jianzhong,Chen, Changya,Vincent, Tiffaney L,Bandyopadhyay, Shovik,Li, Elizabeth Y,Lim, Tristan Lee,Elghawy, Omar,Barsouk, Adam,Karanfilovski, Damjan,Wald, Shira L,Chen, Gregory M,Wu, David Wei,Newman, Haley,Li, Alexander,Sun, Yusha,Chen, Chia-Hui,Bernt, Kathrin Maria,Wood, Brent L,Winter, Stuart Sheldon,Dunsmore, Kimberly P,Raetz, Elizabeth A,Devidas, Meenakshi,Pounds, Stanley B,Loh, Mignon L,Hunger, Stephen P,Chiang, Mark,Diorio, Caroline,Giacomo, Danika Di,Pölönen, Petri,Mullighan, Charles G,Yang, Jun J,Tan, Kai,Teachey, David Trent",08/03/2025,Blood
10.3389/fendo.2025.1527506,novel indicator erectile dysfunction cally index evidence datum nhanes,purpose study explore association c reactive protein albumin lymphocyte cally index erectile dysfunction ed patient method datum participant national health nutrition examination survey nhanes be analyze classify ed non ed separate analysis complete erectile dysfunction be weight multiple logistic regression model be use to assess association cally ed smooth curve fitting be apply to explore linear analysis be conduct to compare predictive accuracy auc cally systemic inflammation response index siri systemic immune inflammation index sii aggregate index systemic inflammation aisi neutrophil lymphocyte ratio nlr platelet lymphocyte ratio plr product platelet count neutrophil count ppn ed result adjustment ln cally be negatively associate ed ci p complete ed ci p high ln cally tertile be associate significantly low risk ed compare ci p similar trend be observe complete ed ci p fitting reveal negative correlation cally type analysis confirm consistent independent exhibit superior predictive performance ed auc complete ed auc compare other marker conclusion high cally level be link reduce ed risk prove superior predictor compare other inflammatory marker,"Huang, Dongli,Wu, Hang,Huang, Yanhua",18/11/2024,Frontiers in endocrinology
10.1186/s12876-025-03747-9,association vitamin c d k intake inflammatory bowel disease risk finding nhane,background micronutrient deficiency be commonly observe patient inflammatory bowel disease ibd role certain dietary trace element risk ibd development remain unclear objective study aim to investigate relationship vitamin c d k intake ibd risk method study include participant national health nutrition examination survey nhanes multivariable logistic regression be conduct to assess association vitamin c d k intake ibd risk control multiple confounder subgroup analysis be employ to test robustness association participant various characteristic additionally restrict cubic spline rcs analysis be conduct to investigate potential nonlinear relationship result fully adjust model mcg increase vitamin d intake be link approximately decrease ibd risk adjust ci p benefit appear strong woman individual hypertension non smoker statistically significant association be find vitamin c vitamin k intake ibd risk however individual diabetes mcg increase vitamin k intake be associate approximate reduction ibd risk adjust ci p rcs analysis suggest linear relationship dietary micronutrient intake ibd risk vitamin d p nonlinearity p overall vitamin c p nonlinearity p overall vitamin k p nonlinearity p overall conclusion increase vitamin d intake may reduce risk ibd more pronounced benefit certain subgroup highlight potential vitamin d supplementation novel therapeutic approach ibd prevention management future well design study should far test therapeutic effect vitamin d supplementation investigate association other dietary trace element ibd risk to well inform prevention treatment approach,"Li, Hui,Li, Wen-Chao,Hu, Xia-Rong",30/11/2024,BMC gastroenterology
10.1080/0886022X.2025.2472981,causal impact elevated body mass index diabetic kidney disease integrated mendelian randomization global burden disease study analysis,background elevate body mass index bmi have be implicate pathogenesis diabetic kidney disease patient type diabetes mellitus however establish causal relationship quantify resultant global health impact remain challenging method two sample mendelian randomization mr analysis be conduct use summary level datum obtain ieu database multiple mr approach include inverse variance weight ivw mr egger regression weight median weight mode simple mode method be implement to ensure robust causal inference parallel global burden disease study gbd be analyze to determine trend mortality disability adjust life year dalys attributable high bmi hbmi joinpoint regression be use to estimate average annual percent change aapc bayesian age period cohort bapc model be then apply to project disease burden result mr analysis provide strong evidence causal relationship elevated bmi gbd analysis reveal sustained global increase hbmi burden past three decade result aapc indicate persistent upward trend burden be particularly high old adult high impact observe east asia middle socio demographic index sdi region hbmi relate disease burden be project to continue rise conclusion elevated bmi be significant causal risk factor integration mr gbd datum underscore urgent need target public health intervention to reduce bmi level especially high risk region age population,"Chen, Ye-Xin,Hu, Dong-Sen,Lin, Mao-Xuan,Gao, Zi-Heng,Hong, Han-Zhang,Hu, Yu-Xin,Yao, Ling-Zi,Cui, Gai-Wen,Wang, Lin",17/03/2025,Renal failure
10.1016/j.cgh.2025.01.024,early occurrence hepatic encephalopathy follow tip insertion be link impaired survival multicenter cohort study,background aim hepatic encephalopathy he be common complication follow transjugular intrahepatic portosystemic shunt tip insertion however prognostic significance overt post tip remain controversial method screen patient undergo tip insertion eight german tertiary care center patient pre emptive tip placement hepatocellular carcinoma miss datum non ptfe cover stent be exclude compete risk analysis be perform consider liver transplantation compete event to correct immortal time bias landmark analysis be conduct landmark be set day post tip outcome datum be assess to month post tips insertion result total patient median meld iqr age iqr male tip be include overall post tip be link impaired survival shr however be only confirm occur first day post tip early shr additionally patient history shr history early post tip shr show impaired survival finding be confirm landmark multivariable analysis conclusion early post tip be associate significantly reduce survival therefore patient experience early have history should be closely monitor physician constitute particularly vulnerable group impaired survival,"Kabelitz, Martin A,Sandmann, Lisa,Praktiknjo, Michael,Mauz, Jim B,Auer, Timo Alexander,Bruns, Tony,Chang, Johannes,Fehrenbach, Uli,Hinrichs, Jan,Jansen, Christian,Klöckner, Roman,Kluwe, Johannes,Köhler, Michael,Meyer, Carsten,Piecha, Felix,Pollmanns, Maike Rebecca,Ripoll, Cristina,Schultheiss, Michael,Seifert, Leon Louis,Stöhr, Fabian,Sturm, Lukas,Trebicka, Jonel,Zipprich, Alexander,Labenz, Christian,Bettinger, Dominik,Maasoumy, Benjamin",27/09/2024,Clinical gastroenterology and hepatology : the official clinical practice journal        of the American Gastroenterological Association
10.1002/ejhf.3642,to handle polypharmacy heart failure clinical consensus statement heart failure association esc,multiplicity coexist comorbiditie affect patient heart failure hf together availability multiple treatment improve prognosis hf reduced ejection fraction have lead increase number prescribe medication patient polypharmacy be define regular use multiple medication last year have become emerge aspect hf care particularly old frailer patient be more frequently multiple treatment be therefore more likely expose tolerability issue drug drug interaction practical difficulty management polypharmacy negatively affect adherence treatment be associate high risk adverse drug reaction impaired quality life more hospitalization bad prognosis be important to adopt implement strategy management polypharmacy other medical discipline include medication reconciliation therapeutic revision treatment prioritization be also essential to develop new hf specific strategy primary goal avoid use redundant treatment minimize adverse drug reaction interaction finally improve adherence clinical consensus statement document heart failure association european society cardiology propose rationale pragmatic multidisciplinary approach drug prescription current era multimorbidity multi medication hf,"Stolfo, Davide,Iacoviello, Massimo,Chioncel, Ovidiu,Anker, Markus S,Bayes-Genis, Antoni,Braunschweig, Frieder,Cannata, Antonio,El Hadidi, Seif,Filippatos, Gerasimos,Jhund, Pardeep,Mebazaa, Alexandre,Moura, Brenda,Piepoli, Massimo,Ray, Robin,Ristic, Arsen D,Seferovic, Petar,Simpson, Maggie,Skouri, Hadi,Tocchetti, Carlo Gabriele,Van Linthout, Sophie,Vitale, Cristiana,Volterrani, Maurizio,Keramida, Kalliopi,Wassmann, Sven,Lewis, Basil S,Metra, Marco,Rosano, Giuseppe M C,Savarese, Gianluigi",23/12/2024,European journal of heart failure
10.7554/eLife.96519,microglia clonal inflammatory disorder alzheimer disease,somatic genetic heterogeneity result post zygotic dna mutation be widespread human tissue can cause disease however few study have investigate role neurodegenerative process such alzheimer disease ad here report selective enrichment microglia clone carry pathogenic variant be not present neuronal glia stromal cell blood patient ad comparison age match control notably microglia specific ad associate variant preferentially target mapk pathway include recurrent cbl ring domain mutation variant activate erk drive microglia transcriptional program characterize strong neuro inflammatory response vitro patient natural history ad associate microglial clone be difficult to establish human microglial expression mapk pathway activate variant be previously show to cause neurodegeneration mouse suggest ad associate neuroinflammatory microglial clone may contribute neurodegenerative process patient,"Vicario, Rocio,Fragkogianni, Stamatina,Weber, Leslie,Lazarov, Tomi,Hu, Yang,Hayashi, Samantha Y,Craddock, Barbara,Socci, Nicholas D,Alberdi, Araitz,Baako, Ann,Ay, Oyku,Ogishi, Masato,Lopez-Rodrigo, Estibaliz,Kappagantula, Rajya,Viale, Agnes,Iacobuzio-Donahue, Christine A,Zhou, Ting,Ransohoff, Richard M,Chesworth, Richard,Abdel-Wahab, Omar,Boisson, Bertrand,Elemento, Olivier,Casanova, Jean-Laurent,Miller, W Todd,Geissmann, Frédéric",14/03/2025,eLife
10.1016/j.amjmed.2025.03.010,vaccine international traveler current status recent development,immunization malaria chemoprophylaxis insect repellent use prevention management traveler diarrhea be cornerstone pretravel consultation report update one topic vaccine immunization adult international traveler,"Murray, Henry W",09/08/2024,The American journal of medicine
10.1002/advs.202413253,citrullination nf κb novel therapeutic target modulate macrophage polarization acute lung injury,mediate protein citrullination peptidyl arginine deiminase have recently be report to influence macrophage phenotype however mechanism macrophage function pseudomona aeruginosa acute lung injury syndrome ali remain unclear utilize single cell rna sequence mass spectrometry base proteomic new citrullination site arginine be discover nuclear κb nf κb catalyze modulate nf κb importin pathway downstream macrophage polarization build finding cell specific target therapeutic strategy use gold nanoparticle aunps conjugate novel inhibitor intercellular adhesion antibody be develop approach enable selective delivery inhibitor polarize macrophage pa infect alveolar niche vivo nanomedicine reduce excessive inflammation promote polarization to inhibit ali study highlight role mediate citrullination macrophage polarization introduce promising nanoparticle base therapy pa induce ali,"Yu, Xin,Song, Yujing,Dong, Tao,Ouyang, Wenlu,Quan, Chao,Shao, Liujiazi,Barasa, Leonard,Thompson, Paul R,Zhang, Mao,Ma, Jianjie,Kurabayashi, Katsuo,Li, Yongqing",11/02/2025,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"
10.1016/j.jbc.2025.108323,cyclophilin j limit linear ubiquitin signal control colorectal cancer progression,,"Sheng, Chunjie,Yao, Chen,Wang, Jing,Mao, Yizhi,Fu, Lingyi,Chen, Shuai",12/03/2025,The Journal of biological chemistry
10.1021/acsami.4c19748,stem cell human exfoliate deciduous tooth derive exosome treatment acute liver injury liver fibrosis,mesenchymal stem cell msc play crucial role regenerative medicine regenerative potential however traditional msc base therapy be hinder issue such microvascular obstruction low cell survival transplantation exosome derive msc msc exo provide cell free nanoscale alternative mitigate risk offer therapeutic potential liver disease nonetheless functional variability msc different source complicate clinical application stem cell derive human exfoliate deciduous tooth shed offer advantage such ease procurement robust proliferative capacity secretome particularly shed exo remain underexplored context liver disease therapy study analyze msc exo various source small rna sequence to identify difference microrna profile aid selection optimal msc source clinical use shed exo be subsequently test acute liver injury model show notable regenerative effect include enhanced hepatocyte proliferation macrophage polarization reduce inflammation strong liver target property rapid hepatic clearance shed exo limit effectiveness chronic liver disease to address challenge gelma base hydrogel be develop situ delivery ensure sustain release enhance antifibrotic efficacy provide promising strategy chronic liver disease management,"Wang, Ziyuan,Zhong, Danyang,Yan, Tingting,Zheng, Qiang,Zhou, Enjie,Ye, Zhichao,He, Xiaoyan,Liu, Yu,Yan, Jianing,Yuan, Yuyang,Wang, Yifan,Cai, Xiujun",15/03/2025,ACS applied materials & interfaces
10.1126/sciadv.adq9111,regulate endoreplication synergistically promote fzr deubiquitination stabilization,endoreplication be characterize multiple round dna replication cell division determine growth final size endoreplicate cell tissue eukaryote cyclic ubiquitination degradation several cell cycle regulator be require endoreplication progression however deubiquitinase deubiquitinate stabilize key factor to modulate endoreplication remain unknown here find endoreplicate drosophila salivary gland bombyx silk gland depletion ubiquitin specific peptidase lead endoreplication arrest decrease gland size mechanistically show interact fizzy relate fzr protein conserve master regulator endoreplication thereby deubiquitinate stabilize fzr to modulate endoreplication moreover molecular chaperone heat shock protein mediate proper folding fzr increase interaction fzr thereby promote deubiquitination stabilization fzr together study demonstrate regulate endoreplication synergistically maintain fzr stability deubiquitination,"Qian, Wenliang,Zhang, Xing,Yuan, Dongqin,Wu, Yuting,Li, Hao,Wei, Ling,Li, Zheng,Dai, Zongcai,Song, Pei,Sun, Qiaoling,Zhou, Zizhang,Xia, Qingyou,Cheng, Daojun",19/03/2025,Science advances
10.3389/fendo.2025.1528801,safety efficacy fix dose combination dapagliflozin saxagliptin patient type diabete mellitus phase study india,objective to determine post marketing safety profile once daily fix dose combination fdc dapagliflozin mg saxagliptin mg give orally week discontinuation indian patient type diabetes mellitus dm be stable dose metformin design prospective single arm multicenter study set adult patient dm enrol april march study site india outcome measure primary objective be to determine adverse event ae profile fdc additionally assess change glycated hemoglobin fast plasma glucose fpg systolic blood pressure body weight week compare baseline result patient median age range to year analyze be male mean standard deviation duration dm year overall present comorbidity most frequent being hypertension week total patient experience ae majority have mild aes most frequent aes include urinary tract infection pyrexia nasopharyngitis balanoposthitis aes special interest report be genital tract infection hypoglycemia serious aes be report none aes require treatment discontinuation three patient have aes lead temporary interruption study drug death be report study mean absolute change fpg mg dl weight kg baseline week be statistically significant p conclusion study demonstrate safety efficacy once daily fdc dapagliflozin saxagliptin add to metformin indian patient dm,"Wangnoo, S K,Bhadada, Sanjay Kumar,Farishta, Faraz,Jayaram Naidu, Girithara Gopalakrishnan,Pattnaik, Indira,Manohar, K N,Singh, K P,Gupta, Sandeep Kumar,Bharath, H S,Ghosh, Sujoy",15/11/2024,Frontiers in endocrinology
10.3389/fphar.2025.1486357,identification glycolysis relate gene signature prognosis therapeutic target idiopathic pulmonary fibrosis,background glycolysis play crucial role fibrosis specific gene involve glycolysis idiopathic pulmonary fibrosis ipf be not well understand method three ipf gene expression dataset be obtain gene expression omnibus geo glycolysis relate gene be retrieve molecular signature database msigdb differentially express glycolysis relate gene degrg be identify use limma r package diagnostic glycolysis relate gene grgs be select least absolute shrinkage selection operator lasso regression regression support vector machine recursive feature elimination svm rfe prognostic signature be develop use lasso regression time dependent receiver operating characteristic roc curve be generate to evaluate predictive performance single cell rna sequence scrna seq datum be analyze to examine grg expression various cell type immune infiltration analysis gene set enrichment analysis gsea gene set variation analysis gsva be perform elucidate potential molecular mechanism bleomycin pulmonary fibrosis mouse model be use experimental validation via reverse transcription quantitative polymerase chain reaction rt qpcr result grg vcan mertk tpbg aurka artn pgp pklr pfkm agrn be identify diagnostic marker ipf seven artn aurka mertk pfkm form prognostic model demonstrate predictive power auc scrna seq reveal cell type specific grg expression particularly macrophage fibroblast immune infiltration analysis link grg imbalance immune response experimental validation bleomycin induce fibrosis model confirm upregulation grg such aurka drug prediction identify inhibitor such tozasertib aurka potential therapeutic agent conclusion study identify grg potential prognostic biomarker ipf highlight role modulate immune response fibrotic lung microenvironment notably aurka mertk be associate pathway link fibrosis progression represent potential therapeutic target finding provide insight metabolic reprogramme ipf suggest target glycolysis relate pathway may offer novel pharmacological strategy antifibrotic therapy,"Gao, Han,Sun, Zhongyi,Hu, Xingxing,Song, Weiwei,Liu, Yuan,Zou, Menglin,Zhu, Minghui,Cheng, Zhenshun",26/08/2024,Frontiers in pharmacology
10.1016/j.eclinm.2025.103121,effect lifestyle intervention mental health child adolescent overweight obesity systematic review meta analysis,background childhood obesity mental health disorder be increasingly prevalent lifestyle intervention be widely recognize effective manage obesity child adolescent effect mental health remain unclear study aim to systematically evaluate effect lifestyle intervention mental health outcome child adolescent overweight obesity method systematic review meta analysis search five database pubme embase medline central cinahl relevant randomise control trial rct non randomised study intervention nrsis publish database inception december language restriction lifestyle intervention be define structured program promote health relate behavioural change diverse domain such physical activity dietary adjustment cognitive training psychosocial support include study assess effect lifestyle intervention mental health outcome child adolescent overweight obesity two reviewer independently screen record eligibility extract study level datum assess risk bias rct nrsis revise cochrane risk bias tool randomise control trial rob risk bias non randomised study intervention robin i certainty evidence grading recommendation assessment development evaluation grade approach rct be prioritize primary source evidence nrsis serve supplementary evidence random effect meta analysis model be perform to calculate pool standardized mean difference smds confidence interval cis subgroup analysis stratify age body mass index bmi category intervention type theoretical framework duration world bank income region be far conduct to identify potential source heterogeneity review protocol be register prospero finding identify record study rct nine nrsis involve child adolescent overweight obesity be include mental health outcome assess include depression anxiety self concept self efficacy negative affect quality life emotional functioning lifestyle intervention evaluate encompass physical activity health education emotion regulation diet multicomponent approach rct reduction depression smd ci to i square i improvement quality life smd ci be observe moderate certainty subgroup analysis reveal great reduction depression adolescent participant obesity program involve multicomponent approach last three month use behavioural cognitive theory be conduct high income country hic quality life great improvement be observe participant overweight obesity program base behavioural cognitive theory conduct middle income country lmic meanwhile nrsis reduction depression smd ci as well enhancement self concept smd ci quality life smd ci emotional functioning smd ci be note however effect other mental health outcome include anxiety negative affect self efficacy remain inconclusive interpretation lifestyle intervention modestly improve depressive symptom quality life child adolescent overweight obesity additional benefit self concept emotional functioning observe nrsis finding underscore potential lifestyle intervention to address physical mental health future research should focus evaluate long term psychological outcome develop cost effective culturally tailor intervention funding study be support national natural science foundation china,"Zhou, Jiali,Song, Yuan,Ying, Jiayao,Zhang, Chenhao,Wu, Jing,Shan, Shiyi,Zha, Jindian,Zhou, Liying,Xiao, Wenhan,Song, Peige",05/11/2024,EClinicalMedicine
10.1172/JCI181671,epigenetic therapy sensitize anti refractory head neck cancer immunotherapy rechallenge,backgroundimmune checkpoint blockade icb be effective treatment subset patient diagnose head neck squamous cell carcinoma hnscc however majority patient be nonrandomize open label phase clinical trial participant recurrent metastatic r m hnscc be treat low dose azacytidine aza daily day combination durvalumab tremelimumab progression icb primary objective be to assess biologically effective dose aza determine molecular change pair baseline treatment tumor biopsy secondary objective be eight percent participant evaluable pair tissue sample have great fold increase baseline ifn γ signature program cell death protein ligand pd expression tumor microenvironment tme be associate increase t cell infiltration decrease infiltration t regulatory cell mean neutrophil lymphocyte ratio nlr decrease great sd sd median overall survival os be month ci year os rate be ci treat participant demonstrate prolong os great finding suggest low dose aza can reprogram systemic host immune response local tme to increase ifn γ pd expression increase expression establish biomarker correlate prolong os icb,"Qin, Tingting,Mattox, Austin K,Campbell, Jean S,Park, Jong Chul,Shin, Kee-Young,Li, Shiting,Sadow, Peter M,Faquin, William C,Micevic, Goran,Daniels, Andrew J,Haddad, Robert,Garris, Christopher S,Pittet, Mikael J,Mempel, Thorsten R,ONeill, Anne,Sartor, Maureen A,Pai, Sara I",17/03/2025,The Journal of clinical investigation
10.1172/JCI188358,add insult injury spectrum tubulointerstitial response acute kidney injury,acute kidney injury aki encompass pathophysiology range glomerular hypofiltration tubular cell injury outflow obstruction review will focus tubulointerstitial process underlie most case aki tubular epithelial cell tec injury can occur distinct insult include ischemia nephrotoxin sepsis primary immune mediate process follow initial insult tubular cell can activate survival repair response can develop mitochondrial dysfunction metabolic reprogramming cell cycle arrest program cell death develop evidence suggest fate individual tubular cell to survive proliferate undergo cell death senescence be frequently determine biphasic immune response initial proinflammatory macrophage neutrophil lymphocyte infiltration exacerbating injury activate program cell death alternatively activate macrophage specific lymphocyte subset subsequently modulate inflammation promote repair functional recovery require reparative phase support proteolytic degradation tubular cast proliferation survive tecs restoration tec differentiation incomplete resolution persistence inflammation can lead fail tubular repair fibrosis chronic kidney disease extensive research animal model translate preclinical finding to therapy remain challenge emphasize need integrated multiomic approach to advance understanding treatment,"Baker, Megan L,Cantley, Lloyd G",17/03/2025,The Journal of clinical investigation
10.1002/advs.202410764,target promote renal fibrosis follow ischemia reperfusion injury,chronic kidney disease ckd be global health challenge acute kidney injury aki ischemia reperfusion injury iri common cause study explore role hepatocyte nuclear factor alpha renal fibrosis ckd iri kidney biopsy specimen ckd patient mouse model iri unilateral ureteral obstruction show upregulation fibrotic kidney link renal function decline additional experiment demonstrate deletion mitigate iri induce renal fibrosis overexpression lead increase fibrosis examination potential mechanism transcriptome sequence sequencing suggest promote renal fibrosis increase expression nck associate protein formerly know hematopoietic protein vital component wave complex play significant role cytoskeletal regulation cell migration result underscore critical function renal fibrosis follow iri also identify potential therapeutic target thus open new avenue research potential therapeutic intervention ckd renal fibrosis,"Hou, Ling,Guo, Yan,Xu, Shuang,Bai, Mi,Cao, Weidong,Zhang, Yue,Jia, Zhanjun,Zhang, Aihua",20/02/2025,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"
10.1186/s12929-025-01129-7,metformin sensitize triple negative breast cancer histone deacetylase inhibitor target,background triple negative breast cancer tnbc be characterize high malignancy strong invasiveness propensity distant metastasis lead poor prognosis relatively limited treatment option metformin first line oral hypoglycemic agent have garner widespread research interest recent year potential cancer prevention treatment however efficacy vary significantly different tumor type histone deacetylase inhibitor hdaci such saha have demonstrate antitumor activity tnbc respond poorly hdaci monotherapy possibly due feedback activation jak stat pathway explore synergistic potential underlying mechanism combine metformin hdaci tnbc treatment be crucial method predict synergistic effect metformin saha tnbc use multiple computational method cmap dtsyn drugcomb also develop cancer specific compound mimic library cdtsl apply three step strategy to identify gene fit metformin sensitization model subsequently evaluate synergistic effect metformin saha tnbc cell line cell proliferation colony formation apoptosis assay furthermore investigate molecular mechanism combine treatment use technique such transcriptome sequence chromatin immunoprecipitation chip western blotting measurement extracellular acidification rate ecar additionally assess in vivo antitumor effect combine therapy nude mouse subcutaneous xenograft model result cmap dtsyn drugcomb predict synergistic effect saha metformin tnbc screening result reveal play key role metformin sensitization find combination metformin saha exhibit synergistic antitumor effect combination index ci tnbc cell line mechanistically metformin inhibit histone acetylation thereby block feedback activation downstream pathway induce saha furthermore metformin interfere glycolysis process induce saha alter metabolic reprogramme tumor cell vivo experiment combine treatment metformin saha significantly inhibit growth subcutaneous tumor nude mouse conclusion metformin enhance sensitivity tnbc hdac inhibitor block pathway interfere metabolic reprogramming use combination saha metformin exhibit synergistic antitumor effect study provide theoretical basis combine application hdac inhibitor metformin potentially offer new strategy treatment tnbc,"Gu, Zhangyuan,Ye, Fugui,Luo, Hong,Li, Xiaoguang,Gong, Yue,Mao, Shiqi,Jia, Xiaoqing,Han, Xiangchen,Han, Boyue,Fu, Yun,Cheng, Xiaolin,Li, Jiejing,Shao, Zhiming,Wen, Peizhen,Hu, Xin,Zhuang, Zhigang",07/02/2024,Journal of biomedical science
10.1002/anie.201608807,heck matsuda process synthesis β arylethenesulfonyl fluoride selectively addressable bi electrophile sufex click chemistry,heck matsuda process synthesis otherwise difficult to access compound β arylethenesulfonyl fluoride be describe ethenesulfonyl fluoride vinylsulfonyl fluoride esf undergo β arylation stable readily prepare arenediazonium tetrafluoroborate presence catalyst acetate to afford e isomer sulfonyl analogue cinnamoyl fluoride yield β arylethenesulfonyl fluoride be find to be selectively addressable bis electrophile fluoride exchange sufex click chemistry alkenyl moiety sulfonyl fluoride group can be exclusive site nucleophilic attack define condition make rather simple core attractive covalent drug discovery,"Qin, Hua-Li,Zheng, Qinheng,Bare, Grant A L,Wu, Peng,Sharpless, K Barry",08/09/2016,Angewandte Chemie (International ed. in English)
10.1186/s40001-025-02412-x,vitamin d calcium supplementation woman undergo pharmacological management postmenopausal osteoporosis level evidence systematic review,present systematic review investigate different dose vitamin d calcium supplementation woman postmenopausal osteoporosis undergo antiresorptive therapy have association bmd spine hip femur neck serum marker osteoporosis bone alp ntx ctx rate pathological vertebral non vertebral fracture adverse event mortality systematic review be conduct accord prisma guideline pubme google scholar embase scopus database be access september randomise clinical trial rct compare two more treatment postmenopausal osteoporosis supplement vitamin d calcium be access only study indicate daily vitamin d calcium supplementation dose be access datum rct patient be retrieve patient receive mean mg ui calcium vitamin d supplementation respectively mean length follow up be month mean age patient be year mean bmi be kg be evidence statistically significant negative association daily vitamin d supplementation gastrointestinal adverse event r p mortality r p additional statistically significant association be evidence postmenopausal woman undergo antiresorptive treatment osteoporosis vitamin d be associate low frequency gastrointestinal adverse event mortality calcium supplementation do not evidence association endpoint evidence level systematic review rct,"Migliorini, Filippo,Maffulli, Nicola,Colarossi, Giorgia,Filippelli, Amelia,Memminger, Michael,Conti, Valeria",19/12/2023,European journal of medical research
10.1038/s41467-025-57401-9,er o glycosylation synovial fibroblast drive cartilage degradation,arthritic synovial fibroblast sfs activate cartilage ecm degradation remain unclear galnt enzyme initiate o glycosylation golgi relocate er activity stimulate ecm degradation here show human rheumatoid osteoarthritic synovial sfs galnt be relocate er ra mouse model galnt relocation occur shortly arthritis symptom abate animal recover er galnt inhibitor prevent cartilage ecm degradation vitro expression chimeric protein sfs result protection cartilage one er target galnt be resident protein calnexin be export cell surface arthritic sfs calnexin participate matrix degradation reduce ecm disulfide bond anti calnexin antibodie block ecm degradation protect animal ra sum er o glycosylation be key switch arthritic sfs glycosylate surface calnexin could be therapeutic target,"Tran, Le Son,Chia, Joanne,Le Guezennec, Xavier,Tham, Keit Min,Nguyen, Anh Tuan,Sandrin, Virginie,Chen, Way Cherng,Leng, Tan Tong,Sechachalam, Sreedharan,Leong, Khai Pang,Bard, Frederic A",11/06/2021,Nature communications
,occurrence case bovine spongiform encephalopathy closed dairy herd,fourteen case bovine spongiform encephalopathy bse be diagnose basis clinical examination closed herd british friesian cow month period october june diagnosis be confirm histopathological examination brain tissue five six sample submit main presenting clinical sign be altered behaviour apprehension anxiety hyperaesthesia one cow be euthanize short period recumbency remain cow be slaughter humane economic ground protein animal origin have be feed heifer cow herd past year have be direct contact sheep epidemiology bse report suggest postulate morgan be correct infection be ingest first month life there then follow year period clinical sign appear,"Winter, M H,Aldridge, B M,Scott, P R,Clarke, M",01/03/1989,The British veterinary journal
10.1002/advs.202415563,homocysteine promote pathogenesis atherosclerosis circ axis,previous study have establish possible link hyperhomocysteinemia hhcy dyslipidemia circular rnas circrnas play important regulatory role development atherosclerosis however biological function potential molecular mechanism circrna hhcy induce lipid accumulation lead atherosclerosis be still unclear study be determined homocysteine hcy downregulate expression circ global circrna expression profiling circ inhibit hcy mediate lipid accumulation foam cell pathogenesis atherosclerosis act sponge circ be identify potential diagnostic biomarker hhcy associate atherosclerosis male apolipoprotein e knockout mouse mechanistically circ activate adenosine protein kinase pathway regulate hcy mediate modification nuclear export circ to increase lipid accumulation foam cell accelerate pathogenesis atherosclerosis take together result highlight role circ hcy mediate pathogenesis atherosclerosis suggest potential application prognostic biomarker atherosclerosis induce hhcy,"Ma, Shengchao,Ma, Fei,Ding, Ning,Xie, Lin,Yang, Anning,Shen, Jiangyong,Jiao, Yun,Wu, Kai,Chai, YueE,Bai, Zhigang,Xiong, Jiantuan,Li, Nan,Zhang, Huiping,Jiang, Yideng",26/01/2025,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"
10.1007/s40264-025-01526-9,qt interval antipsychotic correlate patient schizophrenia cross sectional datum multicentric real world face sz,background life expectancy patient schizophrenia be reduce partly due cardiovascular disease antipsychotic be associate qt interval prolongation be risk factor arrhythmia cardiac arrest difference antipsychotic regard qt interval prolongation be not well understand objective aim be to compare qt value associate different antipsychotic real world population subject clinically stable form schizophrenia method face sz cohort comprise subject psychotic disorder refer schizophrenia expert cent qt interval be measure as well treatment psychotropic other follow maintenance treatment schizophrenia be analyse cross sectionally aripiprazole clozapine haloperidol amisulpride olanzapine quetiapine risperidone age sex smoking status body mass index blood potassium level co prescription qt prolong treatment be use adjustment factor multivariable linear regression analysis result patient mean correct qt qtc interval sample patient monotherapy be ms mean age be year majority be male comparison rest sample clozapine be associate long qtc interval β ci aripiprazole be significantly associate short qtc interval β ci other antipsychotic be not associate significant variation qtc conclusion prescription antipsychotic should always be accompany close monitoring qtc interval to prevent risk severe cardiac arrhythmia particularly concern clozapine,"Gerentes, Mona,Lajnef, Mohamed,Szöke, Andrei,Aouizerate, Bruno,Berna, Fabrice,Cléry, Maud,Chéreau, Isabelle,Coulon, Nathalie,Clauss-Kobayashi, Julia,Fakra, Eric,Dorey, Jean-Michel,Dubertret, Caroline,Fond, Guillaume,Godin, Ophélia,Goze, Tudi,Lançon, Christophe,Leboyer, Marion,Leignier, Sylvain,Llorca, Pierre-Michel,Mallet, Jasmina,Misdrahi, David,Oriol, Nicolas,Rey, Romain,Roux, Paul,Schorr, Benoit,Urbach, Mathieu,Véry, Etienne,Schürhoff, Franck,Pignon, Baptiste",09/02/2025,Drug safety
10.1016/j.autrev.2025.103804,efficacy safety tolerability antifibrotic agent rheumatoid arthritis associate interstitial lung disease systematic review meta analysis,objective to evaluate efficacy safety tolerability antifibrotic agent nintedanib pirfenidone treatment rheumatoid arthritis associate interstitial lung disease ra ild method systematic literature review be conduct follow prisma moose guideline study assess nintedanib pirfenidone ra ild be include meta analysis be perform use random effect model result six study randomize control trial observational involve ra ild patient meet inclusion criterion total receive nintedanib receive pirfenidone nearly have usual interstitial pneumonia pattern pool analysis reveal mean fvc decline ml year ci p mean difference p exclude influential study p impact pdlco have be less extensively evaluate mean difference p exclude influential study effect size p change pulmonary function test be comparable nintedanib pirfenidone mortality rate range respiratory specific mortality report lung transplantation rate be antifibrotic therapy be associate pooled adverse event ae rate ci p gastrointestinal symptom hepatotoxicity be most frequently report treatment discontinuation aes occur nearly patient ci p conclusion antifibrotic agent demonstrate stabilization pfvc less robust evidence pdlco ra ild nearly one quarter patient discontinue therapy aes,"Narváez, Javier,Aguilar-Coll, Martí,Roig-Kim, Montserrat,Palacios-Olid, Judith,Maymó-Paituvi, Pol,de Daniel Bisbe, Laia,LLop, Dídac",12/01/2025,Autoimmunity reviews
10.1016/j.autrev.2025.103804,efficacy safety tolerability antifibrotic agent rheumatoid arthritis associate interstitial lung disease systematic review meta analysis,objective to evaluate efficacy safety tolerability antifibrotic agent nintedanib pirfenidone treatment rheumatoid arthritis associate interstitial lung disease ra ild method systematic literature review be conduct follow prisma moose guideline study assess nintedanib pirfenidone ra ild be include meta analysis be perform use random effect model result six study randomize control trial observational involve ra ild patient meet inclusion criterion total receive nintedanib receive pirfenidone nearly have usual interstitial pneumonia pattern pool analysis reveal mean fvc decline ml year ci p mean difference p exclude influential study p impact pdlco have be less extensively evaluate mean difference p exclude influential study effect size p change pulmonary function test be comparable nintedanib pirfenidone mortality rate range respiratory specific mortality report lung transplantation rate be antifibrotic therapy be associate pooled adverse event ae rate ci p gastrointestinal symptom hepatotoxicity be most frequently report treatment discontinuation aes occur nearly patient ci p conclusion antifibrotic agent demonstrate stabilization pfvc less robust evidence pdlco ra ild nearly one quarter patient discontinue therapy aes,"Narváez, Javier,Aguilar-Coll, Martí,Roig-Kim, Montserrat,Palacios-Olid, Judith,Maymó-Paituvi, Pol,de Daniel Bisbe, Laia,LLop, Dídac",12/01/2025,Autoimmunity reviews
10.1016/j.ahj.2025.03.006,cardiac auscultation skill medical trainee,many expert suspect have be gradual decline cardiac auscultation skill physician study have examine hypothesis to well evaluate long term change cardiac auscultation skill perform repeat cross sectional study to analyze medical trainee performance cardiac auscultation simulation test year period datum demonstrate decline simulation test score time medical student study underscore importance broad investment strategy teach cardiac auscultation order to preserve improve valuable skill,"Zhang, Neil S,Yang, Joy Y,Goldhaber, Joshua I,Phan, Binh An P,Cheitlin, Melvin D",17/01/2025,American heart journal
10.1038/s41467-025-57902-7,asgard arf gtpase can act membrane associate molecular switch potential to function organelle biogenesis,inward membrane bud bending membrane cytosol be essential form maintain eukaryotic organelle eukaryote arf gtpase initiate inward bud research show asgard archaea genome encode putative arf protein aarfs aarfs possess structural element characteristic eukaryotic counterpart express yeast mammalian cell aarfs display gtp dependent membrane targeting vitro aarf associate eukaryotic archaeal membrane yeast aarfs interact be regulate key organelle biogenesis player express aarf lead massive proliferation endomembrane organelle include endoplasmic reticulum golgi aarf interact copii vesicle coat component gtp dependent manner finding suggest certain aarfs be membrane associate molecular switch functional potential to initiate organelle biogenesis evolution functional coat could be next critical step establish eukaryotic cell architecture,"Zhu, Jing,Xie, Ruize,Ren, Qiaoying,Zhou, Jiaming,Chen, Chen,Xie, Meng-Xi,Zhou, You,Zhang, Yan,Liu, Ningjing,Wang, Jinchao,Zhang, Zhengwei,Liu, Xipeng,Yan, Wupeng,Gong, Qingqiu,Dong, Liang,Zhu, Jinwei,Wang, Fengping,Xie, Zhiping",26/06/2024,Nature communications
10.1007/s00018-025-05642-8,target glioblastoma reshapes immune infiltrate enhance response immune checkpoint blockade,glioblastoma gbm be aggressive primary brain tumor dismal clinical prognosis resistance current therapy gbm progression be facilitate tumor microenvironment tme immune infiltrate dominate tumor associate microglia macrophage tam regulatory t cell treg tme be also characterize hypoxia expression hypoxia inducible factor hifs emerge potential regulator tumor progression however role gbm immunosuppression remain unknown here investigate use inhibitor to modulate tme immunocompetent mouse gbm model administration vivo decrease tumor volume prolonged survival tumor bear mouse affect viability vitro notably inhibition alleviate immunosuppressive tme synergize immune checkpoint blockade icb use antibodie to promote long term survival comprehensive analysis immune infiltrate single cell rna sequence flow cytometry reveal combine icb reduce number pro tumoral macrophage treg increase number microglia corresponding transcriptional modulation anti tumoral profile tam vitro deletion microglia impede polarization pro tumoral like profile inhibition impair treg migration result show target can switch immunosuppressive tme one favor robust sustained response icb base immunotherapy finding establish clinically relevant inhibitor should be explore not only malignancy defect axis also exhibit immunosuppressive tme limit immunotherapy responsiveness,"Espinoza, Felipe I,Tankov, Stoyan,Chliate, Sylvie,Pereira Couto, Joana,Marinari, Eliana,Vermeil, Thibaud,Lecoultre, Marc,El Harane, Nadia,Dutoit, Valérie,Migliorini, Denis,Walker, Paul R",16/08/2024,Cellular and molecular life sciences : CMLS
10.3389/fimmu.2025.1513806,integration scrna seq bulk rna seq to reveal association potential molecular mechanism metabolic reprogramme regulate lactylation chemotherapy resistance ovarian cancer,objective ovarian cancer oc rank foremost cause mortality gynecological malignancy chemoresistance be primary factor contribute unfavorable prognosis work seek to clarify mechanism resistance relate lactylation oc intend to offer novel theoretical foundation therapy strategy address chemoresistance method combine analysis bulk rna seq single cell rna seq datum initially find lactylation gene link to chemoresistance subsequently employ differential expression analysis survival analysis enrichment analysis other methodology to far investigate role molecular mechanism gene tumor resistance ultimately investigate differential expression gene resistant non resistant tissue cell experimentation result find two candidate gene associate lactylation chemoresistance analysis single cell datum indicate tumor cell represent primary cell subpopulation relevant resistance study subpopulation analysis indicate several tumor cell subtype be markedly link resistance elevated expression level resistant subpopulation notably correlate various immunological metabolic pathway analysis metabolic pathway indicate oxidative phosphorylation glycolysis activity be elevate resistant subpopulation lactic acid buildup be associate chemoresistance investigation marker gene protein protein interaction network resistant subgroup elucidate intricate interaction gene expression level oc tissue platinum resistant cohort be markedly elevate compare sensitive cohort considerable rise expression observe resistant oc cell demonstrate co localization lactylation conclusion work elucidate significant function lactylation oc chemoresistance identifie possible gene associate drug resistance finding enhance comprehension mechanism chemoresistance oc offer critical insight formulation novel therapeutic option,"Ren, Fang,Pang, Xiaoao,Jin, Feng,Luan, Nannan,Guo, Houhua,Zhu, Liancheng",19/10/2024,Frontiers in immunology
10.1172/JCI184283,high level maintain inhibition drive chemoresistance high grade serous ovarian cancer,protein arginine methyl transferase prmts be generally upregulate cancer however mechanism lead upregulation biological consequence be poorly understand here identify main symmetric arginine methyltransferase critical driver chemoresistance high grade serous ovarian cancer hgsoc level enzymatic activity be induce platinum resistant pt resistant state protein level to reveal potential regulator high protein level optimize intracellular immunostaining condition perform unbiased crispr screening identify kelch like ech associate protein top score negative regulator mechanistic study show directly interact lead ubiquitin dependent degradation normal physiological condition genomic level chip study show elevated directly interact promoter stress response gene positively regulate transcription combined inhibition pt result synergistic cellular cytotoxicity vitro reduce tumor growth vivo pt resistant patient derive xenograft tumor overall finding study identify critical therapeutic target pt resistant hgsoc cell reveal molecular mechanism lead high level pt treat chemo resistant tumor,"Ozturk, Harun,Seker-Polat, Fidan,Abbaszadeh, Neda,Kingham, Yasemin,Orsulic, Sandra,Adli, Mazhar",28/06/2024,The Journal of clinical investigation
10.3389/fnut.2025.1508106,relationship ratio non high density lipoprotein cholesterol high density lipoprotein cholesterol nhhr masld advanced liver fibrosis evidence nhanes,background non hdl c to hdl c ratio nhhr be dependable lipid marker link atherosclerotic trait study examine potential relationship nhhr metabolic dysfunction associate steatotic liver disease masld advanced liver fibrosis method study investigate relationship nhhr level masld advanced liver fibrosis use datum national health nutrition examination survey nhane united states first conduct baseline characteristic analysis population base nhhr quartile second employ multivariable weight linear regression model to examine association nhhr masld as well advanced liver fibrosis third utilize restrict cubic spline rcs to assess potential non linear relationship fourth perform subgroup analysis finally roc curve analysis be conduct to evaluate effectiveness nhhr result main analysis study include total participant follow multivariable logistic regression comprehensive adjustment elevated nhhr level group be significantly link masld odd ratio ci ci respectively p trend elevated nhhr level group remained significantly link decrease risk advanced liver fibrosis odd ratio ci p ci p respectively rcs analysis reveal u shaped nonlinear association nhhr masld p p nonlinear advanced liver fibrosis p p nonlinear subgroup analysis find relationship be significant only certain subgroup roc curve analysis reveal nhhr exhibit good predictive performance diagnose masld base fatty liver index fli optimal cutoff point nhhr predict masld use fli be determined to be sensitivity specificity value respectively conclusion nhhr may serve predictive marker masld advanced liver fibrosis highlight potential significance risk assessment prevention strategy,"Li, Juyi,Kou, Chunjia,Chai, Yuwei,Li, Yuchen,Liu, Xue,Zhang, Li,Zhang, Haiqing",08/10/2024,Frontiers in nutrition
10.1038/s41571-025-01008-y,emerge importance tumorigenesis cancer therapy,be member her erbb family receptor tyrosine kinase together egfr have only weak intrinsic kinase activity can contribute oncogenic signal ligand induce heterodimerization other family member evidence indicate be alter aberrantly express variety tumour type can be associate poor clinical outcome anticancer agent target egfr have be approve decade drug target have be approve very recently initial targeting monoclonal antibody single agent combination other therapeutic produce disappointing clinical result subsequently effort have be make to target novel agent such antibody drug conjugate bispecific antibody promise efficacy observe several trial encompass various tumour type december bispecific antibody zenocutuzumab be grant fda accelerate approval treatment non small cell lung cancer pancreatic cancer harbouring fusion involve gene encode high affinity ligand neuregulin review provide essential guide signalling oncogenesis expression cancer prognostic implication oncogenic somatic mutation as well rare fusion might depend signal role resistance cancer therapy also highlight effort to target diverse therapeutic strategy potential interplay antitumour immune response,"Garrett, Joan T,Tendler, Salomon,Feroz, Wasim,Kilroy, Mary Kate,Yu, Helena",24/02/2025,Nature reviews. Clinical oncology
10.7150/thno.104557,tumor derive exosome induce neutrophil infiltration reprogramme to promote t cell exhaustion hepatocellular carcinoma,rationale high neutrophil infiltration hepatocellular carcinoma hcc be associate poor prognosis patient hcc tumor derive exosome tde have be prove to be important reprogramming tumor associate neutrophil tans role mechanism have not be fully clarify method role hcc exosome reprogramme neutrophil tumor progression be evaluate den hcc mouse model block neutrophil infiltration deplete neutrophil neutrophil adoptive transfer transcriptome sequence flow cytometry be perform to investigate effect hcc exosome phenotype function neutrophil mobilization apoptosis neutrophil be evaluate transwell experiment annexin aad staining respectively moreover detect effect hcc exosome reprogramme neutrophil t cell flow cytometry next use nf κb pathway inhibitor inhibitor mimic to determine molecular mechanism lastly construct sponge to validate targeted therapeutic potential result find hcc exosome induce neutrophil infiltration t cell exhaustion liver den hcc mouse promote tumor progression block neutrophil infiltration deplete neutrophil diminish promotive effect hcc exosome addition hcc exosome reprogramme neutrophil display proinflammatory protumor phenotype can directly induce t cell exhaustion vitro transfer hcc exosome reprogramme neutrophil exacerbate tumor progression induced t cell exhaustion evidence downregulation ifn γ tnf α upregulation t cell mechanistically find hcc exosome upregulate expression neutrophil activate nf κb signal pathway target cyld promote survival recruitment neutrophil hcc mouse block suppress neutrophil infiltration attenuate t cell exhaustion suppress hcc progression conclusion study clarify role hcc exosome neutrophil infiltration reprogramme identify potential target hcc treatment,"Bi, Wenchao,Li, Xue,Jiang, Yu,Gao, Tongtong,Zhao, Huajun,Han, Qiuju,Zhang, Jian",02/10/2024,Theranostics
10.1126/sciadv.ads8694,multimodal defect rich nanoreactor trigger sono piezoelectric tandem catalysis iron metabolism disruption implant infection,track eradicate drug resistant bacteria be critical combat implant associate infection effective antibacterial therapy remain elusive herein propose oxygen vacancy rich nanoreactor piezoelectric sonosensitizer spatiotemporal ultrasound drive chemodynamic tandem catalysis to amplify antibacterial efficacy piezoelectric charge carrier build electric field synchronize reaction efficiently generate electron rich oxygen vacancy modulate local electronic structure fe site facilitate reactive oxygen specie generation piezoelectric electron accelerate valence state cycle to achieve sustained maintenance hydroxyl radical chemodynamic reaction lead bacterial membrane damage transcriptomic analysis reveal intracellular fe overload induce excessive dysregulation two component system disrupt bacterial metabolism trigger bacterial ferroptosis like death thus porous titanium scaffold engineer piezoelectric nanoreactor demonstrate superior antibacterial efficacy ultrasound facilitate osteogenesis piezoelectric immunomodulation activate therapy,"Zheng, Fuyuan,Wan, Xufeng,Zhang, Yangming,Yue, Yan,Li, Qiaochu,Zhang, Zhuang,Li, Shuoyuan,Xu, Hong,Su, Qiang,Chen, Xiaoting,Tong, Le,Zhao, Long,Cao, Jian,Tang, Xin,Yang, Xiao,Wu, Jiagang,Li, Jian,Lv, Xiang,Zhou, Zongke,Wang, Duan",14/03/2025,Science advances
10.1038/s41586-025-08697-6,tgfβ link ebv to multisystem inflammatory syndrome child,subset child adolescent sars infection induce severe acute hyperinflammatory term multisystem inflammatory syndrome child mis c four to eight week infection mis c be characterize specific t cell systemic pathogenesis mis c remain largely unknown here show acute mis c be characterize impaired reactivation virus reactive memory t cell depend increase serum level cytokine tgfβ resemble occur severe ref functional impairment t cell reactivity be accompany presence tgfβ response signature t cell b cell monocyte reduce antigen presentation capability monocyte can be reverse block tgfβ furthermore t cell receptor repertoire patient mis c exhibit expansion t cell express resemble epstein barr virus t cell clone capable eliminate ebv infect b cell additionally serum tgfβ patient mis c can trigger ebv reactivation be reversible tgfβ blockade clinically tgfβ induce defect t cell reactivity correlate high ebv seroprevalence patient mis c compare age match control occurrence ebv reactivation finding establish connection sar infection sequelae child impair t cell cytotoxicity trigger tgfβ overproduction lead ebv reactivation subsequent hyperinflammation,"Goetzke, Carl Christoph,Massoud, Mona,Frischbutter, Stefan,Guerra, Gabriela Maria,Ferreira-Gomes, Marta,Heinrich, Frederik,von Stuckrad, Anne Sae Lim,Wisniewski, Sebastian,Licha, Jan Robin,Bondareva, Marina,Ehlers, Lisa,Khaldi-Plassart, Samira,Javouhey, Etienne,Pons, Sylvie,Trouillet-Assant, Sophie,Ozsurekci, Yasemin,Zhang, Yu,Poli, Maria Cecilia,Discepolo, Valentina,Lo Vecchio, Andrea,Sahin, Bengü,Verboom, Murielle,Hallensleben, Michael,Heuhsen, Anja Isabelle,Astudillo, Camila,Espinosa, Yazmin,Vial Cox, Maria Cecilia,Dobbs, Kerry,Delmonte, Ottavia M,Montealegre Sanchez, Gina A,Magliocco, Mary,Barron, Karyl,Danielson, Jeffrey,Petrov, Lev,Unterwalder, Nadine,Sawitzki, Birgit,Matz, Mareen,Lehmann, Katrin,Gratopp, Alexander,von Bernuth, Horst,Burkhardt, Lisa-Marie,Wiese, Niklas,Peter, Lena,Schmueck-Henneresse, Michael,Amini, Leila,Maurer, Marcus,Roehmel, Jobst Fridolin,Gewurz, Benjamin E,Yonker, Lael M,Witkowski, Mario,Kruglov, Andrey,Mall, Marcus Alexander,Su, Helen C,Ozen, Seza,Radbruch, Andreas,Belot, Alexandre,Durek, Pawel,Kallinich, Tilmann,Mashreghi, Mir-Farzin",04/07/2023,Nature
10.1016/j.cell.2025.02.009,engineering mtdna deletion reconstitute end join human mitochondria,recent breakthrough genetic manipulation mitochondrial dna mtdna have enable precise base substitution efficient elimination genome carry pathogenic mutation however reconstitute mtdna deletion link mitochondrial myopathy remain challenging here engineer mtdna deletion human cell co express end joining ej machinery target endonuclease use mitochondrial ej mito ej mito scai generate panel clonal cell line harbor kb mtdna deletion full spectrum heteroplasmy investigate cell reveal critical threshold delete genome oxidative phosphorylation oxphos protein depletion metabolic disruption impair growth galactose contain medium be observe single cell multiomic profiling identify two distinct nuclear gene deregulation response one trigger deletion threshold progressively respond heteroplasmy ultimately show method enable modeling disease associate mtdna deletion cell type could inform development target therapy,"Fu, Yi,Land, Max,Kavlashvili, Tamar,Cui, Ruobing,Kim, Minsoo,DeBitetto, Emily,Lieber, Toby,Ryu, Keun Woo,Choi, Elim,Masilionis, Ignas,Saha, Rahul,Takizawa, Meril,Baker, Daphne,Tigano, Marco,Lareau, Caleb A,Reznik, Ed,Sharma, Roshan,Chaligne, Ronan,Thompson, Craig B,Pe'er, Dana,Sfeir, Agnel",27/08/2024,Cell
10.1038/s41598-025-93357-y,comparative efficacy l glutamine celecoxib glucosamine sulfate osteoarthritis management,to explore therapeutic efficacy l glutamine l gln pathological progression clinical symptom osteoarthritis oa compare glucosamine sulfate gs celecoxib cxb rat be administer sodium chloride l gln gs cxb gavage eight week start fifth week sham operation anterior cruciate ligament transection aclt medial meniscectomy mmx then severity knee oa rat be evaluate serological analysis histological examination imaging examination addition patient mild primary oa be administer l gln gs cxb orally week accordance randomization principle efficacy end point be change baseline week pain physical function subscale score western ontario mcmast university index womac lequesne score treatment l gln alleviate increase concentration serum cartilage degradation marker cause oa rat histological test show improvement knee joint cartilage destruction treatment three dimensional ct scan reconstruction reveal reduction osteophyte formation subchondral bone loss l glutamine perform as well well glucosamine sulfate celecoxib comparative measure three treatment group clinical trial womac pain physical function subscale score as well lequesne score decrease baseline three patient group follow up significant difference observe group research indicate l gln be comparable cxb improve pathological progression clinical efficacy oa make promising drug treatment osteoarthritis,"Hu, Zhongyao,Wang, Changming,Wang, Chen,He, Junyan,Yan, Yiqun,Xu, Zelin,Yu, Yangmang,Yu, Ya,Cheng, Huan,Liu, Lei,Tang, Miao,Zhang, Chun,Yu, Haoran,Jing, Juehua,Cheng, Wendan",07/11/2024,Scientific reports
10.1186/s40337-023-00900-1,case series to test acceptability feasibility preliminary efficacy avatar therapy anorexia nervosa,background patient anorexia nervosa tend to experience inner eat disorder voice struggle to recognise assert own identity illness identity relate powerless subordinate position avatar therapy be develop to help patient psychosis to gain great power control distressing voice goal study be to test feasibility acceptability safety preliminary efficacy adaptation avatar therapy anorexia nervosa method twelve adult patient anorexia nervosa be recruit ten complete assessment session five to seven therapy session assessment session consist creation avatar to represent eat disorder be accomplish manipulate auditory visual characteristic specialist computer software therapy session patient interact avatar to assert own desire will patient complete baseline end intervention follow up week online questionnaire non concurrent multiple baseline single case experimental design sce be use feasibility acceptability safety preliminary efficacy intervention be assess result therapy meet pre specified criterion relate feasibility sample recruit three month retention rate end treatment phase therapy completion rate safety serious adverse event associate intervention acceptability mean rating sd ten scale acceptability complete satisfaction regard efficacy participant report significantly low level distress associate eat disorder voice high level self compassion end treatment other significant change be observe frequency eat disorder voice voice characteristic such omnipotence malevolence eat disorder symptom symptom anxiety depression stress patient feedback indicate therapy have help ability to stand illness make positive change eating increase motivation to recover self compassion conclusion avatar therapy anorexia nervosa be feasible acceptable safe patient large study be need to test clinical efficacy trial registration study be pre registered registry,"Thompson, Alistair,Calissano, Chiara,Treasure, Janet,Ball, Hannah,Montague, Alice,Ward, Thomas,Cardi, Valentina",28/03/2023,Journal of eating disorders
10.1080/2162402X.2025.2477872,efficacy anti anti combination checkpoint inhibitor therapy head neck squamous cell carcinoma genetically engineer mouse model,head neck squamous cell carcinoma hnscc continue to be most common malignancy worldwide limited treatment option patient target axis be currently only fda approve immune checkpoint inhibitor treatment hnscc novel therapy target other pathway be need along test combinational approach to find new more efficient way to treat disease utilize tamoxifen inducible pten deletion mouse model to explore efficacy combined anti anti therapy tongue hnscc determine underlie immunological mechanism combine anti anti therapy be effective decrease tumor burden lymphatic metastasis compare anti treatment not compare anti treatment alone anti tumoral effect anti anti anti combined therapy be associate increase t cell proliferative response secondary lymphoid organ increase t cell tumor infiltration anti treatment potentiate anti tumoral property t cell treat anti include enhanced systemic ifn γ production tnf α production tumor microenvironment far anti tumoral cytotoxic t cell effector function granzyme b production be enhance anti combinatorial anti anti immunotherapy result great tumor cell death result demonstrate anti have potential to enhance efficacy anti therapy however humanize mouse model well recapitulate human disease fda approve antibody be need to far characterize efficacy treatment viable treatment option hnscc patient,"Lamenza, Felipe F,Roth, Peyton,Upadhaya, Puja,Shrestha, Suvekshya,Jagadeesha, Sushmitha,Kazmierowicz, Natalie,Horn, Natalie,Pracha, Hasan,Dasari, Sonali,Oghumu, Steve",18/03/2025,Oncoimmunology
10.1016/j.ejphar.2025.177520,explore alzheimer disease treatment establish therapy novel strategy future care,alzheimer disease ad be progressive neurodegenerative disorder characterize gradual decline cognitive function memory impairment alteration behavior predominant etiology dementia ad affect million individual worldwide hallmark pathological feature be accumulation amyloid beta aβ plaque disrupt neuronal function progressively compromise brain structure early clinical manifestation often include forgetfulness disorientation social withdrawal primarily impact elderly population ad significantly impairs daily function diminish overall quality life current therapeutic approach ad mainly focus symptomatic relief decelerate disease progression cholinesterase inhibitor such donepezil rivastigmine increase acetylcholine ach level to enhance cognitive function individual mild to moderate ad individual more advanced stage disease nmda receptor antagonist modulate glutamate activity to mitigate excitotoxicity addition pharmacological intervention lifestyle modification such adherence balanced diet regular physical activity cognitive engagement be advocate to support brain health novel therapeutic avenue be be explore to address underlie pathophysiological mechanism such metal ion dysregulation brain furthermore non pharmacological approach include cognitive behavioral therapy patient support group provide essential behavioral emotional support cut edge research continue to investigate innovative treatment such immunotherapy target amyloid plaque tau tangle neuroprotective compound derive natural source goal multifaceted strategy be to alleviate symptom enhance quality life offer hope individual family affect ad review provide comprehensive summary establish emerge therapeutic intervention management ad,"Soni, Urvashi,Singh, Kuldeep,Jain, Divya,Pujari, Rohini",02/02/2025,European journal of pharmacology
10.7150/thno.100786,artificial intelligence enhance retinal imaging biomarker systemic disease,retinal image provide non invasive accessible mean to directly visualize human blood vessel nerve fiber grow study have investigate intricate microvascular neural circuitry retina interaction other systemic vascular nervous system link retinal biomarker various systemic disease use eye to study systemic health base connection have be give term oculomic advancement artificial intelligence ai technology particularly deep learning have far increase potential impact study leverage technology retinal analysis have demonstrate potential detect numerous disease include cardiovascular disease central nervous system disease chronic kidney disease metabolic disease endocrine disorder hepatobiliary disease ai base retinal imaging incorporate establish modality such digital color fundus photograph optical coherence tomography oct oct angiography as well emerge technology ultra wide field imaging show great promise predict systemic disease provide valuable opportunity systemic disease screen early detection prediction risk stratification personalize prognostication ai big datum research field grow mission transform healthcare also face numerous challenge limitation datum technology application natural language processing framework large language model other generative ai technique present opportunity concern require careful consideration review not only summarize key study ai enhance retinal imaging predict systemic disease also underscore significance advancement transform healthcare highlight remarkable progress make thus far provide comprehensive overview state art technique explore opportunity challenge rapidly evolve field review aim to serve valuable resource researcher clinician guide future study foster integration ai clinical practice,"Wang, Jinyuan,Wang, Ya Xing,Zeng, Dian,Zhu, Zhuoting,Li, Dawei,Liu, Yuchen,Sheng, Bin,Grzybowski, Andrzej,Wong, Tien Yin",10/07/2024,Theranostics
10.1001/jama.2025.1132,adjuvant blockade camrelizumab nasopharyngeal carcinoma dipper randomize clinical trial,importance approximately to patient locoregionally advanced nasopharyngeal carcinoma npc experience disease relapse definitive chemoradiotherapy program cell death blockade camrelizumab have demonstrate considerable value recurrent metastatic npc role locoregionally advanced npc be unclear objective to evaluate efficacy safety adjuvant camrelizumab patient locoregionally advanced npc design setting participant randomize open label multicenter phase clinical trial conduct august november center china enrol patient npc have complete induction concurrent chemoradiotherapy final date follow up be march intervention patient be randomize to receive adjuvant camrelizumab mg intravenously once week cycle observation standard therapy group main outcome measure primary end point be event free survival freedom distant metastasis locoregional relapse death cause secondary end point include distant metastasis free survival locoregional relapse free survival overall survival safety health relate quality life result participant mean age sd year woman median follow up iqr month camrelizumab group have year event free survival rate standard therapy group have rate stratify hazard ratio ci p grade adverse event be report patient camrelizumab standard therapy group reactive capillary endothelial proliferation be most common adverse event relate camrelizumab occur patient grade patient have grade event be significant deterioration quality life associate camrelizumab treatment conclusion relevance adjuvant blockade camrelizumab significantly improve event free survival manageable toxicity highlight potential role management locoregionally advanced npc trial registration identifi,"Liang, Ye-Lin,Liu, Xu,Shen, Liang-Fang,Hu, Guang-Yuan,Zou, Guo-Rong,Zhang, Ning,Chen, Chuan-Ben,Chen, Xiao-Zhong,Zhu, Xiao-Dong,Yuan, Ya-Wei,Yang, Kun-Yu,Jin, Feng,Hu, Wei-Han,Xie, Fang-Yun,Huang, Ying,Han, Fei,Tang, Ling-Long,Mao, Yan-Ping,Lu, Li-Xia,Sun, Rui,He, Yu-Xiang,Zhou, Yang-Ying,Long, Guo-Xian,Tang, Jie,Chen, Lu-Si,Zong, Jing-Feng,Jin, Ting,Li, Ling,Lin, Jie,Huang, Jing,Gong, Xiu-Yun,Zhou, Guan-Qun,Chen, Lei,Li, Wen-Fei,Chen, Yu-Pei,Xu, Cheng,Lin, Li,Huang, Shao-Hui,Huang, Sai-Wei,Wang, Ya-Qin,Huang, Cheng-Long,Feng, Hui-Xia,Hou, Min,Chen, Chun-Hua,Zheng, Su-Fen,Li, Ying-Qing,Hong, Shu-Bin,Jie, Yu-Sheng,Li, Hao,Yun, Jing-Ping,Zang, Sheng-Bing,Liu, Song-Ran,Lin, Qing-Guang,Li, Hao-Jiang,Tian, Li,Liu, Li-Zhi,Zhao, Hong-Yun,Li, Ji-Bin,Lin, Ai-Hua,Liu, Na,Zhang, Yuan,Guo, Rui,Ma, Jun,Sun, Ying",13/09/2025,JAMA
10.1101/2025.03.03.641186,recurrent pattern widespread neuronal genomic damage share major neurodegenerative disorder,amyotrophic lateral sclerosis al frontotemporal dementia ftd alzheimer disease ad be common neurodegenerative disorder mechanism drive neuronal death remain unclear single cell whole genome sequencing neuron three al six ftd seven ad twenty three neurotypical control brain reveal significantly increase burden somatic single nucleotide variant ssnv insertion deletion sindel three disease condition mutational signature analysis identify disease associate ssnv signature suggestive oxidative damage sindel process affect al ftd ad neuron only control neuron disease control p disease associate sindel be primarily two basepair deletion resemble signature be previously link to topoisomerase mutagenesis duplex sequence confirm presence sindel identify similar single strand event potential precursor lesion associate sindel mutagenesis result genome instability may thus represent common mechanism neurodegeneration,"Zhou, Zinan,Luquette, Lovelace J,Dong, Guanlan,Kim, Junho,Ku, Jayoung,Kim, Kisong,Bae, Mingyun,Shao, Diane D,Sahile, Bezawit,Miller, Michael B,Huang, August Yue,Nathan, William J,Nussenzweig, Andre,Park, Peter J,Lagier-Tourenne, Clotilde,Lee, Eunjung Alice,Walsh, Christopher A",17/03/2025,bioRxiv : the preprint server for biology
10.7150/thno.104573,drive upregulation facilitate ocular angiogenesis pathway,background pathological ocular neovascularization characteristic feature proliferative ocular disease be primary contributor global vision impairment dynamic tubulin be crucial maintain ocular homeostasis closely link cellular proliferation angiogenesis elucidate molecular mechanism drive process be vital formulate effective therapeutic strategy method multiple transcriptome analysis reveal upregulation endothelial tubulin chain oxygen induce retinopathy oir laser induce choroidal neovascularization cnv mice model transwell migration assay wound heal assay tube formation assay flow cytometry immunofluorescent stain be employ to identify role knockout ko vitro effect silence retinal angiogenesis choroidal neovascularization be subsequently evaluate result identify upregulated expression retina oir mouse combination analysis single cell rna sequence scrna seq bulk rna seq rna expression profile endothelial cell ecs proliferative diabetic retinopathy pdr patient age relate macular degeneration namd patient also exhibit elevation notably be abundantly express ec pericyte be predominantly localize proliferative ec vascular tip cell functional study demonstrate knockdown reduce expression proliferative tip cell marker vitro deficiency decrease vascular sprouting tip cell formation oir mice retina retard cnv progression vivo mechanistically rna bind protein be identify upstream regulator bind untranslated region maintain mrna stability transcriptome analysis far link activity wnt pathway silence suppress wnt signal pathway identify downstream target conclusion collectively research shed light pivotal function maintain ocular homeostasis uncover pathway involvement sprout angiogenesis target develop specific inhibitor could pioneer new approach treat ocular microvascular disease,"Zhang, Ye-Ran,Li, Wei-Qi,Zhang, Zhong-Hong,Sun, Ru-Xu,Zhu, Hong-Jing,Qian, Hui-Ming,Yuan, Song-Tao,Wang, Yu-Liang",02/10/2024,Theranostics
10.1186/s13561-025-00611-0,cost effectiveness analysis combination therapy involve novel agent first second relapse patient multiple myeloma markov model approach calibration technique,background number randomize clinical trial rct demonstrate survival benefit combination therapy previously treat multiple myeloma mm patient increase be essential to determine most cost effective treatment robust economic evaluation study aim to assess cost effectiveness combination therapy first second relapse mm patient perspective chinese healthcare system method markov model be develop to evaluate three combination therapy group base primary drug bortezomib lenalidomide carfilzomib economic evaluation be conduct group individually rather different group clinical input model be derive rct report healthcare cost be source zhejiang province bidding database retrospective analysis utility value be obtain site survey use chinese version euroqol five dimensional five level questionnaire one way probabilistic sensitivity analysis be perform to assess robustness base case result result bortezomib group bortezomib dexamethasone vd yield quality adjust life year qalys cost willingness pay wtp threshold three time capita gdp china pomalidomide bortezomib dexamethasone be most cost effective therapy qaly group lenalidomide group lenalidomide dexamethasone rd result qaly cost compare rd incremental cost effectiveness ratio icer elotuzumab lenalidomide dexamethasone qaly ixazomib lenalidomide dexamethasone qaly carfilzomib lenalidomide dexamethasone qaly daratumumab lenalidomide dexamethasone qaly exceed wtp threshold carfilzomib group carfilzomib dexamethasone kd result qaly cost compare kd icer daratumumab carfilzomib dexamethasone qaly isatuximab carfilzomib dexamethasone qaly also exceed wtp sensitivity analysis confirm robustness base case result conclusion study do not fully account heterogeneity subsequent treatment regimen first second relapse mm patient highlight substantial financial burden associate combination therapy involve novel agent pose significant challenge justify economic value,"Wu, Weijia,Tang, Fengyuan,Wang, Yannan,Yang, Wenqianzi,Zhao, Zixuan,Gao, Yuan,Dong, Hengjin",03/09/2024,Health economics review
10.1093/cvr/cvaf023,opportunity challenge use human sample translational cardiovascular research scientific statement esc working group cellular biology heart esc working group cardiovascular surgery esc council basic cardiovascular science esc scientist tomorrow european association percutaneous cardiovascular intervention esc heart failure association esc,animal model offer invaluable insight disease mechanism can not entirely mimic variability heterogeneity human population increase prevalence multi morbidity consequently employ human sample such whole blood fraction valvular vascular tissue myocardium pericardium human derive cell be essential enhance translational relevance cardiovascular research instance myocardial tissue slice preserve crucial structural functional characteristic human heart can be use vitro to examine drug response human blood serve rich source biomarker include extracellular vesicle various type rna mirna lncrna circrna circulate inflammatory cell endothelial colony form cell facilitate detailed study cardiovascular disease primary cardiomyocyte vascular cell isolate human tissue be invaluable mechanistic investigation vitro case be unavailable human induce pluripotent stem cell serve effective substitute specific limitation however use human sample present challenge such ethical approval tissue procurement storage variability patient genetic treatment regimen selection appropriate control sample biobank be central efficient use scarce valuable resource scientific statement discuss opportunity to implement use human sample cardiovascular research specific clinical contexts offer practical framework acquire utilize different human material present example human sample application specific cardiovascular disease provide valuable resource clinician translational basic scientist engage cardiovascular research,"Davidson, Sean M,Andreadou, Ioanna,Antoniades, Charalambos,Bartunek, Jozef,Basso, Cristina,Brundel, Bianca J J M,Byrne, Robert A,Chiva-Blanch, Gemma,da Costa Martins, Paula,Evans, Paul C,Girão, Henrique,Giricz, Zoltan,Gollmann-Tepeköylü, Can,Guzik, Tomasz,Gyöngyösi, Mariann,Hübner, Norbert,Joner, Michael,Kleinbongard, Petra,Krieg, Thomas,Liehn, Elisa,Madonna, Rosalinda,Maguy, Ange,Paillard, Melanie,Pesce, Maurizio,Petersen, Steffen E,Schiattarella, Gabriele G,Sluijter, Joost P G,Steffens, Sabine,Streckfuss-Bömeke, Katrin,Thielmann, Matthias,Tucker, Art,Van Linthout, Sophie,Wijns, William,Wojta, Johann,Wu, Joseph C,Perrino, Cinzia",03/08/2024,Cardiovascular research
10.1097/HEP.0000000000001307,hla risk hepatitis b virus relate hepatocellular carcinoma,background aim human leukocyte antigen hla locus be implicate hepatocellular carcinoma hcc chronic hepatitis b virus hbv carrier investigate association hla variant amino acid polymorphism zygosity evolutionary divergence he d hbv relate hcc han chinese explore biological mechanism approach result examine association hla variant impute digit classical allele amino acid polymorphism zygosity d hbv relate hcc discovery set hbv relate hcc case chronic hbv carrier taiwan significant signal be validate independent set case control qidong pr china use logistic regression adjust sex age top genetic principal component bonferroni correction multiple testing evaluate predict peptide bind affinity control viral load viral population diversity inflammatory marker significant signal hla be most significantly associate hbv relate hcc discovery validation set ormeta pmeta three amino acid peptide bind region hla hla hla be positively associate hcc hla be associate low bind affinity hbv nucleocapsid antigen high hbv dna load serum soluble program cell death hla heterozygosity be inversely associate hcc independent hla pmeta conclusion hla three key amino acid be associate increase hbv relate hcc risk association may be explain low bind affinity to hbv antigen result poor control viral load increase inflammation evidence level,"Zhang, Ting,Huang, Chih-Jen,Chen, Hai-Tao,Huang, Yu-Han,Pan, Mei-Hung,Lee, Mei-Hsuan,Viard, Mathias,Hildesheim, Allan,Pfeiffer, Ruth M,Carrington, Mary,Chen, Chien-Jen,Zhu, Bin,Lenz, Tobias L,Jiang, Deke,Yang, Hwai-I,Liu, Zhiwei",24/12/2024,"Hepatology (Baltimore, Md.)"
10.1016/j.ccell.2025.02.015,hypoxia inducible drive cancer resistance cuproptosis,cuproptosis represent new type cell death intricately associate copper homeostasis protein lipoylation cuproptosis suppression have be characterize hypoxic tumor microenvironment tme here reveal hypoxia inducible be driver cuproptosis resistance solid tumor find activate pyruvate dehydrogenase kinase result decrease expression dihydrolipoamide s acetyltransferase dlat target copper promote accumulation metallothionein sequester mitochondrial copper lead resistance cuproptosis hypoxic condition furthermore discover high level copper reduce ubiquitination increase stability protein affect mrna level inhibition increase susceptibility cancer to cuproptosis vivo study unveil multifaceted role cuproptosis demonstrate molecular mechanism hypoxia promote carcinogenesis,"Yang, Zhou,Su, Wei,Wei, Xiyi,Pan, Yitong,Xing, Mengying,Niu, Lili,Feng, Baijie,Kong, Weiyu,Ren, Xiaohan,Huang, Feng,Zhou, Jingwan,Zhao, Wei,Qiu, Yingyi,Liao, Tian,Chen, Qi,Qu, Shuang,Wang, Yunjun,Guan, Qing,Li, Duanshu,Zen, Ke,Chen, Yun,Qin, Chao,Wang, Yu,Zhou, Xiang,Xiang, Jun,Yao, Bing",23/01/2024,Cancer cell
10.1097/RLI.0000000000001179,emerge trend innovation radiologic diagnosis thoracic disease,past decade investigative radiology have publish numerous study have fundamentally advance field thoracic imaging review summarize key development image modality computational tool clinical application highlight major breakthrough thoracic disease lung cancer pulmonary nodule interstitial lung disease ild chronic obstructive pulmonary disease copd pneumonia pulmonary embolism outline future intelligence computer aid detection system radiomic analysis have notably improve detection classification pulmonary nodule photon counting detector ct pcd ct low field mri offer enhance resolution radiation free strategy lung cancer ct texture analysis perfusion imaging refine prognostication therapy planning ild assessment benefit automated diagnostic tool innovative imaging technique such pcd ct functional mri reduce need invasive diagnostic procedure improve accuracy copd dual energy ct base ventilation perfusion assessment dark field radiography enable early detection staging emphysema complement deep learning approach improved quantification research have underscore clinical utility chest ct radiograph ai base algorithm rapid triage disease severity evaluation follow up furthermore tuberculosis remain significant global health concern highlight importance ai assist chest radiography early detection management meanwhile advance ct pulmonary angiography include dual energy reconstruction allow more sensitive detection pulmonary innovation demonstrate power merge novel imaging technology quantitative functional analysis ai drive tool to transform thoracic disease management ongoing progress promise more precise personalized diagnostic therapeutic strategy diverse thoracic disease,"Song, Jiyoung,Hwang, Eui Jin,Yoon, Soon Ho,Park, Chang Min,Goo, Jin Mo",19/03/2025,Investigative radiology
10.3389/fimmu.2025.1490491,car t therapy treat hematologic malignancy hide danger be next neighbor security,target chimeric antigen receptor car t cell therapy have achieve marvelous result treatment patient relapsed refractory b cell lymphomas b cell acute lymphoblastic leukemia multiple myeloma new treatment method have change exist treatment paradigm have be short time emergence fda approval however increase number case passage time hide problem have gradually be expose review summarize long term toxicity such secondary t cell tumor lethal car tumor patient hematologic malignancy treat car t cell include cytokine release syndrome crs ican secondary malignancy low occurrence rate high mortality such secondary t cell tumor lethal car tumor may be relate gene modification mechanism viral vector currently approve car t cell also discuss potential investigational strategy design to improve safety car t cell therapy,"Ye, Xueshuai,Ge, Min,Tan, Mengtian,Wu, Yongqiang,Zhang, Haiqiang,Fu, Zexian",03/09/2024,Frontiers in immunology
10.3389/fimmu.2025.1515838,prognostic analysis identification g immune relate gene lung squamous cell carcinoma,background recent year clinical application target therapy immunotherapy have significantly improve survival outcome patient lung however few mutation lung squamous cell show limited efficacy targeted immunotherapy result notably low year survival rate compare lung adenocarcinoma g modification play important role tumorigenesis progression immune evasion therapeutic response study aim to develop novel scoring system base g modification immune status to clinically predict prognosis patient lusc to provide new therapeutic target method study utilize rna seq datum tcga lusc database training set geo database validation set immunotherapy datum be obtain immport database g datum previous research use bioinformatics develop prognostic model lusc base pathway relate immune gene characteristic analyze correlation prognostic model clinical pathological feature lusc as well model independent prognostic capability subsequently patient be divide high risk low risk group examine difference enriched pathway immune cell infiltration correlation drug sensitivity two group result g immune relate gene fga increase survival risk patient lung squamous cell carcinoma nt exert protective effect prognostic risk model lung squamous cell carcinoma lusc base g immune relate gene expression demonstrate overall survival high risk group be significantly poor low risk group conclusion risk model develop base g immune relate gene can help predict clinical prognosis lusc patient guide treatment decision,"Wenhui, Li,Nan, Wu,Jiayi, Han,Ye, Xu,Chunyu, He,Zhongzhou, Li,Hongtao, Lei,Hui, Tian",23/10/2024,Frontiers in immunology
10.1038/s41413-025-00411-6,organelle tuning condition robustly fabricate energetic mitochondria cartilage regeneration,mitochondria be vital organelle impairment lead numerous metabolic disorder mitochondrial transplantation serve promising clinical therapy however widespread application be hinder limited availability healthy mitochondrion dose require reach mitochondria injection patient necessitate sustainable tractable approach produce high quality human mitochondria study demonstrate highly efficient mitochondria produce strategy manipulate mitobiogenesis tune organelle balance human mesenchymal stem cell msc utilize optimize culture medium mito condition develop established formula achieve fold increase mitochondria production compare normal msc culture day mitochondria be not only significantly expand also exhibit superior function isolation atp production level reach time normal mitochondria mechanistically reveal activation ampk pathway establishment novel cellular state ideal mitochondrial fabrication characterize enhanced proliferation mitobiogenesis suppress other energy consume activity furthermore vivo function mitochondria be validate mitotherapy mouse osteoarthritis model result significant cartilage regeneration week period overall study present new strategy shelf fabrication human mitochondria provide insight molecular mechanism govern organelle synthesis,"Chen, Xuri,Zhou, Yunting,Yao, Wenyu,Gao, Chenlu,Sha, Zhuomin,Yi, Junzhi,Wang, Jiasheng,Liu, Xindi,Dai, Chenjie,Zhang, Yi,Wu, Zhonglin,Yao, Xudong,Zhou, Jing,Liu, Hua,Chen, Yishan,Ouyang, Hongwei",30/04/2024,Bone research
10.1007/s00018-025-05616-w,loss cause oligoasthenoteratozoospermia male infertility mouse,centrosomal protein cep crucial scaffold molecule play pivotal role biogenesis centriole regulation cell cycle date mutation have be report to be closely associate multiple morphological abnormality flagella mmaf human however specific mechanism spermatogenesis detailed role male infertility remain largely unexplored study present compelling evidence function pathogenic gene responsible oligoasthenoteratozoospermia oat male infertility mouse selectively delete premeiotic germ cell use cre mouse cross flox mouse observe knockdown produce abnormal sperm morphology germ cell apoptosis consequentlybecame complete infertility do not impact premeiosis scan transmission electron microscopy reveal defect acrosome flagellum head tail connection spermatogenesis proteomic analysis far indicate deletion lead significant reduction protein mainly associate acrosome formation sperm head sperm flagellum microtubule assembly additionally interact spermatogenic protein regulate expression stability deficiency interact protein result ciliary shortening conclusion study profoundly unveil central role spermatogenesis male fertility discovery not only deepen comprehension spermatogenesis also furnish solid theoretical foundation experimental evidence can guide formulation therapeutic preventive strategy male infertility,"Liu, Hui,Zhang, Haozheng,Qin, Guanghao,Song, Tingting,Liu, Xin,Wen, Zongzhuang,Liu, Min,Wang, Xianmei,Fu, Xiaolong,Gao, Jiangang",21/10/2024,Cellular and molecular life sciences : CMLS
10.1172/JCI186889,cellular molecular feature asthma mucus plug provide clue formation persistence,backgroundmucus plug form acute asthma persist chronic disease eosinophil be implicate mechanism mucus pathology many mechanistic detail mucus plug formation persistence asthma be histology spatial single cell proteomic characterize mucus plug airway nontransplantable donor lung patient asthma fatal asthma nonfatal asthma individual act control chronic obstructive pulmonary disease free lung disease additionally use airway epithelial cell eosinophil aec eosinophil coculture model to explore aec mucus affect eosinophil mucus plug be tethered to airways show infiltration innate lymphoid type cell hyperplasia smooth muscle cell express goblet cell asthma mucus plug be infiltrate immune cell be mostly dual positive eosinophil peroxidase epx neutrophil elastase suggest neutrophil internalize epx degranulate eosinophil indeed eosinophil expose mucus activate aec undergo glycan dependent cytolytic degranulation dual positive granulocyte vary frequency mucus plug paucigranulocytic plug be rich granulocytic plug have mix extracellular dna trap paucigranulocytic plug occur more frequently acute fatal asthma granulocytic plug predominate chronic nonfatal datum suggest mucin rich mucus plug fatal asthma form acute goblet cell degranulation remodeled airway granulocytic mucus plug chronic asthma persist sustain niche characterize epithelial cell mucin granulocyte grant,"Liegeois, Maude A,Hsieh, Aileen,Al-Fouadi, May,Charbit, Annabelle R,Yang, Chen Xi,Hackett, Tillie-Louise,Fahy, John V",10/09/2024,The Journal of clinical investigation
